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ABSTRACT 
Imprinting is an epigenetic phenomenon that silences one allele of a gene, so that 
expression in one or more cell types is exclusively monoallelic, and dependent on 
parental origin. Approaches used to identify novel imprinted genes rely on 
characteristic features such as the clustering of imprinted genes, or their association 
with differentially methylated CpG islands. 
An imprinted tumour suppressor gene involved in pathogenesis of neuroblastoma is 
believed to lie within chromosome 1p36. In this region, a search was initiated for 
imprinted genes in the vicinity of the imprinted gene TP73. The DFFB gene, 
encoding the apoptotic nuclease DNA fragmentation factor, was identified, and its 
intron -exon structure was elucidated. A pseudogene was also identified on 
chromosome 9. The tumour suppressor candidacy of DFFB was assessed through a 
comprehensive mutation screen of 42 neuroblastoma DNAs. No tumour -specific 
mutations were identified. Imprinting was then assessed by RT -PCR, which revealed 
biallelic expression of DFFB. It is unlikely that DFFB acts as a tumour suppressor 
in neuroblastoma. 
During a systematic screen, a differentially methylated CpG island, NV 149, had been 
identified. In the present study, this locus was mapped to 6q24. The nearest gene 
was found to be the cell -cycle control gene, ZAC. Monoallelic expression of ZAC 
from the paternal allele only was demonstrated in a range of fetal tissues. ZAC may 
possess a dual role in disease, such that upregulation by paternal duplication or 
paternal uniparental disomy of chromosome 6 results in transient neonatal diabetes 
mellitus (TNDM), whereas loss or down regulation of ZAC results in loss of cell 
cycle control, and hence tumorigenesis. Through analysis of a panel of B cell 
lymphomas, evidence was found for hypermethylation of the NV 149 CpG island, 
which may be one mechanism through which expression of ZAC is lost in tumours. 
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Genomic imprinting is an intriguing epigenetic phenomenon. The defining 
characteristic of imprinted genes is monoallelic expression, which defies the 
underlying principles of traditional Mendelian inheritance. Until the discovery of 
imprinting, the concepts of biparental inheritance and expression had remained 
unchallenged, and it was widely accepted that the maternal and paternal alleles of a 
gene were functionally equivalent, and that both were required for normal 
development. 
Differential expression of the alleles of an imprinted gene is determined by their 
parental origin, such that in the case of a maternally imprinted gene, the paternal 
copy is expressed whereas the maternal copy is silenced. Conversely, a paternally 
imprinted gene will be expressed solely from the maternally inherited allele. 
1.1.1 The discovery of imprinting 
Parent -of origin effects were described in the two rodent species Peromyscus 
polionotus and Peromyscus maniculatus, in which a cross between a female of the 
former species and a male of the latter resulted in offspring that were 40% smaller 
than either parent, whereas the reciprocal cross produced oversized offspring that 
often died before birth (Dawson, 1965). The first formal demonstration of 
imprinting, however, was made through a series of experiments that demonstrated 
the non -equivalence of the parental genomes in the developing embryo (Barton et al. 
1984; Surani et al. 1984; McGrath, Solter 1984). A key experiment was that of 
Surani et al. (Surani et al. 1984), in which reconstituted diploid eggs were generated 
using haploid parthenogenetic eggs as recipients for either a paternal or a maternal 
pronucleus derived from fertilized eggs. The critical observation was that those 
receiving a male pronucleus sometimes developed to term, whereas those receiving a 
female pronucleus generally showed poor development. Specifically, the few eggs in 
this second category that did manage to implant were notably retarded in growth, and 
2 
had very poorly developed extraembryonic tissues and trophoblast. The conclusions 
that were drawn from these results were that both male and female pronuclei are 
essential to allow full term development. A similar conclusion regarding the non- 
equivalence of the maternal and paternal genomes was reached by Cattanach et al. 
(Cattanach, Kirk 1985), who, taking a different approach, generated mice with 
uniparental disomies for particular chromosomal regions. In several cases, the 
observed phenotypic effects were dependent on the parental origin of the disomy, 
indicating that there is a differential contribution from the maternal and paternal 
genomes. 
1.1.2 Imprinting mechanisms 
Gaining an understanding of the mechanisms that govern the establishment and 
maintenance of the imprint is a key area of imprinting research (Constancia et al. 
1998; Pfeifer 2000; Reik, Walter 1998). What is the imprint mark? How and when 
is it established in the germline, and how is it maintained in somatic cells? 
Definitive answers to these questions have not yet emerged but elucidating the 
mechanisms that underlie the possible erasure, establishment and reprogramming of 
the imprint will be a significant advance in this field of research. 
1.1.2.1 Nature of the imprint 
In taking a logical view of the process of imprinting, it is clear that the parental 
origin of chromosomes must be distinguished by a mark of some kind, which directly 
or indirectly gives rise to the monoallelic expression that we recognise as the 
defining feature of imprinting. The imprint, which in effect `labels' each 
chromosome as either maternal or paternal, must possess several properties. Firstly, 
it must have stability, since it must be maintained throughout cell division and 
differentiation. Secondly, it must be consistently recognisable, since it is `read' in 
the somatic cells, and converted into differential expression. Thirdly it must be 
reversible, since the parental nature of the imprint may require to be switched 
between successive generations. This reprogramming of the imprint is crucial, 
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because an allele of paternal origin in one generation, for example, may subsequently 
reside in the female germline, at which point the imprint must be reset or switched to 
represent a maternal origin. 
It is now well established that differential, parent- specific methylation of nearby 
CpG islands is a hallmark of imprinted genes, and it seems likely that methylation 
plays a critical role in either establishing or maintaining the imprint mark. As a 
candidate medium for carrying the information it satisfies all of the criteria 
mentioned above, in that it is stable, recognisable by the transcriptional machinery, 
and reversible. Differential methylation was first demonstrated for the genes H19 
(Ferguson -Smith et al. 1993; Bartolomei et al. 1993), Igf2 (Sasaki et al. 1992), and 
Igf2r (Brandeis et al. 1993), and in agreement with a mechanistic function of this 
differential methylation, a loss of imprinting of all three genes was observed in mice 
that were deficient in DNA methyltransferase (Dnmtl) activity (Li et al. 1993). 
1.1.2.2 Imprinting in development 
Given the necessary properties of the imprint that have been described above, it is 
predicted that an imprint that signals the parental origin of the chromosomes should 
be resistant to the global genomic demethylation that occurs in pre- implantation 
development (Monk et al. 1987). However, many imprinted genes with a 
differentially methylated region do appear to become demethylated at this time, 
along with other non -imprinted genes (Brandeis et al. 1993). The parental identity of 
the chromosomes in the embryo must still be recognised though, in order for the 
correct imprints to be maintained and manifested in the form of monoallelic 
expression in the somatic cells. This implies that not all differentially methylated 
regions (DMRs) act as primary signals of parental origin. Some studies have now 
identified specific regions of differential methylation that are inherited from the 
gametes, and retained through all stages of development, including the global 
demethylation, as predicted. This suggests that there is a subset of differentially 
methylated regions that act as primary gametic imprints, stably marking the 
chromosomes with their origin. To date, at least six such putative primary gametic 
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imprints have been detected, associated with the genes H19, Igf2r, Gnas, U2afbp- 
rs /U2af1 -rsl , Snrpn, and Kcnql. The best studied of these is the gametic imprint 
mark associated with the maternally expressed imprinted gene H19. 
A bisulphite analysis of the paternal specific H19 methylation during 
spermatogenesis has shown that a 2kb region of paternal -specific methylation is 
inherited from sperm, and stably propagated and maintained in the preimplantation 
embryo (Tremblay et al. 1997; Tremblay et al. 1995). It is believed that this 2kb 
DMR subsequently extends, to render the H19 promoter and gene body of the 
paternal allele hypermethylated (Pfeifer 2000). This 2kb paternal- specific 
methylation upstream of H19 appears to represent a primary, gametic imprint since it 
is present in sperm, absent from oocytes, and is conserved at all stages of 
embryogenesis that have been analysed. 
Other than H19, potential gametic imprint marks have been reported for at least five 
other genes: Gnas apparently has a region of differential methylation that is present 
in oocytes, but not in spermatozoa, and is maintained at preimplantation stages of 
development (Liu et al. 2000a); U2afbp- rs /U2afl -rs1 carries an oocyte- specific 
methylation imprint mark that is maintained throughout development, and like the 
H19 paternal specific imprint mark, the methylation is expanded before implantation 
to assume the final methylation pattern (Shibata et al. 1997); Igf2r has also been 
shown to carry a gamete -specific methylation mark that is preserved during early 
embryogenesis (Brandeis et al. 1993). The mouse Snrpn gene has two regions of 
differential methylation that are inherited from the gametes, and are protected from 
methylation changes in the embryo, and thus represent a gametic imprint mark 
(Shemer et al. 1997). Similarly, the CpG island of the Kcngl gene associated with 
the antisense transcript Kcngl otl , is methylated in oocytes, unmethylated in sperm, 
and these differences appear to be stably conserved in the embryo (Engemann et al. 
2000). 
The discovery of primary gametic imprint marks has indicated that imprinting may 
be under the control of a small number of more permanent methylation signals, 
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which direct the establishment of other DMRs associated with imprinted genes 
within the locus. If this is the case, then it stands to reason that each imprinted 
domain of the genome may be dominated by such a signal, and that more are yet to 
be identified. 
1.1.2.3 Imprint erasure and reprogramming in the germline 
Much of the investigation in this field has attempted to address the questions of how 
and when the imprint can be erased from the chromosomes and reset in either the 
same or opposite parental pattern for subsequent generations. One school of thought 
also questions whether it is actually necessary for the imprint to be erased from the 
parental chromosome that is of the same sex of the germline - for example, in the 
male germline does the imprint derived from the sperm become erased only to be 
reset with the same paternal mark in the germline, or are same -sex imprints retained? 
Irrespective of which scenario is accurate, it is widely believed that the 
reprogamming of imprints must occur during gametogenesis when the parental 
genomes are entirely independent from each other. The gametes in both males and 
females originate from the primordial germ cells (PGCs), which migrate from the 
epiblast, through extraembryonic tissue, to the gonad primordia in the genital ridge. 
In the mouse they reach their destination by 10.5 to 11.5 days postcoitum (dpc). 
Until this point their development is identical in both male and female embryos, but 
subsequent to this, in the female germline, the cells enter meiotic prophase, and 
oocyte growth proceeds after birth. In the male germline, the germ cells undergo 
mitotic arrest until after birth when they enter mitosis again, and subsequently 
undergo meiotic differentiation (Constancia et al. 1998). 
The majority of studies have analysed the establishment of the imprints in the mouse, 
and nearly all of the work has examined the H19 imprint, since this is one of the best 
characterised imprinted genes. One of the key points in the reprogramming of the 
germline imprints is a demethylation event in the primordial germ cells early in fetal 
development, which is followed later by a de novo methylation event (Razin, Shemer 
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1995). Estimates of the exact timing of this process are variable, but suggest that the 
demethylation occurs between 8.5dpc and 12.5dpc. Accurate estimates are difficult 
due to the technical problems associated with analysing material of early stages such 
as these. The finding of biallelic expression of H19 in PGCs of the genital ridge at 
11.5dpc led Szabo and Mann (Szabo, Mann 1995) to infer that imprinting is already 
erased, or at least not recognised in the genital ridge by this stage. However, 
observation of such biallelic expression does not necessarily prove that imprints are 
completely erased at this stage - as described, H19 has a gametic imprint in the form 
of the upstream 2kb DMR, but this may not be directly responsible for allelic 
silencing of the paternal allele. Rather, it may be responsible for marking the 
parental origin of that chromosome, and acting as a signal for the further methylation 
that colonises the downstream promoter and gene at a later stage. So, biallelic 
expression at this early stage, and paternal- specific methylation of the 2kb DMR are 
not necessarily mutually exclusive. 
Ueda et al. (Ueda et al. 2000) attempted to determine the timing of the H19 imprint 
reprogramming in mouse. They showed that in both male and female PGCs, the H19 
imprint was incompletely erased at 12.5 and 13.5dpc despite the global 
demethylation. In the maternal germline, the H19 imprint of the paternally derived 
chromosome was completely erased on entry into meiosis at 16.5dpc, whereas in the 
paternal germline, the partial methylation was overlaid with full methylation as a 
continuous process in mitotically arrested gonocytes of fetal and postnatal 
development. Interestingly, Ueda et al. noted that the establishment of the new 
imprint in the paternal germline occurred more quickly on the paternal chromosomes 
than on the maternal chromosomes. Overall, it could be interpreted from the results 
of this study that the methylation imprint of H19 is not completely erased, but is 
maintained in at least some PGCs. However, it is not possible to conclude that this is 
definitely the case, since a complete erasure of the imprint may have occurred at 
earlier stages than were investigated. 
Kerjean et al. (Kerjean et al. 2000) performed one of the few studies of imprint 
establishment in human. They analysed H19 and the oppositely imprinted, 
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maternally methylated gene PEGI /MEST. Their main finding, in contrast to that of 
Ueda et al. (Ueda et al. 2000), was that the original methylation imprints of both 
genes were completely erased before the fetal spermatogonia stage in the male 
germline. Subsequent to this, and in agreement with Ueda et al., they showed that 
the H19 imprint is re- established in spermatogonia. Conversely, PEGI /MEST 
remains unmethylated in the male germline. 
Davis et al. (Davis et al. 1999) discovered that in postnatal male germ cells the 
mouse H19 DMR is methylated on the paternal chromosome, and also on a 
significant proportion of the maternal chromosomes. As with the results of Ueda et 
al., this implies differential acquisition of the paternal imprint on the chromosomes 
in the male germline during spermatogenesis. A more recent study by Davis et al. 
(Davis et al. 2000) has reiterated this point, that the paternal allele acquires the H19 
DMR methylation before the maternal allele. However, Davis et al. make the critical 
point that if methylation imprints are completely erased before this point (as they 
have shown them to be), then the maternal and paternal chromosomes remain 
distinguishable and non -equivalent even in the absence of methylation. There must 
therefore be some mark, other than methylation, which continues to signify the 
parental origin of the chromosomes, even though it is not necessary for them to be 
distinguishable at this point. Davis et al. (Davis et al. 2000) propose a model to 
explain this. They point out that since the paternal allele appears to acquire its 
methylation at a similar timescale to other genes, between 15.5 and 18.5dpc (Kafri et 
al. 1992), it is the maternal allele that is somehow resistant or less receptive to 
methylation. As discussed further in 1.2.1.1.3, the maternal allele of H19 is bound 
by the CTCF protein (CCCTC binding factor) due to the unmethylated status of the 
DMR on this allele. This functions as a boundary element in the regulation of 
reciprocal imprinting of the H19 and IGF2 genes. However, when carried by the 
maternal chromosome into the male germline, this additional epigenetic marking 
may initially prevent access of methyltransferases. Later in development, the 
binding of CTCF to the maternally derived chromosome may be lost by degradation 
of the protein or other means, resulting in methylation of the maternal allele so that it 
assumes the correct paternal identity in the sperm. Thus, a link is made between the 
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role of methylation, and the structure of chromatin, in marking the parental identity 
of the chromosomes, and in establishing the imprint in the germline. 
1.1.2.4 Other possible epigenetic mechanisms 
Methylation has been a focus in the attempts to understand the mechanisms of 
imprinting. However, as suggested by the association of differential methylation 
with binding of the CTCF protein in the H19 DMR (a full explanation of this is given 
later in 1.2.1.1.3), the role of methylation may be to determine the chromatin 
structure. Thus, chromatin structure may be the element that controls the 
monoallelic expression, whereas methylation may be the underlying imprint that 
determines the establishment of local chromatin structure. 
Analysis of chromatin structure has utilised the DNaseI footprinting techniques. 
Hark and Tilghman (Hark, Tilghman 1998) identified hypersensitive sites that were 
specific to the unmethylated maternal H19 allele. Similarly, Feil et al. (Feil et al. 
1997) detected hypersensitive sites on the unmethylated paternal allele of the U2afl - 
rs1 gene, but not on the methylated maternal allele. Both studies suggest that the 
differential methylation of the two parental alleles may act to allow or prevent 
binding of non -histone proteins, which determine the chromatin organisation. Along 
these lines, Watanabe et al. (Watanabe et al. 2000) correlated imprinting with 
differential chromatin packaging. They showed that the chromatin of the non- 
transcribed allele of Igf2r was packaged more compactly than in the transcribed 
allele, whereas this difference was not found in the case of a nearby non -imprinted 
gene, Sod2. 
Changes in chromatin packaging may determine which alleles are transcribed. 
Additionally, it has been suggested that the binding of proteins to DMRs, and the 
specialised chromatin structure may protect the unmethylated allele of imprinted 
genes against de novo methylation, in a role of maintenance (Bird 1992). It might 
also be expected therefore, that the methylated allele might be protected against 
demethylation. Some studies have indicated that proteins that bind exclusively to 
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methylated DNA, e.g. MeCPs, may be involved. Indeed, the protein MeCP2 has 
been demonstrated to bind to methylated DNA, and recruit a multi -protein complex 
that includes histone deacetylases, which could have the effect of decreasing the 
levels of histone acetylation, thus altering the conformation of the chromatin towards 
a hypoacetylated, transcriptionally inaccessible state (Jones et al. 1998; Nan et al. 
1998). 
The emerging picture seems to indicate, therefore, that the imprinting mechanism 
may be a process that encompasses not only methylation, but also alterations in 
chromatin structure, directed by the actions of specific proteins. 
1.1.3 Evolution of imprinting 
It is clear that imprinting is required for normal development. The extent to which 
aberrant, defective or lost imprinting can cause disease will be discussed later in this 
chapter. However, the question remains as to why imprinting evolved initially, and 
why it is evolutionarily conserved in mammals and also in some plants. There is a 
significant cost to those organisms that imprint parts of their genome, because the 
protection against deleterious mutations granted by diploidy is lost. Imprinting 
renders the genome partly hemizygous, and since nearly all imprinted genes are 
known to have critical roles in development, the evolutionary benefits of imprinting 
must therefore outweigh the disadvantages of the vulnerability that is associated with 
hemizygosity. There must be a reason why mammals imprint a subset of their genes, 
and why this subset appears to include those with a critical developmental role, thus 
conveying an increased susce ptibility to disease, particularly cancer. 
1.1.3.1 Hypotheses to explain the evolution of imprinting 
To date, there have been several proposed hypotheses attempting to offer an 
explanation for the evolution of imprinting. These have included ideas suggesting 
that imprinting acts effectively as a speciation mechanism in mammals (Varmuza 
1993), as a host defence system to protect against invasion by the DNA of foreign 
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organisms (Barlow 1993), or as a surveillance mechanism allowing detection of 
chromosome loss (Thomas 1995). However, perhaps the two most convincing 
proposals are that imprinting arose as a means to protect females against 
trophoblastic disease (Varmuza, Mann 1994), or that it exists as a result of the 
different selection pressures, and thus competition, between the maternal and 
paternal genomes within the developing embryo (Moore, Haig 1991). These two 
hypotheses are discussed below. 
1.1.3.2 Imprinting as a mechanism of protection against trophoblastic 
disease 
One of the more feasible models proposes that imprinting may serve to limit the 
potential malignancy of ovarian germ cell tumours. It has been estimated that 25% 
of benign ovarian tumours that arise in humans are derived from parthenogenetically - 
activated oocytes (Varmuza, Mann 1994). These oocytes develop in situ, but have 
particularly undeveloped extra -embryonic tissues. The significance of this is that the 
trophoblast, by definition, has a role of invasion and vascularisation, and in the 
absence of imprinting of the genes responsible for trophoblast development, these 
tumours might possibly be more invasive, metastatic, and consequently more lethal. 
Varmuza and Mann (Varmuza, Mann 1994), propose that the selective pressure for 
maternal imprinting of these genes is therefore high, and offers protection to females 
against trophoblastic disease. The model has however attracted strong criticism, and 
has been challenged on the basis of several weak points (Solter 1994; Haig 1994; 
Moore 1994). Firstly, it does not offer a convincing evolutionary explanation for the 
imprinting of paternally derived genes, because it accounts only for the imprinting of 
genes that would act to restrain the development of the trophoblast, and suggests that 
only the maternal genome has a role in imprinting. Similarly, it does not rationalise 
the imprinting of genes that have any other function unrelated to trophoblast 
development. The authors account for both of these points by suggesting that some 
genes become imprinted through being `innocent bystanders', rather than requiring to 
be imprinted for a valid functional reason. This idea has not been generally 
accepted, because there is no explanation for the evolutionary maintenance of 
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imprinting in these genes. Additionally, it does not account for the existence of 
imprinting in any plants, yet imprinting has been observed in plant genes (Chaudhuri, 
Messing 1994). This model, whilst offering a novel idea to explain the evolution of 
imprinting, is perhaps not sufficiently robust to account for our current understanding 
of imprinting. 
1.1.3.3 The parental conflict hypothesis 
The most widely accepted hypothesis for the evolution of imprinting is the parental 
conflict model (Moore, Haig 1991). This model identifies the different selection 
pressures that operate on paternally and maternally derived alleles in an embryo, 
suggesting that they have conflicting interests, and are therefore in competition with 
each other. The model applies to any species in which multiple paternity is a 
possibility, because it is in the interests of the maternal genome to limit fetal growth 
in order to restrain the demands made on the maternal resources, such that the 
success of future pregnancies is protected. The paternal genome however, does not 
share these interests, and is not subject to selection pressures that benefit other 
fetuses. The paternal interests in a fetus are therefore selfish, to the cost of both the 
mother and future, paternally -unrelated offspring. The nature of the model therefore 
makes several predictions. Of greatest importance is that maternally expressed genes 
will be growth suppressing, and paternally expressed genes will be growth 
enhancing. The second prediction is that imprinting should be crucial in embryo 
development, but its effects are not expected to persist after weaning. Thirdly, the 
degree to which multiple paternity occurs in a species should be reflected in the 
`intensity' of imprinting (Hurst, McVean 1998), although evolutionary rates could 
affect this, and it may not be valid to make a judgement of the intensity of imprinting 
given that some species are evolving more rapidly than others. 
For many years the parental conflict model has been accepted as the most likely 
explanation for the evolution of imprinting. Early discoveries of imprinted genes 
were felt generally to support the model. In particular, in the mouse, the genes Igfl 
and Igor represent prime examples conforming to the conflict model. The paternally 
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expressed Igf2 gene encodes a growth factor, and functions to promote growth, 
whereas the oppositely imprinted maternally expressed gene Igf2r encodes a receptor 
for Igf2, and in effect is a suppressor of growth because it activates growth 
inhibitors, and targets Igf2 for lysosomal degradation (Hankins et al. 1996). In 
accordance with the parental conflict model, the functions of these reciprocally 
imprinted genes are antagonistic, or perhaps mutually interactive (Hurst, McVean 
1998). Additionally, the respective growth enhancing and growth suppressing 
properties of these genes are notably lost in a parent- specific way in transgenic 
knockout mice, with growth deficiency occurring in paternally Igf2- deleted mice, 
and fetal overgrowth occurring in the absence of maternal Igf2r (DeChiara et al. 
1991; Lau et al. 1994). However, it is now known that the equivalent human gene, 
IGF2R, is not imprinted. The conflict model has recently been critically reviewed 
(Hurst, McVean 1998), and the flaws are beginning to emerge. An increasing 
number of exceptions to the model are becoming apparent, in terms of genes that do 
not display the predicted effects in knockout experiments, such as Snrpn, which is 
paternally expressed, but shows no phenotypic consequences when an intragenic 
region is knocked out (Yang et al. 1998); and ZAC, which is the subject of Chapters 
4 and 5 of this thesis, and is a growth suppressor despite being paternally expressed. 
Post -weaning effects that contravene the predictions of the model are seen in the case 
of the paternally expressed gene Pegl /hest. Lefevbre et al. (Lefebvre et al. 1998) 
generated a disruption of the Mest gene in embryonic stem cells, and found that when 
transmitted paternally, the resulting Mest -deficient female offspring showed 
abnormal maternal behaviour in the care of their litter, including absence of 
placentophagia. This phenotype was the first demonstrated imprinting effect in 
adults, but the imprinting of a gene that affects adult behaviour is not predicted by 
the conflict model. Furthermore, the discovery of imprinting in the obligately selfing 
plant Arabidopsis thaliana is neither predicted nor accounted for by the model, 
because the reproductive nature of this species presents no selective difference 
between the paternal and maternal genomes (Hurst, McVean 1998). 
In summary, it would appear that whilst the predictions of the parental conflict model 
are fulfilled by the features of many imprinted genes, it cannot fully explain the 
13 
evolution of imprinting since there are several exceptions to the model. As 
suggested by Hurst and McVean (Hurst, McVean 1998), the acceptance of this 
model has been more due to the lack of a convincing alternative, than to the 
compelling nature of the model itself. 
1.2 IMPRINTED GENES 
There are now at least thirty known imprinted human genes, but estimates of the total 
number of imprinted genes suggest that the number could be as high as one or two 
hundred (Barlow 1995). Most of the known imprinted genes have been identified on 
the basis of the classic, diagnostic features of imprinting, namely monoallelic, 
parent -of- origin expression, and association with differentially methylated CpG -rich 
regions. A representative selection of imprinted genes is discussed below, in relation 
to some of the characteristic traits of imprinted genes, such as clustering in the 
genome, the involvement of regulatory imprinting centres, and the possible 
regulation of imprinting by antisense transcripts, in addition to some of the more 
unusual features, such as isoform -, promoter- and tissue -specific imprinting. 
1.2.1 Clustering of imprinted genes 
The clustering of imprinted genes has become recognised as a classic feature of 
imprinting, and as more genes are identified, the extent to which clustering occurs 
will become apparent. Currently, the majority of known imprinted genes are part of 
the two major clusters, at human chromosome 11 p 15.5, and 15q11-q13. However, 
there is at least one potential new cluster emerging from recent research on 
chromosome 7. The clustering of imprinted genes raises obvious questions about 
regional control and coordinate regulation, and about the evolution of such regions. 
The 11p15.5 cluster is discussed below. 
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1.2.1.1 Cluster at 11p15.5 
Perhaps the most intensively studied imprinted genes to date are those which reside 
in a cluster on human chromosome 11p15.5. This cluster, spanning a megabase, 
contains the first identified imprinted gene IGF2, along with at least ten other genes, 
of which the majority are imprinted. IGF2 itself has been well characterised, yet a 
complete picture of the regulation and maintenance of imprinting in this region 
remains elusive. 
1.2.1.1.1 Igf2, the first known imprinted gene 
Igf2 encodes a growth factor with a crucial role in embryonic growth. It is expressed 
in many tissues at high levels during development, and is thought to function in an 
autocrine /paracrine manner (DeChiara et al. 1991). Igf2 was the first known 
imprinted gene in mouse; imprinting was demonstrated through a series of transgenic 
experiments in which the major observation was that transmission of a null 1gf2 
mutation through the paternal germline resulted in growth deficient heterozygous 
progeny, whereas transmission of the same mutation through the maternal germline 
resulted in phenotypically normal mice (DeChiara et al. 1991). This result indicates 
that only the paternally inherited copy of Igf2 is functionally active. Additional 
evidence for parental imprinting of Igf2 from this study was apparent in the fact that 
homozygous mutant mice (carrying the deletion on both chromosomes) and 
heterozygous Igf2 mutants (in which the deletion had been inherited paternally) were 
phenotypically indistinguishable. DeChiara et al. also demonstrated switching of the 
imprint through the germline in successive generations by mating each type of 
heterozygote (i.e. those with the paternally- derived deletion, and those with the 
maternally -derived deletion) with wild type siblings. Given that allele switching is a 
key requirement of imprinting, these experiments provided indisputable evidence for 
the imprinting of Igf2. 
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1.2.1.1.2 IGF2 and H19 are reciprocally imprinted 
In humans, IGF2 is closely linked to the H19 gene on chromosome 11 p15.5. H19 
itself encodes an untranslated RNA. The suggestion that the genes may be 
coordinately regulated came from the observations that they lie in close proximity to 
each other, and are reciprocally imprinted - IGF2 is paternally expressed, and 
maternally silenced, whilst H19 is maternally expressed and paternally silenced 
(Mutter et al. 1993). 
1.2.1.1.3 Proposed mechanisms for imprinting regulation of IGF2 and H19 
The characteristic clustering of imprinted genes implies that regulation of imprinting 
may, in some cases, be controlled by common, regionally acting elements. In the 
case of IGF2 and H19, which are reciprocally imprinted, a model was proposed 
which suggests that these two genes compete for the action of the enhancers which 
lie downstream of H19 (Leighton et al. 1996). By the enhancer competition model, 
the H19 gene on the maternal chromosome has exclusive use of these enhancers, 
either because of its closer proximity than IGF2, or because of the H19 promoter 
having some advantage in enhancer preference over IGF2. Either way, the maternal 
H19 gene monopolises the enhancers, and the outcompeted maternal IGF2 gene 
remains silent. On the paternal chromosome however, the allele -specific methylation 
of H19 silences this copy, such that the competition from H19 is eliminated, and the 
upstream gene IGF2 is therefore granted exclusive use of the enhancers (Schmidt et 
al. 1999). 
The enhancer competition model was widely accepted as a potential mechanism for 
regulating the imprinting of IGF2 and H19, and several experiments have provided 
substantiating evidence (Leighton et al. 1995). However, more recently, 
experimental evidence has failed to fulfill the predictions of the enhancer 
competition model, and has brought to light the possibility that imprinting regulation 
may occur by an alternative mechanism. The evidence against the enhancer 
competition model lies in the results of experiments by Schmidt et al. (Schmidt et al. 
1999), in which they generated a deletion of the H19 promoter. The enhancer 
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competition model predicts that the outcome of the resulting loss of H19 
transcription (and elimination of the competition) would cause transcription of the 
previously silent maternal IGF2 allele. This prediction was not fulfilled, as the 
imprinting of the IGF2 gene was not affected by the deletion. If transcription from 
the H19 promoter is not the factor that prevents transcription of IGF2, then another 
mechanism of imprinting regulation must be involved (Schmidt et al. 1999). 
Recent research has established an alternative model, which is becoming increasingly 
favoured over the original enhancer competition model. The model proposes that 
`insulator' elements located in the imprinting control region between H19 and IGF2, 
act to delimit the boundaries between transcriptionally active euchromatin, and 
inactive heterochromatin (Wolffe 2000). The central concept of the model is that the 
DNA binding protein CTCF recognises and binds to the 21bp CpG -rich insulator 
sequences via a domain comprising 11 zinc fingers, to prevent activation of upstream 
IGF2 by the enhancers located downstream of H19. The most crucial aspect of the 
model is that the binding of CTCF is dependent on the sequence being unmethylated. 
Thus, on the maternal chromosome, which is unmethylated at this region, CTCF 
binds, and insulates IGF2, preventing enhancer access, and effectively silencing the 
gene, whilst H19 remains active. Conversely, on the paternal chromosome, which is 
methylated at this region, CTCF is unable to bind, so IGF2 has full access to the 
downstream enhancers. The methylation on the paternal chromosome extends to 
encompass the H19 promoter region and part of the gene, and this directly represses 
transcription. Through DNA footprinting experiments, Szabo et al. (Szabo et al. 
2000) demonstrated the methylation- sensitive nature of CTCF binding in vivo; DNA 
footprints representing the presence of bound protein were identified on the 
unmethylated maternal chromosome at all four 21bp repeat sequences in the 
imprinting control region between H19 and IGF2, but were not detected on the 
paternal chromosome. Similarly, Bell and Felsenfeld (Bell, Felsenfeld 2000) and 
Hark et al. (Hark et al. 2000) found evidence in vitro that CTCF was bound to all 
four insulator sites on the maternal chromosome, but when the chromosome was 
methylated prior to the assay, no CTCF binding was detected. Using gel shift assays 
and chromatin immunopurification analyses, Kanduri et al. (Kanduri et al. 2000) 
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contributed additional evidence to confirm that binding of the CTCF is methylation- 
sensitive and specific to the parental origin of the chromosome. The evidence 
accumulating from all of these studies is convincing, and indicates that CpG 
methylation in this region (as found on the paternal chromosome) can directly inhibit 
the binding of the CTCF protein. Interestingly, an earlier study (Thorvaldsen et al. 
1998) had shown that maternal inheritance of a deletion of this region resulted in 
activation of the IGF2 gene and downregulation of H19 expression; an explanation 
for this is now apparent on the basis of these more recent findings, in that the 
deletion likely eliminated the insulator, preventing CTCF binding, and permitting 
activation of IGF2 by the enhancers. 
The precise action of the insulator, and its association with CTCF is still under 
scrutiny, but possibilities are that the insulator element determines the boundaries 
between transcriptionally active euchromatin, and inactive heterochromatin, or that it 
retargets or binds the transcription factors that are required for gene regulation 
(Wolffe 2000). The model itself may be more complex still, in that newly described 
tissue -specific `silencer' elements may have a role in the repression of IGF2 and 
H19, depending on the parental origin of the chromosome on which they reside 
(Ferguson -Smith 2000). Drewell et al. (Drewell et al. 2000) showed that deletion of 
a silencer element upstream of H19 on the paternal chromosome resulted in 
activation of H19, without any effect on the insulator element or the expression of 
the IGF2 gene. Clearly, our understanding of the regulation of this region is far from 
complete, but is being deciphered piece by piece. Figure 1 illustrates the enhancer 










Figure 1. Proposed models for the regulation of imprinting at H19 /IGF2. a) The enhancer 
competition model. H19 and IGF2 compete for the enhancers (large black circles) downstream of 
H19. Methylation (small grey circles) on the paternal chromosome prevents transcription of H19, 
allowing IGF2 to use the enhancers. The maternal chromosome is unmethylated, so H19 has full use 
of the enhancers. The expressed genes are shown by shaded rectangles; silenced genes are shown by 
open rectangles. 
b) The insulator model. The CTCF protein (grey diamonds) binds to the unmethylated maternal 
chromosome, blocking access of enhancers to IGF2, so only H19 is expressed. On the paternal 
chromosome, CTCF is prevented from binding because of methylation of the insulator sequence, so 
the enhancers can activate IGF2. Transcription of HI9 from this chromosome is prevented by 
methylation of the promoter. 
Adapted from Maher et al. (2000) and Szabo et al. (2000). Not to scale. 
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1.2.1.1.4 Other genes, both imprinted and non -imprinted within the 11p15.5 
cluster 
The concepts of reciprocal imprinting and communal regulation of the genes IGF2 
and H19 have commanded the focus of most of the research to date, yet the 
imprinted cluster at 11 p15.5 also contains the genes TSSC3, TSSC5, CDKN1 C 
(p57KJP2)5 KCNQ1 (KvLQT1), TSSC4, TAPA1, TSSC6, ASCL2, and INS. Exclusively 
maternal expression has been demonstrated in the majority of these genes in the 
human, but TSSC4 and TSSC6 show a biallelic expression pattern, and thus represent 
non -imprinted genes within a predominantly imprinted cluster (Lee et al. 1999a). 
The gene CDKN1 C encodes a cyclin dependent kinase inhibitor, which is a negative 
regulator of cell proliferation. Overexpression of this gene causes cells to arrest in 
the G1 phase of the cell cycle. This gene was found to be imprinted; it is maternally 
expressed in both mouse (Hatada, Mukai 1995), and human (Matsuoka et al. 1996). 
KCNQ1 encodes a potassium channel, and lies within the 700kb interval between 
CDKN1 C and H191 IGF2 KCNQ1 is subject to imprinting, being maternally 








































































































































































































































































1.2.1.1.5 Beckwith -Wiedemann Syndrome (BWS) is associated with 
aberrant imprinting of one or more genes in this cluster 
Whilst much of the investigation of this imprinted gene cluster has focussed on the 
regulation and maintenance of the imprinted genes under normal circumstances, the 
study of aberrant imprinting and deregulation of this cluster, and the consequential 
outcomes can be informative not only in understanding the resulting diseases, but 
also in understanding more about the normal control of imprinting. 
Beckwith -Wiedemann syndrome is a disease characterised by prenatal overgrowth, 
macroglossia, organomegaly, hypoglycemia, and a predisposition to cancer, 
particularly the embryonal tumour Wilms' tumour (Reik, Maher 1997). The 
inheritance patterns in familial BWS, and the presence of uniparental disomy and 
duplications of chromosome 11 that occur in some cases, are suggestive of an 
imprinting effect (Henry et al. 1991; Reik et al. 1994). 
It is now apparent that BWS can arise through several different mechanisms, some of 
which are alternative routes to the same genetic outcome, and some of which are 
unique. The main mechanisms are: paternal uniparental disomy for chromosome 11, 
paternal duplications of a region at l 1p15.5, loss of imprinting at IGF2 independent 
of structural chromosomal abnormalities, maternally -inherited mutations of 
CDKN1 C, and maternal chromosomal rearrangements (Li et al. 1997; Reik, Maher 
1997). Of these genetic events, the first three (paternal UPD 11, paternal duplications 
and LOI at IGF2) have a common outcome in that they all lead to biallelic 
expression of the paternally- expressed IGF2 gene, which could therefore have a 
significant causative effect. In 40% of familial BWS cases, the only identifiable 
genetic alteration is maternal mutation of the more centromeric gene CDKN1 C, 
which represents a cause of BWS that operates independently of any IGF2 
involvement. Maternal chromosomal rearrangements are infrequent, but represent an 
additional causative mechanism of BWS that probably acts through disruption of 
imprinting in the region. 
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Loss of imprinting (LOI) of IGF2, and the resulting biallelic expression is the 
leading cause of sporadic BWS cases. It has been shown that LOI of IGF2 can occur 
either in conjunction with H19 hypermethylation, or conversely, completely 
independently of changes in H19 methylation (Joyce et al. 1997). This discovery, in 
addition to the fact that imprinting of KCNQ1 and CDKN1 C is unaffected by 
deletions of H19 (Caspary et al. 1998), is indicative of two separate, independent 
imprinting control centres in this cluster. A study by Smilinich et al. (Smilinich et al. 
1999) has identified an antisense transcript, KCNQIOTI (LIT]), which may be the 
key to the function of the second, H19- independent control centre. KCNQIOTI is 
located in an intronic region of the KCNQ1 gene, and is associated with a maternally 
methylated CpG island, and expressed exclusively from the paternal allele (Mitsuya 
et al. 1999). 
In accordance with these ideas, it seems that BWS may be caused by mutations in 
either of these imprinting control regions. Mutations in the first control centre are 
associated with hypermethylation of the H19 DMR, resulting in LOI and biallelic 
expression of IGF2. In these cases there is normal, maternal- specific methylation of 
the KCNQIOTI CpG island. In contrast, cases in which the second putative 
imprinting control centre is involved display normal methylation patterns at H19, 
may have LOI and biallelic expression of IGF2, but are also accompanied by a loss 
of methylation at KCNQIOTÌ that would be predicted to result in biallelic 
expression of this antisense transcript (Smilinich et al. 1999). It is clear from all of 
these results that there are two distinct imprinting centres. However, the second 
imprinting control centre, which is strongly associated with the demethylation of the 
KCNQIOTI CpG island within KCNQ1, is less well understood than the H191IGF2 
imprinting centre. In particular, there remains some confusion about whether the 
LOI at the KCNQ1 CpG island, and the resulting biallelic KCNQIOTI expression, 
are associated with LOI of downstream IGF2. Smilinich et al. had initially proposed 
the ideas regarding this imprinting control centre as an H19- independent mechanism 
of IGF2 LOI because they identified two distinct groups of BWS patients: those with 
H19 hypermethylation but normal KCNQ1 imprinting; and those with normal H19 
imprinting, but LOI at the CpG island within KCNQI. In both categories the patients 
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had biallelic IGF2 expression. However, Lee et al. (Lee et al. 1999b) and Mitsuya et 
al. (Mitsuya et al. 1999) found LOI of KCNQIOTI in BWS, but did not find an 
association with biallelic IGF2 expression. 
Important goals now include the elucidation of the mechanisms by which mutations 
in each of these imprinting centres can cause BWS, especially in the case of the 
putative KCNQI- associated centre, which on present evidence may cause BWS 
independently of biallelic IGF2 expression. 
1.2.1.1.6 KCNQ1 carries a gametic imprint mark 
The evidence that has emerged from the study of BWS patients has suggested that 
two independent imprinting centres control the imprinting of genes in this cluster. 
The first of these domains includes the H19 /IGF2 cluster. The second, proposed by 
Smilinich et al. ( Smilinich et al. 1999) includes the KCNQI gene and its associated 
antisense transcript. A comprehensive study by Engemann et al. (Engemann et al. 
2000), in which they compared the mouse and human sequences in the region of the 
putative second imprinting control centre, offered new insights into the cluster's 
overall regulation. The 1 Mb imprinted region is divided into two separate domains 
by an interval that is predominantly non -imprinted. This region contains the genes 
LTRPC5 to TSSC6, of which most are biallelically expressed. Of note, however, is 
that this region displays differences between human and mouse - imprinting is not as 
well conserved in this region as it is in other parts of 11p15.5, since LTRPC5 is 
imprinted in human but biallelic in mouse, whereas TSSC4 shows tissue -specific 
imprinting in mouse but is biallelic in human. However, Engemann's sequence 
comparison of this region revealed strong conservation of gene order and 
transcriptional orientation between the two species. A site of particularly strong 
conservation was identified in the 3' region of the KCNQI gene, including the 
intronic sequences and the antisense transcript. Such an unusually high degree of 
similarity between mouse and human implies that this region may have a crucial role 
in regulation. Engemann et al. pursued this hypothesis in the mouse and 
demonstrated that the CpG island associated with the Kcnql antisense transcript 
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(Kcngl otl) was significantly methylated in oocytes, and unmethylated in sperm. 
These epigenetic differences were maintained in zygotes and embryonic stem cells, 
indicating that this CpG island has a germline methylation imprint. The only other 
known germline imprint mark in this region is at the H19 DMR, and thus it appears 
almost certain that the KCNQIOTI CpG island has a pivotal role in the second 
imprinting control centre. 
1.2.1.1.7 Summary 
In summary, this cluster of imprinted genes is a model exemplifying some of the 
imprinting control mechanisms that exist in humans. The reciprocal imprinting of 
maternally expressed H19 and paternally expressed IGF2 appears to be regulated by 
a form of enhancer competition, with a `switch' mechanism involving the activity of 
a methylation- sensitive insulator or boundary element. Biallelic expression of IGF2, 
through loss of imprinting, causes BWS, and may occur by two separate pathways, 
either in conjunction with H19 hypermethylation, or completely independently of it, 
with accompanying loss of methylation of KCNQI and biallelic expression of an 
antisense transcript, KCNQI OT1, in the latter. Thus, by studying the breakdown of 
imprinting control in a disease such as BWS, at least two different mechanisms of 
IGF2 imprinting regulation have been elucidated. BWS is also caused in a 
significant proportion of cases by mutations of the gene CDKN1 C. The fact that 
BWS can arise as a result of aberrations of two distinct genes (IGF2 and CDKN1 C), 
yet cases in each of these two categories are indistinguishable, implies that these 
genes may act in a common pathway. Evidence to support this idea has emerged 
recently, first from a double knockout mouse deficient in CDKN1 C and 
overexpressing IGF2, which indicated that the products of these genes may interact 
antagonistically in cell proliferation (Caspary et al. 1999); and second, from the 
experiments of Grandjean et al. (Grandjean et al. 2000), in which increased levels of 
IGF2 protein have been correlated both in vitro and in vivo to a decrease in CDKN1 C 
expression. Future research may clarify these interactions, and reveal new insights 
into the causative mechanisms of BWS. 
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1.2.1.2 Other clusters in the human genome 
There is one other known major imprinted gene cluster in the human genome, at 
15q11-q13. This is discussed in 1.2.2.1, in the context of imprinting centre control, 
as it represents the best example of this feature. However, it is likely that there are 
other clusters that are as yet unidentified, and one potential candidate may be a 
cluster at the PEGI /MEST locus on chromosome 7. 
1.2.1.2.1 Possible cluster at 7q32 
The first identified imprinted gene on human chromosome 7 was the predominantly 
paternally expressed gene PEGI /MEST (Kobayashi et al. 1997; Riesewijk et al. 
1997), which is discussed further below in 1.2.3.3, in the context of its recently 
demonstrated isoform- specific imprinting. To investigate whether this gene is in fact 
part of a new cluster of imprinted genes on this chromosome, exon- trapping 
experiments were employed to assess the surrounding region (Blagitko et al. 1999). 
Unknown exons were detected, and subsequently found to form part of a novel gene, 
COPG2 (coatomer protein complex subunit), which encodes a protein with 
homology to bovine y -COP. The gene structure was elucidated, and its relationship 
to the adjacent gene PEGI /MEST was determined. The two genes are orientated in a 
tail -to -tail manner, with an overlap of 52bp at the 3' utr of both genes. 
Using an intronic polymorphism in intron 22, Blagitko et al. performed imprinting 
analysis of COPG2 by RT -PCR, which revealed monoallelic expression in almost all 
fetal tissues, except brain and liver (Blagitko et al. 1999). In those tissues subject to 
imprinting, expression of the gene was determined to be exclusively paternal, as in 
PEGI /MEST. The finding of this imprinted gene in the vicinity of another imprinted 
gene thus appeared to define a new cluster of imprinted genes. Subsequent to the 
study of Blagitko et al., however, an independent study has claimed that expression 
of COPG2 is biallelic (Yamasaki et al. 2000). Yamasaki et al. demonstrated biallelic 
expression of the gene in fetal tissues and adult lymphocytes using a single 
nucleotide polymorphism located in exon 17. In addition, they offer an explanation 
for the discrepancy between their study, and the previous study of Blagitko et al.; 
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they identified additional 3' utr sequence for MEST, which extends the overlap of the 
two genes to include the last four exons and introns of COPG2, rather than just the 
previously described 52óp overlap. If this is the case, then, as they propose, the 
imprinting analysis of Blagitko et al. may have been complicated by the overlapping 
origin of the transcripts that were analysed. Indeed, Yamasaki et al. demonstrated in 
their study that the RT -PCR products of Blagitko's experiment were most likely to 
have been predominantly derived from MEST, such that their conclusions of 
monoallelic expression were representative of MEST rather than COPG2. 
However, despite the probable biallelic expression of the COPG2 gene, this region 
remains a potential imprinted domain, since Yamasaki et al. identified CITI , an 
antisense transcript of COPG2 intron 20 that was paternally expressed in fetal brain, 
liver and lung, but not adult lymphocytes. 
1.2.2 Imprinting centres may control the switching of 
imprints in the germline 
From studies of the cluster of imprinted genes at 11p15.5, and experimental data 
from investigations of imprinting mechanisms in germline development, it is 
apparent that the control of imprinting is to some extent due to the action of 
imprinting centres. The concept of a regionally acting element with the capacity to 
influence the imprinting of a chromosomal domain certainly gives some explanation 
as to why imprinted genes typically reside in clusters. Elucidating the role of such 
imprinting centres is currently a popular aspect of imprinting research, and perhaps 
the most significant progress has been made in analysing the cluster of imprinted 
genes at 15q11-q13. 
1.2.2.1 Cluster of genes at 15g11 -q13 may be under the control of an 
imprinting centre 
Along with the cluster at 11p15.5 (see 1.2.1.1), the other most extensively studied 
cluster of imprinted genes is that at 15g11 -q13. Aberrations or loss of imprinted 
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genes in this region are associated with the diseases Angelman syndrome and Prader- 
Willi syndrome. There is strong evidence that this cluster is regulated by the action 
of an imprinting centre, and this represents a prime example of the function of 
imprinting centres. 
1.2.2.1.1 Deficiencies of imprinted gene(s) in a cluster at 15q11-q13 
implicated in Angelman Syndrome and Prader -Willi Syndrome 
The identification of imprinted genes has in many cases only occurred through the 
detection of abnormal inheritance patterns of a disease, and the subsequent 
localisation of the genes responsible. This was the case for the discovery of the 
imprinted gene cluster at 15q11-q13, which was identified through chromosomal 
analysis of patients with Angelman Syndrome (AS) and Prader -Willi syndrome 
(PWS) (Williams et al. 1990; Magenis et al. 1990). Angelman syndrome is 
characterised by severe developmental delay and ataxia, whereas Prader -Willi 
syndrome is a neuro- behavioural disorder characterised by neonatal hypotonia, 
developmental delay and hyperphagia (Lee, Wevrick 2000). Both diseases occur at a 
frequency of 1 in 15000 live births, and both are associated with large deletions of a 
region of chromosome 15q11-q13 in 70% of cases, but the origin of these deletions is 
consistently paternal in PWS and maternal in AS (Knoll et al. 1989). The exclusive, 
parent -specific inheritance associated with each disease suggests that a deficiency of 
at least one gene subject to genomic imprinting may be the underlying cause of each 
disease (Nicholls 1993). 
In support of this idea, nearly all non -deletion cases of PWS are associated with 
maternal uniparental disomy for chromosome 15, and likewise, a smaller, yet still 
significant proportion (3 -5 %) of AS cases are associated with paternal uniparental 
disomy for chromosome 15 (Knoll et al. 1991). The parental origin of both deletions 
and uniparental disomy thus indicates that the absence of a paternally expressed 
imprinted gene(s) causes PWS, whereas the reciprocal situation of the lack of a 
maternally expressed imprinted gene(s) leads to AS. 
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1.2.2.1.2 Imprinting of genes in the 15q11-q13 cluster 
Characterisation and correlation of the breakpoints flanking the deletions in PWS and 
AS patients has defined a common region of deletion, spanning approximately 4 
megabases. Several genes reside in this region, namely a zinc -finger protein, 
ZNF127; the gene encoding the small nuclear ribonucleoprotein -associated 
polypeptide N, SNRPN (Ozcelik et al. 1992); necdin (NDN) (MacDonald, Wevrick 
1997; Jay et al. 1997); and IPW, although this gene does not appear to have any 
coding capacity (Wevrick et al. 1994). These four genes are paternally expressed 
and silent on the maternally inherited allele. A further gene, UBE3A, which encodes 
a ubiquitin -protein ligase (Sutcliffe et al. 1997), is partially imprinted, being 
biallelically expressed in most tissues, but maternally expressed in brain (Vu, 
Hoffman 1997; Rougeulle et al. 1997). Three GABAA receptor genes also reside in 
this interval, but the imprinting of these has either not been established, or the 
evidence for imprinting is contradictory. 
UBE3A has been proposed as a candidate gene for AS, since inactivating mutations 
have been found in this gene in patients with no other abnormality at this region (i.e. 
non -deletion/ non -UPD patients) (Matsuura et al. 1997; Kishino et al. 1997). For 
AS, at least, a loss of this single gene may be sufficient in itself to cause the disease. 
For PWS however, it is not clear whether a single locus, or the involvement of 
multiple genes is responsible for the phenotype. Of these two scenarios, there is 
stronger evidence that PWS is a contiguous gene syndrome, because no mutations 
have been identified that affect the expression of only one of the four paternally 
expressed genes in this region. It is more likely therefore that several of these genes 
must be disrupted for the condition to arise (Lee, Wevrick 2000). The identification 
of novel transcripts in this region of 15g11 -q13 indicates the strong possibility of 
additional genes residing here (Lee, Wevrick 2000). Furthermore, a novel imprinted 
gene in the PWS region, named NDNL1 (NDN -like 1)1 MAGEL2 has recently been 
characterised, and on the basis that it is expressed predominantly in the brain, and 
shows paternal- specific expression, it must be investigated as a further candidate 
gene for PWS (Boccaccio et al. 1999; Lee et al. 2000). 
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1.2.2.1.3 Regulation of imprinting at 15q11-q13 is mediated through an 
imprinting centre (IC), of which mutations are a novel cause of AS and PWS 
The imprinted cluster at 15g11 -q13 is subject to a tightly maintained methylation 
pattern such that the maternal chromosome is predominantly methylated, and the 
paternal chromosome which expresses most of the genes, is unmethylated. Recently, 
a new subgroup of PWS and AS patients has indicated that disruptions to the 
establishment of this pattern may be an alternative cause of the diseases. This 
subgroup of patients does not carry the common 4 Mb deletions, nor do they have 
uniparental disomy. In fact, at the genetic level they have apparently normal, 
biparental inheritance of chromosome 15. However, at the epigenetic level, they are 
found to possess either a typical maternal methylated pattern on both chromosomes 
(in PWS), or a typical paternal unmethylated pattern on both chromosomes (in AS) 
(Buiting et al. 1995; Sutcliffe et al. 1994). In functional terms, the outcome of this is 
presumably comparable to having maternal or paternal uniparental disomy, 
respectively, and the expression pattern of the imprinted genes in this region reflects 
this. 
Based on this finding, it was postulated that an imprinting centre might control the 
resetting and necessary switching of the parental imprint of each chromosome during 
gametogenesis. The subset of patients described above is now known to have 
microdeletions in the 5' region of the SNRPN gene, which is now proposed as the 
imprinting centre (IC). It is possible that mutations of the imprinting centre, in the 
form of microdeletions, prevent the imprint of a chromosome being reset during 
gametogenesis. Such mutations can therefore remain phenotypically silent for 
several generations, but will become phenotypically apparent when the sex of the 
transmitting individual changes. For example, if a female individual carries an 
imprinting mutation of the IC, which prevents the switching of the maternal imprint 
to a paternal imprint, this mutation will be passed on silently through the female 
germline. However, if she passes this mutation to her son, the maternal imprint 
cannot now be reset to a paternal one during spermatogenesis, and his resulting 
offspring will have a 50% chance of inheriting the chromosome that carries an 
eternally maternal imprint. Thus, these offspring, regardless of their sex, would 
30 
carry two copies of chromosome 15 both with a maternal imprint, and would have 
PWS. A similar but reciprocal situation would cause AS in the case of an individual 
with an imprinting mutation that prevents the switching of a paternal imprint to a 
maternal one. This would be passed silently through the male germline until the 
transmitting individual is female, at which point her offspring have a 50% chance of 
inheriting the mutation which will leave them with two paternally imprinted copies 
of chromosome 15, resulting in AS (Ohta et al. 1999). 
Analysis of the extent of the microdeletions in several individual cases of PWS and 
AS IC mutations indicates that the imprinting centre at 15q11-q13 actually comprises 
two parts, which are separately responsible for the switching of the male or female 
germline imprints. The deletion mapping studies have placed the bipartite IC at the 
promoter region of SNRPN. Since it acts on genes both upstream and downstream of 
this locus, it has the ability to control imprinting regulation in cis, and in a 
bidirectional manner. The most recent addition to these established ideas is a 
suggestion that the imprinting centre has a further role of maintenance of the imprint 
in somatic cells (Mann, Bartolomei 2000; Bielinska et al. 2000). This is a novel 
concept, proposing that the imprinting centre is not required solely for germline 
establishment of the imprint, but is also crucial in the postzygotic maintenance of the 
epigenotype. 
Full elucidation of the mechanisms of the action of this imprinting centre is yet to be 
completed, but the demonstration of a controlling element such as the IC in this 
cluster suggests new ideas about imprinting regulation that may well be applicable to 
the other imprinted clusters of the human genome, both those that are known, and 
potentially other as yet unidentified clusters. 
1.2.3 Tissue -specific, promoter- specific, and isoform- specific 
imprinting 
Most imprinted genes have been found to conform to an established pattern of 
imprinting, which is most often consistent with that found in the homologous mouse 
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gene. However, as imprinting research delves further into the finer details of 
imprinting regulation and mechanisms for specific genes, an increasing number of 
genes have been found to show some degree of tissue -specific or time -specific 
imprinting. This temporal and spatial variation in imprinting is accompanied by 
variation between mouse and human, to the extent that not all genes follow the same 
pattern in both species. The two most notable examples of imprinted genes that 
show complex isoform or promoter -specific imprinting patterns, including 
bidirectional imprinting within the same gene, are GNAS1, which has been well 
characterised, and GRBIO, for which the evidence is less well established, and even 
contradictory. Both are discussed below, along with the genes IGF2 and 
PEGI /MEST, which may also show promoter or isoform- specific imprinting 
patterns. 
1.2.3.1 GNAS1 
GNAS1, located at human chromosome 20g13.11, is a prime example of a gene 
showing complex promoter -specific imprinting patterns. The gene encodes the a 
subunit of the G protein (Gsa), which functions to couple receptor binding by a 
variety of hormones, to cAMP generation (Kozasa et al. 1988). 
1.2.3.1.1 Association with PHP -Ia 
Null mutations of GNASI give rise to various phenotypes, most usually causing the 
hormone -resistance syndrome type Ia pseudohypoparathyroidism (PHP -Ia) (Levine 
et al. 1988). In addition to hormone resistance, this condition is associated with a 
50% reduction in erythrocyte Gs activity and a skeletal abnormality known as 
Albright hereditary osteodystrophy (Levine et al. 1986). A milder form of the 
disease, in which patients have most of the symptoms of PHP -Ia, but do not suffer 
hormone resistance, is known as pseudopseudohypoparathyroidism (PPHP). 
The possible involvement of imprinting in this disease was suggested by the familial 
occurrence of PHP -Ia and PPHP within the same families. Indeed, a study of the 
32 
inheritance patterns of GNAS1 mutations revealed that PHP -Ia was consistently the 
result of a maternal transmission, whereas PPHP was always associated with a 
paternal transmission (Davies, Hughes 1993). 
1.2.3.1.2 Biallelic and paternally- derived transcripts, Gsa, and XLas 
At first, biallelic expression of GNAS1 was found to be prevalent in many tissues 
(Campbell et al. 1994). However, the discovery of a novel, alternative promoter and 
first exon of GNAS1, 35kb upstream of the original first exon, identified an 
alternative transcript that encodes the large G protein XLas, and is expressed 
exclusively from the paternally derived allele (Hayward et al. 1998a). 
1.2.3.1.3 A maternally derived transcript, NESP55 
The discovery of both biallelic and paternally derived transcripts confirmed the idea 
that GNAS1 is subject to an imprinting effect, but did not fulfill the predictions of the 
consistently maternal inheritance of PHP -Ia, which suggest the involvement of a 
maternally expressed gene. However, further searches at the GNAS1 locus revealed 
the presence of an alternative promoter and first exon, 11 kb upstream of the XLas 
promoter (Hayward et al. 1998b). This component gives rise to a transcript that, like 
XLas, splices onto GNAS1 exon 2, yet the resulting proteins for each promoter are 
structurally unrelated. The novel 5' exon gives rise to a transcript that is maternally 
expressed, and encodes a neuroendocrine secretory granule protein NESP55. 
1.2.3.1.4 Complex splicing and imprinting patterns of GNAS1 
The imprinting of GNAS1 is not simple. As described above, the gene comprises 
biallelic, paternally and maternally expressed variants, in which the nature of 
imprinting is determined by the use of independent promoters and alternative 
splicing arrangements. There are several other complexities to the GNAS1 situation 
that are not discussed here, including further splicing variations and exon skipping 
events that yield a multitude of different isoforms, and the existence of a fourth 
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potentially imprinted alternative promoter (exon 1A) (Liu et al. 2000a). 
Additionally, an antisense transcript (discussed in 1.2.4) may be involved in 
imprinting regulation (Hayward, Bonthron 2000; Wroe et al. 2000). See Figure 3. 
1.2.3.2 PEG1/MEST 
The mouse Pegl gene had been isolated in a subtractive hybridisation screen for 
novel paternally expressed genes (Kaneko -Ishino et al. 1995), and was found to be 
identical to the previously identified gene Mest, the protein product of which shows 
homology to the alph/beta- hydrolase fold family, and is expressed most abundantly 
in the early embryo (Nishita et al. 1996). The human homologue, PEGI /MEST, has 
been located at the equivalent human chromosomal region of 7g31.3, and found to be 
imprinted, as discussed below. 
1.2.3.2.1 Imprinting of PEGI /MEST 
On the basis that imprinting is generally conserved between mouse and human, 
establishing the imprinting status of the human PEG] /MEST was a natural area for 
research, particularly as no imprinted genes were as yet known to reside on this 
chromosome. Two groups demonstrated predominantly monoallelic, paternal 
expression of PEGI /MEST (Kobayashi et al. 1997; Riesewijk et al. 1997), and 
another investigated the methylation status of the PEGI promoter and found parent - 
specific methylation, with the paternal allele consistently unmethylated, and the 
maternal allele consistently methylated (Lefebvre et al. 1997). 
Although the majority of the imprinting experiments indicated that PEGI /MEST 
follows a strict pattern of paternal monoallelic expression, accompanied by maternal 
methylation of the promoter, one exception to this consensus was detected by 
Riesewijk et al. (Riesewijk et al. 1997), who found biallelic expression of the gene in 
adult lymphocytes. This observation was substantiated by the same group, through 
the detection of PEGI /MEST transcripts in a lymphoblastoid cell line with maternal 
uniparental disomy for chromosome 7. The lack of any paternal chromosome 7 
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contribution in this cell line demands that any expression of the gene must therefore 
be maternally derived. 
1.2.3.2.2 Isoform- specific imprinting of PEGI /MESI 
The discovery of apparently biallelic expression of PEGI /MEST in lymphocytes 
(Riesewijk et al. 1997) has prompted further investigation of the mechanisms that 
cause this loss of imprinting in some tissues. Kosaki et al. (Kosaki et al. 2000) 
assembled ESTs for the 5' region of PEG /MEST, and identified a subgroup that 
included a novel first exon. Indeed, analysis of the genomic region confirmed that an 
alternative first exon, named exon A, was located 6kb upstream of the original exon 
1. Alternative splicing of these two exons onto the remaining exons creates two 
different splice variants of the gene. See Figure 3. The most significant finding is 
that the newly identified isoform of this gene is subject to biallelic rather than 
monoallelic expression. Interestingly therefore, it is not the supposed loss of 
imprinting of the gene in lymphocytes that causes biallelic expression. Rather, it is 
the fact that lymphocytes express both isoforms of this gene, one of which is 
paternally expressed, and the other biallelically expressed. The previous 
experiments, not taking account of this fact, drew their conclusions from RT -PCR 
experiments using primers that were not able to discriminate between isoforms. The 
paternal, monoallelic expression of the original isoform was therefore masked by the 
biallelic expression of the novel isoform in Riesewijk's study. 
What was previously assumed to represent tissue -specific imprinting of PEGI /MEST 
is now explained by isoform -specific imprinting. As pointed out by Kosaki et al. 
(Kosaki et al. 2000), the finding of biallelic expression for other genes may have 
overlooked the possibility that opposite or biallelic imprinting of different isoforms 
of the same gene can mask the results. A re- evaluation of imprinting in genes 
previously thought to be biallelically expressed, particularly in cases where the 








































































































































































































































































































































































































































































































The gene GRB10 encodes a growth factor receptor binding protein, which has the 
capacity to bind both insulin and insulin -like growth factor receptors by means of a 
SH2 domain. This has the effect of inhibiting their tyrosine kinase activity (O'Neill 
et al. 1996; Liu, Roth 1995), and inhibiting IGF1 signalling of cell proliferation 
(Morrione et al. 1997). Binding of the growth hormone receptor (GHR) has also 
been observed (Moutoussamy et al. 1998). The gene is therefore believed to have an 
overall role of growth suppression. 
1.2.3.3.1 Imprinting of GRB10 
A maternally expressed gene, Megl , was identified during a systematic screen for 
novel imprinted genes, using a subtractive hybridisation approach to detect 
differences between the expression profiles of normal and androgenetic mouse 
embryos (Miyoshi et al. 1998). Megl was in fact identical to the known gene Grb10 
on mouse proximal chromosome 11, for which imprinting had not previously been 
reported. It was proposed that the imprinting of this gene, in addition to its function, 
could account for the growth promotion effects associated with paternal duplications 
of this region, and conversely, the growth repressive effects associated with 
equivalent maternal duplications. Similarly, the human homologue of Grb10 on 
chromosome 7 could be a candidate gene for the growth retardation observed in 
human maternal uniparental disomy of chromosome 7 (Miyoshi et al. 1998). 
Evidence for imprinting of human GRB10 has emerged recently, but is somewhat 
complex, and even contradictory. Initially, tentative and speculative evidence for 
GRB10 imprinting came from the asynchronous replication timing that was observed, 
as compared to a non -imprinted gene (Monk et al. 2000). Asynchronous replication 
timing is characteristic of imprinted regions (Kitsberg et al. 1993). 
Yoshihashi et al. (Yoshihashi et al. 2000) examined expression of GRB10 in fetal 
tissues and found exclusively monoallelic expression in fetal brain. To determine the 
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parental origin of the expressed allele they analysed somatic cell hybrids in which the 
human component was derived from human lymphocytes, and concluded that the 
GRB10 gene was only expressed from the maternally derived chromosome. 
However, the imprinting of GRB10 may not be as simple or straightforward as this. 
The experiments of Yoshihashi et al. (Yoshihashi et al. 2000) assume that imprinting 
of the gene is consistent between different tissues, that it is faithfully maintained in 
the somatic cell hybrids, and do not take into account the potentially splice -variant 
specific imprinting such as that which has been observed in GNASI , and discussed 
above. Indeed, the most comprehensive analysis of GRBIO has taken these factors 
into consideration, and has found them to be of significance with regard to the 
imprinted status of GRB10 (Blagitko et al. 2000). Blagitko et al. found biallelic 
expression in all fetal tissues, except brain, in which expression was solely paternal. 
When they extended their analysis to examine the expression status of each of the 
four splice variants separately, one isoform, GRB10y1 displayed monoallelic 
expression exclusively from the maternal allele in the two fetuses analysed. These 
experiments thus present evidence for both biallelic, and monoallelic expression of 
GRB10, with bidirectional imprinting of the latter case, depending on the tissue, and 
the splice variant involved (Blagitko et al. 2000). 
1.2.3.3.2 Silver -Russell Syndrome and the possible involvement of an 
imprinted gene on chromosome 7 
Silver -Russell syndrome (SRS) is a disease characterised by prenatal and postnatal 
growth retardation, and dysmorphic features including triangular facies and fifth 
finger clinodactyly (Silver et al. 1953; Russell 1954). A genetic basis to SRS is 
indicated by the presence of maternal uniparental disomy in approximately 7% of 
cases (Preece et al. 1997; Kotzot et al. 1995). The fact that paternal uniparental 
disomy of chromosome 7 does not cause SRS (Hoglund et al. 1994) specifically 
indicates non -equivalence of the parental chromosomes, and is suggestive of an 
imprinting effect. As with other diseases associated with a uniparental disomy, it is 
inconclusive from the maternal UPD cases alone whether the disease is caused by the 
resultant over -expression of a maternally expressed growth- suppressing imprinted 
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gene, or the effective loss of a paternally expressed growth- promoting imprinted 
gene on this chromosome. The phenotypic effects of both scenarios could result in 
the growth retardation observed in SRS patients, and may be indistinguishable from 
each other. 
It seems probable, therefore, from the significant proportion of SRS cases with 
maternal UPD of chromosome 7, and the other evidence mentioned above, that an 
imprinted gene on chromosome 7 has a fundamental involvement in this disease. Of 
note is that the possibility of SRS being caused by the effects of a recessive gene 
(with two recessive copies exposed by maternal UPD7) is eliminated due to the 
finding of uniparental heterodisomy cases, in which the two copies of chromosome 7 
are derived from the same parent, but are not identical, unlike uniparental isodisomy. 
Whilst the evidence described earlier regarding the imprinted status of GRB10 is 
complex, and variable between studies, it is apparent that there is at least some 
maternal specific expression of this gene, which could be envisaged to cause an 
abnormal and increased amount of the protein product as a result of maternal UPD7. 
Since the protein has a growth suppressing function, the resulting effects could 
feasibly account for the growth retardation observed in SRS. As an imprinted gene 
therefore, GRB10 is a good candidate. Its candidacy is further strengthened by the 
discovery of small duplications of 7p11 -p13 by Joyce et al. (Joyce et al. 1999) and 
Monk et al. (Monk et al. 2000), which, in conjunction with the maternal UPD7 cases, 
clarify for the first time that it is the over -expression of a maternally expressed gene, 
rather than the absence of a paternally- expressed gene, that causes SRS. Joyce et al. 
reported an inverted, interstitial duplication of 7p12.1-p13, including the genes 
GRB10 and IGFBPI (insulin -like growth factor binding protein 1) in a mother and 
daughter, both of whom had characteristic features of SRS. Monk et al. identified a 
similar duplication of 7p11.2 -p13, also including GRB10, IGFBPI and IGFBP3, in 
another child with SRS. The genes IGFBPI and IGFBP3 might be considered 
candidates for the SRS gene on the basis of their chromosomal location in these 
small duplications, but are unlikely to be involved as they are known to be 
biallelically expressed (Wakeling et al. 2000). 
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With regard to the vast majority of Silver Russell cases, which are apparently 
karyotypically normal, and do not possess uniparental disomy or duplications, 
alternative explanations must be identified for the presence of the disease in these 
patients. If upregulation of GRB10, by either maternal uniparental disomy, or 
maternally derived duplications, is the underlying cause of SRS, then there are three 
remaining theoretical routes by which it could also be functionally upregulated. 
First, there may be submicroscopic duplications present, which are undetectable by 
cytogenetic methods. Second, the gene may acquire gain of function mutations, 
which cause an upregulation of its expression, and third, it may suffer loss of 
imprinting or imprinting mutations, such that both copies take on a maternal 
epigenotype, with a similar outcome to maternal UPD or duplications. 
A search for mutations of GRB10 was conducted by Yoshihashi et al. (Yoshihashi et 
al. 2000) in 30 Japanese and 28 European SRS patients. Two of the patients were 
found to have a point mutation resulting in a proline to serine substitution in the 
amino -terminal region of the GRB 10 protein. In both cases the mutation was also 
present in the mother. Grandparental material was available for one case, showing 
that the mother of the proband had inherited the mutation paternally, and thus 
offering an explanation as to why she did not have symptoms of SRS. The 
significance of the parental origin of the mutation, and its absence from normal 
matched controls suggests that it may be important in the disease. However, an 
understanding of the functional effect of the mutation on the protein, and the 
mechanism by which it could upregulate expression of GRB10 to cause increased 
growth suppressing activity is yet to be elucidated. 
Whilst GRB10 is a compelling candidate gene for SRS, another imprinted gene on 
chromosome 7, PEGI /MEST, at 7q32, has not been excluded. Indeed, the possibility 
that the long arm of chromosome 7 carries the SRS gene cannot be dismissed 
because of an interesting case of a patient with SRS who carried paternal isodisomy 
of 7p, and maternal isodisomy of 7q (Eggerding et al. 1994); until the identification 
of this patient all previous uniparental disomies had encompassed the whole of 
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chromosome 7. Whilst this case in itself cannot determine whether it is the loss of a 
paternally expressed gene or the excess of a maternally expressed gene that is the 
cause of SRS, it does imply that the gene is located on the long arm of chromosome 
7. As the first identified paternally expressed imprinted gene on chromosome 7, 
PEGI /MEST (discussed earlier in this chapter in the context of clustering and 
isoform- specific imprinting), was proposed as a candidate for SRS. Given that 
PEGI /MEST is paternally expressed, it would be expected that a loss of function of 
this gene would be related to SRS. Thus, in cases of SRS that do not carry maternal 
uniparental disomy, inactivating mutations might represent an alternative causative 
mechanism. However, in a mutation screen of 49 SRS patients, only three silent 
nucleotide alterations were detected, and methylation patterns of the 5' region of 
PEGI /MEST were found to be normal in 35 SRS patients (Riesewijk et al. 1998). 
The evidence for the involvement of PEGI /MEST in SRS is weak, but a recent and 
very significant study has renewed the interest in 7q; Hannula et al. (Hannula et al. 
2001) detected segmental maternal UPD of chromosome 7, extending from 7g31 -qter 
only. The remainder of the chromosome displayed biparental inheritance. Other 
than the patient mentioned above with maternal uniparental disomy for the entire 
long arm of chromosome 7, this is the first report of segmental maternal UPD7. The 
35Mb segment thus represents a candidate SRS interval, and contains PEGI /MEST 
and COPG2, but excludes GRB10. Focussing on this potential cluster may identify 
further genes, which if imprinted may be considered SRS candidates. 
The evidence regarding the location of the SRS gene is confusing and in some ways 
equivocal in that there has been convincing evidence for both the 7p11-p13 locus 
(containing GRB10), and the 7q32 locus (containing the putative cluster that includes 
PEGI /MEST). It is not impossible that there is more than one locus or gene 
responsible for SRS; indeed, given that the disease itself is so clinically 
heterogeneous, perhaps this reflects genetic heterogeneity. There may be two or 
more distinct genes that result in similar phenotypes. Alternatively, there may be an 
as yet unelucidated reason to explain why the evidence has been so contradictory. 
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1.2.3.4 Promoter specific imprinting of IGF2 
In general, IGF2 is considered to be a paternally expressed imprinted gene. 
However, like GNAS1, GRB10 and PEG1IMEST, IGF2 has a slightly more complex 
expression pattern, which is related to the use of alternative promoters. IGF2 is 
expressed monoallelically, and exclusively from the paternal allele, in fetal tissues, 
including liver, but biallelic expression is observed in adult liver (Kalscheuer et al. 
1993). However, rather than this apparently biallelic expression occurring as a result 
of loss of imprinting, it is proposed that the gene IGF2 utilises one of four different 
promoters P1-P4, and when the promoter P 1 is used (as in adult liver), expression of 
the gene is biallelic. Utilisation of all other promoters results in expression of the 
paternal allele only (Vu, Hoffman 1994). The conclusion from this example is that a 
gene can be imprinted or non -imprinted in a single tissue, depending on which 
promoter is used. 
1.2.4 Antisense transcripts may be involved in imprinting 
regulation 
An increasing number of antisense RNA transcripts associated with imprinted genes 
are being discovered, challenging traditional ideas of the mechanisms by which 
imprinted genes are regulated. These antisense transcripts are also imprinted, 
sometimes coordinately and sometimes reciprocally with respect to the imprinted 
status of the genes with which they are associated. Recent studies of the currently 
small, but increasing number of antisense RNA transcripts suggest that they may 
indeed possess a genuine and novel role in imprinting control. 
1.2.4.1 Antisense transcripts identified to date 
1.2.4.1.1 Mouse Igf2r 
The imprinted mouse Igf2r gene contains two differentially methylated regions. The 
first of these, located upstream of the transcriptional start site, is correlated with 
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expression of the Igf2r gene, in that the paternal allele is methylated at this region, 
and is transcriptionally suppressed, whereas the transcriptionally active maternal 
allele is unmethylated. However, the second differentially methylated region, 
located in the second intron of Igf2r, is methylated in a reciprocal manner, such that 
the maternal allele is methylated and the paternal allele is unmethylated. This second 
differentially methylated region is now known to be the site of a promoter for an 
RNA transcript that is transcribed in a paternal -specific manner from the antisense 
strand (Wutz et al. 1997). 
Analysis of the imprinting of the sense and antisense transcripts at the Igflr locus has 
drawn parallels with the reciprocally imprinted gene pair H19 and Igf2, in the sense 
that an expression competition model may be involved. The experiments of Wutz et 
al. (Wutz et al. 1997) showed that deletion of the second region causes loss of 
imprinting of the sense transcript altogether, resulting in biallelic expression. Their 
explanation is that the reciprocally imprinted overlapping antisense RNA is 
transcribed from the paternal chromosome, (which is unmethylated at DMR2), and 
this transcription prevents expression of the paternal sense transcript. Deletion, 
therefore, eliminates this element of control from the system, allowing transcription 
of both parental alleles from the sense gene. 
The actual mechanisms by which the antisense exerts its negative regulatory effect 
on the sense gene are yet to be deduced, but possibilities are that it somehow 
occludes the Igf2r promoter to prevent binding by transcription complexes, that it 
causes local inactivation of the chromosome by binding to the chromatin, or that 
there is competition between the sense and antisense promoters for shared enhancers 
or transcription factors (Reik, Constancia 1997). 
1.2.4.1.2 GNAS1 
The extraordinary imprinting pattern of the GNASI gene, encoding maternal 
(NESP55), paternal (XL as) and biallelic (Gsa) transcripts has been detailed 
previously (1.2.3.1). However, a further feature of this complex gene is the existence 
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of a spliced, paternally expressed antisense transcript, which originates in the 
differentially methylated region of XL as, and is transcribed through the upstream, 
oppositely imprinted sense NESP55 exon (Wroe et al. 2000; Hayward, Bonthron 
2000). Antisense transcription through sense exons of the associated gene is a 
frequent feature of antisense RNAs, and given the close proximity in this case, it is 
conceivable that transcription of the antisense extending through the NESP exon and 
promoter could be a unique in cis suppression mechanism, to silence the paternal 
copy of NESP (Hayward, Bonthron 2000). 
1.2.4.1.3 KCNQ1 
The maternally expressed gene KCNQ1 in the imprinted cluster at 11p15.5 is 
associated with a reciprocally imprinted, overlapping antisense transcript, 
KCNQIOTI, which is paternally expressed (Mitsuya et al. 1999; Smilinich et al. 
1999). As with mouse Igfl, an intronic CpG island at KCNQ1 is subject to maternal - 
specific methylation, which apparently dictates the paternal -specific expression of 
the antisense transcript. Unlike the GNAS1 antisense, this antisense transcript is not 
spliced, and is thought to span approximately 60kb. 
Of significant note is that loss of maternal methylation at this DMR is linked to 
Beckwith -Wiedemann Syndrome, and may represent an alternative mechanism by 
which the disease can arise. Studies have demonstrated that loss of imprinting and 
resultant biallelic expression of the antisense transcript occurs in a large proportion 
or even the majority of BWS patient samples analysed (Mitsuya et al. 1999; 
Smilinich et al. 1999; Lee et al. 1999b). How does biallelic expression of the 
KCNQIOTI antisense transcript lead to BWS? One possibility is that the loss of 
maternal imprinting that leads to the expression of the normally silent maternal copy 
of the antisense results in silencing of a nearby maternally expressed gene, through 
mechanisms similar to the competition model. A candidate gene for this effect 
would be CDKN1C, as it is known that mutations of this gene alone are another 
cause of BWS. Maternal expression of the KCNQIOTI antisense could create, and 
win, the competition with the upstream gene CDKNJ C, such that the latter gene is 
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silenced, resulting in BWS. This idea is supported by the elegant experiments of 
Horike et al. (Horike et al. 2000), in which they generated targeted deletions of the 
KCNQIOTI CpG island. The effects of this were the elimination of KCNQIOTI 
expression from the paternal chromosome, and the activation of the normally silent 
paternal alleles of the genes KCNQ1 and CDKN] C. The significance of this is that 
the loss of imprinting of KCNQIOTI would result in biallelic expression, and based 
on the findings of Horike et al., this could be expected to inactivate CDK1V1 C, and 
may therefore be a novel underlying mechanism of BWS. 
1.2.4.1.4 UBE3A 
UBE3A is a gene within the cluster at 15g11 -q13, and is expressed maternally in the 
brain, but biallelically in some other tissues. An antisense transcript spanning at least 
the 3' half of the gene has been identified, and found to be oppositely imprinted, 
displaying paternal specific expression in brain (Rougeulle et al. 1998). The authors 
of this study speculate that the orientation, location and expression of the sense and 
antisense elements lend themselves to a competition model, as described earlier. 
Indeed, the fact that tissues lacking the antisense transcript show biallelic expression 
of UBE3A, is in accordance with this idea. 
1.2.4.1.5 ZNF127 
Within the Prader -Willi Syndrome region of human chromosome 15 there is a gene 
ZNF127, for which paternal, monoallelic expression has been found. Both this gene 
and its mouse homologue Zpf127 are associated with an overlapping antisense 
transcript, ZNF127AS /Zpf127as (Jong et al. 1999a; Jong et al. 1999b). However, 
unlike the examples described above, the evidence in this case indicates that the 
antisense transcript is coordinately rather than reciprocally imprinted with respect to 
the sense gene. Both genes are therefore paternally expressed, and interestingly the 
expression patterns differ, such that expression of sense and antisense transcripts is 
mutually exclusive, but in a tissue -specific, rather than allele -specific fashion. One 
postulated idea for the mechanism in these circumstances is that transcription from 
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the sense strand itself prohibits transcription from the antisense strand (Cattanach et 
al. 1997). 
1.2.4.1.6 IGF2 
Similarly, for the mouse gene Igf2, several associated imprinted transcripts have been 
identified. Three of these, which are located in a possible region of imprinting 
control upstream of 1gí2, are transcribed in the antisense orientation (Moore et al. 
1997), and like the sense gene are maternally repressed. The function of these 
transcripts and the significance of their antisense orientation and co- ordinate 
imprinting is as yet unconfirmed, but it seems likely that they possess some 
mechanistic role in the regulation of imprinting of Igf2, and perhaps other genes in 
the same domain. 
1.2.4.2 Possible mechanisms of antisense regulation 
Gaining an understanding of the functions of antisense RNAs and their role in 
imprinting regulation is the subject of much current and future research. The 
generalistic and preconceived idea that differential methylation is the sole underlying 
mechanism of control must now be challenged, to integrate new concepts which may 
be of equal importance. A role for oppositely orientated, imprinted antisense 
transcripts seems increasingly likely, but the actual mechanisms remain to be 
elucidated. A competition model, similar to that proposed for the H19 /IGF2 genes 
on chromosome 11p15.5, is feasible, and could account for antisense transcripts that 
are reciprocally imprinted in relation to their associated sense gene. This category 
includes the majority of the known antisense /sense pairs, but two exceptions are Igf2 
and Zpfl 27, for which the antisense transcript is apparently imprinted in the same 
direction as the sense gene. An alternative mechanism must be operating in these 
cases. 
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1.3 IMPRINTING AND CANCER 
A large proportion of known imprinted genes for which a function has been 
established are involved in embryonic growth and development or cell cycle control. 
This common feature is unlikely to be merely coincidental, and thus brings to light 
ideas that may relate to the evolution of imprinting. Accompanying this however is a 
cost - the role of imprinted genes in developmental pathways is crucial, yet the 
outcome of any aberration in these pathways could lead to a loss of developmental or 
cell cycle control, paving the way for tumorigenesis. 
It is well established that cancer may be a consequence of sequential genetic changes 
such as mutations and deletions of growth- regulating genes. The discovery of an 
increasing number of cancer -related imprinted genes now suggests that epigenetic 
changes may be of more significance than previously believed. 
1.3.1 Evidence for a role of imprinting in cancer 
The non -equivalence of the two parental genomes due to the presence of genomic 
imprinting explains the inability of parthenogenetic and androgenetic embryos to 
survive. The role of imprinting in development is clearly paramount. Furthermore, 
the possibility that genomic imprinting may play a role in cancer is indicated by the 
existence of two types of tumour: hydatidiform mole, and ovarian teratoma. 
Complete hydatidiform mole is an abnormal conceptus usually resulting from the 
fertilization of an enucleate egg by a single haploid sperm which duplicates (Lawler 
et al. 1979), or by two haploid sperm (Ohama et al. 1981). In either case, its genetic 
constitution is diploid, and purely androgenetic (Kajii, Ohama 1977). Hydatidiform 
mole is characterised by a relatively well -developed trophoblast, but very little 
embryonic tissue. In terms of genetic background, the equivalent but opposite 
scenario is benign ovarian teratoma, which arises from a parthenogenetically 
activated egg, and therefore has only a maternal genomic contribution (Linder et al. 
1975; Ohama et al. 1985). This type of tumour is characterised by a poorly 
developed trophoblast, but contains relatively well -developed embryonic tissue. 
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Both types of tumour represent the extreme consequences of complete disomy for the 
entire genome, (which is of paternal origin in the case of hydatidiform mole, and 
maternal origin in ovarian teratoma), and thus exemplify the force of genomic 
imprinting in preventing uniparental conception. The message from this situation is 
that aberrations to normal genomic imprinting can result in major developmental 
errors, of which tumorigenesis is a possible consequence. 
Further evidence that imprinting may play a role in cancer is observed in the 
preferential loss or gain of chromosomal regions of specific parental origin in some 
cancers. In particular, Wilms' tumour shows preferential loss of the maternal 
chromosome 11 (Schroeder et al. 1987; Williams et al. 1989; Mannens et al. 1988), 
rhabdomyosarcoma shows preferential paternal inheritance of the disomic regions of 
chromosome l 1p (Scrable et al. 1989), and neuroblastoma (see Chapter 3) is 
characterised by preferential maternal loss of 1p (Caron et al. 1993). These 
observations imply a role for imprinting in these diseases, because of the non- 
equivalence of the parental chromosomal regions involved in each case. 
1.3.2 Different ways that imprinted genes may be involved in 
cancer 
Imprinted genes are particularly vulnerable components of developmental and cell 
cycle pathways, since they are, by definition, functionally haploid. Therefore, the 
loss of an imprinted tumour suppressor gene or the upregulation of an imprinted 
growth- promoting gene would require only a single event. These are the two main 
ways in which imprinted genes are implicated in tumorigenesis. In addition, defects 
in imprinting centres can be envisaged to cause disruption to the imprinted status of a 
gene, with possible tumorigenic consequences. These ideas are discussed below in 
the context of some well -characterised examples. 
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1.3.2.1 Gain of growth promoting genes 
The overexpression of a gene that has a role in promoting cell growth and division 
will undoubtedly lead to a disruption of control, and inappropriately increased cell 
growth. Tumorigenesis is a likely consequence under these conditions. 
Theoretically, if a growth- promoting gene is imprinted and expressed from only one 
parental allele in the normal situation, it is vulnerable to events that can result in its 
overexpression. These events include firstly a loss of imprinting which would cause 
biallelic expression of the gene, and secondly, uniparental disomy for the 
chromosome carrying the expressed allele which would result in a similar outcome 
due to the doubled gene dosage. At least two imprinted growth- promoting genes, 
IGF2 and PEGI /MEST are now thought to play a role in cancer when upregulated by 
these mechanisms, and are discussed below. 
1.3.2.1.1 IGF2 and cancer 
The cluster of genes at 11 p 15.5 has been implicated in cancer since the discovery of 
loss of heterozygosity (LOH) of this region in Wilms' tumours (Reeve et al. 1989; 
Mannens et al. 1988). Evidence for an imprinting effect was suggested by the non- 
random, parental -specific origin of these losses (Schroeder et al. 1987), which were 
preferentially maternal. Additionally, Beckwith Wiedemann syndrome (BWS), and 
its associated predisposition to embryonal tumours are known to be linked to 
uniparental disomy of chromosome 11, suggestive of an imprinting effect. 
Because of the LOH of this region in Wilms' tumour, it had been expected that a 
tumour suppressor gene might reside in this region. Early studies were focussed 
around this concept, predicting that the loss of a gene with tumour suppressing 
properties might be involved. However, unexpectedly and in contrast to this, 
biallelic expression of the IGF2 gene was detected more frequently than LOH of the 
region. Rainier et al. (Rainier et al. 1993) found that 69% of Wilms tumours that did 
not have LOH displayed biallelic expression of H19 or IGF2, thus highlighting loss 
of imprinting (LOI) as a novel, epigenetic change associated with cancer. At the 
same time, Ogawa et al. (Ogawa et al. 1993) found similar evidence for LOI and 
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biallelic expression of IGF2 in Wilms tumours as a new mechanism underlying the 
development of cancer. 
From these early studies, the focus turned to investigating the extent of LOI of IGF2 
and H19 in cancers, both fetal and adult. Biallelic expression of IGF2 and /or H19 
has been reported in Wilms' tumours (Sullivan et al. 1999); renal cell carcinoma 
(Oda et al. 1998; Nonomura et al. 1997); hepatoblastoma (Rainier et al. 1995; Kim, 
Lee 1997; Li et al. 1995); Ewing's sarcoma (Zhan et al. 1995); head and neck 
squamous carcinoma (el- Naggar et al. 1999); ovarian cancer (Chen et al. 2000; Kim 
et al. 1998); meningiomas (Muller et al. 2000); lung cancer (Kondo et al. 1995; 
Suzuki et al. 1994); testicular germ cell tumours (van Gurp et al. 1994); breast 
cancer (McCann et al. 1996); cervical cancer (Douc -Rasy et al. 1996; Wu et al. 
1997a); gastric adenocarcinoma (Wu et al. 1997b); colorectal cancer (Kinouchi et al. 
1996); and acute myeloid leukaemia (Wu et al. 1997c). 
Each of these studies has provided increasingly strong evidence that LOI of these 
genes may play a significant role in the development of cancer. However, the results 
are also confusing and at times conflicting. Some studies report LOI of IGF2 only, 
whilst others report LOI of both IGF2 and H19 within the same tumour, or LOI of 
H19 only. Establishing a true picture of the involvement of these imprinted genes is 
therefore no easy task. One emerging pattern however, is that the results of the 
studies fall into two main groups; firstly, LOI and biallelic expression of IGF2 has 
been frequently reported to occur in conjunction with hypermethylation or loss of 
expression of H19, suggesting a mechanistic link between imprinting of the two 
genes such that biallelic expression of IGF2 is related to downregulation of H19 
expression. Indeed, this idea is consistent with both the enhancer competition model 
for regulation of H19 and IGF2, and also with the idea that H19 plays a role as a 
tumour suppressor gene. LOI of IGF2 in conjunction with LOI of H19 has been 
observed particularly in Wilms' tumours (Steenman et al. 1994). 
The second emerging pattern is an observed LOI of IGF2 that is not associated with 
any downregulation of the H19 gene, but rather, occurs independently of it. In these 
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cases, H19 maintains normal monoallelic expression whilst IGF2 suffers LOI and 
biallelic expression. This situation is clearly not consistent with the enhancer 
competition model. The cancers falling into this category are the remaining non - 
Wilms' embryonal tumours Ewing's sarcoma, hepatoblastoma and 
rhabdomyosarcoma, and the majority of the adult tumours mentioned above. This 
uncoupling of the imprinting of H19 and IGF2 is reminiscent of one of the 
underlying genetic mechanisms of BWS. As described previously, LOI of IGF2 in 
BWS occurs either with H19 hypermethylation, or independently of it. The latter of 
these two situations is also associated with maternal demethylation of the KCNQ1 
gene and is likely to be related to the biallelic expression and negative regulatory role 
of the antisense gene KCNQIOTI. Thus, from studies of BWS it is proposed that 
there are likely to be at least two separate imprinting centres involved in regulation 
of IGF2 imprinting, of which one is associated with the downstream gene H19, and 
the other is related to the imprinting of the upstream genes KCNQ1, KCNQIOTI and 
CDKN1 C. The results of IGF2 and H19 analyses here suggest that a similar scenario 
is true of the role of imprinting in cancer. In some cancers, particularly Wilms' 
tumour, LOI of IGF2 is strongly mechanistically linked to a downregulation of H19 
expression. In a second subset of cancer types however, the LOI of IGF2 is not 
associated with any changes in H19 imprinting or expression, and thus suggests an 
alternative H19- independent mechanism of IGF2 imprinting control, and argues 
against a tumour suppressor role for H19. In the case of BWS, the H19- independent 
LOI has now been linked to altered regulation of other genes in the cluster such as 
KCNQ1 and KCNQIOTI. 
Nearly all studies regarding LOI in cancer have focussed on only H19 and /or IGF2. 
However, a valuable line of research to follow now would be to assess the effect of 
LOI of IGF2 in cancer on other genes in the cluster, particularly in cases where H19 
is unaffected. It may be that in these cases, the LOI of IGF2 could now be associated 
with epigenetic changes in other genes, in accordance with the postulated ideas 
regarding a second imprinting centre. Indeed, a recent study of imprinting in 
hepatocarcinoma (Schwienbacher et al. 2000) has correlated aberrant imprinting of 
IGF2 and CDKN1 C with loss of maternal specific methylation at the differentially 
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methylated region of KCNQ1. The observed loss of imprinting at this DMR, which 
is normally maternally methylated and associated with a paternally expressed 
antisense transcript, KCNQIOTI, was linked to silencing of the genes CDK1V1 C and 
IGF2. Thus, a loss of imprinting at the KCNQ1 DMR may have a more widespread 
negative effect on the expression of other genes in this imprinted domain, and may 
be important in tumorigenesis. 
One further point of interest is that LOI of IGF2 in one study was accounted for by 
transcription from the biallelic promoter P1 (Chen et al. 2000a). Transcription from 
this promoter is biallelic and occurs normally only in liver. The finding of a switch 
in promoter usage in epithelial ovarian cancer in this study may in fact be a more 
widespread phenomenon, and warrants further study to determine whether this is an 
alternative mechanism of upregulation of IGF2. 
1.3.2.1.2 PEG11MEST 
A high frequency of LOH of the chromosomal region 7g31 -32 has been reported in 
breast cancer, suggesting that the loss of a tumour suppressor gene located in this 
region might be important. However, the imprinted gene PEGl /MEST located in this 
interval has recently been shown to undergo frequent loss of imprinting in invasive 
breast cancer, resulting in biallelic expression (Pedersen et al. 1999). The precise 
function of PEGI /MEST is not known, although the protein shares amino acid 
homology with the alpha/beta hydrolase fold family. Pedersen et al. suggest 
therefore that the upregulation of the gene function that would be expected to occur 
when the normally silent maternal allele is activated could result in degradation of 
the extracellular matrix during tumour development (Pedersen et al. 1999). 
1.3.2.2 Loss of imprinted tumour suppressor genes 
In simplified terms, normal cell growth is controlled by a finely balanced interaction 
between suppression of cell division, and promotion of cell growth and proliferation. 
Tumour suppressor genes are usually involved in inhibiting the cell cycle, or 
52 
inducing apoptosis, and are therefore antiproliferative. When the function of a 
tumour suppressor gene is lost however, the balance is disturbed, and can lead to 
tumour formation. In the 1970s, Knudson and others proposed an elegant two `hit' 
model to account for the development of retinoblastoma in both sporadic and familial 
cases (Knudson 1971). In the familial form of the disease, one mutant copy of the 
retinoblastoma gene (RB1) is inherited. On acquiring one further mutation in a 
single cell, the function of RBI is effectively eliminated, leading to tumour 
formation. Thus, the inherited mutation forms the first `hit', and a subsequent, 
spontaneously occurring mutation forms the second `hit'. In sporadic cases of 
retinoblastoma the model still applies, with the main difference being that both `hits' 
are independently acquired somatic mutations. 
The Knudson model carries great significance in the study of imprinting and its 
relevance to cancer. Imprinted genes by definition already carry one Knudson `hit' 
in the form of the imprinted and usually methylated allele that is functionally silent. 
This is reminiscent of the inherited mutation in the retinoblastoma scenario. Thus, 
only one spontaneous hit is required to inactivate the second allele, so in the case of 
imprinted tumour suppressor genes, there is a greater vulnerability and a much higher 
chance of a complete loss of expression through the two hit model than for a non- 
imprinted tumour suppressor gene. The second hit to inactivate the functional allele 
of an imprinted suppressor may be a mutation or a deletion, but loss could also occur 
through hypermethylation of a normally differentially methylated region such that 
both alleles are silenced. An alternative theoretical mechanism of inactivation of 
imprinted tumour suppressor genes is through uniparental disomy for the non - 
expressed parental copy. 
Imprinted tumour suppressor genes now implicated in cancer are TP73, NOEY2, 
M6P /IGF2R, and H19, which are discussed below. 
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1.3.2.2.1 NOEY2 (ARH1) 
NOEY2 is an imprinted tumour suppressor gene on chromosome 1p31 identified in a 
systematic differential display screen for sequences specifically expressed in normal 
ovarian cells, but not in tumour cells (Yu et al. 1999). This gene is a member of the 
RAS family, and may act as a negative growth regulator in cancers of the breast and 
ovary. Yu et al. not only found monoallelic, paternal- specific expression of the gene, 
but also showed that in four of five patients with LOH at the NOEY2 locus, the lost 
allele was the expressed paternal copy, thus leaving only the inactive maternal allele 
present. In accordance with the Knudson hypothesis described above, the maternal 
imprint acts as the first hit, and the LOH seen in these cases is the second hit, 
preferentially removing the only functional copy of the gene. This offers suggestive 
evidence for a tumour suppressor role for NOEY2. Further evidence from this study 
was the discovery that two of eight breast cancer cell lines were hypermethylated at 
the NOEY2 locus, thus resulting in a complete silencing of the gene. 
1.3.2.2.2 IGF2R 
The insulin -like growth factor 2 receptor (IGF2R) gene is located at human 
chromosome 6q26. The protein product encoded by this gene has a threefold 
function in that it activates the growth inhibitor TGF(3, targets IGF2 for lysosomal 
degradation, and is involved in the intracellular trafficking of lysosomal enzymes 
(Hankins et al. 1996). Interestingly, the homologous mouse gene is imprinted, being 
maternally expressed. The underlying basis of the mouse Igor imprinting, as 
discussed above, is believed to be the existence of two differentially methylated 
regions in the gene, one of which may control the expression of an imprinted 
antisense transcript with a regulatory role (see 1.2.4.1.1). The human gene retains all 
of the differentially methylated regions that appear to control the monoallelic 
expression of the mouse homologue, yet, surprisingly still displays biallelic 
expression (Smrzka et al. 1995; Riesewijk et al. 1996). 
An interesting phenomenon however is that the non -imprinted status of human 
IGF2R gene is not always maintained. A degree of imprinting and maternal -specific 
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IGF2R expression has been found in a subset of individuals, suggesting the 
possibility of polymorphic imprinting (Xu et al. 1993; Smrzka et al. 1995). 
Irrespective of any imprinting effect that may exist in humans, IGF2R has been 
proposed as a tumour suppressor gene. Given its functions in degrading IGF2 and 
activating growth inhibitors, a loss of this gene and these functions would be 
expected to have some effect in both increasing cell proliferation and reducing 
apoptosis, which are the hallmarks of tumour development. Along these lines, 
Hankins et al. (Hankins et al. 1996) found that 30% of informative breast tumours 
had LOH; missense mutations of the remaining allele were found in two of five 
carcinomas in situ that they examined, suggesting that allelic loss of IGF2R is an 
early event in breast cancer. Yamada et al. 1997 (Yamada et al. 1997) performed a 
similar analysis of patients with dysplastic liver lesions or hepatocellular carcinomas 
(HCC), and found approximately 60% LOH. Mutations of the remaining allele were 
detected in 55% of HCCs, suggesting that IGF2R acts as a tumour suppressor in liver 
carcinogenesis. Similarly, Kong et al. 2000 (Kong et al. 2000) found LOH in 58% 
of squamous cell lung cancers, with the remaining allele mutated in 6 of the 11 cases 
analysed. 
The overall conclusion from these results is that allelic loss of IGF2R occurs 
frequently in cancer, and its loss would theoretically result in increased levels of 
IGF2, since IGF2R normally causes degradation of IGF2. In effect, the LOH of 
IGF2R accompanied by mutation of the remaining allele, may be functionally 
equivalent to loss of imprinting (LOI) of IGF2, which results in biallelic expression 
of the gene, and increased levels of IGF2 protein. Since IGF2 LOI is known to be a 
causative factor in many cancers, the LOH of IGF2R could feasibly be involved in 
tumorigenesis as a tumour suppressor gene. 
It is apparent therefore, that IGF2R acts as a tumour suppressor gene in its own right, 
and can be eliminated through a two -hit model, with LOH and mutation being the 
two independent hits. However, the notion of polymorphic imprinting of this gene 
may also be significant. In accordance with the ideas discussed above, individuals in 
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whom IGF2R is subject to imprinting might be more vulnerable to a complete loss of 
function of this gene because they have only one active copy and therefore, as in the 
Knudson hypothesis, require only one additional `hit' to inactivate IGF2R. Thus, 
these individuals who imprint IGF2R may have an increased susceptibility to cancer. 
To investigate this possibility, Xu et al. (Xu et al. 1997) looked at Wilms' tumours, 
in which LOI of IGF2 is common. They found that in seven of sixteen patients with 
Wilms' tumour, there was significant repression of the paternally inherited IGF2R 
allele in both the tumour and normal kidney. Approximately 50% of normal fetal 
kidneys show imprinting of IGF2R, suggesting that the partial imprinting of IGF2R 
in a similar proportion of Wilms' tumours is an abnormal persistence of the fetal 
situation that may contribute to tumour susceptibility. 
1.3.2.2.3 TP73 
The TP73 gene has been proposed to be an imprinted tumour suppressor gene in 
neuroblastoma, lung cancer and renal cell carcinoma, yet the evidence for 
monoallelic expression of this gene is conflicting. However, this subject forms part 
of the next chapter and will not be discussed here. 
1.3.2.2.4 H19 
The H19 gene, in the imprinted cluster at 11p15.5, has been proposed as a tumour 
suppressor based on the preferential maternal LOH of this region in cancers. 
Additionally, the tumour suppressor activity of the H19 RNA has been demonstrated 
in transfection experiments (Hao et al. 1993). However, other evidence is 
contradictory. As discussed above, the LOI of IGF2 in some cancers is related to the 
downregulation and usually hypermethylation of H19, and this could imply that the 
loss of H19 is as important as the gain of IGF2. However, there are many examples 
of LOI and biallelic expression of H19 in cancer, rather than LOH, and this is strong 
evidence against a tumour suppressor role. A recent study found inactivation of the 
H19 gene by LOH or hypermethylation of the maternally inherited (expressed) allele 
in seven of eight sporadic hepatoblastomas that were not associated with BWS 
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(Fukuzawa et al. 1999). This supports a tumour suppressor role for H19, but studies 
of this kind are fewer in number than those which have found opposing evidence in 
the form of biallelic expression of H19. 
1.4 SUMMARY 
Imprinting is a complex phenomenon, which has commanded the focus of a great 
deal of research in recent years. Attaining a greater understanding of the 
characteristics and mechanisms of the imprinting process has been a priority, but 
perhaps of greater significance now is elucidating the relevance of imprinting to 
disease. Imprinting has a crucial role in normal development, but carries a risk, in 
that it renders the genome more vulnerable to disruption at imprinted loci. The study 
of diseases such as Beckwith -Wiedemann syndrome, Prader -Willi syndrome and 
Angelman syndrome has highlighted some of the consequences of aberrant 
imprinting, but these diseases may represent only a small proportion of the possible 
pathological outcomes. A possible imprinting effect has been postulated in many 
other diseases, including Silver -Russell syndrome and transient neonatal diabetes. 
Given that estimates of the total number of imprinted genes predict that we may have 
discovered less than 20% of them to date, and that almost all imprinted genes have 
been associated with disease (when normal imprinting is disturbed), the key goals 
must be to identify the remaining imprinted genes, and to characterise them and 
understand their functions and potential involvement in disease. The widespread and 
frequent occurrence of aberrant imprinting in cancer illustrates that epigenetic 
disruption may be of major significance in cancer, and must therefore be a particular 
focus of future investigation. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 Chemicals and reagents 
2.1.1.1 General chemicals 
All chemicals for general use were supplied by Sigma (Sigma -Aldrich Company Ltd) 
or BDH (Merck Ltd) unless otherwise stated, and were of molecular biology grade. 
Bacterial media were obtained from Difco U.K. Ltd. 
2.1.1.2 Radiochemicals 
All radioactive isotopes were supplied by Amersham Life Sciences. These included 
[a32P] -dCTP at a specific activity of 3000 Ci /mmol for labelling DNA probes, [73211- 
ATP at a specific activity of 1415 Ci /mmol for labelling oligonucleotide probes, and 
[a32P] -UTP at a specific activity of 800 Ci /mmol for use in the transcription reaction 
to generate radiolabelled RNA probes. In addition, for manual radioactive 
sequencing, the four RedivueTM 33P- labelled dideoxynucleotide terminators were 
obtained at a specific activity of 1500 Ci /mmol (4501.1Ci /ml). 
2.1.1.3 Enzymes 
Restriction enzymes were obtained from New England Biolabs. Of particular 
relevance to the work in this study is that a subset of the restriction enzymes used are 
sensitive to CpG methylation, such that cleavage is blocked when CpG sites within 
the recognition sequence are methylated. Exonuclease I for purification of PCR 
products prior to sequencing was supplied from Amersham as part of a kit also 
containing shrimp alkaline phosphatase. The Klenow fragment of E. coli DNA 
polymerase I was provided by Boehringer. Tag polymerase (5U /µ1) and T4 DNA 
ligase were supplied by Gibco BRL Life Technologies. The SP6 and T7 RNA 
polymerases were supplied by Ambion. Desiccated proteinase K and RNase A were 
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obtained from Sigma. SuperscriptTM II reverse transcriptase was supplied by Gibco 
BRL Life Technologies. The RNase inhibitor RNAguardTM, derived from human 
placenta, was supplied by Amersham Pharmacia at a concentration of 29700 
units /ml. 
2.1.1.4 Nucleic acid markers 
The 1kb ladder and 100bp ladder DNA markers were obtained from Gibco BRL Life 
Technologies. For ABI gels, the Perkin Elmer GENESCAN -350 TAMRA marker 
was used. For pulsed field gel electrophoresis the Mid Range PFG Marker 1 from 
New England Biolabs was used. 
2.1.1.5 Components of PCR reactions 
Taq polymerase is detailed elsewhere. The PCR buffer and MgC12 solution supplied 
with the Taq polymerase were generally used. Stocks of dNTPs were obtained from 
Gibco BRL Life Technologies, at a concentration of 100mM each, and a working 
stock consisting of 25mM each dNTP was prepared. PCR primers were synthesised 
at the 50nmol scale by either Genosys, or Life Technologies. A working stock was 
prepared by reconstituting each primer in distilled H2O to a concentration of 
100pmol /111, and then using a subsequent dilution of 20pmo1 /111 for PCR. The 
sequences of the primers used throughout this thesis are given in Appendix 2.A.2. 
They are referred to by name at the appropriate points in the text of each relevant 
chapter. 
2.1.2 DNA samples 
All DNA samples were stored at 5 °C. 
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2.1.2.1 Normal DNA controls 
A set of normal control human genomic DNAs was used frequently for optimising 
PCRs, generating probes, and other general uses. These had previously been 
prepared from blood extractions, and the stocks were generally at a concentration of 
0.511g /µl. Working dilutions of 100ng /µl were prepared. 
2.1.2.2 Parthenogenetic DNA 
A source of human parthenogenetic DNA was available from the chimaeric patient 
described by Strain et al. (Strain et al. 1995). This patient has chimaerism between 
normal cells with biparental contribution, and parthenogenetic cells. The leukocytes 
are completely parthenogenetic, and DNA from a lymphoblastoid cell line 
established from these cells was used for analysis of imprinting in this study. 
2.1.2.3 Fetal DNA panel 
DNA and RNA samples from a panel of 66 first trimester fetuses had previously 
been collected and described (Campbell et al. 1994). The panel comprises fetal and 
corresponding maternal DNAs, together with fetal RNAs from a range of tissues, 
particularly muscle, eye, stomach, testis, cord, adrenal, brain, liver, kidney, heart, 
lung and gut. Table 1 shows further details of the panel. 
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Table 1. Details of the panel of first trimester fetal DNAs. 







1' MB040267 Yes Yes 5 
2' LH260874 Yes Yes 8 
3' MW080265 Yes Yes 3 
4' LF010174 Yes Yes 5 
6' MM060567 Yes Yes 2 
7' CA020275 Yes Yes 9 
8' LH200770 Yes Yes 4 
9' MC260166 Yes Yes 6 
10' JB040570 Yes Yes 2 
11' AF281169 Yes No 6 
12' LM250774 Yes Yes 4 
13' HM170958 Yes Yes 3 
14' AM 121062 Yes Yes 7 
15' AM300969 Yes Yes 7 
16' PM26 Yes Yes 1 
17' MC 151165 Yes Yes 7 
18' MD311268 Yes Yes 3 
19' DMc090964 Yes Yes 6 
20' TS070870 Yes Yes 6 
21' FB111171 Yes Yes 8 
22' JC290868 Yes Yes 5 
23' HW300462 Yes Yes 4 
24' LR190174 Yes Yes 10 
25' MT150964 Yes Yes 2 
26' RL Yes Yes 3 
27' SS 130773 Yes Yes 8 
28' JS020673 Yes Yes 6 
29' SG281070 Yes No 5 
30' SH2401 Yes Yes 7 
31' LR0906 Yes Yes 6 
A SN301070 Yes Yes 3 
B CS280766 Yes Yes 5 
C AS020172 Yes No 8 
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D CB230357 Yes No 7 
E SG70 Yes Yes 5 
F AJ180558 Yes No 6 
G NG100369 Yes Yes 1 
H RT281475 Yes Yes 1 
1 HA040275 Yes Yes 8 
J JM230372 Yes Yes 4 
K JA161159 Yes No 2 
L JR170474 Yes Yes 6 
M FC070271 Yes Yes 3 
N JH210566 Yes Yes 8 
O AJ180558 Yes Yes 6 
P TS070870 Yes No 6 
Q HW150273 Yes No 6 
R CA250568 Yes Yes 2 
S CT111275 Yes Yes 5 
T LB020170 Yes Yes 6 
U AS080172 Yes Yes 8 
V JF101272 Yes Yes 7 
W JC230671 Yes Yes 4 
X GK011268 Yes Yes 2 
1 EH 131162 Yes Yes 3 
2 JA161159 Yes No 2 
3 HW150273 Yes No 6 
5 DL040371 Yes Yes 7 
6 AC 150452 Yes Yes 7 
7 DB200170 Yes No 3 
8 DH270971 Yes Yes 8 
9 DB280773 Yes Yes 3 
10 MS 100972 Yes Yes 8 
11 LM120370 Yes Yes 7 
13 CM311273 Yes Yes 1 
14 CM 181169 Yes Yes 7 
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2.1.2.4 Neuroblastoma DNAs 
A panel of 42 neuroblastoma cell lines and tumours, Merkel cell carcinoma cell lines 
and tumours, and schwannomas was provided by Dr. F. Speleman. Full details of 
these are given in Chapter 3. 
2.1.2.5 Breast cancer and bladder cancer DNAs 
A panel of 11 pairs of breast tumour and matched normal DNA, and 8 pairs of 
bladder tumour and matched normal DNA was provided by Dr. A. McCann, 
University College Dublin. 
2.1.2.6 Breast cancer cell lines 
Six breast cancer cell lines were provided by Dr. V. Speirs, Molecular Medicine 
Unit, St. James's Hospital, Leeds. These were MDA -MB -435, MDA- MB468, T47D, 
ADR -MCF7, MCF7, and MCF7 -Clone 9. The cell lines were grown under standard 
cell culture methods, and DNA extracted as described in 2.2.1.3 below. 
2.1.2.7 Lymphoma samples 
A panel of 21 B -cell non -Hodgkin's lymphomas was provided by Professor K. 
MacLennan. These were provided as blocks of excised tissue, frozen at -70 °C. DNA 
and RNA were extracted as described in 2.2.1.3 and 2.3.1. 
2.1.3 Microbiological resources 
2.1.3.1 Libraries 
2.1.3.1.1 Gridded filters of PAC library 
The human PAC library RPCI1, constructed by Pieter de Jong and his group at the 
Roswell Park Cancer Institute, Buffalo, was obtained through the UK HGMP 
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Resource Centre in the high density gridded filter format. This comprises seven 
double spotted 22.2x22.2 cm filters for screening by hybridisation. 
2.1.3.1.2 Gridded filters of chromosome 1 cosmid library 
The gridded filters of the LLO1NC01 chromosome 1 cosmid library constructed at 
Lawrence Livermore National Laboratory (LLNL) (Trask et al. 1991), were obtained 
through the UK HGMP Resource Centre. 
2.1.3.1.3 Gridded filters of CEPH Mega -YAC library 
The CEPH "mega" YAC library, constructed at CEPH (Centre d'Etudes du 
Polymorphisme Humain) (Chumakov et al. 1992) was obtained through the UK 
HGMP Resource Centre as 8 double spotted 22.2 x 22.2 cm high density gridded 
filters for screening by hybridisation. 
2.1.3.2 Clones 
PAC, YAC, and cosmid clones from the libraries mentioned above were supplied by 
the UK HGMP Resource Centre. In addition, I.M.A.G.E. clones were obtained from 
the I.M.A.G.E. consortium through the UK HGMP Resource Centre. 
2.1.3.3 Vectors 
The vector pCRTMII was supplied by Invitrogen. The vector TVEC was supplied by 
Promega. The pUC18 plasmid vector (Yanisch -Perron et al. 1985) was obtained 
from Stratagene. 
2.1.3.4 Electrocompetent cells 
For transformations, the E. coli strain JM109 (Epicurean Coli) was obtained from 
Stratagene. 
65 
2.1.3.5 Maxiprep and miniprep kits 
The Qiagen maxi -prep kit was used for large -scale DNA preparations from PAC 
clones. Minipreps were either performed using the alkaline lysis method, or the 
SNAPTM miniprep kit. 
2.1.4 Mapping resources 
2.1.4.1 Somatic Cell Hybrid Panel 
For PCR mapping to individual chromosomes, the human monochromosomal 
somatic cell hybrid DNA panel (Originators: S. Povey and N. K. Spurr) (Kelsell et 
al. 1995) was obtained from the UK HGMP Resource Centre. 
2.1.4.2 Radiation Hybrid Mapping panel 
For finer PCR mapping to known markers, the Genebridge 4 radiation hybrid DNA 
panel (Originators: Peter Goodfellow and Jean Weissenbach) (Gyapay et al. 1996) 
was obtained through the UK HGMP Resource Centre. 
The resulting data was analysed at RhyME (Radiation Hybrid Mapping 
Environment), and the Sanger Centre. 
2.1.5 Solutions and buffers 
All solutions and buffers were prepared using distilled water, and autoclaved where 
appropriate under the conditions 15 psi, 121 °C for 30 minutes. Details of the 
components of general solutions and buffers are given in Appendix 2.A.2. 
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2.1.6 Bioinformatics 
The following software and bioinformatics web sites were used during this study: 
GenescanTM software by Applied Biosystems 
Pubmed /Entrez databases at www.ncbi.nlm.nih.goy 
GDB database at www.gdb.org 
Sanger Centre at www.sanger.ac.uk 
LDB genetic map at http \ \cedar.genetics.soton.ac.uk 
Primer3 software at: www- genome .wi.mit.edu/cgi- bin/primer /primera 
GCG- HGMP -RC at www. hgmp. mrc. ac .uk /Registered /Option/gcg.html 
NIX -HGMP -RC at www. hgmp. mrc.ac.uk /Registered /Webapp /nix/ 
2.2 DNA METHODS 
2.2.1 DNA extractions 
2.2.1.1 DNA preparation from PAC clones 
DNA was extracted from PAC clones using the Qiagen plasmid maxi kit. The basis 
of the protocol is an alkaline lysis procedure, followed by binding of the plasmid 
DNA to a Qiagen® tip column containing the Qiagen® anion exchange resin. RNA, 
protein and low molecular weight impurities are selectively removed by a medium 
salt wash, and the plasmid DNA is eluted using a high salt buffer, then precipitated 
with isopropanol. Buffers and solutions mentioned below were provided in the kit. 
Centrifugations were carried out in a Sorvall centrifuge, using the GSA rotor 
(14.5cm radius) for the initial pelleting of the cells, and the SS -34 rotor (10.7cm 
radius) for all subsequent centrifugation steps. A 500m1 culture of a single streaked 
colony was grown overnight at 37 °C with shaking at 225rpm. Following 
centrifugation at 6000xg for 15 minutes at 4 °C, the pellet was resuspended in 10m1 
of buffer P1 (50mM Tris -HC1 pH 8.0, 10mM EDTA, 100µg /ml RNase A). To lyse 
67 
the cells, 10m1 of buffer P2 (200mM NaOH, 1% SDS) was added, and the tubes 
inverted 4 -6 times to mix. Precipitation was performed by adding 10m1 of chilled 
buffer P3 (3M potassium acetate, pH 5.5), mixing gently, and incubating on ice for 
20 minutes. After centrifugation at 20000xg for 30 minutes at 4 °C, the supernatant 
was removed, and centrifuged again for 15 minutes. A Qiagen tip was equilibrated 
by allowing 10m1 buffer QBT (750mM NaCl, 50mM MOPS pH 7.0, 15% 
isopropanol) to run through by gravity flow, and then the supernatant was applied to 
the tip and allowed to enter the resin. The tip was washed with two 30m1 washes of 
buffer QC (1M NaC1, 50mM MOPS pH 7.0, 15% isopropanol), then the DNA was 
eluted with 15ml buffer QF (1.25M NaC1, 50mM Tris -HC1 pH 8.5, 15% 
isopropanol). The DNA was precipitated from the eluate by adding 10.5m1 
isopropanol, mixing, and centrifuging at 15000xg for 30 minutes at 4 °C. The pellet 
was washed with 5 ml 70% ethanol, then air dried and redissolved in 200µ1 TE, pH 
8.0. 
2.2.1.2 Miniprep DNA extractions 
2.2.1.2.1 Alkaline lysis method (Modification of the method of Ish -Horowicz 
and Burke (Ish -Horowicz, Burke 1981)) 
The solutions used in this method are detailed in Appendix 2.A.2. Centrifugations 
were performed in an Eppendorf 5415C benchtop microfuge, using a rotor of radius 
8.2cm. 
A sterile tube containing 4m1 of LB with 20µg /m1 ampicillin was inoculated with a 
single colony and incubated at 37 °C overnight with shaking (-225rpm). Of the 4m1, 
lml was taken for a glycerol stock, and the remaining 3ml were centrifuged at 
4000rpm to pellet the cells. The pellet was resuspended in 100µ1 solution I by 
vigorous vortexing followed by incubation at room temperature for 5 minutes. 200µ1 
of solution II was added, the mixture shaken, and incubated on ice for 5 minutes. 
150µ1 of ice cold solution III was added, the mixture shaken, and incubated on ice 
for 5 minutes. Tubes were then spun at 13000rpm at 4 °C for 3 minutes. The 
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supernatant was transferred to a tube containing 450µ1 phenol:chloroform:isoamyl 
alcohol (25:24:1), vortexed, spun for 1 minute, and the aqueous phase removed to a 
fresh tube. 900µl of 100% ethanol was added and precipitation allowed to proceed 
for 5 minutes at room temperature, followed by spinning at 13000 rpm at room 
temperature for 5 minutes. The pellet was washed with 70% ethanol, air -dried, and 
resuspended in 50µ1 TE containing 50µg /ml RNase. 
2.2.1.2.2 SNAPTM miniprep kit 
High quality miniprep DNA for use in manipulations such as sequencing was 
prepared with the SNAPTM (Simple Nucleic Acid Prep) kit from Invitrogen. The kit 
provides Resuspension Buffer, Lysis Buffer, Precipitation Salt, Binding Buffer, 
Wash Buffer, and 1 xFinal Wash. 
A 4ml culture of LB containing 20µg /ml ampicillin was inoculated with a single 
colony and incubated at 37 °C overnight with shaking (- 225rpm). Of the 4m1, lml 
was taken for a glycerol stock, and the remaining 3ml were centrifuged at 4000rpm 
to pellet the cells, and the pellet resuspended in 150µ1 Resuspension Buffer. The 
cells were lysed with 150µl Lysis Buffer, and incubated at room temperature for 3 
minutes. 150m1 ice cold Precipitation Salt was added, then the contents of the tubes 
mixed, and centrifuged at 14000xg for 5 minutes. The supernatant was removed to a 
sterile tube, 600µl Binding Buffer added, the solution mixed, and transferred onto a 
SNAPTM miniprep column/collection tube. The column/tube was then centrifuged at 
3000xg for 30 seconds, to bind the DNA to the column. To wash the DNA, 500µ1 of 
Wash Buffer was added to the column, and centrifuged as in the previous step. A 
final wash was performed in the same way with 900µl 1 x Final Wash, after which 
the column/collection tube was centrifuged at 13000rpm at room temperature for 1 
minute to dry the resin. The DNA was eluted into 60µ1 TE, which was added to the 
column, incubated for 3 minutes at room temperature, and centrifuged at 13000rpm 
for 30 seconds. To check the yield and quality of the DNA, 2 -3µl was 
electrophoresed on a 1% agarose gel alongside samples of known concentration. 
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2.2.1.3 Extraction of DNA from lymphomas and breast cancer cell lines 
The following protocol was used to extract DNA from both cells and tissues. Tissues 
were minced with a scalpel, on ice, before adding the digestion buffer (details of this 
buffer are given in Appendix 2.A.2). Cells were spun down to a pellet. 
To each tube containing a cell pellet or minced tumour tissue, 500µl digestion buffer 
and 3Oµl proteinase K (10mg /ml) were added, and the tubes vortexed vigorously. 
The digestion buffer contained 50mM Tris-HC1 (pH 8.0), 100mM NaC1, 5mM 
EDTA and 1% SDS in dH2O. The tubes were incubated overnight at 50 °C in a water 
bath, after which 5000 phenol:chloroform:isoamyl alcohol (25:24:1) was added to 
each tube. The tubes were vortexed, and centrifuged at 13,500rpm for 5 minutes at 
room temperature. The supernatant was removed to a fresh tube, 5000 
phenol:chloroform:isoamyl alcohol (25:24:1) added, the tubes vortexed, and 
centrifuged again at 13,500rpm for 5 minutes at room temperature. The supernatant 
was transferred to a fresh tube, and 20µl 5M NaCl and 520µl 100% ethanol were 
added. The contents of the tube were mixed, and then the tubes incubated at -80 °C 
for 30 minutes to precipitate the DNA. The tubes were centrifuged at 13,500rpm for 
10 minutes at room temperature, and the pellet washed in 70% ethanol, then allowed 
to air dry for 5 -10 minutes. The pellet was resuspended in 501.t1 TE buffer, pH 8.0, 
and then subjected to an RNase treatment at 37 °C for 1 hour, with 11.1g /ml RNase. 
To check the quality and estimate the yield of the DNA, 51.t1 of the sample was run 
on a 1% agarose gel alongside samples of known concentration, and visualised with 
ultraviolet light. 
2.2.2 Polymerase Chain Reaction (PCR) 
All PCR reactions were carried out in a total volume of 50111. The reaction mix 
contained: 
lx PCR buffer (10x stock contains 15mM MgC12, 100mM Tris-HC1 (pH 8.0), 
500mM KC1) 
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lOpmol forward primer 
l Opmol reverse primer 
20011M each dNTP 
1 unit Tay polymerase 
Template DNA (usually IOOng genomic DNA) 
Distilled H2O up to 50111 
Cycling conditions were usually 30 to 40 cycles of denaturation at 94 °C for 1 minute, 
annealing at X °C for 1 minute, and extension at 72 °C for 2 minutes. 
Conditions varied slightly between each PCR, depending on the annealing 
temperature required, the expected product length, and other variable factors. In 
some cases where dimerisation of the two primers was judged to be problematic, a 
hot start was used. In cases where a PCR failed repeatedly, the addition of higher 
concentrations of MgC12, or 10% dimethylsulphoxide (DMSO), or 0.1 % -1% Triton 
X -100 was often found to assist in the generation of a product. 
2.2.3 Gel electrophoresis 
2.2.3.1 Agarose gel electrophoresis 
For the purpose of analysing PCR products, checking DNA quality /concentration, 
and analysing digestions, electrophoresis was usually performed in 1% TAE gels, 
prepared with lg agarose per 100m1 1xTAE buffer, and containing 0.51.1g /ml 
ethidium bromide. Gels were run in lx TAE buffer, at 5 Volts per cm, for 30 -60 
minutes, depending on the size of the fragments of interest. Gels were visualised 
using an ultra violet trans- illuminator. 
For resolving smaller fragments, 2% or 3% gels made with NuSieveTM agarose were 
used. 
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2.2.3.2 Pulsed field gel electrophoresis 
For the separation and resolution of larger DNA fragments, such as the products of 
digestion of PAC clones with rare -cutting enzymes, pulsed field gel electrophoresis 
was employed, using the contour -clamped homogeneous electric field (CHEF -DRII) 
system from Biorad. This system comprises a hexagonal arrangement of 24 
electrodes, and operates on the basis of alternating the electric field between pairs of 
electrodes that are orientated at 120° with respect to each other. Gels were 1% 
agarose (14x 13cm), and run in 0.5xTBE at 6V /cm, 14 °C. The switch times between 
the alternating electric fields were ramped from 1 to 10 seconds during a 24 hour 
period. Gels were stained after electrophoresis by immersing in 0.5xTBE containing 
0.5µg /ml ethidium bromide, for 30 -60 minutes, and then visualised with ultraviolet 
light. 
2.2.3.3 Polyacrylamide gel electrophoresis 
2.2.3.3.1 Non -denaturing polyacrylamide gels 
In cases where the resolution of similar sized fragments of DNA was required, e.g. 
restriction digests, polyacrylamide gels were used. These were usually 
20cmx20cmx0.1cm, 6% acrylamide, 0.5xTBE, according to the recipe in 2.A.2. 
Biorad gel rigs were used. Glass plates were cleaned with ethanol before use. Gels 
were poured and allowed to polymerise for 1 hour before use. 
2.2.3.3.2 Denaturing polyacrylamide gels 
For the separation of single stranded DNA, e.g. transcription products, denaturing 
5% acrylamide, 0.5xTBE, 8M urea gels were used. The recipe is given in 2.A.2. 
Gels were poured and run as for non -denaturing gels. 
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2.2.4 Digestion of DNA with restriction endonucleases 
2.2.4.1 Digestion of human genomic DNA 
For the purposes of Southern blotting, 1014 (usually 200) of human genomic DNA 
was digested overnight with 30 -50 units of enzyme (up to a maximum of 10% of the 
reaction volume), in a total volume of 500. Incubations were performed in water 
baths or heating blocks at the stated optimum temperature for each enzyme. 
2.2.4.2 Digestion of PCR products 
Restriction enzyme digestions of PCR products were typically performed in volumes 
of 200, comprising l00 PCR product, 20 appropriate buffer, 2p.1 10x BSA (if 
required), 10 -50 units of enzyme (up to a maximum of 10% of the reaction volume, 
i.e. 2p1 here), and dH2O to 2O0. The reactions were then incubated at the stated 
optimum temperature, in a water bath or heating block, for 4 -16 hours. 
2.2.4.3 Digestion of PAC clones 
For the purposes of analysing the restriction sites within a PAC clone insert 
sequence, or for subcloning of a PAC clone, digestion of 1µg DNA was performed in 
1000 reaction volumes containing up to 50 units of enzyme. Double digestions, 
where required, were performed in the buffer recommended by New England 
Biolabs. In cases where the combination of enzymes was not complementary to any 
of the available buffers, sequential digests were performed by digesting first with one 
enzyme, then performing a phenol chloroform extraction and ethanol precipitation, 
and subsequently digesting again with the second enzyme. 
2.2.5 Southern blotting 
Southern blotting was used to transfer DNA from agarose gels to Nylon membrane 
according to a modification of the original method of Southern, (Southern 1975). 
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After electrophoresis the gel was immersed in 0.25M HC1 for 15 minutes with gentle 
shaking, then rinsed in dH2O. The transfer was performed in a glass dish, containing 
a transfer platform and a 3MM filter paper wick, which was in contact with a 
reservoir of 0.4M NaOH. The gel was placed on the filter paper wick, and a gel - 
sized piece of Hybond -N+ nylon membrane (from Amersham) placed on the surface 
of the gel. Three pieces of 3MM filter paper were placed on top of this, followed by 
a stack of absorbent paper towels, and a weight. Cling film was used to cover the 
area around the gel, to prevent evaporation of the solution. The transfer was allowed 
to proceed, by capillary action, for 16 hours. After transfer, the membrane was 
rinsed in 2xSSC for 5 minutes, and then baked between two sheets of filter paper for 
2 hours at 80 °C. 
2.2.6 Labelling probes for hybridisation 
2.2.6.1 Oligonucleotide probes 
Oligonucleotides of 18 -25bp were labelled with [y32P] ATP using the enzyme T4 
polynucleotide kinase (PNK). Labelling reactions of l0µ1 volume were set up 
containing 30 -50ng of the oligonucleotide (usually 1µl of a 5pmol /p1 stock), 1µl 10x 
PNK buffer, 0.5µl (5 units) PNK, 3p1 [y32P] ATP, and 4.5µl dH2O. Reactions were 
incubated at 37 °C for 30 minutes. 
2.2.6.2 PCR product probes 
Probes were labelled by the random priming method (Feinberg, Vogelstein 1983), 
either by a standard protocol, or by using the Pharmacia kit method, both of which 
are described below. 
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2.2.6.2.1 Standard method 
Typically, 50ng of DNA was labelled. The DNA solution was increased to a volume 
of 33µl with the addition of dH2O, denatured by incubating in a boiling water bath 
for 10 minutes, and then placed on ice to prevent renaturation. To the denatured 
DNA was added 12111 OLB (containing random 6mer primers and a buffered solution 
of cold dATP, dGTP, and dTTP), 4111 [a32P] -dCTP and 1111 Klenow enzyme. The 
labelling reaction was allowed to proceed at room temperature for 4 hours, after 
which the probe was denatured again, and then added to the hybridisation reaction. 
2.2.6.2.2 17QuickPrime® kit method 
The labelling of PCR product probes, or digested fragments of plasmids, was 
performed using the T7QuickPrime® kit from Pharmacia Biotech. The DNA of 
interest was first electrophoresed in a low melting point agarose gel, and then the 
band (containing at least 250ng of DNA) was excised from the gel and weighed. 
Distilled water was added to a volume of 3m1 per gram of gel slice, then the mixture 
heated at 65 °C to melt the agarose. For the labelling reaction, a maximum of 25111 of 
this mixture was used, following preparation by heating at 95 °C for 7 minutes, and 
then incubating at 37 °C for 10 minutes. 
Labelling reactions were set up comprising the following reagents: 
25µ1 denatured DNA (25 -50ng) 
10µ1 Reagent Mix (provided in the kit) 
Sµl [a -32P] dCTP (3000 Ci /mmol) 
Distilled H2O to a final volume of 49µ1 
1µl of T7 DNA polymerase (provided in the kit) was added, then the contents of the 
tube mixed gently, and centrifuged briefly, before being incubated at 37 °C for 15 
minutes. Immediately before hybridisation, the labelled probe was denatured at 95° 
for 3 minutes. 
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2.2.7 Hybridisation of probes to PAC filters /Southern blots 
2.2.7.1 PCR product probes - standard method 
Filters were immersed in 2xSSC buffer, then rolled up and placed in hybridisation 
bottles, each filter being separated from the others with nylon membranes. 20m1 
prehybridisation buffer that had been preheated to 65 °C was added to the bottles 
along with 200111(10mg /ml stock) sonicated salmon sperm DNA (denatured by 
incubating for 10 minutes in a boiling water bath), and the filters were then allowed 
to prehybridise for 1 hour, rotating, in an oven at 65 °C. 
The prehybridisation mix was poured away, and 10m1 of pre- heated hybridisation 
mix was added to the bottles. The labelled probe and 100µl salmon sperm DNA 
(10mg /ml stock) were denatured by incubating in a boiling water bath for 10 
minutes, and were then added to the bottles. The hybridisation was allowed to 
proceed overnight, at 65 °C. 
After the hybridisation the filters were subjected to two 20- minute washes in 
2xSSC /0.1% SDS, and one 20- minute wash in 1xSSC/0.1% SDS, all at 65 °C. The 
filters were wrapped in cling film, and exposed to autoradiographic film with 
intensifying screens at -70 °C, for between 4 and 24 hours. 
2.2.7.2 Oligo Probes - Quick Oligo Hyb method 
Filters were soaked in 2xSSC for 5 minutes, and then rolled up and placed in the 
hybridisation bottles. 10m1 of Quick Oligo Hyb Mix was heated up to 68 °, then 
added to the bottles along with 100111 denatured salmon sperm DNA (10mg /m1 
stock). Prehybridisation of the filters was allowed to continue for 1 hour at 68 °C, 
and then the labelled oligo probe was added to each bottle, and hybridised overnight. 
Three to four 5- minute washes of the filters were performed with 4xSSC /0.1% SDS 
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at 50 °C, and the filters were wrapped in cling film and exposed to autoradiographic 
film in light -proof cassettes with intensifying screens at -70 °C for 4 -24 hours. 
2.2.8 PAC subcloning 
For the subcloning of BamHI and BglII fragments of PAC clones, the vector pUC18 
was used. Prior to ligation with the digest fragments, the vector was digested with 
BamHI itself, and the phosphate groups removed by treatment with shrimp alkaline 
phosphatase, to prevent religation of the vector to itself. For subcloning of NotI -SacI 
fragments, the vector pCRTMII was used, following digestion with Notl and Sacl; for 
subcloning of AscI -SacI fragments the vector TVEC was used, following digestion 
with Mlul and Sacl. 
2.2.8.1 Ligation 
Approximately 1µg of PAC DNA was digested with at least 50 units of the 
appropriate enzymes depending on the fragments required to be subcloned, e.g. Notl- 
SacI double digest, AscI -SacI double digest, BamHI or BglII single digests. The 
fragments were recovered by phenol -chloroform extraction and ethanol precipitation. 
Ligation reactions were set up containing 40ng of the appropriately digested vector, 
500ng of the insert (digested PAC clone DNA), 3p.1 5x ligase buffer, and 1µl of T4 
DNA ligase in a total volume of 15µ1, made up with distilled H2O. A control ligation 
reaction was set up in each case, comprising the same components but distilled H2O 
in place of the insert. Ligation reactions were incubated at room temperature 
overnight, followed by ethanol precipitation. The pellet was resuspended in 5µl 
H2O. 
2.2.8.2 Transformation by electroporation 
The Gene PulserTM (Biorad) apparatus was set to 25µF, 2.5kV and the controller to 
2005. On ice, 1111 of the precipitated ligation reaction was added to 40111 thawed 
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electrocompetent cells (see below for preparation of these cells), then the mixture 
transferred into a chilled electroporation cuvette. The cuvette was pulsed according 
to the conditions above, and then 1 ml LB broth was immediately added to the 
cuvette. The contents of the cuvette were transferred to an autoclaved Eppendorf 
tube, and incubated for 1 hour at 37 °C with shaking at 225rpm, then 100111 and 2O0111 
were plated out onto fresh X- gal /IPTG /ampicillin plates (see 2.A.2), and incubated 
overnight. 
2.2.9 Preparation of electrocompetent cells 
A stock of E. coli strain JM109 (Epicurean Coli) cells was obtained from 
Stratagene. The following protocol was used for preparation of the cells for 
transformation. 
One litre of LB was inoculated with 1 /100 volume of an overnight culture from a 
freshly streaked JM109 colony. The cells were grown at 37 °C with vigorous shaking 
(225rpm) until they reached early to mid -log phase, defined by an OD600 of 0.5 to 
0.7. 
The culture was transferred into 50m1 Falcon tubes, and placed on ice for 15 -30 
minutes. The tubes were centrifuged at 4000rpm for 5 minutes at 4 °C. The 
supernatant was removed, and the pellets resuspended in 50m1 ice -cold water. 
The tubes were centrifuged again, and the pellets resuspended in half the volume of 
ice -cold water, combining two tubes into one. The tubes were centrifuged again, and 
the pellets resuspended in 20m1 ice -cold water, combining all tubes into one. A final 
centrifugation was performed, and the pellet resuspended in 3m1 10% ice -cold 
glycerol. The suspension was divided into aliquots of 45µl, which were immediately 
frozen in liquid nitrogen, and then stored at -70 °C for future use. 
78 
2.2.10 PCR product cloning 
Cloning of PCR products was performed using the pGEM ® -T Easy Vector kit from 
Promega, according to the manufacturer's protocol, as follows: 
2.2.10.1 Ligation 
Ligation reactions were set up at room temperature according to the manufacturer's 
protocol, and contained 5µl Rapid Ligation Buffer, 111l (50ng) pGEM® -T Easy 
Vector, 111l PCR product, 1111 (3 Weiss units /µl ) T4 DNA ligase, and deionized 
water to a total volume of l04 (NB. The buffer, ligase and vector were components 
of the kit). The PCR product insert was always used directly from a 500 reaction 
without any purification step. After mixing, the ligation reactions were incubated at 
room temperature for 4 hours. A control reaction was set up each time containing 
dHZO as a replacement for the insert DNA. 
2.2.10.2 Transformation by heat shocking 
On ice, 2u1 of each ligation was added to a sterile 1.5ml microcentrifuge tube. The 
frozen JM109 competent cells were placed in an ice bath until just thawed, then they 
were gently mixed, and 501.11 carefully transferred to each ligation tube prepared as 
above. The tubes were placed on ice for 20 minutes, and then heat shocked in a 
water bath at exactly 42 °C for 45 -50 seconds. The tubes were returned to the ice for 
2 minutes, and then 950µ1 LB medium was added, and the tubes incubated for 1 hour 
at 37 °C with shaking (-- 150rpm). 
100µ1 of each transformation culture was plated out onto duplicate LB /amp /IPTG /X- 
gal plates (for recipe see 2.A.2), and the plates incubated overnight for 16 hours at 
37 °C. Each plate of the reaction containing PCR product insert typically yielded 
100 -200 white colonies, which generally contained inserts of the expected size. The 
control plates should not yield any white colonies, but may yield a background level 
of blue colonies (no inserts), as a result of non T- tailed or undigested vector. 
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To confirm the presence of the desired insert, colony PCR was performed with 
vector primers Ml3Forward and Ml3Reverse, by making up a PCR mix, then 
transferring a small amount of the colony from the end of a Gilson tip into the mix, 
and proceeding as for a normal PCR, except for allowing an initial 10 minute 
incubation at 94 °C to help lyse the cells. DNA was prepared from the positive 
colonies by the SNAP miniprep kit, as described elsewhere. 
2.2.11 Purification of PCR products for sequencing and other 
subsequent manipulations 
2.2.11.1 Shrimp alkaline phosphatase /exonuclease I purification 
To remove single stranded primers and dNTPs from the PCR reaction prior to 
sequencing, 1µl (1 unit) SAP (shrimp alkaline phosphate) and 1µ1 (10 units) 
exonuclease I were added to 5µl PCR product (from a 50µ1 reaction), and incubated 
at 37 °C for 15 minutes. This was followed by incubation at 80 °C for 15 minutes, to 
inactivate the enzymes. After this treatment, 1 -3µl of the product was used directly 
in the thermosequenase radiolabelled terminator cycle sequencing reaction. 
2.2.11.2 Geneclean purification kit 
For purification of DNA from agarose, the GENECLEAN kit from Bio 101 was used 
according to the manufacturer's protocol, as follows: 
The band of interest was excised from the gel with a scalpel, taking appropriate 
precautions to avoid personal UV exposure. The band was weighed, and then placed 
in a tube with three volumes of 6M sodium iodide, and the tube incubated at 50 °C 
for 5 minutes until the agarose had dissolved. Glassmilk, an aqueous suspension of 
proprietary silica matrix, was added - the volume was dependent on both the amount 
of DNA expected in the gel slice, and the total volume of the sodium iodide solution 
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at this stage, but was generally between 5 and 2Oµ1. After adding the glassmilk the 
tubes were incubated for approximately 15 minutes on a mechanical shaker to allow 
the DNA to bind to the silica matrix. The glassmilk was then pelleted by spinning at 
13000rpm for 5 seconds. The glassmilk (and bound DNA) was washed three times 
by resuspending the pellet in 500µ1 NEW Wash, spinning for 5 seconds, and 
discarding the supernatant. Following the removal of the supernatant from the third 
wash, the tubes were re -spun, in order to remove any residual liquid, before drying 
the pellet for 5 -10 minutes at room temperature. To elute the DNA from the 
glassmilk, the pellet was resuspended in a volume of water equal to the amount of 
glassmilk originally added. After a 30 second spin, the supernatant now containing 
the DNA was removed to a fresh tube. 
Sodium iodide (6M), glassmilk and NEW Wash (containing NaC1, Tris, EDTA and 
50% ethanol) were provided in the GENECLEAN kit. 
2.2.12 33P radiolabelled terminator cycle sequencing 
Templates for sequencing by this method were either PCR products that had been 
purified by the SAP /exonucleasel method described above, or plasmid DNA or PAC 
DNA which were used directly in the reaction. The kit used for this method was the 
thermosequenase radiolabelled terminator cycle sequencing kit from Amersham. 
2.2.12.1 Sequencing reactions 
The termination mixes were prepared for each [a33P] labelled ddNTP (ddATP, 
ddCTP, ddGTP and ddTTP) by combining 111l of dGTP termination master mix 
(containing 7.5µM each of dATP, dCTP, dGTP and dTTP) and 0.25µ1 of each 
radioactively labelled ddNTP. In another tube, a reaction mixture was prepared 
comprising: 1µl of 10x reaction buffer (260mM Tris -HC1 pH 9.5, 65mM MgC12), 1- 
7µl of template DNA (amount depending on the source and nature of the template 
e.g. plasmid, PCR product), l µl of sequencing primer (at a concentration of 3µM), 
1µ1(4U) of Thermosequenase DNA polymerase, and sterile H2O to a total volume of 
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104 To each of the prepared termination mix tubes (A, C, G, and T), 2.25µ1 of this 
reaction mixture was added, and the mixture overlaid with mineral oil. 
The cycle sequencing reactions were performed in a Hybaid Omnigene Thermal 
Cycler, in 96 well microtitre plates. Where the standard dGTP mastermix was used, 
the cycling conditions were 40 -50 cycles of 95 °C for 30 seconds, 55 °C for 30 
seconds, and 72 °C for 1 minute. In the cases where the dITP mastermix was used to 
reduce the effect of GC compressions on the gel (the dITP mastermix contains 
7.5µM each of dATP, dCTP, dTTP and 37.511M dITP), the conditions were 50 cycles 
of 95 °C for 30 seconds, 50 °C for 30 seconds, and 60 °C for 7 minutes. On completion 
of the cycling reaction, 211l of stop solution (95% formamide, 20mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanol FF) was added to each termination reaction. 
The samples were then denatured at 95 °C for 3 minutes and 2.5µ1 of each was loaded 
immediately onto a 6% glycerol tolerant sequencing gel, as described below. 
2.2.12.2 Preparation and running of acrylamide sequencing gels 
The products of cycle sequencing reactions were separated by electrophoresis on 
0.4mmx38cmx50cm Biorad sequencing gel rigs. The acrylamide gel mix was 
prepared as a 950m1 stock (to be made up to the equivalent of 1 litre with 20x 
glycerol tolerant buffer) comprising 8M urea, 6% acrylamide/N,N'- 
methylenebisacrylamide (19: 1, Acrylogel mix 5- Sigma), and distilled water. Each 
gel was then prepared with 95ml of this stock and 5ml 20x glycerol tolerant buffer, 
and polymerised by adding l50µ125% ammonium persulphate and 10011l NNN'N' 
tetramethylenediamine (TEMED) immediately before pouring. Gels were allowed to 
polymerise for 2 hours at room temperature, before running in lx glycerol tolerant 
buffer at 90W for 2 -6 hours, depending on the length of readable sequence required. 
2.2.12.3 Visualisation of results 
Following the electrophoresis of sequencing products, the gel was transferred to 
3MM filter paper, covered in Saran wrap, and dried under vacuum at 80 °C for 1 hour 
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in a Biorad gel drier, after which the Saran wrap was removed. The gel was then 
exposed to autoradiographic film in a light -proof cassette at room temperature, for 1- 
2 days, and developed. 
2.2.13 ABI analysis of polymorphic microsatellite markers 
Five polymorphic dinucleotide repeat microsatellite markers from the Cedar map 
(GDB) were used for detection of loss of heterozygosity (LOH) at chromosome 
6q24-25. In addition, three novel dinucleotide repeat microsatellites were identified 
within the PAC clone sequences of 340 -H11, 197 -L1, and 468 -K18 in the Sanger 
centre database, for which PCR primers were designed. For each pair of primers, the 
5' primer was labelled with one of the fluorescent dyes HEX, TET and FAM. 
2.2.13.1 Preparation of samples 
After amplification PCR products were checked on a 1% agarose gel, and then 
analysed on an ABI 377 machine. Several different microsatellites could be 
electrophoresed in the same lane provided they were labelled with different 
fluorescent dyes or were not of overlapping size ranges. Samples were prepared by 
diluting the PCR products, usually 1:10 with H2O, and using 1.50 of this dilution 
per lane, together with 0.5111 TAMRA 350 marker, and 1.5111 dextran blue /formamide 
dye. Before loading onto the gel, the samples were denatured at 95° for 5 minutes. 
2.2.13.2 Running ABI gels 
The gel was made using 25ml SeqaGel mix (National Diagnostics, 4.25 %), and 
2001_1110% ammonium persulphate was added shortly before pouring. The gel was 
allowed to polymerise for 2 hours before running. The wells were rinsed out 
thoroughly prior to running, to remove urea. Gels were run for 2 hours at 51°C using 
the ABI genescan run module 2400, with a constant voltage of 3kV, 40mW laser 
power, and 2400 scans per hour. 
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2.2.13.3 Analysis of results 
The data was collected and analysed with the ABI Genescan software to determine 
the peak sizes for each sample. 
2.2.14 Bisulphite modification and sequencing 
The protocol for bisulphite modification of DNA detailed below is an adaptation of 
that used in the laboratory of Y. Hayashizaki, as reported in Kamiya et al. 2000 
(Kamiya et al. 2000). Their method is itself a modification of the method used by 
(Clark et al. 1994). 
One microgram of DNA was digested overnight at 37 °C with 25 units of the 
restriction enzyme PvuII in a total volume of SOW. After digestion, the volume was 
increased to 10011l with distilled water, and then 10µ1 3M sodium acetate, 1µl yeast 
tRNA, and 220µ1 100% ethanol were added to precipitate the products of the 
digestion. The mixture was incubated on ice for 30 minutes, then centrifuged for 10 
minutes at 14000 rpm in a microfuge. The pellet was washed with 70% ethanol, and 
then air -dried for 5 minutes, before resuspension in 50µ1 TE buffer (pH 8.0). 
Denaturation was performed by adding S.5µ1 3M NaOH, and incubating at 37 °C for 
15 minutes, after which the bisulphite reaction was set up, by adding 3Oµ1 10mM 
hydroquinone, and 520µ1 sodium bisulphite pH 5.0. The tubes were inverted a few 
times to mix, and then the reaction was overlaid with oil, and incubated in a 55 °C 
water bath for 16 hours. 
The products of the bisulphite reaction were purified with the geneclean kit from 
Bio101 utilising sodium iodide and glassmilk, and eluted into 20µ1 distilled water. A 
further denaturation was performed, by adding 2.2µ13M NaOH, and incubating at 
37 °C for 15 minutes. The denatured bisulphite- modified products were precipitated, 
by the same method as described above, and then finally resuspended in 15µl TE 
buffer, pH 8.0. For PCR, 1µl was used per S0µ1 PCR reaction. 
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2.3 RNA METHODS 
All RNA work was performed with full awareness of the possible risks of 
contamination with RNases. Appropriate precautions were taken to avoid these 
risks, by carrying out RNA manipulations away from the normal working area, using 
clean gloves for each manipulation, using a set of Gilson pipettes specifically 
designated for RNA work, and treating solutions with DEPC where possible. 
Autoclaved tubes and tips were used throughout. Samples of RNA were stored in a - 
70°C freezer, and only defrosted for sufficient time as to remove the amount 
required, before being quickly refrozen. 
2.3.1 RNA extraction 
RNA was extracted from the lymphoma samples using TRIzol reagent from 
GibcoBRL, and a protocol derived from the original method of (Chomczynski, 
Sacchi 1987). 
The lymphoma tissue was rapidly minced on ice using a scalpel, then placed in a 
microcentrifuge tube containing lml of TRIzol reagent. The tubes were vortexed 
vigorously, several times over a 20 minute period, to break up the tissue as much as 
possible. To each tube was added 2000 chloroform, followed by 15 seconds of 
vigorous mixing. The tubes were incubated at room temperature for 2 -3 minutes, 
and then centrifuged at 12,000xg for 15 minutes at 4 °C. The upper aqueous phase 
containing the RNA was transferred to a fresh tube, and the RNA precipitated by 
adding 5000 isopropanol, and mixing well. Following a 10- minute incubation at 
room temperature, the tubes were centrifuged at 12,000xg for 10 minutes at 4 °C. 
The supernatant was removed carefully and discarded. RNA washing was performed 
by adding 1m1 of 75% ethanol, mixing well, and centrifuging at 7,500xg for 5 
minutes at 4 °C. The pellet was dried at room temperature for approximately 10 
minutes, and then resuspended in 500 DEPC- treated distilled water. 
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2.3.2 RNA quantification 
RNA was quantified using a Genequant spectrophotometer. 
2.3.3 RT -PCR 
2.3.3.1 First strand cDNA synthesis 
On ice, the following components were added to a nuclease -free tube: 1011l H2O, 5µl 
primer (Race2), 3p1 (1 µg) RNA. The mixture was overlaid with mineral oil, 
incubated at 85 °C for 3 minutes, then immediately cooled on ice for 2 minutes. To 
each tube was added 6µl 5x RTII buffer, 3µ10.1M DTT, l.5µ1 dNTP (stock 
containing 20mM each), 0.5µ1 (14.8 units) RNAguard, and i p l (200units) 
SuperscriptTM II RT, then the tubes incubated at 42 °C for 60 minutes, 50 °C for 15 
minutes, and 95 °C for 15 minutes. 
2.3.3.2 PCR 
For PCR, 2µ1 of the RT reaction was used per 50µ1 PCR. Typically, a hot start was 
found to be necessary, and the success of the PCR was often improved by the 
addition of components such as 10% DMSO or 0.1 % -1% Triton X -100. 
2.3.4 Ribonuclease Protection Assay (RPA) 
A ribonuclease protection assay was designed for the purpose of assessing 
quantitatively the amount of ZAC transcript in the lymphoma RNA samples. The 
transcription and ribonuclease protection assays were performed using the 
appropriate kits from Ambion. 
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2.3.4.1 Probe design 
The RT -PCR product generated from a normal fetal cDNA by primers 1029- RT5' /3' 
was cloned into the vector pGEM ® -T Easy, by methods as described in 2.2.10. Six 
of the resulting colonies were selected and miniprep cultures were grown, from 
which DNA was extracted by the SNAPTM miniprep kit method. Each clone was 
sequenced with the M13 reverse primer, to identify a clone in the correct orientation 
such that transcription from the T7 polymerase would generate an antisense 
transcript. 
2.3.4.2 Transcription 
The template for transcription was a PCR product generated from the clone 
mentioned above. To ensure that the template was RNase -free it was treated with 
0.1% SDS and 200µg /m1 proteinase K for 2 hours at 50 °C, and then purified using 
the Wizard PCR purification kit. Of this, 100ng (1p1) was added to the transcription 
reaction, which also comprised 8.8µl nuclease -free H2O, 2µl l0xbuffer, 1p1 each of 
10mM ATP, CTP and GTP, and 4µM (3.211l) 25µM [a32P] -UTP. The transcription 
reaction was allowed to proceed for 15 minutes at 37 °C, followed by DNaseI 
treatment, then removal of free nucleotides by ammonium acetate precipitation. 
2.3.4.3 Calculation of yield and specific activity of probe 
Yield and specific activity of the probe were calculated according to the percentage 
incorporation of [a32P] -UTP as determined by TCA precipitation. The hybridisation 
reaction requires 2fmol of probe, so the probe was resuspended in a volume 
containing 2fmol per µl. 
2.3.4.4 Hybridisation 
Hybridisation of the probe and RNA samples was performed essentially as described 
in the manufacturer's recommended protocol. Reactions were set up containing 
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RNA and probe, which were then co- precipitated, resuspended, denatured, and then 
incubated overnight at 42 °C. RNase digestion was performed at 37 °C for 30 
minutes, followed by precipitation. Samples were resuspended in gel loading buffer 
and electrophoresed on 5 %, 8M urea denaturing polyacrylamide gels for 2 hours at 
300 volts. Gels were exposed to autoradiographic film with intensifying screens at - 
70°C for 1 -8 hours. 
2.A APPENDIX 
2.A.1 PCR primers 
NAME SEQUENCE 5'-3' 
GENERAL 
Ml3Forward gttttcccagtcacgacgttgta 
M13 Reverse agcggataacaatttcacacagga 
T7 cgctaatacgactcactataggg 
SP6 gtcgacatttaggtgacactata 
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ABI gel loading buffer 95% deionised formamide, 20mM 
ethylenediamine tetra acetic acid (EDTA. 
disodium salt), 10mg /m1 dextran blue 
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Acrylamide 30% Stock (19: 1) 
28.5% acrylamide, 1.5% N,N'- 
methylenebisacrylamide 
Alkaline Lysis Miniprep - Solution I 50mM glucose, 25mM Tris-HC1 (pH 
8.0), 10mM EDTA 
Alkaline Lysis Miniprep - Solution II 1% SDS, 0.2M NaOH 
Alkaline Lysis Miniprep - Solution III 3M potassium acetate, 2M acetic acid 
Ammonium persulphate 10% or 25% w/v, in dH2O 
Ampicillin 50 mg /ml in H2O stock solution, 20 
µg /ml working concentration. 
Denhardt's solution 5g Ficoll, 5g polyvinylpyrrolidone, 5g 
BSA, H2O to 500m1 
DEPC- treated water Diethylpyrocarbonate added to dH2O to a 
concentration of 0.1%, incubated 
overnight at 37 °C, then autoclaved. 
Digestion buffer for DNA extraction 
from human tissue 
50mM Tris-HC1 (pH 8.0), 100mM NaC1, 
5mM EDTA, 1% SDS 
Dimethylsulfoxide (DMSO) 100% stock 
Ethidium bromide 10mg /m1 in dH2O 
Store in darkness at room temperature 
First strand RTII buffer 5x 250 mM Tris-HC1 (pH 8.3), 375 mM 
KC1, 15 mM MgC12 
Gel loading buffer 0.25% bromophenol blue, 0.25% xylene 
cyanol FF, 15% Ficoll in water 
Glycerol Tolerant Buffer 10x Stock 
1.8M Tris, 1.7M taurine, 10mM EDTA 
Hybridisation mix 5x Denhardt's, 5x SSC, 0.1% SDS, 0.1% 
sodium pyrophosphate, 20% dextran 
sulphate 
Isopropylthio-ß-D-galactoside (IPTG) 100mM in dH2O 
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Filter sterilize to 0.22 microns, store at - 
20°C 
Kanamycin 10 mg /ml in H2O stock solution, 10 
µg /m1 working concentration. 
LB agar 15g Bacto -agar, 10g Bacto- tryptone, 5g 
Bacto -yeast extract, 5g NaC1, pH to 7.0 
with NaOH, to 1 litre with dH2O 
LB /amp/X - Gal /IPTG plates LB plates made with LB agar as above, 
supplemented with 100µg /ml ampicillin, 
0.5mM IPTG and 80µg /ml X -Gal. 
LB broth lOg Bacto- tryptone, 5g Bacto -yeast 
extract, 5g NaC1, pH to 7.0 with NaOH, 
to 1 litre with dH2O 
PCR buffer 10x buffer: 15mM MgCl2, 100mM Tris- 
HC1 (pH 8.0), 500mM KC1, in dH2O 
Phenol:chloroform:isoamyl alcohol 25:24:1 by volume 
PNK buffer 10x 50mM Tris-HC1 (pH 8.0), 10mM MgC12, 
5mM DTT 
Polyacrylamide gel - denaturing (5 %) 28.8g urea, 6ml 10xTBE, 10m1 30% 
acrylamide stock (19:1), dH2O to 60m1. 
Heat to dissolve. Polymerised with 300µ1 
10% ammonium persulphate and 64111 
TEMED. 
Polyacrylamide gel - non -denaturing 
(8 %) 
6.67m130% acrylamide (19:1), 2.5ml 
10xTBE, dH2O to 25m1, polymerised 
with 500 25% APS and 45111 TEMED. 
Prehybridisation mix 5x Denhardt's, 5x SSC, 0.1% SDS, 0.1% 
sodium pyrophosphate 
Quick Oligo Hybridisation Mix 0.5g bovine serum albumin (BSA), 0.5g 
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polyvinylpyrrolidone , 0.5g Ficoll (type 
400), 1 g SDS, 1 g sodium pyrophosphate, 
250m1 20xSSC, 744m1 dH2O 
Sequencing acrylamide 6% stock 200m130% Acrylogel 5, 19:1 stock, 
480.5g urea, made up to 950m1 with H2O 
Sequencing gels 95ml of 6% acrylamide stock and 5m1 
20x glycerol tolerant buffer, polymerised 
with l00µ1 TEMED and 150[1125% APS 
Sodium dodecyl sulphate (SDS) 10% w /v, in dH2O 
Solution/Buffer Components /Recipe 
Standard saline citrate (SSC) 20x stock 
3M NaCI, 0.3M trisodium citrate, pH to 
7.0 with HC1 





Tris acetate electrophoresis buffer (TAE) 50xstock, per litre: 
242g Tris base, 57.1m1 glacial acetic 
acid, 100m1 0.5M EDTA (pH 8.0) 
Tris borate electrophoresis buffer (TBE) 5xstock, per litre: 
54g Tris base, 27.5g boric acid, 20m1 
0.5M EDTA (pH 8.0) 
X -Gal (5- bromo -4- chloro- 3- indolyl -ß -D- 
galactoside) 
20mg /m1 in dimethylformamide 
Store in darkness at -20 °C 
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CHAPTER 3 
CHROMOSOME 1p36, TP73, NEUROBLASTOMA, AND 
CANDIDATE TUMOUR SUPPRESSOR GENES 
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3.1 INTRODUCTION 
The chromosomal region 1p36 has been implicated in a range of human tumours, but 
perhaps most widely studied to date is the significance of this region in 
neuroblastoma, a cancer of the neural crest accounting for 8% of all childhood 
malignancies. Genetic studies, including both classical cytogenetics and more recent 
techniques such as FISH, microsatellite analysis of loss of heterozygosity (LOH), 
and comparative genomic hybridisation (CGH) (Van Gele et al. 1997), have 
demonstrated that the two most common abnormalities specifically associated with 
neuroblastoma are 1p deletions, occurring in 30 to 40% of cases (Brodeur et al. 
1981), and amplification of the oncogene MYCN, occurring in 25 to 30% of cases 
(Seeger et al. 1985; Brodeur et al. 1984). 
MYCN is located at 2p24.1, and has similarity to the classic MYC oncogene (Schwab 
et al. 1983). Since its identification, amplification of MYCN has been identified in a 
large proportion of neuroblastomas, usually detectable by the presence of 
extrachromosomal double minutes, or homogeneously staining regions. A 
correlation between the amplification of MYCN and allelic loss of the short arm of 
chromosome 1 has been found in neuroblastomas, particularly those of a more 
aggressive nature (Schwab 1990; Fong et al. 1989). Indeed, MYCN has become a 
relatively reliable indicator of prognosis in neuroblastoma, with amplified cases 
being significantly associated with advanced stages of the disease (Brodeur et al. 
1984). 
3.1.1 Neuroblastoma suppressor genes at 1p 
The frequent allelic loss that has been detected at 1 p in neuroblastoma suggests that 
this region harbours a tumour suppressor gene whose loss is associated with the 
development of the disease. Mapping of the extent of the 1 deletions in 
neuroblastoma patients, and taking into account the correlation of only some 1p 
deletions with MYCN amplification has now revealed that there may be more than 
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one suppressor gene at 1 p involved in neuroblastoma. Takeda et al. (Takeda et al. 
1994), characterised 108 neuroblastoma tumours for loss of heterozygosity (LOH) at 
1 p. Of the 21 tumours that they identified to be informative for at least one marker, 
two distinct subgroups emerged from the analysis: firstly, those that had relatively 
small, interstitial deletions specifically at 1p36, had a good prognosis, and were not 
associated with MYCN amplification; and secondly, those that had much larger 
deletions extending from 1pter to 1p32, were much more aggressive tumours with a 
poorer prognosis, and had amplification of MYCN in the majority of cases. These 
findings led Takeda et al. to postulate that there could be two tumour suppressor 
genes at 1 p, which are associated with clinically distinct classes of neuroblastoma. 
Similarly, Schleiermacher et al. (Schleiermacher et al. 1994) analysed LOH in 60 
neuroblastoma patients, and detected two distinct consensus regions of deletion, of 
which only the more proximal one was associated with MYCN amplification. 
Furthermore, in agreement with these two studies, Cheng et al. (Cheng et al. 1995) 
characterised the deletions in seven cell lines without MYCN amplification and found 
them to be small, with the shortest region of overlap at 1p36.23 -33, whereas in nine 
cell lines with MYCN amplification there were larger deletions extending from 1p35- 
36.1 to the telomere. As established in the studies by Takeda et al and 
Schleiermacher et al., the overall conclusions from this study are that there are two 
suppressor genes at 1p, of which only one is associated with MYCN amplification. 
3.1.2 One of the putative neuroblastoma suppressor genes is 
likely to be imprinted 
In a study by Caron et al. (Caron et al. 1993), a significant observation was made 
with regard to the parental origin of the lost allele in 1 deleted cases of 
neuroblastoma: in 13 of 15 patients with LOH at 1p36, the lost allele was of maternal 
origin. This study thus provided the first evidence of imprinting at 1p. However, the 
results of a study by Cheng et al. (Cheng et al. 1993) did not support this idea, since 
they found the allelic loss at 1p in neuroblastoma to be of random parental origin. In 
1995, Caron et al. (Caron et al. 1995) studied the extent of deletions and parental 
origin of allelic loss in neuroblastomas with and without MYCN amplification. They 
97 
reported a significant difference in the results between the two groups, such that 
MYCN single -copy tumours had a small consensus region of deletion at 1p36.2-3, 
and the allelic loss was of preferential maternal origin, whereas the MYCN amplified 
cases showed the characteristic large deletion as observed previously, but the allelic 
loss was of random parental origin. This evidence indicates again that there are two 
tumour suppressor genes at 1p, but for the first time suggests that the more distal 
gene at 1p36 is imprinted, whereas the proximal gene is not. Contrary to the study of 
Cheng et al. (Cheng et al. 1993), Caron et al. (Caron et al. 1995) distinguished 
between MYCN amplified and non -amplified cases of neuroblastoma, and in doing 
this they were able to identify the imprinting effect of only one of the putative 
suppressors, whereas this was masked in Cheng's study. Thus, by analysing the 
parental origin of the allelic loss separately in MYCN amplified and non -amplified 
cases, the conflicting evidence from previous studies was reconciled. 
It is now apparent from these results that this chromosomal region harbours two 
distinct tumour suppressor genes. The first, which is more proximal and is 
eliminated by large deletions extending from the telomere to 1p35, may have some 
kind of role as a repressor of MYCN amplification. Its deletion would therefore 
eradicate this function, allowing amplification of the MYCN oncogene, with 
tumorigenic consequences. Neuroblastoma patients with MYCN amplification and 
deletions of this putative suppressor typically have tumours of a clinically aggressive 
nature, and have poor prognoses. The second putative suppressor gene is located 
more distally at 1p36.23 -33, and is likely to be a maternally expressed imprinted 
gene, since there is preferential maternal loss at this locus. This tumour suppressor is 
not associated with the regulation of MYCN amplification, and patients with 
deletions confined to this region have much better survival prospects. 
3.1.3 Candidates for the imprinted suppressor gene 
Focussing in on the putative imprinted tumour suppressor locus, the identification of 
candidate genes in this region is clearly an important goal. However, the criteria to 
be met in identifying this tumour suppressor are stringent: the evidence has indicated 
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that this suppressor is a maternally expressed imprinted gene, and it must therefore 
be shown that it is the maternal allele that is lost in deletion cases. However, since 
not all neuroblastoma cases are associated with 1 deletions, it must also be expected 
that in at least some non -deletion cases the candidate gene function is eliminated by 
other means, such as mutation of the expressed allele. Additionally, the 
neuroblastoma suppressor would be expected to reside in the consensus region of 
deletion at 1p36.23 -33, and possess an appropriate function which, when eliminated, 
could feasibly be responsible for tumour development. To justify further 
investigation, candidate genes must be known to satisfy at least some of these 
criteria. 
To date, several genes have been proposed as candidates for the putative imprinted 
tumour suppressor at 1p36, mostly on the basis of their genomic location. These 
candidates include 1D3, an inhibitor of DNA binding found to exhibit very low levels 
of expression in neuroblastoma (Ellmeier et al. 1992); TNFR2, a tumour necrosis 
factor receptor gene (White et al. 1993); CDC2L1 (PITSLRE), a cell division control - 
related protein kinase gene deleted in some neuroblastoma cell lines (Lahti et al. 
1994); and DAN, (differential screening -selected gene aberrant in neuroblastoma), a 
transcription factor (Enomoto et al. 1994). Attempts to define the extent and precise 
location of the region of deletion in neuroblastoma had narrowed down this region to 
a 72cM or 28Mb interval, but could not delineate it any more accurately (Fong et al. 
1989; Weith et al. 1989; Takayama et al. 1992; Takeda et al. 1994; Schleiermacher 
et al. 1994). However, a study of LOH in a large panel of primary neuroblastoma 
tumours, and analysis of deletions and breakpoints in neuroblastoma cell lines 
enabled White et al. (White et al. 1995) to refine this interval to 39cM or 8Mb. The 
identification of this consensus region believed to contain the putative suppressor 
gene has eliminated the four proposed candidates mentioned above, on the basis that 
they lie outside the critical boundaries of the interval, suggesting that the true gene 
remained to be identified. A good remaining candidate is the gene human kruppel- 
related 3 (HKR3), a zinc - finger transcription factor gene which maps to 1p36.3, and 
is expressed at particularly high levels in fetal and adult nervous tissue (Maris et al. 
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1997). However, the lack of mutations detected in this gene in neuroblastoma 
tumour DNAs and cell lines argues against a tumour suppressor role. 
3.1.4 TP73, a candidate neuroblastoma suppressor gene 
Perhaps the best proposed candidate to date is TP73, which has been shown to be 
maternally monoallelically expressed in some tissues, and whose protein product 
appears to have cell cycle control functions analogous to those of the structurally 
similar p53 protein (Kaghad et al. 1997). Indeed, the protein encoded by TP73 
shares significant amino acid similarity with the three functional domains of the p53 
protein, with 29 %, 63% and 38% identity between their transactivation, DNA 
binding and oligomerization domains, respectively (Kaghad et al. 1997). 
Overproduction of p73 results in transcriptional activation of p53- responsive genes 
such as CDKNIA (also known as p21N"af), and causes inhibition of cell growth by 
induction of apoptosis, in a manner reminiscent of the action of p53 (Jost et al. 
1997). 
Since its initial characterisation in 1997, TP73 has been pursued as the putative 1p36 
tumour suppressor gene, not only in neuroblastomas, but also in a wide range of 
other tumours associated with this region. Does TP73 fulfil the criteria? The crucial 
factors that led to its proposal as a candidate for the neuroblastoma tumour 
suppressor gene were: 
1. The location of TP73 at 1p36.33 -a region which is frequently deleted in a 
wide range of cancers, but particularly neuroblastoma. 
2. High amino acid similarity of the protein product of TP73 to that of the 
known tumour suppressor gene TP53, and the ability to activate p53- 
responsive genes in order to induce apoptosis. 
3. Monoallelic expression of TP73 in neuroblastoma and non -neuroblastoma 
cell lines, and normal blood. 
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Considering the combination of these factors, it seemed logical to hypothesise that 
TP73 was the putative neuroblastoma suppressor gene at 1p36. Being imprinted 
effectively gives TP73 its first `Knudson hit', since only one allele is expressed. To 
achieve a complete loss of function therefore demands that only the single expressed 
allele is lost by mutation or deletion. By losing the sole expressed allele of TP73, the 
function of the protein in inducing apoptosis would be effectively eliminated. A loss 
of control such as this could be expected to result in tumorigenesis. 
Following the initial characterisation of the TP73 gene, subsequent research has 
focussed on analysing the imprinted status of TP73, and attempting to identify 
tumour -specific mutations that might account for the expected `second hit'. 
Contrary to expectation, mutation screening efforts in a diverse range of tumour 
types associated with allelic loss at 1p36 have so far identified very few mutations in 
TP73. It is apparent that there are several common polymorphisms in the genomic 
sequence of TP73, as these have been detected in many of the mutation screening 
studies described below, but very few tumour- specific alterations have been 
identified that could be envisaged to have a specific role in tumorigenesis. 
Neuroblastoma has been an obvious focus for mutation screening analyses. Kovalev 
et al. (Kovalev et al. 1998) screened the entire open reading frame in 16 
neuroblastoma tumours but detected only common polymorphisms, and no tumour - 
specific alterations. Ichimiya et al. (Ichimiya et al. 1999) analysed 140 primary 
neuroblastomas by SSCP, and found only two tumours with amino acid substitutions 
in the C terminal domain that were likely to result in a loss of function. These 
substitutions were a proline to arginine change, and a proline to leucine change, both 
at residues within the domain of the protein that is expected to have a role in 
transactivation. Ejeskar et al. (Ejeskar et al. 1999), and Han et al. (Han et al. 1999) 
analysed 30 and 23 neuroblastomas respectively, but detected only common 
polymorphisms in the gene. 
101 
In lung cancer, Mai et al. (Mai et al. 1998a) and Nomoto et al. (Nomoto et al. 1998) 
analysed 21 and 61 lung cancer cases respectively, detecting only silent nucleotide 
substitutions and polymorphisms that were present in both normal and tumour 
samples. Yoshikawa et al. (Yoshikawa et al. 1999) identified substitutions and 
deletions that affected the amino acid sequence in 3 of 17 lung cancer cell lines. One 
of these cell lines had a glycine to tryptophan substitution. The alterations in the 
other two cell lines were a 12bp deletion in exon 13, resulting in a substitution of one 
amino acid and deletion of the next four; and deletions of 2bp and 4bp in exon 10, 
resulting in the deletion of two amino acids but retaining the reading frame. 
Yoshikawa et al. speculated that these could be cancer related alterations, despite not 
having analysed any normal samples. In hepatocellular carcinoma, Mihara et al. 
(Mihara et al. 1999) were unable to detect any tumour specific mutations in 48 
untreated tumour samples; Peng et al. (Peng et al. 2000) however did identify one 
apparently tumour -specific 5- nucleotide deletion when they analysed 22 pairs of 
tumour and matched normal samples. Mutational analysis of TP73 was performed in 
prostatic cancer by Takahashi et al. (Takahashi et al. 1998), and Yokomizo et al. 
(Yokomizo et al. 1999a), but the few genetic alterations detected were also found to 
be present in normal samples, and were considered to be neutral sequence 
polymorphisms. In colorectal cancer Sunahara et al. (Sunahara et al. 1998) and Han 
et al. (Han et al. 1999), used SSCP techniques to analyse 82 and 43 tumour samples 
respectively, and as with other studies identified common polymorphisms present in 
both tumour and normal samples, but failed to identify any tumour -specific 
alterations in the sequence. Similarly, in gastric cancer, Kang et al. (Kang et al. 
2000), and Han et al. (Han et al. 1999) identified only polymorphisms in their 
mutation screening efforts. To analyse bladder tumour samples for the presence of 
TP73 mutations, Yokomizo et al. (Yokomizo et al. 1999b) employed the denaturing 
high -performance liquid chromatography technique (DHPLC), but identified only 
polymorphisms that had been previously documented. Bladder cancer was also 
scrutinised for mutations in TP73 by Chi et al. (Chi et al. 1999), but their SSCP 
analyses did not reveal any mutations. Breast cancer, for which a high frequency of 
allelic loss at 1p has been established, was screened for mutations by Shishikura et 
al. (Shishikura et al. 1999), Zaika et al. (Zaika et al. 1999), Schwartz et al. (Schwartz 
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et al. 1999), and Han et al. (Han et al. 1999), but apart from several common 
polymorphisms, revealed only one genetic alteration that resulted in an amino acid 
substitution. 
The range of cancer types studied for the presence of mutations in the TP73 gene 
also includes melanoma (Kroiss et al. 1998; Schittek et al. 1999; Tsao et al. 1999), 
ovarian cancer (Ng et al. 2000), oesophageal cancer (Nimura et al. 1998), 
oligodendrogliomas (Mai et al. 1998b; Tsujimoto et al. 2000), and Merkel cell 
carcinomas (Van Gele et al. 2000), but again very few tumour -specific genetic 
alterations have been identified. Whilst the tumour suppressor gene TP53 is mutated 
frequently in most of these cancers, TP73 is rarely subject to alterations that could 
cause a loss or alteration of its function. From the extensive scale of the mutation 
screening studies described above, and the diverse range of tumour types that have 
been analysed, it is justifiable to conclude that mutations of this gene are very 
infrequent. Thus, the possibility that mutation could act as a second `hit' in the 
inactivation of TP73 in a classic tumour suppressor model is unlikely. 
With regard to the imprinting of TP73, despite the initial report of monoallelic 
expression by Kaghad et al. (Kaghad et al. 1997), a significant proportion of the 
evidence generated by subsequent studies has been contradictory to this, revealing 
biallelic expression of TP73 in both fetal and adult normal tissues (Hu et al. 2000; 
Yokomizo et al. 1999a; Yokomizo et al. 1999b; Kovalev et al. 1998; Chen et al. 
2000; Peng et al. 2000). With few exceptions, the results of expression analysis 
generally fall into one of two categories: 
1. The TP73 gene is imprinted, and shows monoallelic expression in normal 
tissues. However, rather than finding loss of the expressed allele in cancer, 
which would be expected in a two -hit suppressor gene model, it was shown 
that TP73 was biallelically expressed in tumours. In effect, the transition 
from monoallelic to biallelic expression of TP73 was associated with the 
development of cancer. In renal cell carcinoma, Mai et al. (Mai et al. 1998c) 
investigated the expression status of TP73 using a polymorphism in exon 2, 
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and demonstrated monoallelic expression in eleven of twelve normal tissues, 
but biallelic expression in eight of the twelve corresponding tumour samples. 
They confirmed monoallelic expression using a different polymorphism in 
two informative families, and were able to attribute the expression to the 
maternal allele in fetal pancreas and thymus. Thus, their results are in 
agreement with the original reports of maternal -specific monoallelic 
expression (Kaghad et al. 1997), and suggest that the loss of imprinting and 
resultant biallelic expression of the gene is a common event that may be 
associated with renal cell carcinoma. Using the same polymorphism, Chi et 
al. (Chi et al. 1999) found that 52.2% of heterozygous bladder cancer 
specimens expressed TP73 biallelically, whereas four non -cancerous samples 
did not, although these were not matched pairs. They did however find 
tumour -specific biallelic expression in one matched pair, suggesting that the 
activation of a silent allele of the gene may be related to the progression of 
cancer. In gastric adenocarcinoma, Kang et al. (Kang et al. 2000) 
demonstrated monoallelic expression in 19 non -cancerous samples, and 
biallelic expression of 23.8% of the corresponding cancer samples, 
suggesting that the biallelic expression of TP73 may be involved in a subset, 
but not all cases of gastric adenocarcinoma. Similarly, a switch from 
monoallelic expression to biallelic expression was identified in 50% of 
neuroblastomas (Liu et al. 2000b), and 27% of oesophageal squamous cell 
carcinomas (Cai et al. 2000), suggesting that this mechanism may be relevant 
in some, but not all cancers. 
Conversely: 
2. The TP73 gene is not imprinted, and shows biallelic expression in both 
normal and tumour DNA. However, the level of expression of TP73 is found 
to be significantly increased in tumours as compared to matched normal 
samples. Studies that fall into this category include those by (Kovalev et al. 
1998) (Yokomizo et al. 1999b) and (Chen et al. 2000b). Kovalev et al. found 
biallelic expression in three of three normal tissues and five of six 
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neuroblastomas, but identified elevated expression of the TP73 gene, such 
that tumours overexpressed the gene up to 90 -fold more than normal tissues. 
Yokomizo et al. found biallelic expression of TP73 in both normal and 
bladder cancer samples, thus refuting evidence for imprinting of this gene, yet 
they detected an average 6 -fold overexpression in 22 of the 23 samples 
analysed, with as much as a 20 -fold increase in some samples. Chen et al. 
identified biallelic expression in 70.8% of normal samples and 91.7% of 
ovarian cancer samples, suggesting that although a minority may undergo a 
switch from monoallelic expression to biallelic expression, the majority 
express the gene biallelically in both normal and cancerous states. However, 
overexpression of the gene was correlated to advanced ovarian cancer rather 
than earlier stages or borderline ovarian tumour, indicating that the elevated 
expression of the gene may be a factor in the progression of tumours. 
Clearly, whether TP73 is actually imprinted remains questionable, perhaps due to a 
complex pattern of tissue -specific, and time -specific imprinting, and even variability 
between individuals. However, what is of more interest from these findings, is that 
irrespective of which of the above scenarios holds true, the consequences are very 
similar - it would appear that overexpression of TP73 is associated with 
tumorigenesis, whether by transition from monoallelic to biallelic expression in the 
tumour, or merely by upregulation of the normal expression levels of the biallelically 
expressed gene. Indeed, most of the studies described above in which a transition 
from monoallelic to biallelic expression was detected, also demonstrated increased 
expression of the gene, which in these cases is likely to be attributable to the switch 
from the expression of one allele to the expression of two. As suggested by Zaika et 
al. (Zaika et al. 1999), since the imprinting of TP73 is so "idiosyncratic ", and a 
consistent pattern has not been established, it is of more relevance to look for 
tumour -specific changes in expression levels of TP73. Along these lines, there are 
several studies that have not investigated the imprinting status of TP73, but instead 
have assessed only the expression levels and found a higher level of TP73 expression 
in tumours as compared to normal DNA controls, for example Sunahara et al. found 
increased TP73 levels in colorectal carcinomas as compared to normal controls 
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(Sunahara et al. 1998); Tannapfel et al. detected elevated TP73 levels in a subset of 
hepatocellular carcinomas (Tannapfel et al. 1999), and Tokuchi et al. found that in 
87% of lung cancers TP73 was expressed at more than twice the level of the matched 
normal sample (Tokuchi et al. 1999). 
Unexpectedly therefore, and in contradiction with the originally proposed hypothesis 
of TP73 acting as a tumour suppressor gene, it is now apparent that the involvement 
of TP73 in cancer is related to its upregulation, rather than its loss. This finding is 
substantiated by the recent report that transgenic mice deficient in TP73 do not have 
an increased susceptibility to spontaneous tumorigenesis (Yang et al. 2000), 
indicating therefore that TP73 is not acting as a tumour suppressor gene. If, 
conversely, it is the upregulation of TP73 that is associated with cancer, what is the 
mechanism by which this overexpression causes cancer? One proposed mechanism 
is that the p73 protein plays a role in controlling p53 function, by inhibiting its DNA 
binding (Vikhanskaya et al. 2000). The experiments that resulted in this postulate 
involved transfection of wild type p73 into a p53- expressing ovarian cancer cell line, 
which had the effect of significantly decreasing the transcriptional activity of p53. 
Similar experiments transfecting the same cell line with a mutant version of p73 
(containing a defect in the DNA binding site) did not cause the decrease in p53 
transcriptional activity. The conclusions from this study were that p73 modulates 
p53 function by inhibiting its DNA binding, and in this way, overexpression of TP73 
could be a novel mechanism of inactivation of TP53. 
In accepting that TP73 is highly unlikely to be the putative neuroblastoma tumour 
suppressor gene at 1p36, future research must be directed at both understanding the 
alternative role of TP73 in cancer, but perhaps more importantly, continuing the 
search for the tumour suppressor gene which remains undiscovered in this 
chromosomal region. To use TP73 as a starting point for the identification of further 
candidate genes is justifiable for two reasons: firstly, TP73 resides in the consensus 
region of deletion as determined by deletion mapping studies in neuroblastoma, and 
secondly, there is evidence for imprinting in this region, which, although conflicting, 
cannot be disregarded. Since imprinted genes tend to be clustered together in the 
106 
genome, it is probable that other imprinted genes will be found in this region. The 
purpose of this study therefore was to systematically investigate the region 
surrounding TP73, to determine whether other genes might reside close to TP73, and 
whether such genes might be imprinted and could be considered as candidates for the 
putative neuroblastoma suppressor gene. 
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3.2 RESULTS 
3.2.1 Isolation and initial characterisation of PAC clone 79- 
L8, containing the TP73 gene 
To begin to analyse the region surrounding TP73, it was necessary to obtain a PAC 
clone containing the gene, since only the cDNA sequence of TP73 was available at 
this time. Using primers p73 -3 and p73 -4, as described in (Kaghad et al. 1997), a 
product of 482bp representing part of exon 2 of TP73 was generated from genomic 
DNA. Sequencing confirmed that it was the correct product. This PCR product was 
labelled and used as a hybridisation probe for identifying a PAC clone from the high - 
density gridded filters of the RPCI1 human PAC library from HGMP. A single 
clone, 79 -L8 was identified. 
In an attempt to identify putative CpG islands within the PAC clone 79 -L8, DNA 
was prepared from the clone, and analysed by digestion with Notl, Ascl, and double 
digestion with Notl and Ascl together. The recognition sequences of the Notl and 
Ascl restriction enzymes are GCGGCCGC and GGCGCGCC respectively. These 
are rare- cutting enzymes, and any sites for these enzymes are highly likely to reside 
within a CpG island due to the presence of the CpG dinucleotides within the 
recognition sequences. 
The products of digestion were separated on a pulsed field gel, shown in Figure 4. It 
appears that there are five fragments generated by digestion with Notl, of 
approximate sizes 55kb, 45kb, 18kb, 16kb and 15kb. The 16kb fragment 
corresponds to the expected size of the vector fragment, since the insert is cloned into 
a Notl site. To distinguish between the similar sized fragments of 15kb and 16kb, an 
unrelated PAC clone was also digested with Notl, and run alongside PAC clone 79- 
L8; the band that is common to both clones represents the vector, thus confirming 
that the other fragment of 15kb is part of the insert of PAC 79 -L8. The fragments 
resulting from digestion with Ascl are of approximate sizes 65kb and 85kb. These 
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results indicate that there are five Notl sites in 79 -L8 (of which three are internal, and 
two are the end sites), and two Ascl sites. Additionally, the results indicate that the 







M Undig. AscI Other Notl Notl Notl /Asa 
<-55kb 
<-45kb 
- 16kb vector 
Figure 4. 1% PFGE gel of restriction digests of PAC clone 79 -L8. M is the NEB 
midrange PFG marker, with bands of sizes indicated on the left. Undig. is a sample 
of undigested PAC clone DNA, to determine the clone size. The PAC clone was 
digested singly with Ascl, NotI, and doubly with both Notl and Ascl. The lane 
marked `Other' is a NotI digest of an unrelated PAC clone, to assist in identification 
of the common 16kb vector band. Electrophoresis conditions were 6V /cm, 14 °C, 
with switch times between the alternating electric fields ramped from 1 to 10 seconds 










































































































































































































































































































































































































3.2.2 Subcloning the Noti and Ascl sites of PAC clone 79 -L8 
for methylation status analysis 
Since the sites recognised by the restriction enzymes Notl and Ascl almost always lie 
within CpG islands, which are themselves associated with genes in at least 60% of 
cases, subcloning fragments adjacent to these sites and analysing their methylation 
status should be an efficient way of detecting differential methylation, which may be 
indicative of an imprinted gene. To this end, DNA from PAC 79 -L8 was double - 
digested with Notl and SacI, and the resulting fragments subcloned into the 
Invitrogen vector pCRII. Similarly, fragments resulting from double- digestion with 
AscI and SacI were subcloned into the Promega vector TVEC. From the results of 
the pulse field gel electrophoresis experiment, it would be expected to obtain eight 
possible different Notl /Sad subclones and four possible different AscI /SacI 
subclones. Figure 5 is a schematic diagram to explain the origin of the eight possible 
NotI /SacI subclones and the four possible Ascl /Sad subclones that would be 
expected from this experiment. 
Following transformation of competent cells with the ligated vector, colonies 
containing inserts were selected by a standard blue -white selection procedure using 
ampicillin/X- Gal /IPTG plates. White colonies were picked, grown overnight, and 
DNA prepared from the cells. To determine insert size, the inserts were digested out 
of both the TVEC and pCRII vectors by a double digest with Notl and SacI, and the 
digest run alongside an uncut sample on an agarose gel. Inserts cannot be digested 
out of the TVEC vector with Ascl and SacI because the MIuI cloning site is destroyed 
by the ligation, but a Notl /Sad double digest is appropriate to release the insert from 
the TVEC vector as well as from pCRII, because the cloning site of TVEC is flanked 
by Notl and SacI sites. Figure 6 shows an example of this analysis for seven of the 
subclones. The objective of this analysis was to identify the eight different classes of 
Notl /Sad subclone, and the four different classes of AscI /SacI subclone, on the basis 
that the different classes are distinguishable by insert size. After several attempts, 
only five of the eight Notl /Sad subclones were identified, including the two Notl 
subclones representing the Notl sites at the ends of the clone, and three others 
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arbitrarily named P3, P20, and P25. All four of the AscI /SacI subclones, named T1, 
T3, T8 and T9, were identified. Sequencing of the beginning of the inserts of the 
subclones with the M13 forward primer enabled the sequences to be checked against 
the BLAST database. There were problems associated with the techniques in this 
experiment, in that approximately 25 -30% of subclones were found to contain inserts 
derived from E. coli sequences. Additionally, it would seem that preferential 
subcloning of some of the Notl /SacI fragments was occurring, to the extent that some 
fragments were never subcloned. This may have been due to a bias in insert size 
preference of the subcloning system under these conditions. 
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Figure 6. Analysis of insert size following subcloning of NotI -SacI digest fragments 
of PAC clone 79 -L8 into the vector pCRII. The gel shows the analysis of insert size 
for four subclones. Each pair of lanes represents a sample of the undigested (U) and 
digested (D) subclone DNA. Digests were performed using NotI and Sacl together. 
Sizes of the lkb ladder bands are given on the left. 
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To analyse the methylation status of the subclones Ti, T3, T8, T9, P3, P20 and P25, 
genomic Southern blots were prepared for each of these subclones, comprising both 
normal and parthenogenetic DNA digested singly with SacI, and doubly with either 
Notl and Sacl, or Ascl and SacI accordingly. The insert of each of the subclones was 
used as a probe to hybridise to the appropriate Southern blot. The purpose of this 
was to detect if differential methylation was present between the paternal and 
maternal alleles. For example, if the NotI site associated with a NotI /SacI subclone 
was differentially methylated on the two parental alleles, the probe would be 
expected to hybridise to a large fragment in the normal SacI digest, but to both this 
fragment and a smaller fragment in the normal NotI /SacI digest (the large SacI 
fragment representing a methylated allele which prevents NotI digestion, and the 
smaller fragment representing an unmethylated site, where NotI has digested the 
large SacI fragment into two smaller fragments, one of which is detected by the 
probe). This would indicate differential methylation. The parental origin of the 
methylated and non -methylated alleles would be apparent from the equivalent 
hybridisation of the parthenogenetic blots, depending on whether the probe 
hybridised to the larger (methylated) or the smaller (unmethylated) fragment. Figure 












Not /Sac Sac Not/Sac Sac 
PG PG N N 
1kb 
SacI 
1. Differential methylation, with 
the maternal allele methylated. 
2. Differential methylation, with 
the paternal allele methylated. 
3. No differential methylation. 
Both alleles methylated. 
4. No differential methylation. 
Both alleles unmethylated. 
Figure 7. Diagram to explain the Southern blot analysis of methylation status. 
A hypothetical 2kb SadI fragment containing a Notl site is shown at the top. 
The visual result of the four possible scenarios with respect to the methylation 
status of the Notl site is given in 1 -4. PG = parthenogenetic DNA. N = 
normal genomic DNA. 
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The subclones T1, T3, T8, T9, P3, P20 and P25 were analysed by this method. The 
results of Ti and T3 are shown in Figure 8. In the case of T1, the AscI site is 
completely methylated, and in the case of T3, the Ascl site is completely 
unmethylated. The pattern is the same for both normal and parthenogenetic DNA, 
and therefore there is no evidence for differential methylation. 
The analysis of all other subclones was unsuccessful. This was due to the presence 
of repeats in the probe sequence in the case of T9 and P3, which resulted in non- 
specific binding of the probe to the filter thus obscuring the genuine result. In the 
case of subclones T8, P20 and P25, the probes did not appear to hybridise to the 
blots, suggesting that the hybridisation conditions were not optimal, yet repeated 
attempts to rectify this did not generate any positive result. 
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AscI-SacI subclone Ti 
PG PG N N kb 
S/A S S/A S 
FT77,;;;, 
Ascl-SacI subclone T3 
PG PG N N kb 
S/A S S/A _..., 
1.6kb 
Figure 8. Analysis of methylation status of AscI sites in PAC clone 79 -L8. The 
inserts of subclones Ti and T3 were used to probe genomic Southern blots of digested 
parthenogenetic (PG) and normal (N) control DNA, digested with Sacl and Ascl 
together (S /A), or with SacI alone (S). The Ascl site associated with subclone Ti is 
methylated, whereas the Ascl site associated with subclone T3 is unmethylated. There 
is no evidence of differential methylation between the maternal and paternal alleles in 
either case. The 1.6kb band of the kilobase ladder marker is visible. 
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The methylation analysis of the NotI and AscI sites of PAC clone 79 -L8 did not show 
any evidence of differential methylation, although as described above, the 
experiments were unsuccessful in some cases due to the presence of repeat 
sequences. Additionally, not all the sites were successfully subcloned, so the results 
are incomplete and do not represent a full analysis of the methylation status of all 
NotI and AscI sites in 79 -L8. Taking a different approach, it was decided to analyse 
the region at the expression level, to look specifically for differential expression of 
TP73 rather than differential methylation of the region. 
3.2.3 Is TP73 imprinted? 
There are now known to be at least eleven common polymorphisms in the coding 
sequence of TP73 (Schwartz et al. 1999). At the time of this study however, there 
were only four identified polymorphisms in TP73. One of these, at residue 1781 of 
the cDNA sequence accession number Y11416 was chosen for RT -PCR experiments 
because it alters a site for the restriction enzyme BstUI, such that the site is present 
when the polymorphic base is `A', but is removed if the polymorphic base is `G'. 
Taking advantage of this fact, it was possible to identify informative fetuses for this 
polymorphism to use in an RT -PCR experiment. 
A panel of 66 first trimester fetal DNAs was available, along with corresponding 
maternal DNAs for the majority of them. Paternal DNAs were not available. Details 
of this panel are given in Table 1 in Materials and Methods. The rationale behind 
this RT -PCR experiment is that if a fetus can be identified that is heterozygous for 
the TP73 1781 polymorphism, with a mother who is homozygous for the same 
polymorphism, then the parental origin of both alleles in the fetus is known, since the 
non -maternal allele in the heterozygous fetus must be derived from the father. 
Performing RT -PCR on RNA from the heterozygous fetus enables the expression 
status of TP73 to be analysed with respect to the parental origin of the expressed 
allele(s). 
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3.2.3.1 Polymorphism 1781 
The panel of fetal DNAs was first genotyped with respect to the polymorphism at 
residue 1781, by using primers 1781POLY5' and p73 -RT3', to generate a PCR 
product of size 179bp, followed by digestion of the PCR products with the restriction 
enzyme BstUI, and electrophoresis of the resulting fragments on 3% NuSieve 
agarose gels. Figure 9 shows the location of these primers, in relation to the 
polymorphic BstUI site. The PCR product contains the polymorphic BstUl site, and 
an additional, non -polymorphic BstUI site, which functions effectively as an internal 
control for complete digestion. When digested, the resulting fragments comprise a 
67bp fragment in all cases, and a 112bp fragment which is intact when the 
polymorphic residue is G, but is further digested into two fragments of 85bp and 






































































































































































































































































































































































































































Four heterozygous (G /A) fetuses were identified, known as 21' (FB 11), 29' (SG28), 
V (JF101272), and 14 (CM181169). Maternal genotyping by the same procedure 
revealed the corresponding maternal DNAs of 29' and 14 to be homozygous (G /G) 
for the 1781 polymorphism. Maternal DNA V was heterozygous, thereby rendering 
this fetal sample uninformative. Corresponding maternal DNA was unavailable for 
the fetus 21'. Irrespective of whether or not each fetus was fully informative with 
respect to parental origin of each allele, all fetuses were analysed, since RT -PCR will 
still demonstrate whether one or both alleles are being expressed. However, should 
monoallelic expression be detected, it is only in fully informative cases that 
expression can be attributed to specific parental origin. 
RT -PCR primers p73 -RT5' and p73 -RT3' were designed so that the RT -PCR product 
spans the splice junction between exons 13 and 14 (Figure 9.) The reason for 
spanning a splice junction is to ensure that the RT -PCR product originates only from 
RNA; the presence of an intron in the genomic sequence means that any 
amplification from contaminating genomic DNA would generate a much larger 
product that also included the genomic sequence of the intron, which would be easily 
distinguishable from the correct RT -PCR product on the basis of size. This is a 
crucial point in the experimental design - without this feature, an identically sized 
RT -PCR product could feasibly be generated from both contaminating genomic 
DNA and reverse -transcribed RNA, and this could significantly distort the results. 
RT -PCR was performed on RNA from various tissues of the heterozygous fetuses 
21', 29', V and 14, using primers p73 -RT5' and p73 -RT3', to give a product of size 
232bp. However, two products were observed; one of the expected size 232bp, and 
another much larger product of approximately 1.2kb. Figure 10 shows the products 
of the RT -PCR experiment for the four fetuses FB11, SG28, JF101272 and 
CM181169. There are two likely explanations for this result. Firstly, the 
amplification conditions may not be sufficiently specific, therefore allowing one of 
the RT -PCR primers to anneal non -specifically elsewhere on the reverse -transcribed 
eDNA, or secondly the larger product may be generated from contaminating 
genomic DNA. Attempts to eliminate the larger band, by both DNaseI pre- treatment 
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of the RNA, and PCR optimisation were not effective. However, the successful RT- 
PCR products from the heart, muscle, lung, eye, and kidney of fetus JF 101272 were 
less affected by this problem (Figure 10), and were digested by BstUI and 
electrophoresed on a 3% NuSieve agarose gel, shown in Figure 11. Digestion of the 
RT -PCR products with BstUI should cleave the 232bp product into fragments of 
67bp and 165bp if the polymorphic base is A, but the 165bp fragment is cleaved 
further into two fragments of 138bp and 27bp if the polymorphic base is G. In all 
five tissues of this fetus, the 232bp RT -PCR product was digested into fragments of 
165bp, 138bp and 67bp (and presumably a band of 27bp which is not visible here), a 
result which suggests that both alleles are expressed, and that TP73 is biallelically 
expressed in these fetal tissues, at least within this individual. 
To confirm the presence of both alleles in the RT -PCR product, the 232bp band 
derived from heart (fetus JF101272) was excised from the gel, purified, and 
sequenced on both strands. At the polymorphic site, both G and A residues can be 
seen (Figure 12), thus confirming the result of the digests described above. 
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Fetus FB11 Fetus SG28 
kbE B A K G H M L B H G EM 
00040 .. 
two opsw <-232bp 
Fetus JF 101272 Fetus CM 181169 
kbG H M A L E K K G M C B T E 
Alh <-232bp 
Figure 10. RT -PCR products for the TP73 polymorphism at residue 1781, for four 
different fetuses. The tissues are as follows: E = eye, B = brain, A = adrenal, K = 
kidney, G = gut, H = heart, M = muscle, L = lung, C = cord, T = testes. The smaller 
product is of the expected size of 232óp. 
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Heart Muscle Lun _Eye__ Kidney 
.-------. .----. .-----, 





Figure 11. TP73 RT -PCR products for heart, muscle, lung, eye and kidney, of fetus 
JF101272, digested with BstUI and electrophoresed on a 3% agarose gel alongside 
corresponding undigested RT -PCR product. The uncut RT -PCR product is 232bp. 
Figure 9 explains the expected digestion products for heterozygous and homozygous 
individuals. Note that the 27bp fragment is not resolved on this gel. The sizes of the 




Figure 12. Example of TP73 RT -PCR product derived from fetal heart, sequenced in 
both forward and reverse directions to demonstrate that both parental alleles are 
present at the polymorphic residue 1781 (A /G on the forward strand; C/T on the 
reverse strand), and that expression of TP73 is therefore biallelic in this case. 
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In summary, this study did not reveal any evidence to suggest that TP73 is imprinted 
in the heart, muscle, lung, eye or kidney of first trimester fetuses. Expression is 
apparently biallelic in these tissues according to the results presented here. However, 
this does not rule out the possibility that TP73 may be imprinted in other tissues, or 
other stages of development. 
Having found no evidence that TP73 is imprinted, the next logical step was to extend 
the search of this region by identifying PAC clones overlapping the PAC clone 79- 
L8. 
3.2.4 Assembly of a contig of PAC clones and cosmids at 
1 p36, and identification of the DFFB gene. 
In order to identify the PAC clones adjacent to PAC clone 79 -L8, for the purpose of 
constructing a contig of clones, an oligonucleotide named E2 -T7, specific to the 
sequence at the T7 end of PAC clone 79 -L8, was hybridised to the high density 
gridded filters of the RPCI1 human PAC library. This identified two overlapping 
PAC clones; 71 -C21 and 286 -D6. Sequencing at the T7 and SP6 ends of each of 
these clones generated approximately 200 -300bp of sequence, which was then 
searched for any similarity to known sequences by BLAST searching. In this way, 
the T7 sequence of PAC clone 71 -C21 was found to be apparently identical to part of 
a known published cDNA encoding the recently identified gene CPAN /CAD /DFFB 
(Halenbeck et al. 1998), (which will be known as DFFB in this study). The BLAST 
match is shown in Figure 13. The identity between the genomic sequence at the T7 
end of PAC clone 71 -C21, with the cDNA sequence of DFFB, spans a region of 
93bp, after which the sequences diverge from each other. This point of divergence is 
likely to represent a splice junction in the cDNA sequence. This is shown in Figure 
13. 
Since the PAC clones 79 -L8 and 71 -C21 containing respectively the genes TP73 and 

































































































































































































































































































































































































































































































































































































































































































































































































The gene DFFB encodes a 40kDa protein that induces DNA fragmentation after 
activation by caspase -3, in response to apoptotic stimuli. The protein was first 
described in the mouse, as DFF (DNA fragmentation factor), by Liu et al. (Liu et al. 
1997). They showed that it exists in a heterodimeric complex of 40kDa and 45kDa 
subunits. The larger of the two subunits is cleaved at two sites by caspase -3 to 
generate an active factor, which has the capacity to induce DNA fragmentation and 
chromatin condensation during apoptosis (Liu et al. 1998). The same protein was 
identified and characterised in the mouse by another group, who called it caspase 
activated DNase (CAD). Similarly, they found that the complex comprised CAD 
together with an inhibitor protein ICAD that contains cleavage sites for caspase -3 
(Enari et al. 1998; Sakahira et al. 1998). The human homologue of the DFF or 
CAD /ICAD complex was first described by Halenbeck et al. (Halenbeck et al. 1998), 
who referred to it as caspase activated nuclease (CPAN). Their experiments 
demonstrated that as a nuclease, CPAN is sufficient to degrade naked DNA and 
induce apoptosis in naïve nuclei. Mukae et al. (Mukae et al. 1998), cloned the 
human CAD independently, and showed it to be expressed in a variety of tissues 
including pancreas, spleen, prostate and ovary. They also concluded that CAD is 
responsible for DNA fragmentation during apoptosis, and that the gene encoding 
CAD /CPAN /DFF40 maps to human chromosome 1p36.3. To summarise, DFFA is 
the gene that encodes ICAD /DFF45, which was previously mapped to 1p36.3 (Leek 
et al. 1997); DFFB encodes CAD /CPAN /DFF40, and also maps to 1p36, close to 
TP73. 
To assemble a contig of the PAC clones 71 -C21, 79 -L8, 286 -D6, their relative 
orientations were determined. A short STS was designed at both the T7 and SP6 
ends of each of the PAC clones 71 -C21, 79 -L8 and 286 -D6, for the purpose of 
orientating each clone with respect to the others. Performing these STS PCRs on 
each of the PAC clones and also on a cosmid, 176 -g8 or 44 -N16 (identification of 
this cosmid is described in detail later) revealed which ends overlapped the other 
clones (Figure 14a), and a contig was assembled by making deductions from this 
information (Figure 14b). 
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The physical and chromosomal relationship between some of these clones was 
examined by FISH /fibre FISH (performed by Dr. F.Speleman and his group). 
Firstly, since DFFA has also been shown to map to the chromosomal region 1p36.2- 
36.3 (Leek et al. 1997), the positions of these two genes relative to the centromere 
were determined. This was performed using dual colour FISH, with the PAC clone 
92 -K14 (found to contain DFFA by Leek et al. (Leek et al. 1997)), and the cosmid 
clone 176 -g8 which contains DFFB. These probes were distinguishable on 
prometaphase chromosomes, with DFFB mapping distal to DFFA, with respect to 
the centromere. An amino acid comparison of DFFA and DFFB reveals significant 
similarity, particularly at the N- terminus. This is shown in Figure 15. Considering 
the close proximity of these genes to each other, it is likely that they evolved at least 
partly through a gene duplication mechanism. 
Secondly, fibre FISH was also used to determine the percentage overlap of clone 71- 
C21 with each of the other clones 79 -L8, 286 -D6 and cosmid 176 -g8. The results of 
this were as follows, with the overlap of 71 -C21 given as a percentage of the length 
of the other clone: 79 -L8: 23 %; 286 -D6: 55 %; 176 -g8: 19 %. These results confirm 
the clone orientations already established by STS analysis as shown in Figure 14, and 
provide additional quantitative data about the extent of each overlap. The results of 
the FISH analysis are illustrated in the paper attached in the Appendix at the end of 





















































































































































































































































































































































































































































Figure 15. Dotplot comparison of the amino acid sequence of DFFB (339 amino 
acids) with DFFA (331 amino acids). Lines represent regions of significant identity 
between the two sequences; there is particular homology at the N terminus. The 
scale represents amino acids. The comparison was performed using UWGCG 
COMPARE (window size 30, stringency 11). 
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3.2.5 DFFB -a candidate tumour suppressor gene for 
neuroblastoma? 
On the basis of its chromosomal location and putative biological role, DFFB already 
satisfies some of the criteria that must be fulfilled by candidates for the 
neuroblastoma tumour suppressor gene (see 3.1). DFFB is likely to reside within 
approximately 200kb of TP73, which is itself inside the consensus region of deletion 
at 1p36.23 -33. Considering its role in apoptosis as a caspase- activated DNA 
fragmentation factor, it is easy to envisage how loss of this function would result in 
failure of apoptotic DNA degradation, thus predisposing to tumour development. 
This idea is supported by the observation that the absence of caspase -3 function in 
mice results in an apoptotic defect, which is confined to the central nervous system, 
and results in the accumulation of abnormal neuronal precursors (Kuida et al. 1996). 
Further investigation of DFFB was therefore considered justified for the reasons 
described above. This first demanded analysis of the genomic organization, in order 
to subsequently address the two main issues of whether DFFB is mutated in tumours 
associated with deletions of this region, and whether it is imprinted. 
3.2.6 Analysis of DFFB gene structure 
No information had been published regarding the gene structure of DFFB, except for 
a partial cDNA sequence (coding region only), which is reproduced in Figure 16 
(Halenbeck et al. 1998). The BLAST match of DFFB residues 770 -678 with 
residues 1 -93 of the T7 sequence of PAC clone 71 -C21 suggests that there is a splice 
between residues 677 and 678, because the PAC sequence diverges from the cDNA 
at this point, and because the genomic sequence shows a consensus splice acceptor 
sequence (Figure 13). In order to locate other splice junctions, sequencing primers 
(CPAN1 - CPAN6) were designed approximately every 120bp in the cDNA, and 
used for sequencing directly on PAC clone 71 -C21. By analysing where the 
resulting sequences diverged from the known cDNA sequence, splice junctions were 
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identified. For each new splice junction that was identified, flanking primers were 
designed, and used to determine the approximate intron size by PCR on both PAC 
71 -C21 DNA and genomic DNA. These primers are named CPAN OF, 3F, 5AR, 
242 -5', 242 -3', 321 -5', 321 -3', 678 -5', 678 -3', OAF, 6F, 7R, 8R, 9R, 4AF, 5BR, 1AR, 
9F, 677- int -R, 677- int -F, 430- int -R, and 4F, and their sequences are given in 
Appendix 2.A.1, Materials and Methods. Five splice junctions were identified, 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Two disadvantages of using PAC clone 71 -C21 became apparent. Firstly, direct 
sequencing on this clone was not consistently successful, perhaps due to the quality 
or amount of the DNA. Secondly, the analysis could not be completed, because PAC 
71 -C21 contains only part of the DFFB gene. All of the sequence which is 3' of base 
771 of the cDNA is absent from the PAC clone. To overcome both of these 
problems, a cosmid clone was obtained, which contained the entire DFFB gene. 
This was done by generating a 311bp genomic PCR product (with primers 6F and 
9R) spanning residues 685 to 995 of the cDNA, for use as a hybridisation probe for 
the filters of the LLO1NC01 chromosome 1 cosmid library obtained from HGMP- 
RC. This PCR product was chosen as the probe because it covers a substantial 
region of the cDNA, and is located in the part of the gene that is absent from PAC 
clone 71 -C21. It would therefore be expected to identify a clone containing at least 
the missing region of the cDNA, if not the entire DFFB gene. A single cosmid clone 
was identified by the hybridisation; 176 -g8 (also known as 44 -N16.) 
NB. As will be explained later, the 6F /9R PCR product used as probe was actually, 
with hindsight, likely to be derived from a chromosome 9 DFFB pseudogene. 
However, since the cosmid was identified within a chromosome -1 specific library by 
hybridisation, it can nonetheless only contain the real DFFB gene, which is on 
chromosome 1. The pseudogene -specific hybridisation probe was still able to detect 
the real gene because there is sufficient sequence homology between this and the 
pseudogene (see below) to allow hybridisation at this stringency. 
Cosmid 176 -g8 was found to contain the entire DFFB gene, so was useful in 
completing the gene structure analysis. PCR across the five introns using cosmid 
176 -g8 as the template allowed the approximate sizes of these to be determined. 







kb 1 kb 2 kb 3 kb 4 kb 
Figure 17. PCRs spanning each intron of DFFB, to determine approximate intron 
size. Lanes 1 -5 correspond to PCRs for introns 1 -5. Template DNA for all PCRs 
was cosmid 176 -g8. The two bands obtained for the PCR across intron 4 were 
sequenced, and the smaller band determined to be the result of non -specific 
annealing of one primer; the larger band represents the intron. 
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3.2.7 Identification of a DFFB pseudogene on chromosome 9 
As described above, during the analysis of the genomic structure of DFFB, a PCR 
product of 311p corresponding to the 3' end of the cDNA, was generated from 
genomic DNA, using primers 6F and 9R. At this stage, analysis of this region of the 
gene could only be performed on genomic- DNA -derived PCR products, since this 
region is absent from PAC 71 -C21. This 6F /9R PCR product was of the expected 
size according to the cDNA, but sequencing of this product revealed several 
differences from the published cDNA sequence, in the form of substitutions, 
deletions and insertions. In contrast, when cosmid 176 -g8 became available, 
sequencing with primers 6F and 9R directly on this chromosome 1- derived cosmid 
generated a sequence identical to the published cDNA with none of these 
inconsistencies, and also revealed a further splice junction between residues 782 and 
783, thereby dividing this large region into exons 6 and 7. 
The most likely explanation for these results is the existence of a pseudogene for 
DFFB elsewhere in the genome. Pseudogenes are non -functional copies of genes, 
and can be processed or non -processed. Within these two categories pseudogenes 
may or may not be expressed. Processed pseudogenes comprise the exonic regions 
of an active gene, and are thought to arise by the integration into the genome of 
cDNA sequences generated by reverse transcription of RNA transcripts. Non - 
processed pseudogenes originate from gene duplication events. In the case of DFFB, 
since at least intron 6 is absent from the pseudogene, it is likely to be processed. 
Non -functionality is certain, because of the numerous substitution mutations and 
deletions that appear to have accumulated in the pseudogene sequence, that include 
frameshifts. A comparison of the sequence differences in this region between the 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PCR with primers 6F and 7R (located in exons 6 and 7 respectively) generates a 
product of 143bp from a genomic DNA template, but a much larger product of 
approximately 1.4kb from cosmid 176 -g8. This is consistent with the pseudogene 
data above; when genomic DNA is the template, the absence of intron 6 in the 
pseudogene causes preferential amplification from the pseudogene rather than from 
the genuine DFFB gene, because the product from the pseudogene is smaller. On the 
other hand, when cosmid 176 -g8 is used as the template, only the real gene is 
available in this clone for amplification. The 143bp product generated with primers 
6F and 7R is therefore specific to the pseudogene. Taking advantage of this fact, I 
screened the somatic cell hybrid panel (details of this panel are provided in the 
Materials and Methods chapter) using this PCR, and was able to map the pseudogene 
to chromosome 9. 
3.2.8 Final gene structure of DFFB 
The final gene structure of DFFB is shown in Figure 19, along with its location and 
orientation relative to the T7 end of PAC clone 71 -C21. The gene spans 
approximately 10kb, and comprises seven exons. The sequences adjacent to each 

























































































































































































































































































































































































































































































































































































































































































































































































































3.2.9 Mutation screening of DFFB in a panel of 
neuroblastomas 
The candidacy of DFFB as a neuroblastoma tumour suppressor gene was next 
addressed. This was performed through rigorous mutation screening of the entire 
coding region of the gene in a panel of DNAs from neuroblastoma patients, and cell 
lines, obtained from Dr. F Speleman. This panel comprises 14 neuroblastoma cell 
lines and 11 primary neuroblastoma tumours. Also included in the panel were DNAs 
derived from 5 Merkel cell carcinoma cell lines, 10 Merkel cell carcinoma tumours, 
and 2 Schwannomas. These were included because they possess some biological 
similarities to neuroblastoma, and have been associated with deletions of 1p (Van 
Gele et al. 1998a; Van Gele et al. 1998b). In total, the panel consists of 42 samples. 




Tumour /Cell Line 
Code 







1 IMR32 Yes 1 3 Yes 
2 N206 Yes 2 3 Yes 
3 UHG -NP Yes 2 4 Yes 
4 TR14 Yes 2 3 Yes 
5 KCNR Yes 1 2 Yes 
6 STA -NB -3 ND 2 4 Yes 
7 STA -NB -8 ND 1 2 Yes 
8 STA -NB -9 ND 1 2 Yes 
9 STA -NB -10 ND 1 2 Yes 
10 STA -NB -12 ND 1 2 Yes 
11 NGP t(1;15) 2 2 Yes 
12 SK -N -AS Yes 1 3 No 
13 GI -ME -N Yes 2 4 No 
14 SK -N -FI No 2 2 No 
Primary Tumours 
15 g3(EM, stl) ND ND ND No 
16 gl l(VDBS, st4S) No ND ND No 
17 g20(VRT, st4) No ND ND No 
18 g22(AY, st4) No ND ND No 
19 g29(VHM, st4) No ND ND No 
20 g25(RM, st4) Yes ND ND Yes 
21 gl(DAM, stl) ND ND ND ND 
22 g2(DSLT, stl) ND ND ND ND 
23 g8(PS, st2) ND ND ND ND 
24 g9(PB, st2) ND ND ND ND 
25 glO(VPS, st2) ND ND ND ND 
Table 2. Details of Neuroblastoma tumours and cell lines used for mutation 
screening of DFFB. MNA = MYCN amplification; ND = not determined. 1p status 
was determined by LOH, and in cell lines was also assessed by FISH with the probes 
D1Z2 at 1p36.33 and D1Z1 at 1q12 (decreased copy number of D1Z2 relative to 
D1Z1 indicates a deletion). 
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Merkel Cell Carcinomas 
Cell lines 
26 MCC 13 No 2 2 No 
27 MCC 14/2 t(X;1) 4 4 No 
28 MCC 26 Yes 3 4 No 
29 UISO ins 1p36 2 2 No 
30 MKL -1 ND- 2 2 No 
Tumours 
31 UGH -VM Yes ND ND No 
32 UGH -RM No ND ND No 
33 UGH -FA No ND ND ND 
34 RJ No ND ND ND 
35 MCC 2T t(1;5) ND ND Yes 
36 K2967 Yes ND ND ND 
37 K1213 No ND ND ND 
38 K681 No ND ND ND 
39 W8179 No ND ND ND 
40 W6388 No ND ND ND 
Schwannomas 
41 PNST AA Yes ND ND No 
42 PNST BC Yes ND ND No 
Table 3. Details of Merkel cell carcinoma tumours and cell lines, and schwannomas 
included in the DFFB mutation screen. 
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Pairs of intronic primers were designed to flank each exon of DFFB, so that in each 
case, approximately 50 -100bp of intron was included each side of the exon amplicon. 
This was to ensure that when sequencing the PCR products, the entire exon and 
splice junctions would be analysed. These primer pairs are named cpan -exl- 
per5'/cpan-exl-per3', cpan -ex2 -per5' /cpan -ex2 -per3' etc (see 2.A.1). Each of the 
seven exons was amplified from each of the 42 DNAs in the panel, and the PCR 
products checked on 1% agarose gels before sequencing radioactively on both 
strands. Sequencing primers were designed internally to the PCR primers, but still 
within the intronic sequence. These primers are named cpan- ex l- seg5', cpan-exl- 
seq3' etc. To simplify the analysis, the sequences were run on the gel in groups of 
approximately six samples, with all `A's run alongside each other, then all `C's, then 
all `G's, and finally all `T's. 
In the 42 samples screened, only three nucleotide substitutions were detected in the 
coding region of DFFB, and seven nucleotide substitutions were detected in intronic 
sequences. However, all of these were detected also in normal DNA samples, 
suggesting that they are common sequence polymorphisms rather than tumour - 
specific alterations. These are detailed in table 4. Of the three exonic 
polymorphisms, two are silent, and the third results in a conservative amino -acid 
substitution of arginine 196 for lysine. The functional effect of this substitution on 
the resulting protein is unknown. However, this polymorphism is not tumour - 
specific, so it is unlikely that it plays any causative role in neuroblastoma. The 
insignificance of both this polymorphism, and the two silent polymorphisms with 
respect to neuroblastoma, is substantiated by their occurrence in normal DNA 
controls, as well as neuroblastomas. Figure 21 shows the detection of the two exon 5 
polymorphisms, and Figure 22 shows the exon 7 polymorphism. 
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Position Nature of polymorphism Allele frequencies in 
normal controls 
Exon 5, residue 21 G -> A Silent G = 18/30 A = 12/30 
Exon 5, residue 77 G -> A Conservative substitution: 
Lysine - Arginine G = 27/30 A = 3/30 
Exon 7, residue 172 G - A Silent G = 58/108 A = 50/108 
5' utr, -38 A G N.D. 
5' utr, -30 T C N.D. 
IVS 1, +15 A -> G N.D. 
IVS 1, +31 T -* G N.D. 
IVS 3, +44 T -* C N.D. 
IVS 3, -72 G -> A N.D. 
IVS 3, -82 T -. C N.D. 
Table 4. Details of polymorphisms within the DFFB gene, identified during 
mutation screening. N.D. = Not Determined. IVS = Intervening Sequence. NB. 
The positions given for the 5' utr are relative to the start codon, whereas positions for 
the other intervening sequences are relative to the splice junctions. 
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A C G T 
12 345612 345612 3456 12 3456 
G/A -> 
(Residue 21) 
Figure 21. Example of sequencing gel showing detection of polymorphisms during 
DFFB mutation screening of neuroblastoma DNAs. Forward sequence from exon 5 
in six individuals (1 -6) is shown, and the G/A polymorphisms at residues 21 and 77 
of exon 5 can be seen. At position 21, individuals 3 and 5 are either homozygous or 
hemizygous for the A allele (depending on whether they have a deletion on one 
chromosome), whereas individual 6 has both A and G alleles and is therefore 
heterozygous at this locus. At position 77, individual 2 is either homozygous or 
hemizygous for the A allele. NB. All As are run in adjacent lanes, followed by all 
Cs, etc, for ease of detection. 
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A C G 











Figure 22. Example of sequencing gel showing detection of polymorphisms during 
DFFB mutation screening of neuroblastoma DNAs. Reverse strand sequencing of 
exon 7 in five individuals (1 -5) is shown, which identifies a C/T polymorphism (G /A 
on forward strand) at residue 172 of exon 7. Individual 5 possesses both the C and T 
alleles, and is therefore heterozygous for the polymorphism, whereas individual 3 is 
either homozygous or hemizygous for the C allele only. 
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3.2.10 Is DFFB imprinted? 
Three exonic polymorphisms and seven intronic polymorphisms were identified 
during the neuroblastoma mutation screen. The most common polymorphism 
identified, at residue 172 of exon 7 alters a site for the restriction enzyme Aval. 
Using the PCR for exon 7, as used in the mutation screen (intronic primers 
CPANex7per -5' and CPANex7per -3'), the fetal DNAs were amplified, and the 
products digested with Aval, to genotype them for this polymorphism. Figure 23 is a 
diagram of the design of the genotyping and subsequent RT -PCR experiments, 
showing the location of the primers. The genotyping PCR product is 410bp, and is 
digested into fragments of 270bp and 140bp only when the polymorphic base is `G' 
rather than `A'. A heterozygote will therefore show the uncut band of 410bp, as well 
as the other two bands of 270óp and 140bp. An example of the genotyping analysis 
performed on the panel of fetal DNAs is shown in Figure 24. Twenty -three 
heterozygous (G /A) fetuses were identified, of which six were found to be fully 
informative since the corresponding maternal DNA sample was shown to be 
homozygous (G /G in four cases, and A/A in two cases). Figure 25 is a gel showing 
the genotyping analysis of these maternal DNA samples. The informative 
heterozygous fetuses were 9' (MC260166), 17' (MC151165), 23' (HW300462), G 














































































































































































































29'30' 31'M N O P Q R T U V W X 
.,.. -r- .... .. .... ._.. 
b 1 2 3 5 6 7 8 9 10 11 14 Un 
14Óbp 
Figure 24. Example of digesting DFFB exon 7 PCR products with Aval to genotype 
fetuses for the polymorphism. The PCR product of 410bp is digested into two 
fragments of sizes 270óp and 140bp when the polymorphic residue is `G', but 
remains uncut if it is `A'. A heterozygote will show all three bands. Lanes 29' -X 
and 1 -14 represent the PCR products of fetal DNAs, digested with Aval. On this gel, 
G/G homozygotes are: P, U, V, X, 1, 7, 10 and 14. G/A heterozygotes are: 30', M, 
O, Q, R, 3, 6, 9 and 11. A/A homozygotes are 29', 31', N, T, W, 2, 5 and 8. Un is an 
uncut reference sample. 
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kb 9' 17' 23' G L M 0 6 9 iit 
WINNOW <-410bp - <-270bp 
<- 140bp 
Figure 25. Aval- digested maternal exon 7 PCRs corresponding to heterozygous 
fetuses. Maternal DNAs homozygous for this polymorphism are: 9', 17', 23', G, L 
and M. The corresponding fetal DNAs of these samples are therefore fully 
informative. 
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An RT -PCR experiment was designed and performed on RNA from fetuses 9' 
(MC260166) and 17' (MC151165). The primers for this RT -PCR, named CPANRT- 
PCR5' and CPANRT- PCR3', span the splice junction between exons 6 and 7, to give 
a product of 259bp. This is digested into bands of 201bp and 58bp when the 
polymorphic Aval site is present. 
Before analysing the parental origin of the RT -PCR products, an experiment was 
designed to ensure that the RT -PCR product was derived only from DFFB, and not 
from the pseudogene identified on chromosome 9, since this could potentially have 
distorted the results. Sequence variations between the pseudogene and the genuine 
DFFB gene remove a site for the enzyme Alw44I from the pseudogene, so a simple 
digest of the RT -PCR products with this enzyme, which showed complete digestion, 
confirmed that the RT -PCR product was solely derived from the genuine message. 
Digestion of the RT -PCR products with Aval revealed bands of 259bp and 201bp in 
all samples, indicating that both allele types are present, and DFFB is therefore 
biallelically expressed. The digests were separated on an 8% polyacrylamide gel, 
which is shown in Figure 26. The 58bp band is not visible on this gel. 
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Fetus MC 1511 
kb ULGB KA S 
Fetus MC2601 
G H EMLBkb 
Figure 26. Aval- digested RT -PCR products from fetuses MC1511 and MC2601, for 
DFFB exon 7 polymorphism. U is an uncut reference sample of the RT -PCR 
product, L = lung, G = gut, B = brain, K = kidney, A = adrenal, S = stomach, H = 
heart, E = eye, M = muscle. The marker is the Gibco BRL 1kb ladder, with band 
sizes as indicated on the right. Note that the 58bp band that results from digestion of 
the 259bp fragment is not resolved on this gel. 
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3.3 DISCUSSION 
The results of attempts to determine the expression status of the recently identified 
gene TP73 have so far proved contradictory. The initial report of its identification 
was accompanied by evidence for monoallelic expression (Kaghad et al. 1997), and 
it was perhaps the combination of several significant factors such as possessing 
tumour suppressor activity and high sequence similarity to p53, in addition to being 
monoallelically expressed, that provoked such a great interest in this gene. 
Subsequent research, however, has yielded results that are conflicting with regard to 
whether TP73 is monoallelically or biallelically expressed, and with a substantial 
number of published papers now providing evidence on both sides of this 
controversy, it seems likely that the imprinting of TP73 is not a simple story. 
The results of experiments presented here indicate that TP73 is biallelically 
expressed in fetal tissues. However, as suggested by Nomoto et al. (Nomoto et al. 
1998), it may be the case that TP73 is imprinted in a tissue -specific and possibly 
time -specific manner, and perhaps imprinting is variable even between individuals. 
A classic example of a gene that is imprinted in a polymorphic manner such as this is 
IGF2R (Xu et al. 1993; Smrzka et al. 1995; and see Chapter 1). Therefore, although 
the RT -PCR experiments in this thesis show no evidence for imprinting, TP73 may 
still be subject to imprinting in some tissues, or in tissues of post -fetal stage. The 
rationale behind using TP73 as a starting point for finding imprinted genes at 1p36 
was based on the known phenomenon of imprinted genes occurring in clusters. 
Despite finding no evidence here that TP73 is imprinted, other studies have 
demonstrated monoallelic expression, and unless it can be proved that TP73 is not 
imprinted, this rationale will remain valid. However, the many studies that have 
found no evidence for mutations of the TP73 gene in neuroblastoma, and the 
overexpression rather than the loss of this gene indicate that TP73 is unlikely to play 
a tumour suppressor role in neuroblastoma. It would seem therefore that a tumour 
suppressor gene remains unidentified as yet in this region. 
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A contig of PAC clones and a cosmid clone was constructed around the TP73 locus, 
and it was by BLAST searching with the end sequences of these clones that part of 
the sequence of the recently discovered gene DFFB (DNA fragmentation factor) was 
found to reside close to TP73. DFFB, also know as CAD (caspase- activated DNase) 
(Sakahira et al. 1998) or CPAN (caspase activated nuclease), encodes a 40kDa 
apoptotic nuclease, capable of degrading DNA to induce apoptosis (Halenbeck et al. 
1998). The protein exists in a heterodimeric complex with its inhibitor 
ICAD /DFF45, and proteolytic cleavage of this inhibitor by activated caspase -3 
releases DFFB in its active state. A possible mechanism by which DFFB could 
function as a tumour suppressor gene is apparent in its role in inducing apoptosis. A 
loss of this function from the cell would naturally result in decreased apoptosis, 
which could lead to tumorigenesis. 
From the published cDNA sequence of DFFB, the complete gene structure was 
deduced. Given the apoptotic role of DFFB, and the genomic location, it seemed an 
excellent candidate for the putative neuroblastoma suppressor gene. A thorough and 
extensive mutation screen was performed on the entire coding sequence of DFFB, in 
a panel of 42 neuroblastoma DNAs and cell lines. This panel deliberately included 
both 1p36- deleted and non -deleted tumours. This was to take into account that there 
are two possible hypotheses regarding the action of the tumour suppressor gene, 
depending on whether or not it is imprinted. Firstly, if the tumour suppressor gene at 
1p36 is imprinted, as predicted, then there is only one functional copy of the gene. 
Therefore, in deletion cases, if it is always the expressed allele that is deleted, then 
there need not be any point mutations in the remaining non -expressed allele. 
However, in non -deleted cases of neuroblastoma, a heterozygous point mutation or 
other inactivating mechanism might be identifiable as the `second hit' in the 
functional copy of the gene, (the first `hit' being the imprint itself), in order for the 
gene to undergo complete loss of tumour suppressor function. By the second 
hypothesis, if the tumour suppressor gene is not imprinted, a `second hit' mutation 
would be expected in all deletion cases. Disappointingly, no mutations were 
detected in any of the tumours analysed. 
157 
Imprinting analysis was performed by RT -PCR, but the result suggested that the gene 
is biallelically expressed. Biallelic expression, together with a complete absence of 
any coding region mutations, now makes it extremely unlikely that DFFB is involved 
in neuroblastoma. However, it cannot be ruled out that DFFB may play a role in 
other tumour types. Deletion and LOH of this chromosomal region has been 
implicated in many different cancers, and there may be several tumour suppressor 
genes associated with 1p36. 
In summary, the expression status of TP73 has been analysed. This gene has been 
found to show biallelic expression, and no evidence of differential methylation at 
nearby CpG islands. This gene is therefore unlikely to act as the putative imprinted 
neuroblastoma tumour suppressor expected at 1p36. A search in the surrounding 
region has identified DFFB as the nearest gene to TP73 and a possible candidate for 
the suppressor due to its genomic location and known apoptotic role. In this study 
the gene structure of DFFB has been established, and a thorough mutation screen 
performed on an extensive panel of neuroblastoma DNAs. No mutations were 
detected, and DFFB was found to be biallelically expressed, thereby making it 
unlikely that it is the putative imprinted neuroblastoma suppressor gene. 
Neither TP73 nor DFFB is likely to function as the neuroblastoma suppressor gene, 
and the genuine suppressor therefore remains to be identified. A very recent study 
identified a 500kb homozygously deleted region at 1p36.2 -36.3 in a neuroblastoma 
cell line, thus narrowing down the candidate interval expected to contain the 
suppressor gene (Ohira et al. 2000). Sequencing across this interval has so far 
identified six genes that may be considered as candidates for the putative suppressor 
gene, including DFF451ICAD, HDNB1 /UFD2, KIAA0591 F (Nagase et al. 1998), 
PEX14 (Will et al. 1999), PGD (Tsui et al. 1996), and CORT (Ejeskar et al. 2000). 
It has been demonstrated by Ohira et al. that expression of the first four of these is 
high in favourable neuroblastomas but low in unfavourable neuroblastomas. They 
also demonstrated that mutations of these genes were infrequent in neuroblastoma, 
but whether any of the genes are subject to imprinting (which acts as a first Knudson 
`hit' and thus may preclude the identification of mutations in deletion cases) has not 
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yet been addressed. In the case of DFF45 /ICAD, since this is the gene encoding the 
inhibitor of DFFB, it is difficult to envisage how a loss of this function would have 
any tumorigenic effect, as this would more likely lead to an increase in apoptosis 
given that DFFB would be uninhibited. However, in vitro experiments by Zhang et 
al. (Zhang et al. 1998a) demonstrated that the cells of mice carrying a mutant DFF45 
gene had no DFF40 nuclease activity, and were resistant to DNA fragmentation and 
chromatin condensation, suggesting that both subunits are needed to produce the 
DNase activity. The loss of either subunit therefore might be considered to have a 
potential role in tumorigenesis. Future studies should be directed at identifying 
further candidates in this region, and analysing them in a similar way for both 
monoallelic expression and tumour -specific coding region mutations. 
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CHAPTER 4 
ZAC, AN IMPRINTED CANDIDATE GENE FOR 




Following the first discovery of the imprinted genes, Igf and Igor, in 1991, there 
are now approximately thirty known genes that show an imprinting effect. The 
identification of several of these genes has been due largely to chance, but the 
development of systematic screening methods for detecting imprinted genes has 
always been regarded as the most effective way to find new imprinted genes. 
The knowledge that imprinted genes are generally associated with differential 
methylation of CpG islands, and differential expression of the two parental alleles, 
immediately provides two key criteria that could form the basis of systematic 
screening methods. Indeed, four successful methods have been developed from these 
starting points: mRNA differential display and cDNA subtractive hybridisation, 
which are based on differential expression; RLGS (restriction landmark genome 
scanning) and RDA (representational difference analysis), which are both based on 
differential methylation. 
As reviewed by Kelsey and Reik, (Kelsey, Reik 1998), the limiting factor in the 
application of any of these screening techniques is the availability of appropriate 
material for comparative analysis. In the case of the mouse, all four techniques have 
been successfully used to identify imprinted genes. This has been possible both 
because of the opportunities that exist for embryo manipulation in mice and because 
of the ability to control the genetic background. In the first place, it is possible to 
generate embryos that are completely uniparental in their genetic background; 
parthenogenetic embryos are produced by the spontaneous or artificial activation of 
oocytes, whereas androgenetic embryos are constructed by pronuclear transplantation 
techniques. Material from these uniparental embryos has proved suitable for the 
identification of imprinted genes by cDNA subtractive hybridisation screening 
(Kaneko -Ishino et al. 1995). A second resource that is of great value in the 
identification of imprinted genes is mice with uniparental disomy for a specific 
chromosome or chromosomal segment. A third resource is mice that are hybrids of 
two different parental strains, in which the parental alleles can be distinguished. 
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Analysis of imprinted genes in this case relies on detecting sequence differences, 
particularly at the RNA level, using RT -PCR, or ribonuclease protection assays. The 
advantage of hybrid mice over the other artificially generated resources is that they 
do not suffer the phenotypic effects of an imbalance in their imprinted gene 
complement, and material can be obtained from all developmental stages. 
These controllable genetic backgrounds are all readily available in mice. Much 
greater difficulties, however, arise in applying similar screening methods to the 
identification of human imprinted genes, where ethical constraints limit the 
availability of suitable material for comparison by these techniques. One biological 
resource which could be exploited using these screening methods for the detection of 
human imprinted genes is DNA from the parthenogenetic chimera patient FD (Strain 
et al. 1995). The leukocytes of this patient are exclusively maternal in origin, and 
therefore represent a human parthenogenetic DNA resource which is highly useful 
for comparison with normal DNA, or with complete hydatidiform mole, a tumour 
derived from androgenetic extra -embryonic tissue (Kajii, Ohama 1977) which is the 
closest, reciprocally equivalent resource to the FD DNA. For both RLGS and RDA, 
the parthenogenetic human cell line derived by EBV transformation of this patient's 
lymphocytes should be a significant resource for detecting differential methylation 
between maternal and paternal genomes. 
4.1.1 Restriction landmark genome scanning (RLGS) 
Restriction landmark genome scanning (RLGS) relies on the use of rare -cutting 
methylation- sensitive restriction enzyme sites, such as Notl as `landmarks' for CpG 
islands. The technique involves digesting the target DNAs with a methylation- 
sensitive enzyme, end labelling the fragments with 32P, and then digesting with a 
second enzyme, before resolving the fragments in one dimension by electrophoresis. 
A further digestion is then performed in situ with another more frequently- cutting 
enzyme, and the gel electrophoresed in a second dimension. The resulting 
autoradiograph reveals up to two thousand spots, each of which represents a site for 
the methylation- sensitive enzyme used in the initial digestion. Where differential 
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methylation of such a site occurs, the methylated allele will not be cleaved, and 
therefore will not give rise to a spot on the final autoradiograph. Conversely, the 
unmethylated allele will give rise to a spot signal, hence the ability of this method to 
detect differential methylation. 
In the laboratory of Y. Hayashizaki, the RLGS technique was used to compare the 
parthenogenetic DNA from FD, with normal DNA, and DNA from androgenetic 
hydatidiform mole, the main genetic difference between these samples being their 
exclusive maternal or exclusive paternal origin respectively. The enzyme 
combinations used were Notl- Pvull -Pstl, Notl- Pstl- Pvull, and Ascl- EcoRV -Mbol. 
Two spots were identified as being differentially methylated (and in both cases 
maternally methylated) by their absence from FD DNA, relative half intensities in 
normal DNA, and full intensities in androgenetic hydatidiform mole DNA. These 
two spots were named A20 (identified from the enzyme combination Ascl- EcoRV- 
MboI), and NV 149 (identified from the enzyme combination Notl- PstI- PvuII). 
Cloning and subsequent investigation of the A20 spot clone revealed that this was 
associated with the imprinted gene GNASI (Hayward et al. 1998a). 
The purpose of this study was to investigate the RLGS spot clone NV 149, identified 
from the RLGS screen described above, on the basis of a differentially methylated 
Notl site. As described below, my initial mapping placed NV 149 on chromosome 6, 
and subsequently refined this location to 6q24. The chromosomal region 6q24 is 
very interesting, not least because of its frequent association with a wide range of 
tumour types, but also because it is now known to carry a paternally expressed 
imprinted gene responsible for transient neonatal diabetes mellitus, or TNDM. Each 
of these aspects is discussed further below. 
4.1.2 Transient neonatal diabetes mellitus (TNDM) 
Transient neonatal diabetes mellitus (TNDM) occurs in approximately 1 in 500 000 
live births (von Muhlendahl, Herkenhoff 1995). It was first described in 1852, and 
accounts for 50 to 60% of neonatal diabetes. The condition presents with 
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intrauterine growth retardation, hyperglycaemia, a general inability to thrive, and in 
some cases dehydration (Milner et al. 1971; Shield et al. 1997). There is always 
inadequate insulin production, which is either very low, or undetectable, and the 
patients require exogenous insulin therapy for the first few months of life. The 
median time of insulin therapy required is 3 months. TNDM presents in the first six 
weeks of life, but resolves spontaneously within the first year, and insulin treatment 
becomes unnecessary after this time. However, despite its transient nature, TNDM 
often predisposes to insulin- dependent diabetes later in life, often within childhood 
(Shield et al. 1997; Von Muhlendahl, Herkenhoff 1995). There is no evidence of 
anti -islet antibodies or type 1- associated HLA class II susceptibility haplotypes, and 
it has been suggested that the condition is related to a defect in I3-cell maturation 
(Shield et al. 1997; Ferguson, Milner 1970). 
4.1.3 The genetic basis of TNDM 
The majority of TNDM cases are sporadic, but in one third of reported cases, familial 
recurrences have been observed, although the inheritance patterns do not follow the 
usual Mendelian laws (Cave et al. 2000). Evidence for a genetic basis to TNDM 
began to accumulate from the diagnosis of affected siblings, cousins, and half - 
siblings in the late 1960s and 1970s; (Coffey, Womack 1967; Ferguson,Milner 1970; 
Milner et al. 1971). However, despite this early knowledge of an underlying genetic 
basis to TNDM, it was not until 1995 when it was first proposed that an imprinted 
gene might be involved in TNDM. Temple et al. (Temple et al. 1995) described two 
TNDM patients, both of whom showed paternal uniparental disomy (UPD) for 
chromosome 6, suggesting that paternal UPD, and either the resultant increased 
dosage of a paternally expressed imprinted gene, or the resultant lack of a maternally 
expressed gene, plays a significant role in TNDM. This report was followed up by 
further studies from the same group, of two unrelated families, both of which 
provided additional, and independent evidence that the underlying genetic cause of 
TNDM is related to a paternally expressed imprinted gene mapping to 6q22-23 
(Temple et al. 1996). In their study, Temple et al. investigated two families with 
affected TNDM individuals. The first family (family A) included a female child 
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with TNDM born to unaffected parents. Using PCR analysis of dinucleotide repeat 
polymorphic markers in the 6q22-23 region, a duplication was detected in the 
affected child, her father, and her paternal grandmother. The duplication was 
detected by the presence of either three (rather than two) alleles of a marker, or 
increased dosage of one allele relative to the other. The experimental method used 
here enabled a critical region to be determined - there was no evidence of duplication 
at markers D6S472 or D6S311, suggesting therefore that these markers flank a 
region containing the putative TNDM gene. See Figure 27. This was the first study 
to precisely define a critical TNDM region, although the defined region itself was 
still relatively large, spanning approximately 60cR, or 16Mb, according to the LDB 
map. This family was particularly useful in gaining an understanding of the genetics 
of TNDM, since it not only allowed the establishment of a critical region, but also 
confirmed what was already suspected with regard to the imprinted status of the 
putative gene. The child had inherited the duplication paternally, and was affected, 
yet her father who carried the same duplication was unaffected, having inherited it 
through the maternal inheritance line. His mother was also unaffected, and it can be 
assumed that she also must have inherited the duplication maternally. In brief, the 
affected child inherited two paternal copies and one maternal copy of the 6q22-23 
region, whereas the unaffected father inherited two maternal copies with one paternal 
copy. By logical deduction therefore, it is the inheritance of two paternal copies of 
this region that gives rise to TNDM. The inheritance pattern in this family 
substantiates the proposal that the TNDM gene is imprinted, and expressed only from 
the paternal allele. 
The second family (family B) investigated by Temple et al. (Temple et al. 1996) had 
previously been reported by Ferguson and Milner (Ferguson, Milner 1970), Milner 
(Milner et al. 1971) and Wilson (Wilson 1991). The four affected individuals in this 
family, in two different generations, appeared karyotypically normal, and molecular 
techniques revealed no apparent duplication, deletion or uniparental disomy. 
However, positive linkage of TNDM with marker D6S310 at 6g23.3 has been shown 
in this family, with a lod score of 2.7. The inheritance pattern also shows an 
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imprinting effect, since the linked D6S310 allele is consistently paternal in origin in 
all affected family members. 
The main conclusions from the study by Temple et al. (Temple et al. 1996) of 
families A and B, are that TNDM is caused by the up- regulation and resultant 
increased expression of a paternally expressed imprinted gene, which resides in a 
60cR critical region of chromosome 6q flanked by markers D6S472 and D6S311. 
Clarification of an important point is needed here: how can we be sure that TNDM 
results from up- regulation of a paternally expressed imprinted gene? It could be 
argued that in TNDM cases with paternal uniparental disomy of chromosome 6, it is 
impossible to distinguish whether it is the presence of two paternal copies of 
chromosome 6 (and the resultant double dose of paternal genes), or the effect of the 
maternal loss of chromosome 6, that is responsible for TNDM. The answer lies in 
two crucial observations: firstly, paternal duplications of the 6q region give rise to 
TNDM in the same way as paternal UPD6, although in duplication cases the 
maternal chromosome is still present, so the common factor between paternal UPD6 
cases and paternal 6q duplication cases is the extra paternal copy of the region, rather 
than maternal loss. Secondly, there have been several reported cases of maternal 
deletions of the 6q region, yet none are associated with TNDM (Pandya et al. 1995). 
The fact that the reciprocal situation of maternal UPD6 or maternal duplications of 
the equivalent 6q region do not cause TNDM (Pivnick et al. 1990), emphasises 
further that the disease is due to the effect of a paternally expressed imprinted gene. 
In order to make progress in identifying the putative TNDM gene, it was essential to 
refine the critical region, by identifying and studying new patients, as well as further 
characterising the duplications in existing patients. In the next report, by Arthur et 
al. (Arthur et al. 1997), the critical TNDM region defined by Temple et al. (Temple 
et al. 1996), was further reinforced, following their diagnosis of TNDM in a girl born 
to unaffected Ashkenazi Jewish parents. Karyotypic investigation of the patient 
revealed an inverted duplication of 6q22-23, and subsequent molecular investigation 
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with polymorphic markers defined the region as spanning at least 10cM. The 
duplication in this case includes markers D6S270, D6S314, D6S 1684, D6S310, and 
D6S308, and covers a very similar region to that described by Temple et al. 
However, uninformative markers in the family prevented the extremes of the 
duplication being accurately defined in this case. 
The first genuine refinement of the critical TNDM region came from Gardner et al. 
(Gardner et al. 1999). Using new information from families A and B, which they 
had characterised previously (Temple et al. 1996), they were able to refine the locus 
to an 18cR (5.4Mb or 3 -4cM) region, between markers D6S1699 and D6S 1010. The 
result which led to this refinement was a combination of data from FISH experiments 
which further defined the duplication in family A, and from a comprehensive 
microsatellite analysis from 14 members of family B which allowed the 
identification of a TNDM haplotype in this family. 
Another significant refinement of the critical TNDM region came from a new, large 
study by Cave et al. (Cave et al. 2000). This group performed microsatellite analysis 
of DNA from 13 affected individuals in 9 families. In particular, comparative 
mapping of the duplications found in three different families allowed a shortest 
region of overlap to be determined, which is flanked by markers D6S308 and 
D6S 1010. These markers are known to be separated by a distance of less than 1cM, 
so this significantly reduces the critical region. Figure 27 illustrates the narrowing 
down of the critical TNDM region by each of the studies described above. 
Having defined this small region of 6q as the critical region containing the putative 
TNDM gene, identification and characterisation of candidate genes within this region 
is the obvious choice for future progress. Several genes mapping to 6q have been 
implicated in diabetes, including PDNPI , encoding a transmembrane glycoprotein 
(Buckley et al. 1990), and the putative diabetes susceptibility loci IDDM15 (6q21) 
(Delepine et al. 1997), IDDM5 (6q24-27) (Davies et al. 1994) and IDDM8 (6q25-27) 
(Luo et al. 1996), but these can now be eliminated from any involvement in TNDM 
because they do not map to the defined region between D6S308 and D6S 1010. The 
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identification of a gene mapping to the correct location would be a valid candidate 
for involvement in TNDM, particularly if it was found to be imprinted, and had an 


































































































































































































































































































































































































































4.2.1 Identification of NV149 through RLGS screen 
By applying the RLGS technique described above to compare normal DNA with 
parthenogenetic DNA from the patient FD, and androgenetic hydatidiform mole 
DNA, two differentially methylated spots were detected. One of these, named 
NV149, was identified using the enzyme combination of NotI -PstI- PvuII. The 
sequence of this clone, derived in the laboratory of Y. Hayashizaki, is given in Figure 
28. 
4.2.2 Identification of an EST clone overlapping the NV149 
clone 
Since NV149 was identified on the basis of differential methylation of the Notl site 
within it, the immediate questions to be answered were whether it was associated 
with a gene, and whether that gene was subject to imprinting. To begin to answer 
these questions, a BLAST search was performed with the NV149 sequence. This 
search identified a match with EST 53019 (Accession number AÁ346811) in the 
database. The BLAST match is shown in Figure 29. The identity between the 
NV149 clone and the EST 53019 is short, since the two sequences overlap at one 
end. The match spans only 21 bases from the 3' end of the NV149 sequence with the 
same region from the 5' end of the EST clone. Because of the very short length of 
this match, the identity detected by the BLAST search appears weak. However, to 
confirm that it was in fact a genuine match, a PCR was designed with the forward 
primer NV149-STS2-5' located in the NV149 sequence, and the reverse primer 
NV149-STS2-3' within the sequence of EST 53019. The location of these primers is 
shown in Figure 30. The PCR was performed on genomic DNA, and the resulting 
product was of the expected size of 295bp, thus confirming that the sequence within 
the EST clone 53019 is contiguous with the genomic sequence of NV149, and is 












Figure 28. The sequence of the differentially methylated spot NV 149, detected by 
RLGS. 
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gbIAA346811.11AA346811 EST53019 Fetal heart II Homo 
sapiens cDNA 5' end. 
Length = 236 
Score = 42.1 bits (21), Expect = 0.055 
Identities = 21/21 (100 %) 
Strand = Plus / Plus 
Query: 400 aaatttcctagatcgggacag 420 
111111111111111111111 
Sbjct: 1 aaatttcctagatcgggacag 21 
Figure 29. Result of a BLAST search of NV 149 against the EST database. The final 
21 bases of the NV 149 sequence have complete identity with the first 21 bases of an 






































































































































4.2.3 Localisation of NV149 to 6q24 
The NV149 sequence, now extended by the overlapping sequence of EST 53019, 
represents a differentially methylated CpG island, since it was identified on the basis 
of differential methylation of the Notl site at the 5' end of the sequence. CpG islands 
are almost always associated with genes, and it was therefore of interest to pursue the 
NV 149 locus and analyse the surrounding region for the presence of genes which 
might be subject to imprinting. To begin this analysis, the NV 149 clone was first 
mapped to a chromosomal region by using the NV149-STS2 PCR described above to 
screen the human monochromosomal Somatic Cell Hybrid DNA panel from the UK 
HGMP -RC. The results of this analysis are shown in Figure 31, and NV149 gives a 
clear positive signal on chromosome 6. 
To map the chromosomal location more finely, two further mapping techniques were 
employed: first, the NV149-STS2 PCR was used to screen the Genebridge 4 
radiation hybrid mapping panel by PCR analysis. The data obtained from this screen 
are given in Table 5. This data was then analysed by RhyME and Sanger systems to 
give lod scores for linkage with markers of known location. A map showing the 
markers with linkage to NV149-STS2 and the corresponding lod scores is given in 
Figure 32. The centimorgan distances between markers are derived from the 
Généthon map. 
Second, the NV149-STS2 PCR product was used as a hybridisation probe for the 
gridded filters of the CEPH Mega -YAC library. This experiment detected three 
positive clones, namely 733 -C6, 774 -H5, and 798 -D8. The sizes of these YACs are 
730kb, 1360kb and 1740kb respectively, and both 733 -C6 and 774 -H5 overlap the 
third clone 798 -D8. All three are known to be located at 6q24, according to the 
CEPH -Généthon mapping data. YACs 733 -C6 and 798 -D8 contain the marker 
D6S 1079, which is not part of the Généthon map, but lies between markers D6S978 
and D6S453 according to the LDB map, and is shown in Figure 32. 
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Together, the mapping data from the Somatic Cell Hybrid panel, the radiation hybrid 
mapping panel, and the CEPH Mega YAC library indicate that NV 149 resides at 
6q24, with linkage at the highest lod score of 9.347 to polymorphic microsatellite 
marker D6S978. 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
202122XYHuH MG G GG GB 
F-295bp 
Figure 31. Somatic cell hybrid panel mapping of NV 149 -STS2 PCR to chromosome 
6. The panel consists of chromosomes 1 -22, X, Y, Human (Hu), Hamster (H), and 
Mouse (M) controls. Five additional human DNAs (G) are included; B= Negative 
control PCR. The 295óp product is present only in the chromosome 6 hybrid, and 
human controls. 
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Table 5. Raw data obtained from PCR analysis of Radiation Hybrid mapping panel. 
0 = negative result; 1 = positive result; 2 = unknown/ambiguous result. 
Tube 
Number 
Cell Line PCR 
Result 
1 4G6 0 
2 4B3 0 
3 4E6 0 
4 4F13 0 
5 4P9 0 
6 4E2 0 
7 4Z11 0 
8 4Z9 0 
9 4BB6 0 
10 4D1 0 
11 4E4 0 
12 4Y9 0 
13 4BB1 1 
14 4BB12 0 
15 4N6 0 
16 4T4 0 
17 4U1 0 
18 4N12 1 
19 4AA7 1 
20 4C11 0 
21 4T10 0 
22 4DD2 1 
23 4Z5 0 
24 4S3 0 
25 4I4 0 
26 4N3 0 
27 405 0 
28 4L6 0 
29 4T11 0 
30 4A5 0 
31 4R1 0 
32 4C3 1 
33 4M4 0 
34 4W1 0 
35 4G7 0 
36 4L4 0 
37 4N7 0 
38 411 0 
39 4R6 0 
40 4BB 10 0 
41 4N5 0 
42 4G11 0 
43 4H12 0 
44 4U3 0 
45 4G1 0 
46 4DD8 2 
47 4H1 2 
48 4J5 0 
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49 4P11 0 
50 4B9 0 
51 4K5 0 
52 4010 0 
53 4H9 1 
54 4J9 1 
55 4M5 1 
56 4F7 1 
57 4Y4 0 
58 4CC8 0 
59 4Z6 0 
60 4K7 1 
61 4B2 0 
62 4R10 1 
63 4Z12 0 
64 4AA5 1 
65 4T3 1 
66 4D7 0 
67 4Q4 1 
68 4P2 0 
69 4R12 0 
70 4K9 0 
71 4A4 1 
72 4Y8 1 
73 4Q2 0 
74 4H8 0 
75 4DD5 0 
76 4S12 1 
77 4F6 0 
78 4L3 1 
79 4510 1 
80 4R2 1 
81 4V2 2 
82 4J2 1 
83 4R3 0 
84 4V7 0 
85 4G5 1 
86 4V8 0 
87 4R5 0 
88 4BB8 0 
89 4K8 0 
90 4S6 0 
91 4K12 0 
92 4V3 0 
93 4E11 1 
94 A23 (Hamster 
control DNA) 
0 
















































































































































































































































































































































































































4.2.4 Identification of a PAC clone containing NV149 
In order to investigate and characterise the region surrounding the NV149 CpG 
island, it was decided to obtain a PAC clone, which would provide approximately 
100 -150kb of genomic sequence at this locus. To identify a PAC clone containing 
NV149, the PCR product of primers NV 149 -STS2 -5'/3' was labelled with 32P, and 
hybridised to the gridded filters of the Human PAC library RPCI1 from HGMP -RC. 
Two positive duplicate spots were detected, corresponding to PAC clones 278 -G21, 
and 262 -B20. These were then ordered from HGMP -RC. To ensure that the correct 
clone, and not any contaminating clone was used for further analysis, the clone was 
streaked onto a kanamycin plate, incubated overnight, and approximately ten of the 
resulting single colonies were picked and tested by colony PCR for NV149-STS2. 
All of the colonies of 278 -G21 were positive, so one was picked and grown as a large 
culture, for DNA extraction. None of the colonies of 262 -B20 gave a positive signal 
for the NV 149 -STS2 colony PCR, suggesting that the clone that had been streaked 
out was either the wrong clone, or was contaminated. It was decided to pursue 278 - 
G21 for further analysis, since it contains the NV149 putative CpG island. 
4.2.5 Analysis of PAC clone 278 -G21 for the presence of rare - 
cutting restriction enzyme sites 
In order to further characterise the PAC clone 278 -G21, DNA was prepared, and then 
digested with a range of rare -cutting restriction enzymes containing a CpG 
dinucleotide within their recognition sequence as follows: BssHII (GCGCGC), EagI 
(CGGCCG), NotI (GCGGCCGC), MIuI (ACGCGT), PvuI (CGATCG), SacII 
(CCGCGG). Following digestion, the resulting fragments were electrophoresed by 
pulsed field gel electrophoresis (PFGE). 
The results of the pulsed field gel of the Notl and EagI digests are shown in Figure 
33. The NotI digest generated fragments of approximately 60kb, 50kb, and a vector 
fragment of 16kb (since the insert is cloned into a NotI site within the vector). EagI 
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(CGGCCG), being contained within the recognition site of NotI (GCGGCCGC) 
always cuts at the same sites as NotI, and in this case the EagI digestion generated 
the same 50kb and 16kb fragments that were observed in the NotI digest. It also 
generates fragments of approximately 40kb and 20kb, suggesting that there is an 
additional EagI site within the 60kb Notl fragment. 
The restriction enzymes BssHII and SacII both generated fragments of approximately 
20kb, 40kb and 65kb, whereas neither MluI nor PvuI appear to have recognition sites 
within this PAC clone sequence (data not shown). 
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Eagl Notl kb M 
Figure 33. Pulsed field gel electrophoresis of PAC clone 278 -G21 digested with 
Notl and Eagl. M =Mid range marker (NEB), marker band sizes are shown at the 
side in kb. The arrows indicate the bands resulting from the Notl digest, which are 
approximately 50kb, and 60kb in size; the 16kb band represents the vector. 
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4.2.6 Subcloning the Notl sites in PAC clone 278 -G21 
The results of the rare -cutting restriction enzyme analysis described above indicated 
that PAC clone 278 -G21 contains one internal Notl site, which cuts the insert into 
fragments of approximately 60kb and 50kb. Based on this result, because the NV 149 
clone lies adjacent to a NotI site, it was decided to subclone the Notl site of this PAC 
clone. DNA from PAC 278 -G21 was digested simultaneously with NotI and SacI, 
and the resulting fragments were ligated into vector pCRII (for details, please see 
Materials and Methods), which was then used to transform electrocompetent JM 109 
cells. Of the resulting white colonies, 18 were picked and grown in 5 ml cultures 
overnight, for miniprep. The inserts were digested out of the vector by a double 
digest with NotI and Sad, and run on a 1% agarose gel to identify the different 
classes of subclone. From the knowledge that PAC clone 278 -G21 contains one Notl 
site, in addition to the artificial Nott sites which flank the insert, four different types 
of subclone are expected from this experiment: two subclones representing the T7 
and SP6 ends of the PAC clones, and two subclones representing the internal NotI 
site detected in the PFGE experiment (including one which represents the NV 149 
sequence, and another which lies adjacent to the NV 149 sequence). Figure 34a is a 
schematic diagram to explain this. 
It was apparent from digesting out the inserts that several classes of insert size were 
present among the 18 subclones. In order to distinguish between these, each 
subclone was sequenced using the M13 forward primer to sequence out of the vector, 
across the Notl site, and into the insert. Approximately 200bp of sequence were 
obtained in each case; the beginning of each sequence is given in Table 6. 
Unexpectedly, eight different classes of subclone insert were detected. Each 
sequence was then compared to the database by BLAST searching, and this revealed 
that one insert was in fact a sequence derived from E. coli, and another represented a 
subclone with no insert. However, excluding these two subclones still leaves six 
different insert types instead of the expected four. 
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Subclones 1, 3, 7, 13 and 16 represent the expected NV149 subclone class. By 
sequencing directly on PAC 278 -G21 with a primer in this NV 149 subclone 
sequence, pointing back towards the Notl site, it was possible to determine that 
subclone 2 represents the adjacent subclone, sharing the same NV 149 Notl site. 
Sequencing of the T7 and SP6 ends of the PAC clone 278 -G21 indicated that 
subclone 12 is the SP6 end subclone, and subclones 6, 9 and 11 represent the T7 end 
subclone. However, the remaining two subclone classes (ie, subclone 10; subclones 
14, 15, 17, 18) remain novel, and surplus to the expected four subclone classes. The 
most feasible explanation for this is that PAC clone 278 -G21 contains another Notl 
site, which was not detected in the PFGE experiment. This is quite possible, 
particularly if the two Notl sites are relatively close to each other, because in addition 
to the two large fragments that were seen, a Notl digestion would also generate a 
very small fragment not visible at the resolution level of PFGE. 
Subsequent to this experiment, sequencing at the Sanger centre chromosome 6 
project produced complete sequences of several PAC clones at this locus. One of 
these, PAC clone 340 -H11, shares a substantial overlap with PAC clone 278 -G21, 
and the sequence data from this clone revealed the above prediction to be correct, 
because there is an additional Notl site only 420óp away from the NV149 Notl site, 
with a SacI site between the two. This explains the additonal two Notl -Sacl 
subclones generated in this study. Figure 34b shows the actual arrangement of PAC 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.7 Identification of IMAGE clone 2073154 (A1540783) at the 
NV149 locus 
The M13 forward sequence of the NV 149 subclone (1, 3, 7, 13 and 16), together with 
that of the adjacent subclone (2), gives a contiguous sequence of 643 nucleotides 
around the Notl site of NV 149. A BLAST search with this sequence identified a 
human cDNA IMAGE clone, 2073154 (AI540783). Figure 35 shows the position of 
this clone. The IMAGE clone 2073154 contains an insert of 1388óp, which I 




























































































































































































4.2.8 PAC clone 278 -G21 is part of Sanger contig 226 
Sequencing at the T7 and SP6 ends of PAC 278 -G21 generated sequences which, 
when compared with the Sanger databases, revealed that this PAC clone is part of the 
Sanger contig 226. Additionally, the T7 sequence of 278 -G21 matched part of the 
PAC clone 197 -L1, which itself was part of a different Sanger contig, 318. Thus, 
PAC clone 278 -G21 links these contigs 226 and 318 together. 
Since PAC 278 -G21 contains the NV 149 CpG island, the two contigs 226 and 318 
are useful for the purpose of characterising the surrounding region. In order to do 
this, a selection of the PAC clones on these contigs was obtained from the HGMP 
Resource Centre. These were: 197 -L1, 210 -B1, 218 -N6, 24 -J7, 80 -G20 and 96 -M11. 
Subsequently, a further selection of clones from the two contigs was obtained from 
the Sanger Centre. These were: 262 -B20, 357 -B1, 430 -G4, 468 -K18 and 1155 - 
M13. 
4.2.9 Contig 226 contains the gene ZACILOT1/PLAGL1 
At this point in the study, sequencing of some of the clones in these contigs was 
underway by the Sanger chromosome 6 sequencing project. In particular, PAC 
clones 197-L1 and 468 -K18 were partially sequenced. Features of 197-L1 included 
two CpG islands. Within PAC clone 468 -K18, the feature of most interest was that 
this clone contained part of the known gene ZAC /LOTI /PLAGLI. A summary of the 
background and details of the identification of this gene is given below in 4.2.11. 
4.2.10 Analysis of PAC clones within the Sanger contigs 226 
and 318 
Two published sequence tagged sites, STS9563 and STS24967 were present on 
contig 226. Both of these are part of the 3' utr of PLAGLI and LOTI, and it was 
decided to screen the HGMP PAC clones for their presence (the Sanger clones had 
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not been obtained at this point). The result of this is shown in Figure 36, which 
indicates that both STSs are present only in PAC clone 80 -G20. All other tested 
clones were negative; 197 -L1, 210 -B1, 218 -N6, 24 -J7 and 96 -M11. 
The PAC clones were characterised further by screening with another PCR, designed 
to amplify part of the coding region of ZAC (primers hzacpolyl- 5'/2237 -3'). This 
PCR was present in PAC clones 80 -G20, 262 -B20, and 357 -B1, as shown in Figure 
37. This PCR was negative on PAC clone 468 -K18, which was an unexpected result 
since this part of ZAC (including the region amplified by this PCR) is known to be 
present in 468 -K18. It was suspected that the clone 468 -K18 was in fact an unrelated 
clone sent by mistake. This seems to be the correct explanation, as in addition to 
lacking the ZAC PCR described above, sequencing at the ends of this clone generated 
sequences which did not match the T7 and SP6 end sequences in the Sanger 
database. This clone was therefore excluded from further analysis. The PAC clones 
containing at least part of ZAC, as determined by this analysis, or from the Sanger 
sequencing data are 80 -G20, 262 -B20, 357 -B1, and 468 -K18. 
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STS 9563 STS 24967 
kb 197 210 218 24 80 96 1 2 B 197 210 218 24 80 96 1 2 B 
1111 
147bp - 122bp 
Figure 36. PCR screening of PAC clones for STS 9563 and STS 24967, both in the 
3' utr of PLAGLI /LOTI. Full PAC clone names are given within the text. 1 and 2 
are genomic control DNAs; B is a negative control PCR containing no template 
DNA. Both STSs are present in PAC clone 80 -G20, but absent from all other PAC 
clones. 
190 
kb 24 80 96 197 210 218 262 278 357 430 468 1155 1 2 3 B 
F- 310bp 
Figure 37. PCR screening of PAC clones for part of the coding region of ZAC (from 
1927 - 2237, according to ZAC cDNA numbering, AJ006354). Full PAC clone 
names are given in the text. 1, 2 and 3 are genomic DNA controls; B is a negative 
control PCR containing no template DNA. PAC clones 80 -G20, 262 -B20, and 357 - 
B 1 are positive for this PCR. 
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4.2.11 ZACILOT1/PLAGL1- a summary of the literature 
describing its initial isolation and characterisation 
In 1997, Spengler et al. (Spengler et al. 1997) cloned a novel mouse gene, encoding 
a zinc finger protein which regulates ápoptosis and cell cycle arrest, which they 
consequently named Zacl. The protein was isolated by a functional expression 
cloning technique, which in this case identified clones that were able to induce 
expression of the gene encoding the type 1 receptor for the peptide PACAP (pituitary 
adenylate cyclase activating polypeptide). One of the cDNA clones that resulted 
from this screen was found to be identical in sequence to the cDNA of the TP53 
gene, whilst another represented a novel sequence, not previously published in any 
database, and it was this clone that represents the cDNA corresponding to the Zacl 
protein. 
Zacl is a protein containing seven C2H2 zinc finger motifs in the N- terminal region. 
It is a member of a family of zinc finger proteins, although at the protein level it 
shows only 30% homology to its closest relatives, the GLI- Kruppel family. Other 
than the zinc finger motifs, Zacl contains three other features of interest, which 
together are suggestive of a possible function as a transcription factor. These 
features are: a C- terminal region rich in amino acids proline, glutamine and glutamic 
acid, which is a common feature of transactivation domains of transcription factors; a 
putative phosphorylation site for cyclin dependent kinases between the second and 
third zinc finger motifs; and a putative protein kinase A phosphorylation site at the 
C- terminus, suggestive of regulation by protein kinases. 
Spengler et al. demonstrated, by a colony -forming assay in soft agar, that Zacl was 
capable of inhibiting proliferation of tumour cells in vitro, and that it could stop 
tumour formation in nude mice in vivo. In fact, their results showed that Zac1 was 
equally as effective as p53 in inhibiting tumour formation in xenografted nude mice. 
In short, the experiments of Spengler et al. demonstrated that Zac1 possesses an 
antiproliferative function, in its capacity to induce separately and independently the 
two processes of apoptosis and G1 arrest. Significantly, the gene encoding Zacl is 
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the first identified gene, other than TP53, which can concurrently induce apoptosis 
and cell cycle arrest, but with separate control of these pathways. Of particular note 
is that Zacl utilises a different mechanism than that of p53 (which is p21- dependent). 
Independently, in 1997, Abdollahi et al. (Abdollahi et al. 1997a) cloned a novel rat 
gene, which they called LOT]. Their aim was to identify genes involved in ovarian 
cancer, and in order to do this they developed a rat tissue culture model of the 
disease. Their rationale was to use differential display to detect gene expression 
differences between normal cells, and the malignant transformants, both of which 
were derived from an identical genetic background. The technique successfully 
identified a transcript that was present in normal cells, but absent from the 
corresponding transformed cells, and therefore could feasibly represent a gene which 
was associated with ovarian tumorigenesis, since its expression was lost on 
transformation. The gene was accordingly named LOT] (lost on transformation 1). 
Abdollahi et al. cloned the human homologue of rat LOT], and mapped it to the 
chromosomal region 6q25, which is a region known to be involved in the 
development of many tumours, including B -cell non -Hodgkin's lymphoma, ovarian 
cancer, breast cancer, melanoma, pancreatic cancer, and many others (Abdollahi et 
al. 1997b). In ovarian cancer, Abdollahi et al. themselves confirmed the allelic loss 
that has been reported at 6q25, and detected a 38% frequency of loss of 
heterozygosity for polymorphic markers in this region. Their experiments with 
human LOT] demonstrated that there are decreased or absent levels of expression of 
the transcript in both spontaneous and experimental human ovarian cancers, and they 
proposed LOTI as a tumour suppressor gene candidate. 
In 1998, Varrault et al. (Varrault et al. 1998), who were the first group to identify the 
mouse gene Zacl, (Spengler et al. 1997), followed up their initial paper with a report 
of the isolation, chromosomal localisation, and functional characterisation of the 
equivalent human gene. They provided good evidence that the mouse and human 
genes were true orthologs, and found 74.6% identity between them at the nucleotide 
level, and 68.5% at the amino acid level. The main difference between the mouse 
Zacl and human ZAC cDNA sequences is the presence of a 34 proline- repeats 
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domain and a glutamic acid -cluster domain in the mouse sequence, both of which are 
absent from the human homologue. The presence of these repeats in the mouse gene 
but not in the human gene may offer an explanation as to the unusual phenomenon of 
a higher degree of nucleotide identity than amino acid identity between the mouse 
and human homologues. The degenerate nature of the genetic code predicts that the 
amino acid composition would be more similar between species than the nucleotide 
composition, but in this case, the calculated identity is perhaps distorted by the 
absence of the two large repeat regions which exist in the mouse gene. 
It became apparent that human ZAC and human LOT] (Abdollahi et al. 1997b) were 
in fact the same gene, although they differed in their 5' untranslated regions. In 
addition, human ZAC is related to the Plag family of zinc finger genes, which are 
thought to have a possible role in tumorigenesis, particularly of pleiomorphic 
salivary gland adenomas. A new member of the Plag family of genes, PLAGLI , was 
cloned by Kas et al. (Kas et al. 1998), and like LOT], this was found to be identical 
to ZAC, except for a different 5' non -coding region. Similarly, it was demonstrated 
that the C- terminal domain of PLAGLI can function as a positive regulator of 
transcription. 
Varrault et al. (Varrault et al. 1998) performed in vitro experiments to establish the 
functional characteristics of ZAC. They discovered that, like the mouse homolog, 
human ZAC had transactivating and DNA -binding activity, and possessed 
antiproliferative properties, in its ability to inhibit tumour cell growth by induction of 
apoptosis and G1 arrest. 
Varrault et al. (Varrault et al. 1998) gave the first defined map location of ZAC by 
FISH, and placed it between markers D6S308 and D6S978. Significantly, this is 
almost exactly the same region defined by Cave et al. (Cave et al. 2000), in their 
attempt to refine the putative TNDM locus at 6q24-25. 
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4.2.12 ZAC -a candidate gene for TNDM? 
The location of ZAC in the critical TNDM region, and its role in cell cycle control 
make ZAC a very compelling candidate gene for TNDM. As already discussed, the 
gene responsible for TNDM is known to be a paternally- expressed imprinted gene, 
and it is the upregulation of this gene, either through paternal duplications of this 
region, or paternal uniparental disomy, that is believed to cause TNDM. Clearly, one 
of the main criteria for assessing candidate TNDM genes is to analyse the expression 
of the gene with respect to imprinting. It was decided therefore to determine whether 
ZAC is imprinted. A positive result would undoubtedly substantiate the candidacy of 
ZAC as the TNDM gene. 
It was decided to test for imprinting of ZAC by determining whether ZAC shows 
monoallelic or biallelic expression. The rationale behind the experiment is to 
identify a sequence polymorphism in the coding region of ZAC, and to genotype a 
panel of first trimester fetal DNAs for this polymorphism. Details of this panel are 
given in Materials and Methods. Identification of a fetus that is heterozygous with 
respect to the polymorphism would allow the two parental alleles to be distinguished 
from each other. Furthermore, maternal DNAs corresponding to the fetal DNAs in 
the panel are available, and with knowledge of the maternal genotype, expression can 
be attributed to specific parental origin, should monoallelic expression be detected. 
4.2.13 Search for sequence polymorphisms in coding region 
of ZACIPLAGL1/LOT1 
To identify a sequence polymorphism in ZAC /LOTI /PLAGLI , primers were 
designed in each of the exons, to amplify regions of the gene in several sections, to 
be sequenced radioactively. As explained above, there are three described cDNA 
sequences, all of which share some exons, but differ particularly in the 5' region 
upstream of the ATG start codon. A schematic diagram to explain the relationship 
between the three different transcripts is given in Figure 38. 
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PCR amplicons were designed to cover the different exons contained in the three 
different splice variants, concentrating particularly on the 5' untranslated region 
which, along with the 3' untranslated region, is more likely to contain a sequence 
polymorphism than the coding region. Figure 39 shows the location of the PCR 
primers used for polymorphism detection, and indicates the postitions at which single 
nucleotide polymorphisms were detected. Two polymorphisms were identified at 
residues 170 and 205 of the LOT] cDNA, and one at residue 875 of ZAC. The 
detection of the ZAC polymorphism at residue 875, through radioactive sequencing 







































































































































































































































































































































































































































































































































































Figure 40. Sequencing gel showing detection of polymorphism at residue 875 of 
ZAC. Eight genomic PCR products are shown on this gel; for ease of detection, all 
`A's are run alongside each other, followed by all `C's, etc. Reverse sequence is 
shown. Individual 4 is heterozygous (A /C on this strand; T/G on the forward strand) 
for this polymorphism. 
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4.2.14 LOT1 is a chimerism artefact 
During the analysis described above, it became questionable whether the 5' utr of the 
published LOT] transcript, from residues 1 to 469, was actually on chromosome 6, 
because of its failure to generate a PCR product from PAC clones known to contain 
inserts derived from chromosome 6. To investigate this, the PCR that was being 
used for polymorphism detection (primers A and B (LOT- A- 5'/3') located as shown 
in Figure 39) was used to screen the human monochromosomal Somatic Cell Hybrid 
DNA panel. The result of this PCR analysis is shown in Figure 41, and clearly 
indicates that this region is derived from chromosome 3, rather than chromosome 6. 
However, the subsequent exons of the LOT] transcript, which are shared with ZAC, 
are known to be located on chromosome 6, so it would seem that the LOTI transcript 
is a chimeric clone, comprising segments from both chromosome 3, and chromosome 
6. (This is shown in the diagram of transcripts in Figure 38). Following this 
discovery, LOT] was excluded from further analysis, since it is not a genuine 
transcript. This unfortunately eliminated the possibility of using the two LOT] 
polymorphisms for expression analysis. 
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kb 1 2 3 4 
,. 
517bp-> la 
8 9 10 11 12 13 14 15 16 17 18 19 
517bp -> =Ir 4.110 
kb 20 21 22 X Y Hu Ha Mo G1 G2 B 
Figure 41. Screening of the somatic cell hybrid panel with a PCR at the 5' utr of 
LOTI (primers LOT1- A- 5'/3'). This region of LOT] maps to chromosome 3. 
kb = 1 kilobase ladder marker, Hu = human genomic DNA control, Ha = hamster 
genomic DNA control, Mo = mouse genomic DNA control, G1 and G2 = further 
human genomic controls, B = negative control PCR. 
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4.2.15 The published ZAC cDNA sequence (AJ006354) 
contains an inversion 
During the search for polymorphisms as described above, primers were designed to 
amplify several regions of ZAC /LOTI /PLAGLI from genomic DNA. One of these 
PCRs, with primers located at residues 3 and 965 of the ZAC cDNA sequence, was 
found to fail repeatedly. Because of this failure, an additional 5' primer was 
designed, starting at residue 68, and the PCR was immediately successful. The 
failure of the original PCR indicated that there might be a sequence error at the start 
of the ZAC cDNA, so I designed a primer starting at residue 89, to sequence towards 
the start of the sequence, and into the upstream region. The result of sequencing with 
this primer revealed that the beginning of the published ZAC cDNA is incorrect. 
Residues 1 -30 are in fact inverted, and located approximately 30bp upstream of the 









































































































































































































































































































































































































































































































































































































































































































































































































































4.2.16 Expression analysis of ZAC by RT -PCR, using 
polymorphism 875 
The G/T polymorphism identified at residue 875 of the ZAC cDNA sequence does 
not alter any restriction sites. However, a mismatched primer, ZAC -RT5', was 
designed starting at base 846, which creates a BsiWI site when the polymorphic 
residue is G, but does not create this site when the polymorphic residue is T. For the 
purpose of genotyping a range of fetal DNAs for this polymorphism, a downstream 
intronic primer, ZAC -621 -3' was used in conjunction with ZAC -RT5', to generate a 
PCR product of 200bp. Figure 43 shows the design of the genotyping PCR and RT- 
PCR, and the location of the primers with respect to the polymorphic residue 875. 
Digestion of the 200bp genotyping PCR product with BsiWI yields bands of 
sizes 171 bp and 29bp in the case of a G/G homozygote, and bands of sizes 200bp, 
171 bp and 29bp in the case of a G/T heterozygote. DNA from 53 fetuses was 
analysed in this way; 4 were found to be G/T heterozygous (AC150452, HM170958, 
JC230671, and RT280475), and 49 were G/G homozygous. An example of the 
genotyping analysis is shown in Figure 44. 
RT -PCR was performed on RNA samples available from tissues of the heterozygous 
fetuses using primers ZAC -RT5' and ZAC- RT3'(2), which generated a product of 
290bp; RT -PCR did not generate a successful product in all cases, but it was not 
possible from this experiment to determine whether this was due to specific absence 
of ZAC expression in these tissues, or PCR failure due to the quality of the sample. 
The successful RT -PCR products that were obtained were from only three of the 
heterozygous fetuses, as detailed below. (RNA was available only from brain for 
Fetus RT280475, and since this was one of the failed samples, this fetus could not be 
included in the expression analysis). 







Fetus HM170958: muscle 





Digestion of the RT -PCR products with BsiWI gives bands of size 290bp if the 
polymorphic base 875 is T, and bands of sizes 261bp and 29bp if it is G. Biallelic 
expression from these heterozgous fetuses would be represented by bands of 290bp, 
261bp and 29bp. The digestion products of the RT -PCR were separated on a 3% 
NuSieve agarose gel, shown in Figures 45 and 46. In all three cases, the RT -PCR 
products were of only one allele type with respect to the 875 polymorphism, despite 
originating from a heterozygous individual. This is clear evidence of monoallelic 
expression. 
Unfortunately, due to the quality of the corresponding maternal DNA samples for the 
four heterozygous fetuses, attempts to determine the maternal genotype for the 875 
polymorphism were unsuccessful, so it was not possible at this stage to establish 











































































































































































































































































































































kb 9' 10' 12' 13' 14' 15' 16' kb 
<-220bp 
Figure 44. Example of heterozygote detection analysis for ZAC polymorphism 875 
in a panel of fetal DNAs. The genotyping PCR product of 200bp is digested into two 
smaller fragments of 171bp and 29óp when the polymorphic residue is a `G' rather 
than a `T', due to the creation of a BsiWI site. Seven fetal DNAs are shown; fetus 
13' is G/T heterozygous for the polymorphism, and all others on this gel are G/G 
homozygous. 
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6 (AC 150452) 
heart kidney 
kb un íßc g d g. undig g. muscle undig. d g. cord undig g. 
290bp 
261 bp 
Figure 45. RT -PCR products for heterozygous fetus 6 (AC150452). In all tissues 
analysed, the RT -PCR product of 290bp is completely digested by BsiWI into two 
fragments of 261 by and 29bp, suggesting monoallelic expression. Undig. _ 
undigested, dig. = digested. 
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13' (HM170958) W (JC230671) 
muscle adrenal lu 
kb undig. dig. undig. dig. undig. dig. 
290bp 
<- 261bp 
Figure 46. RT -PCR products for heterozygous fetuses 13' (HM170958) and W 
(JC230671). Undig. = undigested, dig. = digested. In the case of 13', all of the RT- 
PCR product remains undigested by BsiWI, suggesting that it is derived solely from 
the `T' allele. Conversely, in the case of W, there is complete digestion to the 
smaller fragments of 261bp and 29bp, suggesting that all of the product is derived 
from the `G' allele which is cut by BsiWI. Both results are consistent with 
monoallelic expression. 
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4.2.17 Expression analysis of ZAC by RT -PCR, using 
polymorphism 1029 
A further polymorphism was identified in the laboratory of Y. Hayashizaki, at 
residue 1029 of ZAC cDNA. The nature of this polymorphism is a single nucleotide 
substitution of C for G. Using PCR primers PLAGL 1 ex2r2 and PLAGL 1 ex2f1 
designed by that group, genomic DNA from 44 fetuses was amplified to give a 
product of 368bp. Sequencing directly on the PCR products, with primer ZAC- 
RT3'(2), enabled the fetuses to be typed for this polymorphism. The polymorphism 
is relatively common: 9 out of the 44 fetal DNAs analysed were found to be 
heterozygous at this locus. Maternal DNAs were analysed in a similar way, and two 
of the maternal DNAs, corresponding to heterozygous fetuses SH240167 and 
CM181169 were found to be homozygous (CC), making those fetuses fully 
informative. The maternal DNA for heterozygous fetus RT280475 was found to be 
heterozygous, rendering this sample uninformative in terms of tracing the parental 
origin of expression. For the remaining seven heterozygous fetuses, maternal DNA 
samples were either unavailable, or of inadequate quality and attempts to generate a 
PCR product failed consistently. 
For the two informative fetuses, RT -PCR was performed on RNA from seven 
different tissues from each fetus. RT -PCR primers were ZAC 1029 -RT5' and 
ZAC 1029 -RT3', generating a product of 408bp. The design of the genotyping PCR 
and RT -PCR, along with the relative location of the primers is shown in Figure 47. 
The RT -PCR products were sequenced with primer ZACRT3'(2). 
The following tissues were analysed: 















In all cases, the RT -PCR product showed only the G allele when sequenced (see 
Figures 48 and 49), and since the maternal genotype was known to be CC, this 
indicates that expression of ZAC is solely from the paternal allele. 
In the seven other heterozygous fetuses, RT -PCR was performed on a range of 
tissues. Since the maternal genotype is unknown, these are not informative as to the 
parental origin of the expressed allele, but can still be used to show monoallelic 
expression of ZAC. The following tissues were analysed by RT -PCR by the same 
method described above: 
Fetus SS130773: adrenal 
eye 
kidney 
Fetus JS020673: brain 
stomach 
kidney 




Fetus RT280475: muscle 
Fetus HW150273: brain 
heart 
lung 
Fetus CT111275: heart 
muscle 
gut 
Fetus MS 100972: muscle 
liver 
cord 
In all cases, sequencing of the RT -PCR products showed only one allele type at the 
polymorphic locus 1029, and this is further evidence for monoallelic expression of 
ZAC. A summary of the evidence from these RT -PCR experiments for monoallelic 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.18 ZAC is monoallelically expressed 
The RT -PCR experiments detailed above using the polymorphisms at residues 875 
and 1029 of ZAC show clearly that ZAC is monoallelically expressed in these fetal 
tissues, from only the paternal allele. However, these two polymorphisms are 
specific to the ZAC transcript. Neither of them are contained within the splice 
variant PLAGLI. Because of this, the RT -PCR experiments have only tested the 
origin of the ZAC transcript. In order to examine the expression status of PLAGLI 
with respect to imprinting, it would be necessary to identify an exonic polymorphism 
that was contained within the PLAGLI sequence, and to design primers specific to 
PLAGLI , so that the resulting RT -PCR products were solely of PLAGLI origin. 
Unfortunately, as detailed previously, an extensive polymorphism search was carried 
out, which identified only the ZAC polymorphism 875, and two LOT/-specific 
polymorphisms which are now known to be located in a chromosome 3- derived 
region of this chimeric transcript. PLAGLI contains a unique exon in the 5' utr, but 
no polymorphism was found either within this exon or in the 320bp upstream of this 
exon. The remainder of the PLAGLI transcript comprises common exons that are 
shared with ZAC, in which no polymorphism has been identified. See Figures 38 and 
39. 
It has therefore been impossible at this stage to determine the expression status of 
PLAGLI. The only option for rectifying this is to continue to search for exonic 
sequence polymorphisms. It would clearly be of great interest to investigate 
whether, like ZAC, PLAGLI is also subject to monoallelic expression. 
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4.3 DISCUSSION 
4.3.1 Is ZAC the gene that causes TNDM when upregulated? 
In this study I have performed mapping studies on the differentially methylated 
RLGS spot clone, NV149, and expression analyses of the nearby gene ZAC. NV149 
contains a Notl site that is methylated exclusively on the maternally inherited allele, 
and is derived from a CpG island, which lies within 60kb of the recently identified 
gene ZAC /PLAGLI /LOT]. Given the chromosomal location of this gene, in a region 
known to contain a gene responsible for TNDM, it is logical to postulate that 
ZAC /PLAGLI /LOTI is a candidate for this role. From our knowledge of this disease, 
and the associated chromosomal abnormalities that have been detected in TNDM 
patients, there are four main criteria that must be satisfied by a genuine candidate. 
These are as follows: 
1. The candidate gene must be imprinted, and expressed only from the paternal 
allele. 
2. The candidate gene must reside in the smallest defined critical TNDM region 
between microsatellite markers D6S308 and D6S1010 (Cave et al. 2000). 
3. The gene must encode a protein which possesses a function that could be 
envisaged to cause TNDM by a logical mechanism when upregulated. 
4. TNDM patients must possess abnormalities of this gene such that they have 
an increased dosage of the gene product relative to unaffected individuals. 
To address the first point above, I have performed RT -PCR experiments using two 
different polymorphisms in ZAC, and demonstrated monoallelic expression of the 
ZAC transcript in twelve first trimester fetuses, across a range of twelve different 
tissues. In two cases, the fetuses were fully informative with respect to the parental 
origin of each allele, and it was therefore possible to show in these cases that the 
monoallelic expression observed was derived from the paternal allele. These 
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experiments therefore provide strong evidence for ZAC being a paternally expressed 
imprinted gene. 
Subsequent to these findings there were two further studies of relevance to the 
differential methylation of NV 149 and the monoallelic expression of ZAC. Firstly, 
Gardner et al. (Gardner et al. 2000) mapped a 300 -400kb candidate region 
containing the putative gene to the Sanger chromosome 6 contig 224, and then 
investigated the methylation status of the known CpG islands within this region. In 
PAC clone 340 -H11, approximately 60kb upstream of the gene ZAC, they detected 
differential methylation of a CpG island partially overlapped by IMAGE clone 
2073154. Their CpG island is in fact the same as the NV 149 CpG island in this 
study, and thus confirms the differential methylation at this locus. Secondly, Piras et 
al. (Piras et al. 2000) identified Zacl , along with the epsilon sarcoglycan gene, Sgce 
through a subtractive screen for imprinted genes in the mouse. They demonstrated 
that both of these genes were maternally imprinted, and expressed solely from the 
paternal allele. 
To summarise, there are now three independent studies which provide evidence 
either for differential methylation of the NV 149 /IMAGE 2073154 CpG island 
(Gardner et al. 2000), or for monoallelic expression of Zacl (Piras et al. 2000), or for 
both differential methylation of this CpG island and monoallelic expression of ZAC 
(Kamiya et al. 2000). Collectively, there is indisputable evidence that ZAC is 
imprinted and paternally expressed, thus fulfilling the first of the three criteria 
mentioned above. It is noteworthy, as an aside, that whilst ZAC is clearly imprinted 
and monoallelically expressed, it does not conform to the functional expectations of 
the parental conflict model of Moore and Haig (Moore, Haig 1991) (see Chapter 1), 
since it is paternally expressed, but is growth suppressing, rather than growth 
enhancing. 
The second of the criteria that must be satisfied by candidate genes is the genomic 
location. Cave et al. (Cave et al. 2000) defined a small critical region at 6q24, 
flanked by polymorphic microsatellite markers D6S308 and D6S 1010. The genomic 
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location of ZAC is within this interval, as evidenced by the location of the two 
markers STSG24967 and STSG9563, which are in the 3' utr of the gene, and lie 
between markers D6S308 and D6S 1010 according to the Généthon map. Thus, ZAC 
satisfies the second of the criteria for candidate TNDM genes, and is currently the 
only known gene to reside in this region. 
The third of the criteria is that a candidate TNDM gene must encode a protein which 
possesses a function that could be envisaged to cause TNDM by a logical mechanism 
when upregulated. As explained in detail in the introduction to this chapter, the 
genetic aberrations associated with TNDM are most commonly uniparental disomy 
for the paternal copy of chromosome 6, or paternally derived duplications of part of 
chromosome 6 including at least the 6q24 region. From these observed patterns of 
inheritance, it is apparent that TNDM is the result of upregulation of a paternally 
expressed imprinted gene. Because of this, it is expected that a candidate gene must 
play some role which could lead to TNDM if upregulated. ZAC encodes a protein 
that has been shown to induce both cell cycle arrest, and apoptosis, and one possible 
mechanism for its role in TNDM is the increased apoptosis of pancreatic I3-cells that 
would result from upregulation of the gene, of which the main consequence would be 
significantly decreased insulin production. Another interesting aspect of ZAC's 
function that may have pathological relevance is that it can induce expression of the 
gene for the type 1 receptor for the pituitary adenylate cyclase activating peptide 
(PACAP). This receptor is expressed in the pancreatic islets, and it is known that 
PACAP is produced by the pancreatic neural cells and is a highly active regulator of 
glucose -stimulated insulin release (Filipsson et al. 1999). The ability of ZAC to 
influence expression of the PACAP receptor may be important, because the 
consequence it may have on insulin release in the islet when overexpressed (as in 
paternal duplication or UPD6 cases) could relate directly to some of the pathology of 
TNDM. However, these ideas are theoretical, and remain to be investigated further. 
It would seem that ZAC undoubtedly satisfies the first of the two criteria, since it is 
imprinted, paternally expressed, and lies within the critical TNDM interval, as 
defined by Cave et al. (Cave et al. 2000). In theory, it could satisfy the third criteria, 
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due to its function in inducing cell cycle arrest and apoptosis. As described above, 
this can be envisaged to result in TNDM when upregulated, since an increase in [3- 
cell apoptosis would cause a severe reduction of insulin production leading 
potentially to TNDM. However, this idea is theoretical, and has not yet been 
investigated. It may be the ultimate cause of the permanent diabetes, which appears 
to be the eventual outcome in many cases of TNDM. Whether upregulation of ZAC, 
through modulating the PACAP -PACAP -R axis also directly mediates the earlier 
transient insulin deficiency seen in TNDM, is not clear at present. Clarification of 
this point will need a better understanding of the cellular physiology underlying 
PACAP -R signalling in the pancreatic beta cell. 
The last of the criteria to be met by a candidate gene is that TNDM patients should 
display abnormalities of the gene, which result in an upregulation of its function. 
Such abnormalities could include paternal uniparental disomy and paternal 
duplications of all or part of chromosome 6, but the duplicated segment must 
specifically include the candidate gene. Patients lacking either of these abnormalities 
would therefore be expected to use alternative mechanisms by which the candidate 
gene is upregulated. These could include upregulating mutations in the sequence of 
enhancer or promoter elements, or epigenetic changes that reactivate the normally 
silent maternal allele. This fourth criterion is met partially by the fact that the 
duplications described to date include ZACIPLAGLI /LOT]. However, as discussed 
below, paternal duplications and uniparental disomy do not account for all cases of 
TNDM. 
According to Cave et al. (Cave et al. 2000), by pooling their data with that of 
Gardner's study, there is a total of 33 unrelated children with TNDM in the two 
studies. Of these, 27% have paternal uniparental disomy for chromosome 6, and 
18% have a paternally derived duplication of this region. The remaining 55% of 
these affected children do not appear to have any detectable abnormality of this 
region. What is the basis of TNDM in these cases, and is ZAC or another gene 
involved? 
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Clearly, in order to show definitively that ZAC is the TNDM gene, there are 
experiments that must be done to address the points above. In particular, it could 
considerably strengthen the case for ZAC as a candidate TNDM gene if the 
unaccountable non -UPD and non -duplication cases of TNDM were found to contain 
either previously undetected submicroscopic duplications, or mutations, perhaps in 
the regulatory elements which would cause an upregulation of ZAC, or methylation 
mutations which would effectively give ZAC the paternal methylation pattern on both 
chromosomes and thus lead to the same result as paternal UPD6 or paternal 
duplications of the region. Gardner et al. (Gardner et al. 2000) addressed these 
questions in a recent study, and detected submicroscopic duplications in five patients 
in whom no apparent duplication had previously been detected. More significantly, 
they found that in two of thirteen patients with no chromosomal abnormality to 
account for TNDM there was an alteration of methylation, with both chromosomes 
showing a paternal, unmethylated pattern at the NV 149 CpG island. This may 
represent the functional equivalent of paternal uniparental disomy, since both 
chromosomes carry a paternal epigenotype, and this would be predicted to cause an 
increased dosage of the gene product. The postulate that aberrant methylation could 
have a causative role in TNDM is substantiated by the lack of any similar defect in 
50 normal control individuals (Gardner et al. 2000). It is noteworthy though, that the 
remaining eleven TNDM patients in Gardner's study are still unaccounted for by any 
of the proposed mechanisms for the disease. 
ZAC is clearly a very strong candidate for the TNDM gene, but its role cannot yet be 
considered definitively proven. In particular, the issue of ZAC's function in relation 
to TNDM should be investigated, and one obvious way to show directly that 
upregulation of ZAC causes TNDM would be to develop a transgenic mouse that 
overexpresses ZAC. However, the transient nature of the TNDM phenotype in 
humans, and the major differences in the developmental timeframe between the 
species, suggest that it might not be possible to reproduce the TNDM phenotype in a 
mouse model. 
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More generally, there are unanswered questions regarding the disease itself. How 
does TNDM predispose to adult diabetes? Why does the condition resolve itself 
during the first few months of life? Why are the symptoms variable between patients 
with the same genetic basis to TNDM (Marquis et al. 2000), even to the point that 
some cases go undiagnosed? Perhaps the answers to these questions will become 




IS ZAC A TUMOUR SUPPRESSOR GENE? 
225 
5.1 INTRODUCTION 
5.1.1 The chromosomal region 6q is frequently deleted in 
cancer 
Aberrations of the chromosomal region 6q have been associated with a broad 
spectrum of different tumour types in humans. In particular, deletions of 6q are 
found frequently in a variety of cancers, detectable by cytogenetic techniques or by 
microsatellite analysis for loss of heterozygosity (LOH). Early experimental 
evidence of a link between cancer and the complete or partial loss of chromosome 6q 
was revealed by the observation that this chromosomal region could reduce 
tumorigenicity in melanoma cells when introduced by microcell mediated 
chromosome transfer (Trent et al. 1989). Suppression of tumorigenicity by 6q was 
also observed in MDA -MB -231 breast cancer cells cells following similar 
chromosome transfer experiments (Negrini et al. 1994). 
Evidence is mounting to suggest that the genetic basis to many cancers may be 
linked to the existence of several putative tumour suppressor genes at 6q, and the 
consequential loss of these genes by deletion and /or mutation, yet none of these 
putative genes has so far been definitively identified. Indeed, few candidates have 
been proposed to date. However, many of the studies have concentrated rather on a 
systematic approach of characterising the regions most commonly subject to 
deletion, and thus defining possible locations of these putative suppressor genes. 
5.1.2 The involvement of 6q in breast cancer 
Perhaps the most frequently studied cancer associated with loss of chromosome 6 is 
breast cancer. More than a decade ago, analysis of breast cancers by cytogenetic 
techniques and Southern blotting highlighted this chromosomal region as a hotspot 
(Mars, Saunders 1990; Dutrillaux et al. 1990), and subsequent studies were able to 
define distinct regions of LOH using polymorphic microsatellite markers. A study 
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by Noviello et al. (Noviello et al. 1996) utilised eleven polymorphic CA repeat 
markers to analyse 83 paired tumour and blood DNAs from breast tumour patients. 
The results of this analysis showed that the frequency of LOH was as high as 38.9% 
at some markers, and pointed towards three separate, common regions of allelic loss, 
defined by D6S251- D6S434 (at 6q14-21), D6S292- D6S311 (at 6q22-q23), and 
D6S441- D6S281 (at 6q24-q27). The idea of three commonly deleted regions at 6q 
was also suggested by the results of a study by Sheng et al. (Sheng et al. 1996), in 
which a 48% frequency of LOH was detected in a panel of 80 primary breast 
cancers. The commonly deleted regions in this case, however, were defined as 
D6S251- D6S252 (6g14- 816.2), D6S268- D6S261 (6q22), and D6S287- D6S270 
(6q22). Whilst the first of the three regions defined by Sheng et al. is contained 
within the 6q14-q21 region defined by Noviello et al., there is no overlap between 
any of the other regions identified in that study (Noviello et al. 1996). The relative 
locations of these markers and all others mentioned here are shown in Figure 50 
which is a reference map derived from the LDB map at cedar.genetics.soton.ac.uk. 
Another study, in which tissues from 66 cases of breast cancer were microdissected 
to eliminate any contaminating normal tissue, and then analysed with 15 
polymorphic dinucleotide markers, detected allelic loss of either all or part of 6q in 
80% of tumours (Fujii et al. 1996). This study defined a large common region of 
deletion at 6q23-q24, between markers D6S310/314 and D6S473/255, suggesting the 
presence of a tumour suppressor gene within this interval. 
In the same year, Theile et al. (Theile et al. 1996) demonstrated suppression of 
tumorigenicity in the breast cancer cell line, CAL51, following microcell mediated 
transfer of chromosome 6. Subsequent analysis of the donor chromosome fragment 
in the resulting hybrids defined a critical region at 6q22-q23, containing the marker 
D6S310, and flanked by D6S292 and D6S311. This study also included an analysis 
of LOH for a panel of 24 polymorphic markers, in 46 primary breast cancer DNAs. 
The data suggested that there might be as many as four independent tumour 
suppressor genes mapping to 6q, one of which corresponds to the region defined by 
the chromosome transfer experiments. 
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As an alternative to microsatellite analysis, Zhang et al. (Zhang et al. 1998) 
investigated ten breast cancer cell lines using dual colour fluorescence in situ 
hybridisation (FISH). With this technique they were able to detect large regions of 
deletion extending from 6q12-q16 to 6q27, and a smaller deleted region in one cell 
line between 6q25.1 and 6q27, these results again suggestive of the notion that there 
may be more than one suppressor gene residing at 6q, though again not yielding 
results in close agreement with those of other studies. 
Two of the more recent studies of the association between 6q loss and breast cancer 
are those of Utada et al. (Utada et al. 2000), and Rodriguez et al. (Rodriguez et al. 
2000). Utada et al. examined a large sample of primary breast cancers for LOH at 16 
microsatellite markers along 6q, and found allelic loss for at least one of these 
markers in 55% of the samples. Overall, their results defined two 1cM intervals, at 
D6S1040- D6S262 (6q22), and D6S305- D6S411 (6q25.3). More specifically, they 
were able to correlate losses at 6q22 with more aggressive tumour types (invasive 
solid tubular and schirrhous carcinomas), and correlate losses at 6q25.3 with loss of 
the progesterone receptor. They concluded therefore, that 6q22 and 6q25.3 represent 
the locations of two independent tumour suppressor genes involved in breast cancer, 
with particular relevance to tumour progression and loss of hormonal dependency 
respectively. A similarly large study was conducted by Rodriguez et al. (Rodriguez 
et al. 2000), who assessed the LOH in a panel of 178 paired breast tumour and 
normal DNAs using 30 polymorphic markers. The results of the study indicated a 
76% frequency of allelic imbalance for at least one marker, and highlighted five 
distinct domains of allelic imbalance, defined by D6S300, D6S434, D6S261, 
D6S314- D6S409, and D6S441- D6S415. 
From the many studies to date which have attempted to gain some understanding of 
the role of 6q in breast cancer, the overall conclusion is that this chromosomal region 
harbors at least one, and perhaps several, putative tumour suppressor genes, loss of 
which is strongly associated with tumorigenesis. There is considerable discordance, 
however, between the studies, both in the precise definition of the genomic intervals 
228 
believed to carry these genes, and in the determination of the true frequency of LOH 
at these locations. Indeed, whilst most studies have concluded that more than one 
gene is involved, individual studies have suggested that between one and five genes 
may play a role. As would be expected perhaps, those studies that have used a 
greater number of markers to detect LOH have been able to clarify the regions of 
deletion more precisely, and have consequently defined more separate, independent 
regions. For example, the studies of Theile et al. (Theile et al. 1996) and Rodriguez 
et al. (Rodriguez et al. 2000) employed 24 and 30 markers respectively, and 
identified 4 and 5 distinct regions of LOH, respectively. In contrast, studies such as 
those by Utada et al. (Utada et al. 2000) (16 markers) and Noviello et al. (Noviello et 
al. 1996) (11 markers) were less able to define accurately the true boundaries of the 
commonly deleted intervals, identifying only 2 and 3 distinct regions respectively. 
In addition to this issue, correlating the evidence from different studies is always 
hampered by the use of different genetic maps, between which exists a degree of 
discrepancy with respect to the true order of markers. 
The wide variation in LOH frequencies found may also reflect the quality of the 
samples analysed. The problem of contamination of tumour samples with 
surrounding normal tissue is a source of variation between samples and between 
different studies, and may explain some of the discordance between the quoted LOH 
frequencies. For example, a higher LOH incidence than had previously been 
reported was detected in a study by Fujii et al. (Fujii et al. 1996), and was most 
likely due to their microdissection of tumour tissues to remove contaminating normal 






















































D6S411 Figure 50. Reference map showing the 
D6S1277 locations of the markers mentioned in the 
text, according to the LDB map at 





5.1.3 The involvement of 6q in ovarian cancer 
Ovarian cancer is another important cancer that has been strongly associated with the 
loss of 6q. This type of cancer is the main cause of death among gynaecological 
cancers in the Western world, and has a particularly high mortality rate due to its 
typically late diagnosis (Colitti et al. 1998). Attaining a greater understanding of the 
underlying genetic causes of ovarian cancer, particularly the involvement of tumour 
suppressor genes, is an important goal. Many studies have attempted to narrow 
down the possible locations of such genes, and have concentrated particularly on 
analysing the chromosomal region of 6q27, which has a high frequency of LOH in 
ovarian cancer (Saito et al. 1992). The studies of Saito et al. (Saito et al. 1996), 
Tibiletti et al. (Tibiletti et al. 1996; Tibiletti et al. 1998), Cooke et al. (Cooke et al. 
1996), Suzuki et al. (Suzuki et al. 1998), and Foulkes et al. (Foulkes et al. 1993) 
have confirmed a high frequency of allelic loss at 6q27 in ovarian tumour samples, 
and have analysed the extent of deletions in tumour patients, in order to identify 
common regions of deletion. The involvement of other regions of 6q, however, is 
apparent, for example in the results of a study by Orphanos et al. (Orphanos et al. 
1995), which confirmed the involvement of 6q27, but highlighted three additional, 
more proximal regions which could harbor tumour suppressor genes. Another study 
(Lastowska et al. 1994), identified 6q26-q27, and 6q24 by FISH as possible sites for 
tumour suppressor genes. Focussing on the well- documented LOH at 6q24-q27 in 
ovarian cancer, Colitti et al. (Colitti et al. 1998) performed detailed mapping in this 
interval, and identified a 4cM minimal region of LOH at distal 6q24 between 
markers D6S473 and D6S448, which could contain a putative tumour suppressor 
gene involved in the development and progression of invasive epithelial ovarian 
cancers. 
Recent studies by Shridhar et al. (Shridhar et al. 1999) and Wan et al. (Wan et al. 
1999) have both detected a region of similar extent at 6q23-q24, which may play a 
role in ovarian cancer. Shridhar et al. performed microsatellite analysis of 25 high 
grade, late stage ovarian tumours, and were able to define four independent regions 
of frequent deletion, at 6q21-q22.3 (D6S301- D6S292), 6q23.2-q23.3 (including 
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D6S978, D6S977, D6S311 and D6S1637), 6q26 (D6S411-D6S1277), and 6q27 
(D6S297-D6S193). The second of these was a novel region spanning less than 
500kb, containing the markers D6S311 and D6S977 which were found to have LOH 
frequencies of 89% and 71%, respectively. The study by Wan et al. involved 
microcell- mediated chromosome transfer experiments, to introduce a normal copy of 
chromosome 6 into the highly tumorigenic ovarian cancer cell lines HEY and 
SKOV -3. The resulting cells showed a significantly reduced tumorigenicity. 
Analysis of revertant subclones that had subsequently regained their tumorigenic 
potential enabled deleted regions to be identified, the smallest of which was defined 
by the marker D6S311, and flanked by markers D6S1649 and D6S1564, which were 
retained in the revertant subclones. The experiment thus identifies a region which is 
very likely to contain a tumour suppressor gene. 
It is perhaps noteworthy that through many of these studies there is a recurrence of 
frequent LOH at the marker D6S311. Both Fujii et al. (Fujii et al. 1996) and 
Noviello et al. (Noviello et al. 1996) found D6S311 to be contained within their 
defined intervals of frequent LOH in breast cancer, and as mentioned above, the 
marker D6S311 defines minimal regions of deletion in ovarian cancer in at least two 
studies (Shridhar et al. 1999; Wan et al. 1999). 
5.1.4 The involvement of 6q in lymphoma 
The involvement of 6q in lymphoma was demonstrated in a cytogenetic analysis of 
94 lymphoma patients, which, amongst several other common structural 
abnormalities, revealed that alterations of 6q were present in 31% of cases analysed. 
Even at this early stage in the investigation of 6q, the two distinct bands of 6g21 and 
6q23 were found to be independently deleted in different cases of lymphoma 
(Bloomfield et al. 1983). Other studies have detected loss of 6q in B cell lymphomas 
at a frequency of 50% (Rickert et al. 1999), 38% (Monni et al. 1996), and 47% 
(Weber et al. 2000). 
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The chromosomal region 6q has also been implicated in T cell lymphomas 
(Schlegelberger et al. 1994; Knutsen 1998; Lepretre et al. 2000), and in acute 
lymphoblastic leukaemia (ALL), in which deletions of 6q have been narrowed down 
to the region at 6q14/15-6q21 (Menasce et al. 1994), and similarly, 6q16 (Merup et 
al. 1998), which is contained within the interval defined by Menasce et al. 
In B cell lymphoma, the deletion of up to three independent regions of 6q has been 
detected, suggesting that more than one tumour suppressor gene may be involved in 
the pathogenesis of B cell lymphoma. A study by Gaidano et al. (Gaidano et al. 
1992), identified two distinct regions of minimal deletion (RMD) at 6q25-q27, and 
6q21-q23. The RFLP analysis used to define these intervals detected LOH in 22.5% 
of cases. A subsequent study by the same group further defined the regions of 
minimal deletion (RMD), and associated each with different pathological subsets of 
lymphoma, as follows: RMD1-6q25-27, RMD2-6q21, RMD3-6q23, associated with 
intermediate grade, high grade and low grade NHL respectively (Offit et al. 1993). 
A positional cloning approach was then taken by the same group in an attempt to 
map the location of the putative tumour suppressor gene residing in the RMD 1 at 
6q25-27 (Hauptschein et al. 1998). This generated a YAC contig across the whole 
region, and then defined a smaller minimal region of 5 -9Mb believed to contain the 
gene. One candidate gene, MLLT4 (also known as AF -6, and discussed further in 
5.1.7), was found to reside in the RMD1, but is unlikely to be the true suppressor 
gene as no inactivating mutations were detected. 
Several studies have now refined the frequently deleted regions in non- Hodgkin's 
lymphoma (NHL), and it is apparent that at least two, and possibly three tumour 
suppressor loci may be involved. The emerging consensus is that regions at 6q21, 
and 6q23-25 are most likely to contain tumour suppressor genes, along with a further 
possible locus at 6q26-27. The 6821 interval has been identified in a comparative 
genomic hybridisation (CGH) study by Weber et al. (Weber et al. 2000) in a panel of 
primary diffuse large B cell lymphomas of the central nervous system, in which 47% 
LOH at 6q was detected. A 2 megabase interval of deletion flanked by markers 
D6S447 and D6S246 was detected in a FISH study using YAC probes spanning the 
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region at 6q16-q22 (Sherratt et al. 1997). A similar genetic location emerged from a 
study by Zhang et al. (Zhang et al. 2000), in which a commonly deleted region of 
3cM (4 -5Mb) was detected by FISH, and proposed to contain a tumour suppressor 
gene with a role in ALL, and both low and high grade NHL. A study by Starostik et 
al. (Starostik et al. 2000) detected 42% LOH of part or all of 6q in 31 large B cell 
lymphomas of gastric origin, using 73 polymorphic markers. In particular, this study 
defined two LOH hotspots, at 6q21-22.1 (flanked by D6S246 and D6S261), and 
6q23.3-24 (flanked by D6S310 and D6S441), with 23% and 32% incidence of LOH 
respectively. As in other studies, the recurring 6g21 region was highlighted again, 
along with the less studied region at 6q23.3-24, which has also been detected as a site 
for a putative suppressor gene by Zhang et al. (Zhang et al. 1997). Interestingly, and 
in contrast to Offit et al. (Offit et al. 1993), the commonly deleted region at 6g23- 
q24 identified by Zhang et al. (Zhang et al. 1997) showed no discrimination between 
low or high grade and follicular subsets of lymphoma. 
From the overall consensus of the results in these studies, it seems probable that there 
is a tumour suppressor gene at 6q21 involved in both NHL and ALL, and another 
tumour suppressor gene at 6q23-25 involved in NHL. The latter of the two 
corresponds well to the putative tumour suppressor loci proposed in other cancers, 
such as pancreatic, ovarian and breast cancer (see above and below), suggesting that 
within this interval may be a tumour suppressor gene with a common role in the 
tumorigenic pathway in a wide variety of malignancies. 
5.1.5 The involvement of 6q in other cancers 
Whilst the most frequently studied cancers in the context of 6q loss are breast, 
ovarian, and lymphoma, as discussed above, there are many others in which tumour 
suppressor genes at 6q may be involved. Some of these cancers are perhaps less 
significant in terms of their occurrence in the population, often reflected in the 
proportion of studies that have investigated them, but they are no less significant in 
terms of the frequency with which 6q is involved. 
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Pancreatic cancer has one of the poorest prognoses of all malignancies, so the 
elucidation of the genetic causes of this disease is a subject worthy of perhaps more 
study than it has received in recent years. A recent comparative genomic 
hybridisation (CGH) study showed 6q loss in 39% of endocrine pancreatic cancer 
cases (Speel et al. 1999). A large LOH study of 55 paired pancreatic tumour DNA 
and corresponding normal DNA samples with 30 polymorphic markers revealed that 
three independent regions of 6q might contain tumour suppressor genes (Abe et al. 
1999). These comprise firstly a 500kb region at 6q21 bordered by D6S449 and 
D6S283, showing a LOH frequency of 69 %; secondly, a 7cM region at 6q22-23 
bordered by D6S292 and D6S308, showing 60% LOH; and thirdly, a 13cM region at 
6q25-q27 bordered by D6S305 and D6S264, showing 51% LOH. It is possible that 
all three regions may represent tumour suppressor gene loci. 
In cervical cancer, loss of 6q has been reported at a frequency of 38% (Kirchhoff et 
al. 1999), and a study by Mazurenko et al. (Mazurenko et al. 1999) predicts the 
existence of possibly three tumour suppressor genes, located at 6q23 (D6S311), 
6q26, and 6q27, with LOH frequencies of between 30 and 40% in each case. 
Papillary serous carcinoma of the peritoneum was recently found to be strongly 
associated with the loss of 6q. As with cervical cancer, three minimal regions of 
LOH have been detected and defined as 6q23-q24 (D6S250 -ESR, containing 
D6S311), 6g25.1- g25.2, and 6q27 (Huang et al. 2000). The three intervals show 
LOH frequencies of 42.9 %, 47.2% and 47.4% respectively. 
Cytogenetic analyses established the involvement of 6q losses in the in vitro 
transformation of uroepithelial cells (Wu et al. 1991). Subsequent to this, a 
comparative genomic hybridisation (CGH) study demonstrated that 6q losses were 
among the most frequent of genetic alterations in bladder cancer, occurring in 19% 
of cases analysed (Richter et al. 1998). Similarly, LOH at 6q was shown to occur at 
a frequency of 27% by Bernues et al. (Bernues et al. 1999). In particular, loss of the 
6q22-q23 region has been associated with the progression of bladder cancer, 
suggesting that a tumour suppressor gene resides in this interval (Richter et al. 1999). 
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Salivary gland carcinoma has shown a 47% LOH frequency in a study by Queimado 
et al. (Queimado et al. 1998), and two small, commonly deleted regions have been 
defined at 6q21-q23.3, and 6q27. 
Three common regions of allelic loss have been detected in malignant mesothelioma. 
These are defined by 6q14-q21, 6q21-q23.2, and 6q25 (Bell et al. 1997). 
Allelic loss of 6q has been found in prostate cancer at frequencies of 22% (Visakorpi 
et al. 1995), 39% (Cher et al. 1996), and 33% (Cooney et al. 1996). Similar regions 
of common deletion were detected by (Cooney et al. 1996) and (Srikantan et al. 
1999), representing the interval from 6g14/16.3 to 6g21. Additionally, Srikantan et 
al. detected allelic loss at D6S311 (6q23), which may represent an additional locus 
with some role in prostate cancer. Interestingly, this is a yet another example of the 
recurrence of the marker D6S311; this marker appears to signify a site of frequent 
LOH in many cancers, including non -Hodgkin's lymphoma (Starostik et al. 2000), 
papillary serous carcinoma of the peritoneum (Huang et al. 2000), and breast and 
ovarian cancers as mentioned previously, in addition to prostate cancer. 
5.1.6 Summary 
There is clearly a general consensus that 6q harbors several tumour suppressor genes, 
but correlating the data from many different studies is difficult. Overall, it would 
appear that there may be up to four putative tumour suppressor loci at 6g16, 6g21, 
6q23-q25, and 6q27, but whether the loci are specific to certain cancer types, or 
disease stages, is unclear. However, the fact that similar deleted regions recur in 
many studies, across many cancers, suggests that one or more of these tumour 
suppressor genes may have a common role in tumorigenesis. 
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5.t7 Candidate tumour suppressor genes at 6q 
Despite the accumulating evidence to suggest that several tumour suppressor genes 
reside on the long arm of chromosome 6, few candidates have yet been proposed. 
One candidate is the gene SOD2, which is located at 6q25.3 and encodes the protein 
manganese superoxide dismutase. This gene has been proposed as a candidate 
tumour suppressor gene in melanoma (Bravard et al. 1992). However, the evidence 
for a suppressor role is conflicting, and there is experimental evidence against the 
ability of this gene to suppress tumorigenicity from transfection studies that showed 
that the introduction of a normal chromosome 6 (and intact copy of SOD2) into 
metastatic melanoma cell lines did not suppress tumorigenicity or metastatic 
potential (Miele et al. 1995). 
Another candidate is the gene AF -6 /MLLT4, which was found to reside in the RMD1 
described in lymphoma at 6q27 (Hauptschein et al. 1998). Many acute leukemias 
and acute lymphoblastic leukemias are found to have translocations that break at the 
11q23 region, and result in fusion with another chromosomal region. The gene AF6 
is one of four common fusion sites involved in this translocation, hence its name, 
AF6 (ALL1 Fused Gene from chromosome 6), or MLLT4 (Myeloid /Lymphoid or 
Mixed Lineage Leukemia, Translocated to, 4) (Prasad et al. 1993). Despite its 
apparent association with leukemia, no muations were identified in a small subset of 
B cell NHL cases (Hauptschein et al. 1998). This gene also lies within a commonly 
deleted region defined by Saito et al. (Saito et al. 1996), but similarly, in that 
instance, no mutations of the gene were detected in ovarian cancer, thus suggesting it 
unlikely that AF -6 /MLLT4 is a tumour suppressor gene in these cancers. 
Other candidates are the oestrogen receptor ESR at 6q25, the presence of which has 
been established as an identifying marker for breast cancer patients who have lower 
risk of relapse and a generally good prognosis (Clark, McGuire 1988); and MAS], 
which encodes an integral membrane protein that may function in cell signalling. 
MAS] is an oncogene originally identified from an epidermoid carcinoma cell line 
(Young et al. 1986), and maps to tumour -specific breakpoints at 6q24-27 (Rabin et 
al. 1987). It had been shown to be imprinted by Villar et al. (Villar, Pedersen 1994), 
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but this was later revealed to be incorrect, as the analysis of imprinting by Villar et 
al. was likely to have been distorted by the fact that the last exon overlaps an 
imprinted antisense transcript of the Igf2r gene (Lyle et al. 2000). No compelling 
evidence has come to light as yet to substantiate the involvement of either MASI or 
MLLT4 in a tumour suppressor capacity. The identification of the gene ZAC at 6q24, 
and the accompanying evidence of its anti -proliferative properties was therefore an 
exciting discovery in the search for candidate genes in this region. 
5.1.8 ZAC as a tumour suppressor gene in breast cancer 
The gene ZAC, also known as PLAGLI and LOT], has been proposed as a candidate 
tumour suppressor gene, for three reasons. Firstly, ZAC encodes a zinc finger 
protein, which has DNA -binding, transactivation, and antiproliferative properties, 
and possesses the ability to concurrently induce apoptosis and G1 arrest (Spengler et 
al. 1997), which is reminiscent of the action of p53, although the relevant pathways 
are believed to be distinct for the two genes. Secondly, ZAC was identified 
independently as LOT], through a screen for transcripts specifically lost on 
transformation of normal ovarian cells to cancer cells (Abdollahi et al. 1997a), 
suggesting that it acts as a suppressor of tumorigenicity in ovarian cells. Thirdly, 
ZAC resides in a region of 6823 -25 that has been implicated in many human cancers, 
as described in 5.1.2- 5.1.5. Specifically, the ZAC locus falls within the critical 
regions defined by (Noviello et al. 1996) (breast), (Theile et al. 1996) (breast), 
(Starostik et al. 2000) (large B cell NHL), and (Huang et al. 2000) (papillary serous 
carcinoma of the peritoneum), and is in very close proximity to critical regions 
defined by (Abe et al. 1999) (pancreatic), (Shridhar et al. 1999) (ovarian), (Wan et 
al. 1999) (ovarian), and (Rodriguez et al. 2000) (breast). Figure 51 shows the 
location of ZAC relative to these defined critical regions, which are indicative of a 
tumour suppressor gene locus. No such gene has been identified in this region to 








































































































































































































































































































































































































































The candidacy of ZAC as a tumour suppressor gene in breast was addressed in a large 
study by Bilanges et al. (Bilanges et al. 1999), one of the groups involved in the 
initial identification of ZAC (Spengler et al. 1997). They first demonstrated that ZAC 
is expressed in mammary epithelial cells - an important finding, since this tissue is 
the origin of the large majority of breast tumours. They then performed 
microsatellite analysis of DNA from a panel of breast tumours together with their 
corresponding peripheral blood lymphocyte DNA samples, using 5 microsatellite 
markers in the vicinity of ZAC at 6q24-25. From this analysis they were able to 
select a panel of 45 breast tumours that showed loss of heterozygosity at this locus. 
The hypothesis proposed and tested by Bilanges et al. was that these 45 breast 
tumours showing LOH had suffered a Knudson hit (Knudson 1971; Knudson 1986), 
inactivating one allele. If it could subsequently be shown that a second hit had been 
acquired in these cases, in the form of a coding region mutation, this would account 
for complete loss of ZAC function in the tumours, thus substantiating ZAC as a 
candidate tumour suppressor gene. They tested their hypothesis by undertaking 
thorough mutation screening of the entire ZAC coding region by SSCP -PCR, but did 
not find any mutation in any of the 45 breast tumours, and so concluded that if ZAC 
were involved in tumorigenesis in these samples, a Knudson two -hit model was 
unlikely to be applicable. 
5.1.9 Imprinting of ZAC may influence its tumour suppressor 
role 
Unfortunately, performed without the knowledge that ZAC is in fact an imprinted 
gene, the study by Bilanges et al. may have been a fruitless effort from the outset. 
Had they known of ZAC's imprinted status, being maternally methylated at the 
NV 149 CpG island and expressed exclusively and monoallelically from the paternal 
allele (See previous chapter, and (Kamiya et al. 2000; Piras et al. 2000)), this would 
certainly have altered their hypothesis and the way they might have conducted their 
experiments. As discussed in previous chapters, if a tumour suppressor gene is 
imprinted, it has in effect already acquired one Knudson hit by the silencing of one 
allele by methylation. In the case of ZAC, it is the maternal allele which is 
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consistently methylated, therefore leaving only the paternal allele in an active state. 
This in itself is a precarious situation for a tumour suppressor gene, since the 
subsequent loss of the one remaining allele is all that is required for a complete loss 
of function, which could lead to tumorigenesis. In the panel of breast tumours 
selected in the Bilanges study showing LOH at 6q24-25, it is perhaps not surprising 
that no mutation was detected in the remaining allele, because it is quite feasible that 
the lost allele was the active paternal copy, and the retained allele was the inactive 
maternal copy in all cases. 
5.1.10 Purpose of this study 
With the knowledge that ZAC is imprinted, a new hypothesis can be tested. In 
tumours with LOH, if it can be shown that the single retained allele is consistently of 
maternal origin and thus inactive, then this would be strongly suggestive of a tumour 
suppressor role for ZAC. 
In a previous chapter within this study, I have demonstrated the monoallelic 
expression and imprinting of ZAC by RT -PCR. Confirmation of this finding has 
recently been published in a study by another group who independently identified 
Zac along with another maternally methylated gene in a systematic screen for 
imprinted genes in the mouse (Piras et al. 2000). With this substantiated knowledge 
of ZAC's expression status, an important hypothesis to test now would be whether 
the origin of the retained allele is consistently maternal in a panel of tumours with 
LOH at the ZAC locus. 
To test this hypothesis it would first be necessary to analyse a panel of tumours using 
a range of microsatellite markers close to the ZAC gene. On establishing a subset of 
tumours showing LOH, the origin of the remaining allele would be determined by 
analysing the methylation of the NV 149 CpG island upstream of ZAC, using the 
technique of bisulphite modification and sequencing. The expected result is that 
tumours with LOH at this chromosomal region would show only the maternal 
methylation pattern, indicating that the single allele that they have retained is 
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methylated and thus functionally silent. A particularly important aspect of the 
experiment is that the methylation status of the subset of tumours without LOH 
should be tested; to remain consistent with the proposed hypothesis, these tumours 
should display both a maternal and paternal methylation pattern at the CpG island, 
since they possess both parental alleles. This point would show that the exclusively 
maternal methylation pattern observed in LOH tumours is specifically due to the 
LOH of the paternal allele, rather than any silencing of the paternal allele through 
tumour -specific methylation. A recent RLGS study has assessed the frequency of 
aberrant methylation of CpG islands in different tumour types and concluded that on 
average, 600 of the estimated total of 45000 CpG islands in the human genome were 
aberrantly methylated in tumours. However, the results of this study also indicated 
that aberrant methylation was rarer in certain types of tumour, including breast, head 
and neck, and testicular tumours, whereas it occurred more frequently in colon 
tumours, gliomas, and acute myeloid leukemias (Costello et al. 2000). 
To summarise, the basis of the argument in this study is as follows: if, as predicted, 
preferential loss of the active paternal ZAC allele is occurring in tumours, those that 
are shown to have LOH will be expected to show a maternal methylation pattern at 
NV 149, whereas those without LOH would, by definition, retain both parental alleles 
and would therefore be expected to show both a maternal and a paternal methylation 
pattern. There is a possibility, however, that de novo tumour -specific methylation of 
NV 149 may be occurring. By including the non -LOH tumours in the methylation 
analysis, this possibility can be assessed - if de novo methylation were prevalent, 
both LOH cases and non -LOH cases would show a maternal methylation pattern at 
NV 149, because this event would be non -discriminating. Thus, the analysis of the 
non -LOH cases allows distinction between whether a maternal methylation pattern in 
the LOH cases represents preferential paternal allele loss, or de novo methylation in 
the tumours. 
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5.2 DEVELOPMENT OF EXPERIMENTAL STRATEGY AND 
OPTIMISATION OF TECHNIQUES 
5.2.1 Selection of microsatellites 
Five polymorphic dinucleotide repeat microsatellites were chosen for the purpose of 
analysing the LOH at ZAC/NV 149. These were as follows: D6S308, D6S311, 
D6S279, D6S977, and D6S1703. The markers were selected on the basis of their 
close proximity to the ZAC/NV 149 locus, and their high heterozygosity, which 
maximises the chances of the samples being heterozygous and therefore informative 
for the markers. 
Figure 52 shows the relative locations of the markers. The map positions and genetic 
distances between markers are according to the LDB database (genetic Location 
























































































































































5.2.2 Optimisation of microsatellites 
The five microsatellites were tested and optimised first on a panel of normal DNA 
controls. A standard set of cycling conditions was used initially (e.g. 94 °C /1 min; 
55 °C /1 min; 72 °C /2 min, for 35 cycles), and then modified as appropriate for each of 
the microsatellites on the basis of the results obtained. The markers D6S308 and 
D6S311 were immediately successful and a satisfactory product was consistently 
obtained. However, markers D6S279, D6S977 and D6S 1703 failed to give an 
adequate or visible product after many optimisation attempts. On referring back to 
the original sequences, it was discovered that the published primer sequences were in 
some cases incorrect, and in other cases perhaps too short to be effective. For these 
reasons, new primer sets were designed for D6S279, D6S977 and D6S 1703 based on 
available genomic sequence, and the optimisation procedure repeated. This time 
each set of primers consistently generated a product that was of satisfactory quality 
for ABI analysis. 
5.2.3 Identification of three novel CA repeats in the PAC 
clones 197 -L1, 340 -H11, and 468 -K18 
Whilst the five CA repeat microsatellites described above are all located at 6q23, the 
closer the markers are to ZAC and NV 149, the more accurate the results will be as an 
indication of the true LOH at the ZAC locus. For this reason, the sequences of the 
three PAC clones, 197 -L1, 340 -H11 and 468 -K18, which surround ZAC, were 
searched for novel CA repeats, and this revealed the presence of one such CA/GT 
repeat in each of these PAC clones. These were named CA197, CA340 and GT468 
accordingly, and primers were designed to amplify a region of approximately 250- 
300 bp around each dinucleotide repeat. Since these three microsatellites were novel 
markers, it was important to establish firstly whether they were polymorphic, and if 
so, what was the degree of heterozygosity for each. This was done by amplifying a 
panel of 27 normal human genomic DNA controls for each microsatellite, and 
analysing the sizes of the resulting products on ABI gels, as described below. The 
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results of this analysis are given in Table 9. The heterozygosity values observed are: 
CA197, 80 %; CA340, 58 %; GT468, 80 %. Clearly, CA197 and GT468 are extremely 
useful due to their high degree of heterozygosity, because they are likely to be 
informative in approximately 80% of cases. However, despite the lower 
heterozygosity of the marker CA340 (58 %), this marker may still be useful in 
conjunction with the others, and is particularly important in this study as it is the 




CA197 (Hex) CA340 (Tet) GT468 (Fam) 
1 230/240 247/257 241 
2 242/252 245 241/245 
3 238/240 245 245/251 
4 240/242 245 239/241 
5 230/240 245/247 239/241 
6 232/244 253/257 237/241 
7 230/242 245/247 241 
8 234/246 257/259 241/245 
9 238/240 247 241 
10 230/244 243/255 237/239 
11 234/240 245 243/245 
12 236 239/245 239/241 
13 230/240 247/257 241/245 
14 234/240 245 241/245 
15 240 247/253 235/239 
16 230/240 247/251 241/245 
17 - 245 - 
18 240 245 239/243 
19 240 245 243/245 
20 240/242 245 241/245 
21 238/240 243/245 243 
22 230/244 245/247 237/243 
23 234 257 245/249 
24 230/248 251/257 241/245 
25 240/242 245/247 239/241 
26 234/240 247/257 243 
Heterozygosity (20 of 25) = 80% (15 of 26) = 58% (20 of 25) = 80% 
Table 9. Results of ABI analysis of microsatellite PCR products for the novel 
markers CA197, CA340, and GT468. DNA sample numbers 1 -27 are normal human 
genomic DNA controls. The sizes of the alleles detected on the ABI are shown in 
the appropriate columns. Where only one allele size is given, it is assumed that the 
individual is homozygous for that particular marker. A dash ( -) indicates an 
ambiguous ABI result, or failed PCR. The observed heterozygosities of each marker 
are given at the end of the table. 
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5.3.4 ABI 377 analysis of microsatellites 
The forward primer of each primer pair was labelled with Hex, Tet or Fam. The 
PCR products of either two or three different markers could be electrophoresed 
together in the same lane because they were labelled with different coloured dyes, 





D6S 1703 (Fam) 
CA 197 (Hex) 
CA340 (Tet) 
GT468 (Fam) 
Details of the ABI analysis are given in Materials and Methods. Typically, the PCR 
products were diluted 1:10 or 1:15, depending on the quality, and 1.51.tl loaded. 
5.3.5 Optimisation of the bisuiphite modification protocol 
Bisulphite modification has now been used for a number of years as an effective 
technique for analysing the methylation status of cytosine residues within CpG 
dinucleotides (Clark et al. 1994). The underlying basis of the technique is the 
capacity of sodium bisuiphite to efficiently convert unmethylated cytosine residues 
to uracil in single stranded DNA. In the event of a cytosine residue within a CpG 
dinucleotide being methylated, and existing as 5- methylcytosine, it is resistant to 
modification, and is not converted to uracil. In effect, therefore, the only remaining 
cytosines in a DNA strand after bisulphite modification should be those which were 
methylated in the original sequence. 
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There are three main steps in the chemical reactions that form the modification 
process. Figure 53 is a schematic diagram to illustrate the process, which is 
discussed in more detail by Clark et al. (Clark et al. 1994). Briefly, the first step 
involves addition of bisulphite to the 5 -6 double bond of cytosine, to form a 
sulphonated cytosine derivative. The second step is a hydrolytic deamination of 
cytosine -S03, to give uracil-S03. The third step is an alkali treatment to remove the 
sulphonate group, yielding uracil. During the modification of the DNA, 
unmethylated cytosines will be converted to uracil, whereas methylated cytosines 
will remain as cytosine. This can be readily detected in the sequence following the 
modification, by amplifying the region of interest by PCR, during which the uracil 
residues in the modified sequence are copied to thymine. Thus, the sequence of the 
PCR product enables the methylation status of C in CpG dinucleotides of the original 
sequence to be determined, because CpGs that are detected as TpGs in the PCR 
product will represent unmethylated CpGs in the original sequence, and any 























Figure 53. Schematic diagram of the conversion of cytosine to uracil in the bisulphite 
modification process. Redrawn after Clark et al. (Clark et al. 1994). 
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A particularly important advantage of bisulphite modification and sequencing over 
alternative methods of methylation analysis is that bisulphite modification can be 
successfully employed with limited amounts of DNA. In practice the technique has 
been shown to work efficiently on amounts of genomic DNA as low as 200pg (Clark 
et al. 1994). In contrast, Southern blotting, which is the traditional method used for 
methylation analysis, can require several micrograms of DNA. In the case of the 
tumour samples analysed in this study, DNA amounts were a significantly limiting 
factor, hence the choice of the bisulphite modification method rather than Southern 
blotting. An additional advantage of this method is that it permits the analysis of 
many CpGs within a sequence, whereas Southern blotting restricts the analysis only 
to those CpGs within methylation sensitive enzyme sites. 
The development of a working bisulphite modification protocol required 
optimisation at all stages of the technique: primer design, modification, PCR, 
sequencing and cloning, which are discussed below. 
5.3.5.1 Primer Design 
The CpG island containing NV 149 is shown in Figure 54. The CpG dinucleotides 
are highlighted to show their high density in this region. In designing primers to 
amplify bisulphite modified DNA, several factors must be taken into account, 
particularly with regard to the sequence. 
(i) After complete modification, the two strands are no longer complementary to each 
other. Therefore, unlike a standard PCR, a separate pair of primers would be 
required to amplify each strand. For the purpose of this experiment, one set of 
primers was designed with specificity for the top strand only. 
(ii) After modification, there are two possible resultant sequences at every position 
which was a CpG dinucleotide in the original sequence, depending on the 
methylation status of the cytosine within the CpG, i.e. The cytosine residue within a 
CpG dinucleotide will remain as cytosine if methylated, but will be converted to 
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thymine if unmethylated. Unless the methylation status of all CpGs is already 
known, primers must be designed to accommodate the possibility of a `C' or a 
occurring at every CpG within the primer sequence. 
(iii) In general, it is recommended that primers for amplifying bisulphite- modified 
DNA should be designed slightly longer than typical PCR primers (Clark et al. 
1994). This is to account for the lower affinity /specificity of the primers for their 
complementary sequence, which is reduced by the presence of the potentially 
variable sequence at CpG sites, and by the fact that the conversion of C to T reduces 
the sequence complexity of the target DNA. 
(iv) Smaller regions are more efficiently amplified from modified DNA than larger 
ones. In this experiment several pairs of primers were designed, to attempt to 
generate the largest possible product, thus permitting analysis of a greater number of 
the CpGs within the island. However, a successful PCR product was only obtained 
using a pair of primers designed by our collaborators (Kamiya et al. 2000), which 
amplified only 154óp of the sequence. The location of these primers (Bssu2 and 
BSS12) is shown in Figure 54. 
(v) The modification process involves an initial digestion with a relatively common 
restriction enzyme. It is therefore imperative that the region to be amplified does not 
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Figure 54. The NV 149 CpG island, showing location of the bisulphite PCR primers 
Bssu2 (forward) and BSS 12 (reverse), indicated with boxes, in the directions shown 
by the arrows. The region amplified by these primers is indicated with a bracket. All 
CpGs are highlighted, and the Notl site of NV 149 is shown with a double box. 
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5.3.5.2 Modification protocol 
The development of a consistently reliable protocol for the bisulphite modification of 
DNA was viewed as one of the most crucial aspects underlying the success of this 
study, so a significant proportion of the time was spent on optimising this technique. 
In particular, several published methods were tested and adapted (Warnecke et al. 
1998; Olek et al. 1996; McDonald et al. 1998; Clark et al. 1994). 
In the optimisation stages, the protocol was tested on a panel of normal control 
DNAs, along with parthenogenetic DNA. At first, no product was obtained with any 
of the primer sets tested, but it was difficult to know whether this was due to a PCR 
failure, or a failure at an earlier stage of the modification process. Indeed, it is 
difficult to monitor the recovery of DNA after the modification process, because the 
DNA is single- stranded at this point, and visualisation can be difficult. Silver 
staining is an option, but limits the availability of DNA for subsequent 
manipulations. 
To overcome the problem of deducing which stage of the modification/PCR process 
was failing, a published set of methylation specific PCR primers for SNRPN were 
employed as a test for complete modification (Kubota et al. 1997). This is a positive 
test, as the primers are known to be reliable in amplifying the products of expected 
size. The primers themselves were designed for the differentially methylated 
SNRPN locus, to amplify maternal and paternal products of distinct sizes from 
bisulphite modified DNA. In this study, the primers were tested on modified DNA 
that had failed in all PCR attempts with other primers. The result is shown in Figure 
55. The primers generated the products of expected size in all cases, showing both 
parental alleles in normal DNAs, and a maternal product only in the case of 
parthenogenetic DNA, confirming that the modification was in fact successful. 
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Figure 55. Methylation specific SNRPN PCR performed on bisulphite modified 
normal (N1 and N2) and parthenogenetic (PG) DNAs, as a test for complete 
modification. A normal sample should generate products of 174bp and 100bp, 
representing the maternal and paternal alleles respectively. A parthenogenetic sample 
should generate only the maternal band, as seen here. U is a PCR containing 
unmodified template DNA; B is a negative control PCR containing no template. 
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5.3.5.3 PCR on the bisuiphite- modified DNA 
It was decided to use the primer pair designed for this region in the laboratory of Y. 
Hayashizaki. The PCR cycling conditions that they had used for this set of primers 
were tested. The conditions were subsequently modified slightly to optimise the 
yield and quality of the PCR product. Conditions are given within the modification 
protocol detailed in Materials and Methods. An important control in this experiment 
is that a sample of unmodified DNA should be tested with these PCR primers and 
conditions. The primers should not anneal to unmodified DNA, and no product 
should be generated. If a product was detected with unmodified DNA as the 
template, this would suggest that the conditions were not sufficiently stringent, and 
that the product generated from bisuiphite- modified DNA samples might include 
unmodified products, which would confuse the final result. 
No PCR product was amplified from unmodified DNA template. An example of the 
PCR result is shown in Figure 56. 
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Figure 56. Example of an agarose gel of the bisulphite PCR products generated from 
some normal control DNAs and parthenogenetic DNA. U is a control PCR 
containing unmodified normal DNA; N1 -N6 are normal DNAs; PG is the 
parthenogenetic DNA; B is a negative control PCR containing no template. The 
sizes of bands in the 1 kb ladder marker are given on the right. 
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5.3.5.4 Sequencing the PCR products 
The PCR products amplified as described above were sequenced using an internal 
forward primer. A panel of normal control DNA samples and a parthenogenetic 
DNA sample were sequenced to establish the normal methylation pattern of the 
CpGs within the amplified region. The typical result obtained by a standard dGTP 
sequencing protocol is shown in Figure 57. The sequence on the right is that of a 
PCR product amplified from bisulphite- modified parthenogenetic DNA, and by 
definition should therefore represent only the maternal methylation pattern. Within 
this sequence it is clear that all cytosine residues within the CpGs are methylated, 
thus affording them protection against conversion to thymine during the bisulphite 
modification. This result is in agreement with that of experiments conducted in the 
laboratory of Y. Hayashizaki, and the consistent retention of cytosine within all 
CpGs at this locus confirms that NV 149 is methylated solely on the maternal allele. 
In addition, this result demonstrates that the modification protocol used here is 
successful, and complete. 
The sequence on the left is that of a PCR product amplified from a normal bisulphite- 
modified DNA sample, and is somewhat more difficult to interpret. On the basis that 
the maternal allele is completely methylated, and that there is differential 
methylation at this locus, a normal DNA sample containing both a paternal and a 
maternal allele would be expected to show variation at each of the CpG dinucleotides 
within the bisulphite PCR product. Initially it was anticipated that at each CpG in 
the sequence, the C would be accompanied by a T of equal intensity (the C 
representing the methylated maternal allele, and the T representing the unmethylated 
paternal allele). In practice however, the sequence appears more complex than this, 
and in fact it appears as if two superimposed sequences are present. It is 
occasionally possible to detect, as predicted, a C and a T alongside each other in the 
same position on the gel at a position where the parthenogenetic sequence shows a 
methylated CpG - one such example is indicated by a box in Figure 57, however, the 
clarity of the sequence is very poor. More illuminating is the distinct and unexpected 
pattern present in the A lane of the biparental sample. A comparison of this to the 
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equivalent lane in the parthenogenetic sample reveals that for every A residue in the 
parthenogenetic sample, there are two bands in the normal sample. Neither the 
modified nor the unmodified predicted sequence contains double As, yet there 
consistently appears to be two A bands at each expected A residue in the normal 
sample. These are indicated by arrows in Figure 57. The most likely explanation for 
this is that the sequences of the maternal and paternal alleles, being differentially 
methylated, deviate considerably from each other in sequence after modification. 
When run on a gel, the mobilities of the paternal and maternal alleles are sufficiently 
different from each other to cause the staggered effect seen in Figure 57. The 
specific cause of the altered mobilities of the sequences is unknown, but may be a 
result of secondary structure formation, and C/G compressions. These factors 
certainly play some role, since dITP sequencing was able to resolve the effect to 
some extent. 
Sequencing directly on the bisulphite PCR products is useful as a preliminary 
indication of the methylation status of the sample, but in the case of a differentially 
methylated sequence such as this, the resultant sequence comprises a mixture of 
paternally - and maternally- derived products. The intended strategy in this 
experiment was to assess the methylation status (and thus determine the parental 
origin) of the remaining allele in tumours where loss of one allele had previously 
occurred by deletion. Clearly, the successful excision of most tumours results in the 
unavoidable presence of some surrounding normal cells in the sample. This 
contamination of the tumour sample with normal material can significantly affect the 
results, unless the experimental design accounts for the effect. A potential solution 
to the problem of such contamination, and to the sequencing problem described 
above is to clone the PCR products and sequence a selection of the resulting clones, 




Figure 57. The result of sequencing the bisulphite PCR products amplified from 
normal and parthenogenetic (Partheno.) bisulphite- modified DNAs. The arrows and 
the box indicate distinctive features of the sequences, which are discussed in the text, 
and are used subsequently in classifying the methylation patterns of tumour samples. 
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5.3.5.5 Cloning the PCR products 
For the purpose of this experiment, the plan was to clone each of the PCR products 
amplified from bisulphite- modified tumour DNA (and normal DNA where 
available), and sequence approximately 20 -30 clones in each case. The nature of the 
cloning system means that each clone will be either maternal or paternal in origin, 
this being determined from the sequence at each CpG as described above. The 
cloning of a bisulphite PCR product derived from normal DNA should be expected 
to generate on average 50% paternal clones and 50% maternal clones, and a result 
close to this ratio should be observed if sufficient clones are analysed. In analysing 
the tumour samples, the hypothesis is that a tumour with LOH retains only one allele, 
and if ZAC plays a suppressor role, showing that the retained allele is always the 
inactive, methylated, maternal copy will substantiate this idea. By this hypothesis, 
cloning the bisulphite PCR product of a tumour sample with LOH should therefore 
generate clones which are all maternal. However, as explained, the contamination of 
the sample with a small proportion of normal tissue may affect this, so that a small 
number of paternal clones may be identified. 
To develop and optimise the cloning part of the protocol, the PCR products of 
normal bisulphite modified DNA were tested. The PCR product was used in the 
ligation reaction directly; ligation into the pGEM ® -T Easy vector, and transformation 
into JM109 cells was performed essentially as described in the Promega protocol, 
and the cells were plated out onto ampicillin selective LB plates, also containing X- 
gal and IPTG (this procedure is detailed in full in Materials and Methods). On 
average, around 200 colonies were observed on the plates after overnight incubation, 
and of these, 20 were picked for miniprep. Colony PCR confirmed that they all 
contained an insert of the expected size, and thus there was no evidence of the 
cloning of primer -dimer bands. Miniprep extractions were performed using the 
SNAPTM miniprep kit, and the inserts sequenced using the M13 forward primer 
within the vector sequence. 
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Unexpectedly, the sequencing of 20 clones that originated from the normal control 
DNA, revealed that only two were maternal in origin, with the remainder being 
paternal. Though statistically unlikely, this result is possible with a relatively small 
sample. However, repeating the PCR and the cloning procedures as before generated 
a similar ratio of three maternal clones to 17 paternal clones, suggesting that there is 
a consistent cloning bias. The reason for this is unknown, but the fact that the 
cloning system has a preference for paternal over maternal PCR products renders it 
useless as a means of determining the ratio of maternal and paternal alleles present in 
the original sample. 
5.3.5.6 Final strategy for analysis of breast tumours, bladder tumours 
and lymphomas 
As a result of the procedures described above, the strategy for the analysis was 
finalised as follows: 
Microsatellite analysis to be performed as described, to classify the tumours into two 
subgroups, comprising those showing LOH at the markers tested, and those not 
showing any LOH. 
Bisulphite modification, PCR and direct sequencing (dGTP) of PCR products to be 
carried out on all normal and tumour samples. Cloning of the PCR products is 
eliminated from the final strategy due to the observed bias for paternal products. 
Bisulphite sequencing gels to be analysed essentially by a comparison with the 
normal and parthenogenetic controls, with particular reference to the A residues, 
since the two parental alleles have been found to migrate differently on the gel in a 
consistent and reproducible manner. Therefore, the presence of a double A band on 
the gel at each adenine position indicates a biparental methylation pattern. The 
presence of only the lower A band indicates a maternal methylation pattern only. 
Consistent differences in intensity between the upper (paternal) and lower (maternal) 
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bands of each doublet might also serve to indicate incomplete loss of either allele or 
changes in methylation at this locus. 
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5.3 RESULTS - BREAST TUMOURS AND AND BLADDER 
TUMOURS 
5.3.1 The panel of tumour DNAs 
A panel of 11 paired breast tumour /normal DNAs and 8 paired bladder 
tumour /normal DNAs was obtained from Dr. A. McCann, University College 
Dublin. Approximately 21.1.g of each was available, of which 1µg was required for 
the bisulphite modification analysis. The remaining 1µg was used for the 
microsatellite PCRs. 
5.3.2 Microsatellite analysis 
The tumours and their corresponding normal DNAs were analysed with the five 
microsatellites D6S279, D6S308, D6S311, D6S977, and D6S1703. The three novel 
markers CA197, CA340 and GT468 were not available at this time, and there was 
insufficient DNA remaining from these tumours when they later became available, 
so only the original five markers were included in this analysis. 
The results of the analysis are summarised in Table 10. Loss of heterozygosity was 
apparent in several cases, as judged by the reduced peak height of one of the alleles 
in the tumour DNA relative to the normal DNA control. However, the results were 
found to be distorted by the apparent contamination of tumour DNA with normal 
DNA. This proved to be a significant problem, since LOH was only barely 
detectable in some cases. 
One breast tumour showed some loss of heterozygosity at three of the five markers, 
with the remaining two markers being uninformative. These results for this 
tumour /normal DNA pair (N94/T94) are shown in Figure 58. The `diagnosis' of 
LOH in this case is based on a visual assessment of the peak heights. A numerical 
analysis may be more appropriate, although the peak heights vary greatly between 
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markers and between individual PCR products depending on the quality of each PCR 
product. 
In summary, judging by the reduced peak heights, five of eight bladder tumours 
(62.5 %) showed some degree of loss for one allele of at least one of the markers 
tested. Three of eleven breast tumours (27 %) showed similar loss for at least one 
marker. However, the problem of contamination of these tumour samples with 





D6S308 D6S279 D6S1703 D6S311 D6S977 
N1 199 287 218 226/236 228/232 
T1 199 287 218 226/236 228/232 
N7 193/199 291/295 214/218 226/236 226/232 
T7 193/199 291/295 214/218 226/236 226/232 
N12 201 285 218/222 236/256 224/232 
T12 201 285 218/222 236/256 224/232 
N32 193/203 285 216/222 224/238 222/232 
T32 193/203 285 216/222 224/238 222/232 
N53 199/201 285 216/218 220/238 222/226 
T53 199/201 285 216/218 220/238 222/226 
N65 197/203 287/293 218 240 230/232 
T65 197/203 287/293 218 240 230/232 
N73 193/199 291 216/222 254/262 222 
T73 193/199 291 216/222 254/262 222 
N82 199 291 216/220 234/236 222 
T82 199 291 216/220 234/236 222 
N84 193/201 289 214/218 223/252 222 
T84 193/201 289 214/218 223/252 222 
N94 193/199 287 216 254/256 226/230 
T94 193/199 287 216 254/256 226/230 
N95 199 291/293 218/224 236/258 222/232 
T95 199 291/293 218/224 236/258 222/232 
Table 10. Results of ABI analysis of microsatellite PCR products for paired breast 
normal and tumour DNAs. In cases where there was apparent partial loss of one 






















Figure 58. Example of the LOH analysis for normal/breast tumour pair 94. In this 
case, there is apparent LOH for three of the markers (D6S308, D6S311 and D6S977) 
in the tumour; the lost allele is shown with an arrow. The markers D6S279 and 
D6S 1703 are non -informative. The boxes under the peaks show the allele sizes; 
where there are two boxes, the lower box in each case shows the peak area. 
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5.3.3 Analysis of methylation by bisulphite modification and 
sequencing 
Despite the problems of detecting LOH in the breast and bladder tumours, bisulphite 
modification was performed on the DNAs, and the PCR products sequenced as 
described previously. The result of this suggested that a normal, biparental 
methylation pattern was present at NV 149 in all samples. This could be a genuine 
result, showing that both alleles are present. However, it could also be the case that 
there is true LOH at NV 149, for example in N94/T94 (which had LOH at all 
informative markers), but despite there being only one true allele present in the 
tumour, the normal DNA that is unavoidably present in the tumour sample is 
distorting the result of the bisulphite sequencing. Other than microdissecting the 
tumour samples to eliminate non -neoplastic cells, one possible solution to overcome 
the problem is to quantitatively assess the intensity of the two A bands in each 
doublet of the bisulphite sequence. Given that the upper band is known to be derived 
from the paternal allele, and the lower band from the maternal allele, a ratio of the 
intensities of the two bands may reveal a bias that could correlate with the expected 
proportion of non -neoplastic material in the tumour sample. 
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5.4 RESULTS - BREAST CANCER CELL LINES 
5.4.1 The breast cancer cell lines 
Six breast cancer cell lines were obtained from Dr. V. Speirs, Molecular Medicine 
Unit, St. James's Hospital, Leeds. These were MDA -MB -435, MDA -MB -468, 
T47D, MCF7, MCF7 -Clone 9, and ADR -MCF7. Unlike the breast and bladder 
tumours analysed previously, this panel of breast cancer cell lines (and the panel of 
lymphomas - see 5.5) has no matched normal DNA for use as a control. Despite 
this, it was decided that they could still be analysed in a similar way to the breast and 
bladder tumours, with one main difference in the LOH experiments. Clearly, without 
a normal DNA control, it is impossible to say for certain that loss of heterozygosity 
has occurred solely in the tumour /cell line, yet if apparent homozygosity was 
observed at several of the microsatellite markers, one could make an assumption 
about the possibility of this representing LOH, based on the statistical unlikeliness of 
this multiple homozygosity occurring by chance. This type of analysis has been 
described and utilised by Goldberg et al. (Goldberg et al. 2000), in order to identify 
regions of hemizygous deletion in melanoma cell lines lacking matched controls. 
They designated the method as HOMOD, (homozygosity mapping of deletions), and 
established a significance level of 0.001, below which they would assume 
hemizygosity rather than homozygosity. To attain this level of statistical 
significance, apparent homozygosity (implicated by a single allele) at five or more 
adjacent markers was usually required. By this method, Goldberg et al. detected 
deletions in 20 of 40 cell lines, represented by homozygosity of between 7 and 30 
adjacent markers. In conjunction with standard LOH results of matched normal and 
tumour pairs, the results of the HOMOD analysis of cell lines enabled them to define 
six small consensus regions of deletion, corresponding to putative melanoma tumour 
suppressor genes on chromosome 11. 
In the context of this study, if a breast cancer cell line (or lymphoma sample, see 5.5) 
was found to contain only one allele at every one of the eight microsatellite markers 
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analysed, the probability of that cell line being genuinely homozygous with two 
identically -sized alleles for all markers can be calculated as follows: 
Referring back to the heterozygosity values for each marker, the homozygosity 









Probability of being genuinely homozygous at all eight markers, assuming no linkage 
disequilibrium= 0.25 x 0.19 x 0.23 x 0.08 x 0.23 x 0.20 x 0.42 x 0.20 
= 3.38 x 10-6, 0.000338%, or 1 in 263157. 
Clearly therefore, a finding of apparent homozygosity at all eight markers would be 
strongly suggestive of hemizygosity or deletion in the cell line /tumour. 
Similarly, homozygosity for only the first five of the markers would still be 
statistically unlikely at 1 in 4974, and probabilities of other combinations of apparent 
homozygosity can be calculated accordingly. 
Analysis of the both the breast cancer cell lines and the panel of lymphomas was 
continued with on the basis of this assumption, so that those showing apparent 
homozygosity at multiple adjacent markers could be `diagnosed' as cases with 
deletion at this chromosomal region. 
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5.4.2 Microsatellite analysis 
The analysis of LOH in the cell lines was performed essentially as with the breast 
and bladder tumours, but as explained above, LOH was judged by apparent 
homozygosity at multiple adjacent markers. The results are shown in Table 11. Of 
the six breast cancer cell lines, one (ADR -MCF7) was found to have only a single 
allele for all eight markers analysed. The probability of this representing true 
homozygosity rather than hemizygosity is 1 in 263157, suggesting that it is more 
probable that this cell line has a deletion across this chromosomal region. Other than 
this, the cell line MDA -MB -468 is apparently homozygous for the three adjacent 
markers D6S 1703, D6S311 and D6S977, which may represent hemizygosity for this 
region, but is not significant in the context of loss of ZAC, because this cell line is 
clearly heterozygous for the three markers that are closest to ZAC/NV 149 (CA 197, 
CA340, GT468). In summary therefore, it is likely that only the cell line ADR -MCF 
is hemizygous for the chromosomal interval from D6S308 to D6S977 (containing 



































































































































































































































































































































































































































5.4.3 Analysis of methylation by bisulphite modification and 
sequencing 
By the hypothesis stated earlier in this chapter, if ZAC is a tumour suppressor gene 
involved in the malignancies investigated here, a cell line (or tumour) demonstrating 
LOH at the ZAC locus might be predicted to have lost the active paternal allele of the 
gene, thus retaining only the silent, non -functional copy. The bisulphite analysis of 
the differentially methylated NV 149 CpG island enables distinction between the 
parental alleles present in the sample on the basis of their methylation status, given 
that the maternal allele is known to be methylated and the paternal allele 
unmethylated. Bisulphite analysis was performed on the cell lines, and the PCR 
products generated from the modified DNA samples were sequenced as described 
earlier. The results are shown in Figure 59. Given that the cell line ADR -MCF7 was 
shown to carry a deletion of the ZAC locus, it might be expected that the remaining 
allele in this case would be the inactive maternal (methylated) copy. However, the 
result of the bisulphite analysis suggests that this is not the case, and in fact the 
methylation pattern of this cell line indicates that there is a predominance of the 
paternal (unmethylated) pattern. Additionally, whilst it is very clear from the LOH 
analysis that ADR -MCF7 carries only one allele for this region, and seemingly it is 
the maternal rather than paternal allele that is deleted, there is some evidence from 
the sequencing gel of a methylated allele. If the cell line is deleted, and there is only 
one allele present, then the presence of a methylation pattern reminiscent of both 
parental alleles suggests that some subsequent methylation of a subset of the paternal 
alleles has occurred. 
The analysis of MDA -MB -468, MCF7 and MCF7 -Clone 9 appears normal in that 
both methylated (maternal) and unmethylated (paternal) alleles are present, as 
predicted by the normal biparental results of the LOH analysis which showed no 
evidence for deletion. The result of the cell line MDA -MB -435 is not clear. Of 
particular interest however is the result of the cell line T47D. This cell line also 
appeared to have a normal biparental contribution, as judged by the LOH analysis, 
yet the bisulphite sequencing shows that there is a predominantly maternal 
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methylated pattern, similar to the result obtained from the parthenogenetic sample. 
The paternal allele (upper A band in each doublet) is still faintly visible, but it would 
seem that there is a predominance of maternal -typical alleles (lower A band in each 
doublet). This is a significant result because there is no evidence for deletion in this 
case. Whilst it cannot be ruled out that there is an undetected microdeletion, it is 
possible that this result is caused by hypermethylation of the NV 149 locus, such that 
the majority of alleles adopt a maternal -type methylated status. This 
hypermethylation could be predicted to silence the ZAC gene, and may therefore 
represent an alternative means, other than deletion, by which the function of the gene 
is ablated. 
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Figure 59. Bisulphite sequencing for the breast cancer cell lines. A normal sample 
and the parthenogenetic sample are shown on the left for the purpose of comparison. 
The order of the lanes in each sequence is A, C, G, T. The cell line T47D has an 
apparent predominantly maternal methylation pattern, whereas ADR-MCF7 has a 
predominantly paternal methylation pattern, as judged by the doublet A bands in 
which the upper band is derived from an unmethylated allele, and the lower band is 
derived from a methylated allele. See text for discussion. 
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5.5 RESULTS - LYMPHOMAS 
5.5.1 The panel of lymphomas 
A panel of 21 large B -cell non -Hodgkin's lymphoma (NHL) samples was obtained 
from Professor K. MacLennan, Department of Pathology, St. James's Hospital, 
Leeds. The samples were excised tissues, frozen at -70 °C for up to five years. DNA 
and RNA were extracted from these as described in Materials and Methods. The 
tumour content of the lymphomas in this panel is generally known from 
histochemical criteria to be approximately 80 %, indicating that contamination with 
normal DNA could be expected to pose less of a problem for LOH analyses than 
with the breast tumours. 
5.5.2 Microsatellite analysis 
The panel of 21 lymphoma DNAs was amplified for each of the eight microsatellite 
markers, and the PCR products analysed on an ABI 377. The results of the analysis 
are shown in Table 12. 
As discussed above (5.4.1), LOH could be assumed if a lymphoma showed only one 
allele for several of the eight markers, such that the probability of this representing 
true homozygosity rather than hemizygosity would be very low. In Table 12, each 
marker that is apparently homozygous is indicated by a shaded box. Only three of 
the lymphomas displayed homozygosity for four or more markers: L /05, L /14, and 
L/21. However, these are unlikely to represent true deletions, since the markers that 
are homozygous are not contiguous. In any case, the three markers nearest to ZAC 
and NV 149 (CA197, CA340 and GT468) are the most significant loci at which to 
find deletion, and only one lymphoma (L /21) is homozygous for two of these. All 
other lymphomas were heterozygous for two or three of these three markers. 
Overall, it is therefore unlikely that any of the lymphomas have genuine LOH at the 
NV149/ZAC locus. To find such a lack of LOH in this panel of lymphomas is 
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somewhat surprising, because it is evident from the published literature that an 
average LOH of 30 -40% could be expected in non -Hodgkin's lymphoma. This result 
could be due to chance, but it is perhaps more likely that some instances of LOH 
have been missed because of the lack of matched normal samples for comparison. 
Indeed, where a lymphoma sample was apparently heterozygous for a marker, a true 
hemizygous result may have been obscured by the presence of the two original 





































































































































































































































































































































































5.5.3 Analysis of methylation by bisuiphite modification and 
sequencing 
Despite the apparent lack of LOH in the lymphoma DNAs, all samples (L /01 -L /21) 
were subjected to bisuiphite modification and PCR, and then the PCR products 
sequenced as described previously. The lack of normal DNA for comparison 
demanded therefore that the lymphomas be closely scrutinised against a bisulphite- 
modified normal and parthenogenetic DNA control, in order to establish the parental 
origin of the methylation pattern at NV 149. 
The lack of LOH in the lymphomas indicates that both alleles are present at the 
NV 149 CpG island. Since both alleles are present, the initial hypothesis would 
predict a biparental methylation pattern at NV 149, displaying both the methylated 
maternal allele and the unmethylated paternal allele. Results of the bisuiphite 
sequencing for lymphomas L /01 -L /08 are shown in Figure 60. Whilst the majority 
of the sequences show the typical pattern, represented by two superimposed 
sequences, with a double A band at each A site in the original sequence, there are 
two lymphomas which clearly deviate from this expected result. Lymphoma sample 
L /06 appears completely methylated, as the sequence appears identical to that of the 
parthenogenetic DNA control. Only the lower A band representing the maternal 
allele is present, suggesting that both alleles are methylated. There is no evidence of 
any unmethylated sequence in this sample. The absence of LOH, in conjunction with 
the complete methylation observed at NV 149 in this lymphoma, suggests that 
NV 149 has become hypermethylated. Because methylation is normally associated 
with the silent allele of ZAC, the occurrence of de novo methylation in the tumour 
may be hypothesised to result in ablation of function, since both alleles are now 
effectively silenced. 
The lymphoma sample L /05 also appears to have undergone hypermethylation at 
NV 149, since the bisulphite sequence for this sample too shows a predominantly 
maternal methylation pattern. This sample does have a low, but detectable level of 
unmethylated sequence. This is quite likely, however to represent the small 
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proportion of non -neoplastic cells within the lymphoma samples. Histological 
examination shows that, in contrast to the breast and bladder tumours, these samples 
of large B -cell lymphoma are comparatively homogeneous, consisting of at least 
80% tumour cells. 
Thus, although this was not our original expectation, it appears that as with the breast 
cancer cell line T47D, lymphomas L /05 and L /06 have hypermethylation at the 
NV 149 CpG island, and that this event could play a significant role in silencing both 
copies of ZAC in these patients, thus causing a loss of function. To pursue this idea, 
it would be necessary to show that the hypermethylation of the NV 149 CpG island in 
these cases is associated with a lack of expression at the mRNA level. This would 
strengthen the postulate that hypermethylation causes a reduction or complete loss of 
ZAC mRNA, and that the absence of the resulting protein could have a pathological 
outcome. The technique of RNase protection (RPA) was chosen to assess expression 
of ZAC in the lymphomas, as described below. 
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Normal Partheno. L/01 L/02 L/03 L/04 L/05 L/06 L/07 L/08 
Figure 60. Analysis of NV 149 methylation status by bisulphite sequencing. The 
normal DNA and parthenogenetic DNA references are shown on the left of the 
gel. Samples L /01 to L /08 are the bisulphite PCR products of lymphoma DNAs 
L /01 to L /08. Lymphoma L /06 shows a completely methylated pattern, identical 
to that of the parthenogenetic reference. Lymphoma L /05 also shows a similar 
pattern, but with a limited degree of paternal contribution. The arrows indicate 
the A doublets, as discussed in the text. 
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5.5.4 Ribonuclease Protection Assay (RPA) 
For the quantification of ZAC levels in the lymphomas, a ribonuclease protection 
assay was chosen, since it is more sensitive and less demanding with regard to the 
quality of sample RNA than the Northern blotting technique. 
5.5.4.1 Background information 
The ribonuclease protection assay (RPA) is a sensitive method for detecting and 
quantifying a specific target RNA fragment in a sample of total RNA. The technique 
involves generating a radioactively labelled antisense RNA probe that is 
complementary to the target RNA. The probe is synthesised such that it is longer 
than the target; this is usually achieved by cloning the target sequence into a vector 
(pGEM Easy in this case), and then transcribing in vitro from one of the polymerase 
promoters within the vector (either directly on the linearised plasmid, or on a PCR 
product generated from it), such that the probe comprises the target sequence, and an 
additional region that represents the vector sequence between the cloning site and the 
relevant promoter. The probe is then hybridised to the sample RNA, followed by 
digestion with ribonuclease, which degrades any unhybridised probe, and also 
degrades the part of the probe described above that is not complementary to the 
target sequence. Thus, when electrophoresed on a polyacrylamide gel, the full - 
length probe is distinguishable in size from the protected fragment that will remain 
after the digestion. The protected fragment can be visualised by autoradiography, 
and represents the hybrid of probe and target. Provided there is a molar excess of 
probe relative to target in the hybridisation reaction, the intensity of the protected 
fragment is directly proportional to the amount of target RNA in the sample, and thus 
allows accurate quantification. 
5.5.4.2 Generating a ZAC antisense RNA probe 
Figure 61 is a schematic diagram to explain how an antisense RNA probe was 
generated for ZAC. The RT -PCR product 1029 (see 4.2.17) of a fetal heart cDNA 
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was cloned into the vector pGEM®T Easy, and DNA was prepared from six of the 
resulting colonies. PCR was performed with primers M13F and ZACPROBE5' to 
identify a clone in the correct orientation such that transcription with T7 RNA 
polymerase would generate an antisense rather than sense probe. These primers 
should generate a product only from those clones that are in the required orientation; 
Figure 62 shows the result, which indicates that clones 2, 5 and 6 conformed to this 
requirement. Clone 2 was selected for further procedures. The PCR product 
described above was prepared for use as a template in the transcription reaction, by 
treating with SDS and proteinase K to remove any nucleases, and then purifying with 
a Wizard prep column. For transcription, 100ng was used. The transcription 
reaction was performed as recommended in the Ambion protocol (see Materials and 
Methods). The amount of limiting nucleotide was optimised first in an unlabelled 
reaction, and a final concentration of 4µM limiting nucleotide was chosen as the 











































































































































































































































































kb 1 2 3 4 5 6 B 
1000bp-* miaow 
500bp -> 
Figure 62. PCR from M13F to an internal primer ZACPROBE5', to determine the 
orientation of the insert. 1 -6 are clones, B is a negative control PCR containing no 
template. Clones 2, 5 and 6 contain the insert in the correct orientation. See text for 
more details. 
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5.5.4.3 RPA experiments 
Several pilot experiments were set up as recommended in the Ambion protocol, to 
try to optimise the amount of RNA and concentration of enzyme to use in the assay. 
However, despite generating a full- length probe in each transcription reaction, no 
protected fragment was observed after hybridisation and digestion. The sample RNA 
used in these pilot experiments was derived from a lymphoblastoid cell line. 
Because of these results, it was suspected therefore that the ZAC transcript might be 
too rare to detect by this technique. To ensure that the RPA method was working, 
the only positive control available was to generate a sense transcript from the original 
clone, using SP6 polymerase. This transcript is the complement of the T7 antisense 
probe in the region where they overlap each other. A further RPA experiment was 
performed, using increasing amounts of the SP6 transcript as positive control 
samples, and LCL RNA as test samples. Increasing amounts of SP6 transcript were 
used, ranging from 0.6pg to 600pg. These were chosen to represent the approximate 
equivalent amounts of ZAC transcript that would be expected in a 10µg sample of 
total RNA, assuming abundances of ZAC in the range between 1 in 100000 mRNA 
molecules (represented by 0.6pg SP6 transcript) and and 1 /100 mRNA molecules 
(represented by 600pg SP6 transcript), taking into account the shorter length of the 
SP6 transcript as compared to a mRNA transcript of average length. The result is 
shown in Figure 63. Despite the apparent premature termination of the probe, there 
is no protected fragment in any of the LCL test lanes, but a protected fragment is 
evident in the SP6 control lane with the highest amount of SP6 transcript, equivalent 
to an abundance of 1 /100 mRNA molecules, and is weakly visible in the lane 
representing an abundance of 1 /1000 mRNA molecules. This result suggests that the 
experimental method is working, but that the ZAC transcript may be too rare to allow 
it to be detected by this technique. Published literature that has commented on the 
rarity of ZAC mRNA includes Basyuk et al. (Basyuk et al. 2000). However, it 
should be possible to detect the SP6 transcript at lower amounts than 60pg, since this 
is equivalent to an abundance of 1 /1000 mRNA molecules, which is relatively high. 
It is possible therefore that either the quantification of the SP6 transcript was 
incorrect, or that the RPA parameters used here were not optimal. 
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LCL 
SP6 transcript RNA Enzyme 
0.6 6 60 600 -- - probe 
Figure 63. RPA experiment with SP6 transcript and LCL RNA as test samples. 
Increasing concentrations of 0.6pg to 600pg of SP6 transcript were used. For the 
lanes with LCL as the sample, increasing amounts of RNA (and constant amount of 
enzyme), and then decreasing amounts of enzyme (and constant amount of RNA) 
were used. The far right lane contains undigested probe. 
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5.5.5 Expression analysis by RT -PCR 
As described, the rarity of the ZAC transcript may have precluded its detection by 
RPA. As an alternative technique to investigate whether the hypermethylation 
observed in two of the lymphomas in the previous experiments may be associated 
with transcriptional silencing of the gene, a semi -quantitative RT -PCR approach was 
chosen. This technique relies on quantifying the resulting RT -PCR product of the 
ZAC gene, in relation to the product generated from a typical housekeeping gene, 
such as GAPDH. Expressing the relative amounts of ZAC transcript as a proportion 
of GAPDH eliminates the variation between samples of the quality or amount of 
template in the reaction. 
Total RNA was extracted from the same lymphoma samples used for the DNA 
analysis. In preliminary experiments, the timing of the exponential phase was 
determined for both the GAPDH RT -PCR and the ZAC RT -PCR (using primers 
1029 -RT5' and 1029 -RT3' which were used previously in Chapter 4). A series of 
duplicate PCR reactions were set up and cycled for a range of cycle numbers. The 
templates for the RT -PCRs were cDNAs from two fetal RNA samples and two non- 
hypermethylated lymphomas. The results of this experiment are shown in Figure 64. 
It is apparent that whilst a product for GAPDH appears at 20 cycles in the fetal 
samples, it is not amplified visibly from the lymphoma samples until much later, at 
26 cycles. This may indicate poor quality of the NHL RNAs, since GAPDH is 
assumed to be present at comparable levels in most cells. Similarly, for the ZAC RT- 
PCR, amplification from the fetal samples is visible at 30 cycles, but is only very 
weak in the lymphoma samples at 36 cycles with no visible product before this point. 
As with the RNase protection assay, this technique indicates the probable rarity of 
the ZAC transcript. However, because of the difference in the success of 
amplification of GAPDH between the fetal samples and the lymphomas, it is 
apparent that the quality of these RNA or cDNA samples is poor. Indeed, the 
lymphoma tissue samples had been stored for a lengthy period of time at -70 °C 
before these experiments were carried out, and it is likely, as judged by these results, 
that some degradation had occurred. The difficulties in amplifying even a widely- 
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expressed housekeeping gene such as GAPDH suggest that a quantitative assessment 
of the relative levels of ZAC and GAPDH in these samples by this technique may not 


















































































































































































































































































































































































































In this study, the initial hypothesis being tested predicted that the active paternal 
allele of ZAC will be preferentially lost in tumours carrying a deletion. The basis of 
this is that ZAC is an imprinted gene, and is known to be expressed exclusively from 
the paternal allele, with functional silencing of the maternal allele being associated 
with differential methylation of the upstream CpG island NV 149. 
If tumours with LOH at this locus showed consistent preferential loss of the active 
allele of ZAC, then a complete ablation of function would presumably result, due to 
the retention of only the silent maternal allele. This would offer an explanation as to 
why no inactivating mutations have been detected in ZAC in tumours which have 
suffered an initial Knudson `hit' through deletion of this region (Bilanges et al. 
1999). 
Microsatellite analysis of a panel of paired normal and tumour DNAs from 11 breast 
tumours and 8 bladder tumours revealed infrequent LOH. In fact, possible LOH was 
detected in only one breast tumour. However, the contamination of these tumour 
samples with normal tissue was found to be a significant source of distortion in the 
bisulphite sequencing analysis. There are ways of overcoming this problem, for 
example by establishing the normal ratio of maternal to paternal alleles on the 
bisulphite sequencing gel, using a phosphorimager, and then measuring the altered 
ratio of tumours with LOH, which might be predicted to show a predominantly 
maternal and reduced paternal contribution as compared to the normal. 
Alternatively, LOH could be detected by FISH techniques, which could be more 
precise if a probe containing the ZAC gene itself was used. 
The microsatellite analysis was performed similarly on a panel of six breast cancer 
cell lines. The results indicated that the cell line ADR -MCF7 carries a deletion of 
the ZAC/NV 149 region, but the retained allele is predominantly unmethylated and 
therefore presumably the paternal (active) copy, rather than the maternal (inactive) 
copy. There is however some evidence of a methylated allele by the presence of a 
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faint lower `A' band, so this may be representative of secondary methylation. LOH 
in this case would not implicate ZAC as a tumour suppressor gene as the cell line 
predominantly carries the unmethylated and presumably still functional paternal copy 
of ZAC. There was no other significant LOH at the ZAC/NV 149 locus in the panel of 
cell lines, although the bisulphite analysis did nonetheless show that the cell line 
T47D has a predominantly maternal -like methylation pattern. This suggests that 
hypermethylation had occurred, and could implicate ZAC as a tumour suppressor 
gene, because both maternal and paternal chromosomes carry a maternal methylation 
pattern which would be predicted to silence the gene. 
The panel of 21 non -Hodgkin's lymphomas also revealed very little LOH at the 
markers tested. However, the bisulphite sequencing, which was anticipated to show 
biparental methylation in all tumours (since both parental alleles are present) 
produced an unexpected result. While most of the lymphomas did show the 
predicted biparental methylation pattern, two were found to have only the maternal 
methylated pattern at NV 149. As with the breast cancer cell line T47D, this result is 
suggestive of hypermethylation at NV 149, which might result in silencing of both 
alleles, and thus a complete ablation of function of ZAC in these tumours. 
This study was designed to test the hypothesis that imprinting of ZAC acts as a `first 
hit', inactivating the maternal allele, and when accompanied by a `second hit' 
deletion of the remaining active paternal allele, the tumour suppressor function of 
ZAC is eliminated, thus paving the way for tumour development. In fact, 
inactivation by this mechanism has not been found in the tumours analysed here, but 
there is evidence of hypermethylation as an alternative, epigenetic mechanism of 
ZAC inactivation in some lymphomas. Indeed, hypermethylation of tumour 
suppressor genes has been reported for several other genes in a variety of different 
cancers, for example CDKN2A (p16INK4a) in breast, prostate, renal and colon cancers 
(Herman et al. 1995), VHL in renal cancer (Herman et al. 1994), CDH1 (E- cadherin) 
in breast and prostate cancers (Graff et al. 1995), and BRCA1 in sporadic breast and 
ovarian cancers (Esteller et al. 2000). In addition, the biallelic hypermethylation of 
normally imprinted tumour suppressor genes has also been reported: the TP73 gene 
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has been found to be hypermethylated in lymphomas (Kawano et al. 1999; Corn et 
al. 1999), and H19 is subject to hypermethylation in some Wilms' tumours and 
hepatoblastomas (Fukuzawa et al. 1999). Hypermethylation at NV 149 could, 
similarly, be a mechanism of inactivation of ZAC, resulting in a loss of its anti - 
proliferative, anti -apoptotic function. 
To support this idea, attempts were made to analyse ZAC expression in the 
lymphomas. However, the rarity of the ZAC transcript prevented quantification of 
this loss by RNase protection assay, since the transcript was undetectable even in 
normal LCL RNA. Furthermore, it became apparent that the quality of the RNA 
samples was insufficient to allow a valid quantification by RT -PCR. 
To determine the role of hypermethylation as a mechanism of ZAC inactivation in 
lymphoma, further efforts will be required involving the analysis of a further, larger 
sample of lymphomas. An antibody capable of detecting ZAC protein would also be 
very useful, for assessing the levels of protein in tumours with LOH or 
hypermethylation compared to controls. 
Future work could focus on establishing the extent to which this phenomenon may be 
involved in tumorigenesis, as well as the actual mechanisms by which it occurs. In 
the panel of tumours in this study, an extensive mutation screening effort may 
identify inactivating point mutations in those samples which had neither LOH nor 
hypermethylation, because if ZAC is acting as a tumour suppressor gene in these 
samples, then they might be predicted to have acquired a second `hit' in the form of a 
mutation. 
Extending the analysis to a wider range of tumour types would also be interesting, 
particularly in those tumour types which, like non -Hodgkins' lymphoma, have a high 
frequency of LOH at this chromosomal region. Ultimately, a transgenic ZAC 
knockout mouse would be of great interest to allow an assessment of the effects of a 
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Abstract We have characterised the DFFB gene, encod- 
ing the active subunit of the apoptotic nuclease DNA frag- 
mentation factor (DFF40). DFFB maps to Ip36, near the 
imprinted putative tumour suppressor gene TP73. The 
DFFA gene (encoding the inhibitory DFF45 subunit) also 
maps to 1p36.2 -36.3, and we show by FISH that DFFB 
lies distal to DFFA. We have also mapped a processed 
DFFB pseudogene to chromosome 9. DFFB itself has 
seven coding exons spanning 10 kb. Exhaustive mutation 
screening of 41 neuroblastomas and other tumours in 
which a 1p36 tumour suppressor gene is implicated 
showed no tumour- specific mutations. A coding region 
polymorphism was used to demonstrate uniformly bial- 
lelic expression in human fetal DFFB transcripts. Since 
the putative neuroblastoma tumour suppressor gene in 
distal Ip36 is predicted to be maternally expressed, the 
lack of imprinting and absence of somatic mutations in 
DFFB indicate that it is probably not the neuroblastoma 
tumour suppressor gene. 
Introduction 
Neuroblastoma is one of the most common childhood tu- 
mours, accounting for 8% of all childhood cancers. There 
is a wide range of outcomes, from cases in which the tu- 
mour regresses, with excellent survival prospects, to those 
in which the disease is much more aggressive and the 
prognosis poor (Brodeur 1995). A number of chromoso- 
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mal abnormalities specifically associated with neuroblas- 
toma have been identified by classical cytogenetics, loss 
of heterozygosity (LOH) analyses, and more recently by 
comparative genomic hybridisation (Brodeur and Fong 
1989; Takita et al. 1997; Vandesompele et al. 1998). One 
abnormality correlating strongly with a poor outcome is 
deletion of chromosome 1p (Caron et al. 1996; Maris et 
al. 1995). Analysis of such deletions suggests that region 
Ip36 contains more than one tumour suppressor gene 
(Cheng et al. 1995). From analysis of tumours with 
MYCN amplification, in which 1p deletions are usually 
large, a tumour suppressor locus is thought to be located 
at 1p36.1, just distal to D1S7. In these tumours, LOH is 
not selective for one or the other parental allele (Caron et 
al. 1995). A second commonly deleted region is located at 
1p36.2- p36.3. In contrast to the putative 1p36.1 tumour 
suppressor gene, LOH at this more distal locus usually re- 
sults from loss of the maternal allele, suggesting the im- 
printed nature of the tumour suppressor gene (Caron et al. 
1993; Caron et al. 1995). Either deletion or mutation of 
the maternal allele of this gene might be important in the 
pathogenesis of neuroblastoma. This gene could also be 
implicated in many other tumours, as 1 p deletion has re- 
cently been documented as a recurrent aberration in an in- 
creasing number of neoplasms. These include common 
cancers such as melanoma, breast cancer and colon cancer 
(Schwab et al. 1996) and rare ones such as Merkel cell 
carcinoma (Van Gele et al. 1998a; Van Gele et al. 1998b) 
and malignant schwannoma (Van Roy et al., unpub- 
lished). 
Recently, the TP73 gene at Ip36 has been proposed as 
a candidate neuroblastoma tumour suppressor gene 
(Kaghad et al. 1997). Its protein product appears to have 
cell cycle control functions analogous to those of the 
structurally similar p53 protein (Jost et al. 1997). In addi- 
tion, as predicted for the 1p36.2 -p36.3 neuroblastoma tu- 
mour suppressor, TP73 is monoallelically expressed, at 
least in some tissues (Kaghad et al. 1997; Kovalev et al. 
1998; Mai et al. 1998; Nomoto et al. 1998). However, be- 
cause of the failure to identify somatic mutations in TP73, 
this gene's importance in the pathogenesis of neuroblas- 
toma remains unproven (Kovalev et al. 1998). The identi- 
fication of other candidate genes in this region is therefore 
an important goal. 
Since imprinted genes are often clustered within chro- 
mosomal regions containing several imprinted and non- 
imprinted genes (Reik and Maher 1997), we have 
searched for novel imprinted genes in the region sur- 
rounding TP73. We have thereby identified, at a distance 
of 100 -200 kb from TP73, the gene encoding the apop- 
totic nuclease variously known as caspase- activated nu- 
clease (CPAN) (Halenbeck et al. 1998), caspase -activated 
DNase (CAD) (Enari et al. 1998; Mukae et al. 1998) or 
DNA fragmentation factor (DFF40) (Liu et al. 1997). This 
gene (here referred to as DFFB) encodes a 40 kDa nucle- 
ase that is activated by caspase 3, and is capable of de- 
grading DNA during apoptosis. DFF40 activity is regu- 
lated by its inhibitor, ICAD/DFF45 (Liu et al. 1997; 
Sakahira et al. 1998). DFF45 exists in a heterodimeric 
complex with DFF40 and is proteolytically degraded by 
activated caspase 3. 
The chromosomal location and putative biological role 
of DFFB make it an excellent candidate tumour suppres- 
sor gene for neuroblastoma and other tumours frequently 
exhibiting 1p deletions. Loss of DFFB activity by dele- 
tion or point mutation could cause failure of apoptotic 
DNA degradation and hence predispose to tumour devel- 
opment. Support for this idea comes from the fact that ab- 
lation of caspase 3 function results in an apoptotic defect, 
which interestingly is confined to the CNS, and results in 
accumulation of abnormal neuronal precursors (Kuida et 
al. 1996). 
We have therefore determined the genomic organisa- 
tion of the CPAN /CAD/DFF40 gene (DFFB), and ad- 
dressed the two main questions of whether this gene is 
mutated in tumours with frequent occurrence of 1p dele- 
tions, and whether the gene is imprinted. 
Materials and methods 
Contig assembly 
PAC clones were identified by hybridisation to grids of the RPCI1 
library (Ioannou et al. 1994), provided by the UK Human Genome 
Mapping Project (HGMP) Resource Centre. The probes and con- 
ditions were as follows: PAC 79 -L8 was identified using a 32P -la- 
belled 482 -bp fragment containing exon 2 of TP73, generated by 
PCR using primers as in Kaghad et al. (1997). PCR conditions 
were 94 °C /1 min, 59 °C/1 min, 72 °02 min, for 40 cycles, in 
10 mM Tris.HCl/50 mM KCl/12.5 mM KOH/1.5 mM MgC12/0.1% 
Triton X -100, in a volume of 50 pl. Overlapping PACs 71 -C21 
and 286-D6 were identified by hybridisation to oligonucleotide 
dACAGAAGGCTCGCACTATCGT, derived from the T7 end of 
PAC 79 -L8. Cosmid 176g8 from the LLOINC01 library (Gingrich 
et al. 1996; Trask et al. 1991) was identified by hybridisation to a 
311 -bp PCR product from the 5' end of DFFB, amplified from ge- 
nomic DNA. The primers for this PCR were dCCCTTTGACATG- 
GACAGCTGC and dTGCTTCCGCTTCAACCTTGT. Conditions 
were 94 °C/1 min, 57 °C /1 min, 72 °C /2 min for 40 cycles, in PCR 
buffer as described above. PAC and cosmid DNAs were extracted 
using the Qiagen maxiprep kit. 
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Gene structure 
Positions of splice junctions were established by sequencing using 
the Thermosequenase 33P- terminator cycle sequencing kit (Amer - 
sham). The DFFB pseudogene was detected through sequencing of 
PCR products generated from genomic DNA. A pseudogene -spe- 
cific PCR, using primers dCCCTTTGACATGGACAGCTGC and 
dATTGCTTCCACCAGTGTAGG, was then used to map the 
pseudogene on a human monochromosomal somatic cell hybrid 
panel (Kelsell et al. 1995), obtained from the HGMP Resource 
Centre. Cycling conditions were 94 °C /1 min, 57 °C/1 min, 72 °C/ 
2 min, for 35 cycles, in the PCR buffer as described above. 
FISH on prometaphase and interphase nuclei and fibre -FISH 
Probe labelling, in situ hybridisation and immunocytochemical de- 
tection were performed as described (Van Roy et al. 1994). Chro- 
mosome slides were prepared from synchronised PHA -stimulated 
peripheral blood lymphocytes (PBL). Fibre -FISH slides were pre- 
pared from freshly fixed suspensions of PHA -stimulated PBL as 
described (Speleman et al. 1997). Images were captured with a 
high- sensitivity integrated monochrome CCD camera (Sony 
IMAC -CCD S30) and dedicated software (ISIS, MetaSystems, 
Germany). 
DNA samples and cell lines 
In total, 41 DNA samples were screened for DFFB mutations. 
Fourteen neuroblastoma cell lines and five Merkel cell carcinoma 
cell lines were analysed (for details of their 1p and MYCN status, 
see Table 1). Three stage 1, three stage 2, four stage 4 and one 
stage 4S neuroblastoma tumours were included (cases 1, 2, 3, 8, 9, 
10, 11, 20, 22, 25 and 29 in the study by Vandesompele et al. 
(1998), where detailed genetic analysis of these tumours is de- 
Table 1 Neuroblastoma and Merkel cell carcinoma cell lines. 
Chromosome 1p status was evaluated by loss of heterozygosity 
and also by FISH using probes for D1Z2 (1p36.33) and DIZI 
(1q12); decreased copy number of D/ Z2 versus DIZI indicates the 
presence of a 1p deletion. Cell line UISO has an insertion at 
1p36.2. (LOH loss of heterozygosity, MNA amplification of 
MYCN, ND not determined) 
Cell lines LOH 1p D1Z2 copy DIZI copy MNA 
Neuroblastoma cell lines 
IMR32 Yes 1 3 Yes 
N206 Yes 2 3 Yes 
UHG -NP Yes 2 4 Yes 
TR14 Yes 2 3 Yes 
SMS -KCNR Yes 1 2 Yes 
STA -NB -3 ND 2 4 Yes 
STA -NB -8 ND 1 2 Yes 
STA -NB -9 ND 1 2 Yes 
STA -NB -10 ND 1 2 Yes 
STA -NB -12 ND 1 2 Yes 
NGP t(1;15) 2 2 Yes 
SK -N -AS Yes 1 3 No 
GI-ME-N Yes 2 4 No 
SK -N -FI No 2 2 No 
Merkel cell lines 
MCC 13 No 2 2 No 
MCC 14/2 t(X;1) 4 4 No 
MCC 26 Yes 3 4 No 
UISO No 2 2 No 
MKL -1 ND 2 2 No 
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scribed). Nine Merkel cell carcinoma tumours were investigated, 
of which two have a known 1p loss. Finally, two malignant 
schwannomas with 1p deletions (Van Roy et al., in preparation) 
were included. 
Mutation screening 
PCR cycling conditions for amplification of each exon were 
94 °C/1 min, X°C/1 min, 72 °C/2 min, for 35 cycles where X°C is 
the primer -specific annealing temperature. Forward and reverse 
PCR primer sequences and X°C were as follows: exon 1: 
dCCAGCTTGCAGAGCTCAC, dGCTGAGGCGAACGAAAAC - 
TA, 57 °C; exon 2: dTGTAAAACGACGGCCAGTCAGCCT - 
GAGCCTGCTTC1rtA,dCAGGAAACAGCTATGACCTGAGA- 
CCCGAGAGTTCACAG, 65 °C; exon 3: dTGTAAAACGACGG- 
CCAGTCTCAAGTCTGAGTCCTGGTGATT,dCAGGAAACA- 
GCTATGACCATGAGCACATTTTCTTCCAAGTC, 60 °C; exon 4: 
dCCACTTGGAAGTCTGAGGCAGG, dCTCCCTCACCAGAG - 
CAGCCCCA, 65 °C; exon 5: dTGTAAAACGACGGCCAGTT- 
GGAGTGAGATGGATCGAGA,dCAGGAAACAGCTATGAC- 
CAGGGCAAGGGCTGAAGGT, 58 °C; exon 6: dGGAGGTTG- 
TAGTAAGCCGAGA, dGAAACCCAAGGAGGCAACAC, 58 °C; 
exon 7: dTGTAAAACGACGGCCAGTACTGTGACTGCAATA- 
CACTGC, dCAGGAAACAGCTATGACCTTAAAATGATGC- 
CCACGTCA, 60 °C. 
Mutation screening was performed by direct sequencing using 
the Thermosequenase 33P- terminator cycle sequencing kit (Amer - 
sham). The following nested sequencing primers (sense, antisense) 
were used: exon 1: dATCTGAGCAGCTGGGCAG, dCCTAT- 
TCTCCCCACACGCCT; exon 2: dAGCACAGCTCATTCCG- 
GTCGT, dTGATGGGCACCTGGAGCTAAG; exon 3: dAGGA- 
TGTGTCTTCAGCTGGACCG, dATGAGCACATTTTCTTCC- 
AAGTC; exon 4: dAGGACACAGACCCAGACCC, dACAGA- 
GCCTGGCTTCAAAAA; exon 5: dGCGCTGTGCACCAGGC - 
TCACCCA, dGCTGTGTTCCACAGGCCAGC; exon 6: dACT- 
CCAGCCTGGCGACAGAGCGA, dACAGGGCCCTGCAGGC- 
ACTCGT; exon 7: dTGCCTGTGGCACTGTCACCACAG, dAT- 
GATGCCCACGTCACGCCTCAA. 
RT -PCR analysis of DFFB imprinting 
RT -PCR analysis of DFFB imprinting was performed using modi- 
fications of previously described methods and materials (Hayward 
et al. 1998). Initially, fetal genomic DNA -derived exon 7 PCR 
products were digested with Ava! to type the codon 318 DFFB 
polymorphism. 10 pl of PCR product were digested overnight at 
37 °C, with 30 U of enzyme in a volume of 20 µl, and analysed on 
2% agarose gels. 
RT -PCR was next performed on RNA samples from heterozy- 
gous fetuses with homozygous mothers. RNA was combined with 
500 nM of primer dGAGCTCGAGTCGACATCGA(T)17, in wa- 
ter, incubated at 85 °C for 3 min, and cooled on ice for 2 min. Re- 
verse transcription components were added to give 50 mM Tris- 
HCI (pH 8.3), 75 mM KCI, 3 mM MgC12, 10 mM DTT, 1 mM 
each dNTP, 100 U Superscript II (GibcoBRL), and 39 U RNA - 
guard (Pharmacia), in a total volume of 30 µl. The mix was incu- 
bated at 42 °C /60 min, 50 °C /15 min, 95 °C /15 min. For PCR, 2 µl 
of this RT mix was used in a 50 p.1 reaction, containing 10 mM 
Tris -HC1, 50 mM KCI, 1.5 mM MgC12i 10 pmol each primer 
(dATCCTCTTCAGCACCTGGAA and dGTTTCCGCACAGG- 
CTGCT), 200 p.M each dNTP, 10% DMSO and 1 U Amplitaq 
Gold (Perkin Elmer). Cycling conditions were 94 °C/45 s, 54 °C/ 
45 s, 72 °C/120 s, for 40 cycles. Digestion of 25 µl of product was 
performed in a volume of 40 µl, with 40 U Aval, at 37 °C for 3 h, 
and products were analysed on 8% polyacrylamide gels. 
Results 
Contig 
Initially, a PAC clone (79 -L8) was isolated, that contains 
the TP73 gene. Using an STS at one end of its insert (T7 
end), two overlapping PACs (71 -C21 and 286 -D6) were 
then identified. The sequence of the non -overlapping end 
of 71 -C21 proved to be identical to part of a cDNA en- 
coding CPAN /CAD/DFF40 (Halenbeck et al. 1998). In 
fact, this PAC clone (71 -C21) has one end within exon 6 
of DFFB, the gene encoding CPAN/CAD/DFF40 (see be- 
low). Finally, therefore, an STS from this end of PAC 
71 -C21 was used to isolate a cosmid (176g8) containing 
the complete DFFB gene. 
FISH 
The DFFA gene encodes DFF45, the inhibitor of DFF40 
(the DFFB product). Like DFFB, DFFA has previously 
been mapped to chromosome 1p36.2 -p36.3 (Leek et al. 
1997). We were interested by this co-localization of DFFA 
and DFFB, especially since a dot matrix comparison of 
the DFFA/DFF45 and DF1473/DFF40 amino-acid se- 
quences reveals regions of similarity (Fig. 1). The largest 
such region is at the N- terminus of both proteins, the end 
of this region (DFF40 residue 80) corresponding to the 
position of intron 2 in the DFFB gene. This suggested 
that, although the exon -intron structure of DFFA has yet 
to be defined, DFFA and DFFB may have evolved partly 











Fig.1 Dot -matrix comparison between peptide sequences of 
DFF45 (DFFA gene product) and DFF40 (DFFB gene product). 
The comparison was performed using UWGCG COMPARE (win- 
dow size 30, stringency 11) 
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Fig. 2 Two -colour hybridisation on prometaphase chromosomes 
of a PAC clone 79-L8 (TP73, green) and cosmid clone cos176g8 
(DFFB, red), b cosmid clone cos176g8 (DFFB, green) and PAC 
clone 92 -K14 (DFFA, red), c fibre-FISH for PAC clone 79-L8 
(TP73, red) and PAC clone 71-C21 (green) 
To map the relative positions of DFFA and DFFB, dual 
colour FISH with PAC clone 92 -K14 (containing DFFA; 
Leek et al. 1997) and cosmid 176g8 (DFFB; this study) 
was performed. On prometaphase chromosomes, these 
probes could be clearly separated, with DFFB (green) 
mapping distal to DFFA (red) (Fig. 2b). In contrast, as ex- 
pected from their physical proximity, signals from the 
DFFB -containing cosmid and the TP73 PAC clone 79 -L8 
overlapped, both on prometaphase chromosomes (Fig. 2a) 
and in interphase nuclei (not shown). 
The gene for atrial natriuretic peptide precursor A 
(NPPA) is also known to map to this region of 1p36 (Ar- 
den et al. 1995; Yang -Feng et al. 1985). To define the map 
position of DFFA relative to NPPA, the DFFA PAC 
92 -K14 was co-hybridised with a cosmid probe for NPPA. 
In 13 metaphases, hybridisation signals for both probes 
overlapped, in 6 metaphases NPPA mapped distal and in 
one metaphase the inverse order was observed (not 
shown). Therefore, DFFA maps in the vicinity of (and 
most likely proximal to) NPPA. 
The integrity and physical relationship between the 
clones in the TP73 DFFB contig was confirmed by fibre- 
FISH. Pair -wise hybridisations were performed for clones 
286 -D6 and 79 -L8, 71 -C21 and 286 -D6, 71C-21 and 
79 -L8, cos176g8 and 71 -C21 and finally, cos176g8 and 
79-L8. Overlaps were observed in all but the last of these 
experiments. For clone 71 -C21, the following overlaps 
were calculated, as percentages of the length of the other 
clones: 23% (79 -L8; Fig. 2c), 55% (286 -D6) and 19% 
(cos176g8). 
Overall, these FISH experiments confirm the physical 
relationships (Fig. 3) between the clones isolated around 
DFFB and TP73, and suggest the map order tel -DFFB- 
NPPA- DFFA -cen within 1p36. There is a small possibility 
that the order of NPPA and DFFA is reversed (see above). 
Genomic structure 
Direct sequencing and PCR on the PAC and cosmid tem- 
plates was next used to determine the exon - intron struc- 
ture of DFFB. This showed that there are seven coding 
exons, spanning approximately 10 kb. This genomic 
structure is presented in Fig. 3. The genomic sequences 
















Fig. 3 The exon -intron organisation of the DFFB gene. The upper 
part shows the relationships between the clones used in this study, 
with the small arrow indicating the position and direction of tran- 
scription of DFFB. Below, the approximate intron sizes (in kilo - 
bases), and exact exon sizes (in base pairs) are given. For exons 1 
and 7, the figure is for the size of the coding region, since the cap 
and poly(A) sites have not been defined 
Attempts to amplify DFFB from genomic DNA using 
primers located in the 3' part of the DFF40 coding region 
(exons 6 and 7) yielded products differing in sequence 
from the published CPAN /DFF40 cDNA sequence 
(Halenbeck et al. 1998). These sequences proved however 
to be identical to those of a putative transcribed CAD 
pseudogene (Mukae et al. 1998). Since intron 6 was ab- 
sent from our pseudogene- derived genomic DNA product, 
we conclude that this pseudogene is probably processed. 
A pseudogene -specific PCR assay was then designed, us- 
ing new primers in exons 6 and 7. Under the conditions 
used, this PCR fails to amplify across intron 6, and gener- 
ates only a 143 -nt product specific for the pseudogene. In 
this way, the pseudogene was mapped to chromosome 9, 
using a single -chromosome somatic cell hybrid panel 
(Kelsell et al. 1995). 
Mutation screening 
The candidacy of DFFB as a neuroblastoma tumour sup- 
pressor gene was next addressed, through rigorous muta- 
tion screening, by complete DNA sequencing. A panel of 
41 tumour or tumour cell line (Table 1) DNAs was used. 
Both 1p36- deleted and non -deleted tumours were analys- 
ed, since alternative hypotheses concerning the putative 
tumour suppressor gene are tenable. If the tumour sup- 
pressor gene were not imprinted, "second hit" mutations 
in the non -deleted allele might be expected, inviting 
analysis of 1p36- deleted tumours. On the other hand, if 
the tumour suppressor gene were imprinted, point muta- 
tions might not be needed as second hits in deleted cases, 
whereas non -deletion cases might have heterozygous 
point mutations. 
We sequenced all seven DFFB exons, in all 41 DNA 
samples. No coding region mutations were detected in 
any of the samples. However, seven intronic and three 
coding region polymorphisms were detected (Table 3). 
Two of the three exonic polymorphisms are silent, while 
the third results in a conservative amino acid substitution 
of arginine for lysine 196. All three exonic polymor- 
phisms were found in both tumour DNAs and normal con- 
trols. 
Table 2 Sequences at the DFFB splice junctions. Exon sequences are underlined. Twenty bases of intron sequence are given at each 
side of each splice junction; for exons 1 and 7 the first and last 20 bases of the open reading frame are shown 















Table 3 Details of polymor- 
phisms within the DFFB gene, 
identified during mutation 
screening. The numbering of 
nucleotides in the 5' untrans- 
lated region is relative to the 
first nucleotide of the ATG 
translation start codon (ND not 
determined, nt nucleotide, UTR 
untranslated region) 
Position 
Exon 5, nt 21 
Exon 5, nt 77 
Exon 7, nt 172 
5' UTR, -38 
5' UTR, -30 
IVS 1, +15 
IVS 1, +31 
IVS 3, +44 
IVS 3, -72 
IVS 3, -82 
Nature of polymorphism Allele frequencies in normal controls 
G->A Silent G=18/30 A=12/30 
G->A Lys196- Arg 0=27/30 A=3/30 
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Fig.4 Analysis of the allelic origin of DFFB transcripts. Ethidium 
bromide- stained polyacrylamide gel, showing Aval- digested RT- 
PCR products spanning a polymorphic site at codon 318 in exon 7 
of DFFB. Samples from two fetuses of opposite genotype are 
shown: Aval -m / +p (MC1165) and +m /-P (MC0166). Undigested 
RT -PCR product is shown in the lane (L) adjacent to the marker. 
Marker band sizes are in bp. Predicted sizes for the undigested 
(`A' allele) and digested (`G' allele) products are 259 and 203 bp, 
respectively. (L lung, G gut, B brain, K kidney, A adrenal, S stom- 
ach, H heart, E eye, M muscle) 
Imprinting 
We have previously used a panel of first trimester fetal tis- 
sues to examine the allelic origin of transcripts of genes 
suspected to be imprinted (Campbell et al. 1994; Hayward 
et al. 1998). We genotyped 54 fetal DNA samples at the 
exon 7 DFFB polymorphism, which results in loss of an 
Aval site if the `A' allele is present. Twenty-eight fetuses 
were heterozygous, of which six had a homozygous 
mother and were therefore informative as to the origin of 
each allele (paternal samples were not available). To de- 
termine whether DFFB is imprinted, we chose one het- 
erozygous fetus with a G/G mother (Aval +'" /-P), and one 
with an A/A mother (Aval - m / +P). RNA samples from a 
range of tissues were available for each of these fetuses. 
RT -PCR was performed using primers in exons 6 and 7, 
followed by Aval digestion to determine which alleles 
were represented in the RT -PCR products. The results in- 
dicated that both parental alleles were represented in the 
RNA samples, and it is therefore unlikely that DFFB is 
imprinted (Fig. 4). 
Discussion 
Various genes have been proposed as candidates for the 
putative tumour suppressor at 1p36.2 -36.3 (Kaghad et al. 
1997; Maris et al. 1997). However, none of these has yet 
been shown to carry coding region mutations, making it 
less likely that they play significant roles in the pathogen- 
esis of neuroblastoma. 
In this paper, we describe the structure of the newly 
identified gene DFFB that encodes the active subunit of 
DNA fragmentation factor (DFF40, CAD or CPAN). We 
have also assessed the candidacy of this mediator of apop- 
totic DNA fragmentation as the putative 1p36 tumour 
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suppressor gene. Comprehensive mutation screening of 
the seven DFFB exons in a panel of 41 tumours and cell 
lines revealed several polymorphisms, but no tumour -spe- 
cific mutations. As for other candidate genes lacking mu- 
tarions, our results suggest that DFFB is unlikely to act as 
a tumour suppressor gene in neuroblastoma or Merkel cell 
carcinoma. 
Despite this negative result, there are reasons for not 
completely discounting the potential role of DFFB in neo- 
plasia. Firstly, the fact that DFFB maps to a chromosomal 
region believed to be subject to genomic imprinting raises 
the question of whether DFFB itself could be imprinted. 
This possibility is not completely excluded by our 
RT -PCR experiments. If DFFB were an imprinted gene, 
expressed solely from one parental allele, consistent dele- 
tion or inactivation of the active allele could result in loss 
of DFF40 activity without the presence of a "second -hit" 
mutation in the remaining allele. This possibility, how- 
ever, is made less likely by the fact that we have found no 
evidence for DFFB mutations in non -deleted neuroblas- 
tomas, in which two hits might be expected to be required. 
Secondly, the investigation of DFFB in other tumours 
may be worthwhile. Several tumours other than neurob- 
lastoma have been associated with genetic alterations in 
the 1p36 region, including dysplastic naevus and familial 
melanoma (Ping et al. 1998), breast cancer (Bieche et al. 
1998; Nagai et al. 1995), parathyroid adenoma (Tahara et 
al. 1997), ovarian cancer (Thompson et al. 1997), non- 
small -cell lung cancer (Gasparian et al. 1998), and renal 
oncocytoma (Thrash- Bingham et al. 1996). 
Finally, the failure to find point mutations within indi- 
vidual candidate tumour suppressor genes within 1p36 may 
still allow the possibility that simultaneous haploinsuffi- 
ciency for several clustered genes (such as TP73 and 
DFFB) with roles in cell cycle control, differentiation and 
apoptosis could be a step in the process of transformation. 
This suggests that other functional assays for investigating 
the role of genes such as DFFB may need to be considered. 
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We describe a screen for new imprinted human 
genes, and the identification in this way of ZAC (zinc 
finger protein which regulates gpoptosis and cell 
cycle arrest)IPLAGL1 (pleomorphic adenoma of the 
salivary gland gene like 1) as a strong candidate gene 
for transient neonatal diabetes mellitus (TNDM). To 
screen for imprinted genes, we compared partheno- 
genetic DNA from the chimeric patient FD and andro- 
genetic DNA from hydatidiform mole, using 
restriction landmark genome scanning for methyla- 
tion. This resulted in identification of two novel 
imprinted loci, one of which (NV149) we mapped to 
the TNDM region of 6q24. From analysis of the corre- 
sponding genomic region, it was determined that 
NV149 lies -60 kb upstream of the ZACIPLAGL1 
gene. RT -PCR analysis was used to confirm that this 
ZACIPLAGL1 is expressed only from the paternal 
allele in a variety of tissues. TNDM is known to result 
from upregulation of a paternally expressed gene on 
chromosome 6q24. The paternal expression, map 
position and known biological properties of ZACI 
PLAGL1 make it highly likely that it is the TNDM gene. 
In particular, ZACIPLAGL1 is a transcriptional regu- 
lator of the type 1 receptor for pituitary adenylate 
cyclase- activating polypeptide, which is the most 
potent known insulin secretagog and an important 
mediator of autocrine control of insulin secretion in 
the pancreatic islet. 
INTRODUCTION 
Genomic imprinting refers to differential contributions from 
the two parental genomes, especially in the development and/ 
or differentiation of the mammalian embryo. Its existence was 
originally demonstrated by nuclear transplantation experi- 
ments (1,2). The non -equivalence of the parental genomes has 
been explained by the differential expression of genes from 
one or other allele (1,3). Approximately 35 mouse (4) and 40 
human genes regulated by imprinting have been reported, 
many of which, however, have not been fully characterized (5). 
It has become clear that imprinting is involved in a number of 
human genetic disorders, such as Beckwith- Wiedemann 
syndrome, Wilms' tumor, Prader -Willi syndrome and 
Angelman syndrome (5). One approach to identifying the 
genes involved in imprinted diseases is to screen systemati- 
cally for and map imprinted loci. Strong candidate genes may 
be more readily identified through this approach than through 
traditional positional cloning, because such candidate genes 
will by definition satisfy both criteria of correct chromosomal 
location and imprinted expression pattern. 
In order to achieve this goal, systematic screening for human 
imprinted genes is required. Several methods for systemati- 
cally searching for imprinted genes within the mouse genome 
have been reported (6). The methylation -based screening 
method, restriction landmark genomic scanning with methyla- 
tion- sensitive restriction endonuclease (RLGS -M), was devel- 
oped by our group (7). The mouse strategy relies on comparing 
the polymorphic RLGS -M patterns derived from reciprocal 
crosses between inbred parental strains. Another approach is to 
rely on differential mRNA expression; differential display or 
subtraction cloning using mRNA from parthenogenetic and 
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androgenetic embryos is therefore also a successful method for 
identifying imprinted genes (6). 
In contrast, screening for human imprinted genes has several 
technical and ethical limitations in terms of the availability of 
the samples. RLGS -M relies on polymorphic differences 
between inbred strains. The required reciprocal crosses are not 
available in humans. As far as expression cloning is concerned, 
both the differential display and subtractive cDNA cloning 
approaches require uniparental RNA samples prepared by 
embryo manipulation, and therefore again are not applicable to 
human material. Furthermore, those human genes which are 
orthologs of mouse imprinted genes are not always imprinted 
(8). Thus, a new method for the screening for human imprinted 
genes is required, which relies neither on inheritance of DNA 
polymorphisms nor on the study of the human orthologs of 
mouse imprinted genes. 
One reagent which has proven valuable in systematic screening 
for human imprinted genes is DNA from the parthenogenetic 
chimera FD. This was the first reported patient with chimerism 
between normal (biparental) and parthenogenetic cells (9). The 
leukocytes, in particular, were found to be 100% parthenogenetic. 
For comparison with the FD sample, complete hydatidiform mole is 
also useful; this tumor is derived from androgenetic extraembryonic 
tissue (10). An mRNA -based comparison between these two tissues 
is not appropriate, since: (i) the amount of the available material 
from the patient is limited; and (ii) only a limited number of genes 
are expressed in these specific tissues. On the other hand, DNA 
methylation appears to be an invariable accompaniment to genomic 
imprinting, and a screening system based on methylation is there- 
fore attractive, and not restricted to the subset of genes expressed in 
any one tissue. We have therefore analyzed DNAs from the above - 
mentioned human uniparental sources by RLGS -M. This method 
employs 32P- end -labeling of rare -cutting restriction sites in genomic 
DNA, followed by high resolution two- dimensional electrophoresis 
separation of the fragments (11). It permits analysis of >2500 loci 
on one autoradiograph. It also preferentially targets transcription 
units because of its dependence on cleavage at rare CpG -containing 
sites. In addition, RLGS -M is dosage -sensitive, and can distinguish 
haploid and diploid intensity of single -copy genes. This important 
property confers the ability to screen for imprinted genes by 
comparing spot intensity in parthenogenetic and androgenetic 
DNA, without having to rely on polymorphisms to distinguish the 
parental alleles. 
Transient neonatal diabetes mellitus (TNDM) is one genetic 
disease that shows an imprinting effect; it appears to result 
from upregulation of a paternally expressed gene in 6q24, 
since this phenotype can result from paternal uniparental 
disomy of chromosome 6 and from duplications of this chro- 
mosomal region (12 -14). TNDM patients have insulin - 
dependent diabetes lasting for the first few months of life. In 
many cases, the diabetes subsequently returns permanently in 
mid- childhood. In this paper, we report the results of a methyl - 
ation -based RLGS screen for human imprinted genes, using 
parthenogenetic and androgenetic DNAs, and the principle that 
differential methylation `tags' an imprinted locus (7,15). In 
this screen, we identified two imprinted genes: GNASI, located 
on human chromosome 20813.2 (16), and, as reported here, 
ZAC (zinc finger protein which regulates apoptosis and cell 
cycle arrest). ZAC is known to be capable of inducing G1 cell - 
cycle arrest and apoptosis, and to be a transcriptional regulator 
of the type 1 receptor for the pituitary adenylate cyclase acti- 
vating peptide (PACAP1 -R) (17,18). PACAP is an important 
intra -islet regulator of insulin secretion (19,20), and this, 
together with the finding that the imprinted ZAC gene maps to 
the TNDM region of 6q24, makes ZAC a compelling TNDM 
candidate gene. 
RESULTS 
RLGS -M screening for imprinted genes using FD and 
hydatidiform mole DNA 
RLGS is a multiplex genome scanning system allowing visual- 
ization of >2500 spots /loci, based on the principle that restric- 
tion enzyme sites can be used as landmarks. The technology 
employs direct labeling of genomic DNA and high resolution 
two -dimensional DNA electrophoresis (11,21). The use of 
methylation- sensitive enzymes enables detection of the meth - 
ylation status of the restriction landmark (22). A methylated 
landmark is not cleaved by the landmark enzyme and yields no 
spot signals whereas, if the landmark is unmethylated, the 
cleaved end of the restriction fragment is labeled to produce 
spot signals. Haploid and diploid copy number of the unmeth- 
ylated restriction landmark give half and full intensity of the 
autoradiographic spots, respectively (23). 
In higher organisms, the 5' position of cytosine residues is the 
only site for DNA methylation, the bulk of which occurs at the 
dinucleotide CpG. The total number of `CpG islands', often 
located upstream of genes, is estimated to be -30 000 (24). Meth - 
ylation of cytosines within a CpG island often reflects transcrip- 
tional silencing of the gene (22). Rare cutting restriction enzymes 
with GC -rich recognition sites cleave preferentially within CpG 
islands. For example, 90% of total NotI sites (GCGGCCGC) are 
located in CpG islands, which in turn implies that 90% of RLGS 
spots produced using NotI have the potential to reflect the tran- 
scriptional status of a CpG island -associated gene (7,11). 
Leukocytes from the patient FD are 100% parthenogenetic 
and isodisomic (9). Conversely, complete hydatidiform mole is 
derived from androgenetic extraembryonic tissue (25). 
Although in previous applications of RLGS (7,15,26), the 
segregation of polymorphic spots was used to provide informa- 
tion about linkage or imprinting, a comparison between parthe- 
nogenetic and androgenetic materials allows the use of all non - 
polymorphic spots, providing a very powerful screening tool. 
The enzyme combinations of NotI -PvuIl -PstI, NotI -PstI- 
Pvull and AscI-EcoRV-MboI were used for the screening. 
Because of the uniform isodisomy of all 23 chromosome pairs, 
the spot intensities on RLGS -M of FD blood DNA are very 
uniform (Fig. la). The spot intensities of androgenetic tissue 
from hydatidiform mole were not as uniform, due to the addi- 
tional methylation changes occurring during tumorigenesis 
(data not shown). A schematic figure of the strategy used to 
identify imprinted spots/loci is shown in Figure lb. In this 
figure, loci A and C are maternally and paternally methylated, 
respectively, whereas B is a non -imprinted locus, unmethyl- 
ated on both alleles. Since FD leucocytes have two maternally 
inherited alleles, maternally methylated locus A is not cleaved 
with Notl, resulting in the disappearance of the corresponding 
spot (Fig. lb, FD). On the other hand, this spot shows diploid 
intensity in the complete mole (Fig. lb, mole), corresponding 
to the presence only of unmethylated paternal alleles. In the 
normal biparental DNA, such a spot shows half intensity (Fig. 
a) 21) PAGE. 
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Figure 1. The two- dimensional profile of restriction landmark genomic 
scanning using methylation- sensitive restriction endonuclease (RLGS -M). 
(a) RLGS -M profile of FD blood DNA produced by the enzyme combination 
of NotI- Pstl- Pvull. The arrow indicates the imprinted spot, NV149. (b) The 
principle of screening for imprinted spots. Spots A and C represent maternally 
and paternally methylated imprinted loci, respectively. Spot B is from a normal 
unmethylated locus. The imprinted spots show half intensity (haploid; open 
circle) and the non -imprinted unmethylated spot shows full intensity (diploid; 
closed circle). The maternally methylated spot (A) disappears in the 
parthenogenetic sample, FD, but this spot shows diploid intensity in 
androgenetic hydatidiform mole. Conversely, a spot which is paternally 
methylated appears in parthenogenetic DNA, and is absent from androgenetic 
DNA. (e) Close-up of RLGS -M profiles of NV149 and A20. The A20 RLGS -M 
profiles were produced by enzyme combination Asc1- EcoRV -Mbol. Since 
these two spots were both maternally methylated, their intensities were zero, 
half and full in FD, normal and mole, respectively. 
lb, normal). Conversely, the spot representing a paternally 
methylated locus C shows diploid, haploid and null intensity in 
RLGS -M profiles of FD, normal and mole, respectively. 
Using these criteria, two spots named NVI49 and A20 were 
identified as candidate imprinted loci. These are shown in 
Figure lc. NV149 was detected using the enzyme combination of 
Notl Pstl Pvull and A20 using Ascl -EcoRV Mbol (Table 1). 
These two spots were excised from the gel and cloned. The 
Honran Molecular Genetics, 2000, Vol. 9, No. 3 455 
Table 1. RLGS -M spots and related diseases 
Spot name Enzyme combination Locus Gene Related disease 
NV149 Notl- Pstl -PvulI 6q24 ZAC TNDM 
A20 Ascl-EcoRV-Mbol 20q13.2 GNASI PHP-IA 
results of subsequent analysis of A20, which is located 
upstream of the imprinted GNASI locus, have been previously 
reported (16). In this paper, we focus on the further analysis of 
the NV149 clone. 
Maternal allele- specific methylation of the NV149 locus 
The methylation status of NV149 locus was analyzed using 
Southern blotting and sequencing (Fig. 2). The methylation status of 
the NotI, BssHlI and Smal sites, located within the DNA fragment 
of the NV149 spot clone (Fig. 3a), was analyzed by Southern blot- 
ting (Fig. 2a). Genomic DNA digested by Pvull yields a 1.18 kb 
band (Fig. 2a, lane 1). About half of the molecules of this fragment 
were cleaved by each of the three methylation- sensitive restriction 
enzymes, confirming the likelihood of monoallelic methylation. To 
confirm the parental specificity of this monoallelic methylation (i.e. 
imprinted methylation), PCR direct sequencing was performed 
using DNA from a normal individual and his parent In this assay 
(Fig. 2b), a DNA fragment spanning both the NotI site and a nearby 
single -nucleotide polymorphism was amplified, using primers 
NV149um1 and NV14911 (Fig. 3a). The NV149u1 primer was 
used for sequencing (Fig. 3a). The paternal (A) and maternal (G) 
alleles at nucleotide 167 can be identified from the genotypes of the 
homozygous parents. Their progeny showed a heterozygous pattern 
of A/G (Fig. 3c). However, NotI digestion of the genomic DNA 
prior to PCR amplification eliminated the sequence signal from the 
paternal A allele. These data indicate that only the maternal allele is 
methylated, and that the methylation pattern of the genomic DNA at 
NV149 is imprinted in the manner predicted from the RLGS screen. 
NV149 maps to chromosome 6q24 
As the next step, the spot clone NV149 was mapped using a 
radiation hybrid panel and a gridded CEPH megaYAC library 
to human chromosome 6q24 (data not shown). Further analysis 
and library screening showed that NV149 lies within PAC 
contig Chr_6ctg224 ( http : / /webace.sanger.ac.uk/HGP /Chr6 ), 
as shown in Figure 3. In particular, PAC clone dJ340H11 
(GenBank accession no. AL 109755) contains the NV149 spot 
clone sequence. PAC dJ340H 11 also contains the whole of the 
gene encoding the C2H2- type zinc finger protein, ZAC. ZAC 
was originally reported as a human gene orthologous to mouse 
Zacl, which is a regulator of the type 1 receptor for PACAP 
and also an inducer of apoptosis and cell cycle arrest (17). 
PACAP is also known as an islet neuropeptide involved in the 
autocrine stimulation of insulin secretion (19,20). 
ZACIPLAGLI expression profile 
Three variants of the human ZACIPLAGLI transcripts have been 
reported, named ZAC (27), PLAGLI (28) and LOTI (lost on trans- 
formation 1) (29). The genomic structure of the ZACIPLAGLI 
region is shown in Figure 3c. From further analysis, we concluded 
that two alternative promoters, of Z9C and PLAGLI, are located in 
this region, but that LOTI is a chimerism artifact. The 5'- untrans- 
lated region (5' -UTR) of LOTI is not present in PAC contig 
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Figure 2. Imprinted methylation of genomic DNA in the NV149 locus. 
(a) Southern hybridization using NV149 clone as a probe. Noti, BssHII and 
SmaI were used to test the monoallelic methylation in this region. Normal 
placental DNA was digested with Pvull (lane I), Pvull and Noti (lane 2), Pvull 
and BssHII (lane 3) or Pvull and SmaI (lane 4). Note that half of the Pvull 
fragments were cleaved by each methylation -sensitive enzyme, indicating the 
monoallelic methylation of these sites. (b) PCR direct sequencing analysis of 
methylation imprinting. The genomic DNAs were amplified with primers, 
NV 149um1 and NV 14911, after treatment with ( +) or without ( -) Noti. PCR 
products were sequenced with the primer, NV 149u1. The arrow indicates the 
polymorphic (G /A) site. Only the maternally derived G allele was amplified 
after Noti digestion. 
Chr 6ctg224, and on radiation hybrid (RH) mapping analysis was 
found to be on chromosome 3. This LOTI 5' -UTR sequence also 
completely matches part of the sequence of clone RPCI4- 736H12 
(GenBank accession no. AC006060) which again has been mapped 
to chromosome 3. We therefore conclude that the LOTI gene is a 
chimeric clone, carrying sequences derived from chromosome 3 
and from the ZAC coding region on chromosome 6. We therefore 
excluded LOTI from further analysis. PLAGLI was identified by 
sequence similarity to NAG (pleomorphic adenoma of the salivary 
gland gene) which is transcriptionally activated in these salivary 
gland tumors as a result of promoter swapping caused by the chro- 
mosome translocation, t(3;8)(p21;g12) (30). As shown in Figure 3c, 
PLAGLI and ZAC have different 5' ends, but utilize common 
downstream exons. 
To test the imprinted expression of ZAC, we identified poly - 
morphisms within the ZAC exons. The first is a G/T substitu- 
tion located at nucleotide 219 (ZAC exon 1). Direct sequencing 
across this site was performed on genomic PCR products and 
RT -PCR products derived from placental mRNA. The results 
are shown in Figure 4a. Maternal DNA has G at this position, 
whereas the father is a G/T heterozygote. Their daughter is also 
heterozygous. Her placental RT -PCR product was derived 
exclusively from the paternal T allele, showing that the expres- 
sion of ZAC is monoallelic and paternal. Using a further G/T 
polymorphism at nucleotide 875, expression was subsequently 
examined in other tissues. Only 4 of 53 human fetuses were 
heterozygous at nucleotide 875. Monoallelic expression was 
seen in fetal heart, kidney, muscle, cord, adrenal gland and 
lung. However, ZAC is unfortunately biallelically expressed in 
white blood cells, precluding the analysis of TNDM patients' 
blood for evidence of relaxation of imprinting. 
Both of the above polymorphisms lie within the ZAC- 
specific portion of ZAC exon 1, and are not found within the 
PLAGLI splice form. In order to examine PLAGLI expression, 
another polymorphism (C /G) in exon 2 (at nucleotide 1029 of 
ZAC) was employed. This polymorphism is detectable by 
restriction digestion with Avail, which cuts the G allele 
(GGWCC), but not the C allele (GCWCC). RT -PCR primers 
PLAGL I ex 1 b+2f and PLAG l ex2r2 were designed to flank 
this polymorphism and be cDNA specific. They generate a 304 
bp cDNA- specific product from both ZACI and PLAGLI 
mRNA species. Avail digestion products are 148, 130 and 26 
bp for a nucleotide 1029 C allele, the G allele splitting the 148 
bp fragment into 103 and 45 bp. For PCR on genomic DNA, 
the alternative upstream primer PLAGLlex2fl was used, 
yielding a 90 bp band in place of the 26 bp cDNA- specific 
band. The result, using placental mRNA and DNA from two 
individuals, is shown in Figure 4b. Both individuals' DNA is 
heterozygous at nucleotide 1029 (103 + 45 bp from the C allele 
and 148 bp from the G allele). Individual 1 is C /GP and 
individual 2 Gmat /CP t (data not shown). The RT -PCR product 
was derived exclusively from the paternal allele in both 
individuals (Fig. 4b, lanes 1 r and 2r). Since this product 
represents a mixture of PLAGLI and ZAC transcripts, it 
suggests that, at least in placenta, both the ZAC and PLAGI 
promoters are active only on a paternal allele. 
DISCUSSION 
ZAC /PLAGLÎ is a strong candidate gene for TNDM 
As described above, ZAC /PLAGLI is located at 6q24, in the same 
chromosomal region as the imprinted TNDM locus (Fig. 5) (14). 
TNDM was mapped to an 18.72 cR region between D6S1699 and 
D6SI010. The distal flanking marker, D6S1010, was defined by 
the extent of the region trisomie in an insertional translocation 
case [46XX, der(2) ins(2;6)(2pter-2p22.2::6q722.32- 
?6023.1::2p22.2- 2gter)]. The proximal flanking marker, 
D6S1699, was defined by linkage analysis in a family with inher- 
ited TNDM. The TNDM candidate interval between D6S1699 
and D6S1010 is 18.72 cR, equivalent to <5.4 Mb. ZACIPLAGLI , 
in comparison, maps 12.05 cR distal to D6S1699 and 5.17 cR 
proximal to D6S1010, clearly within the TNDM critical region. 
Physiological role of ZACIPLAGLl 
A number of functional properties of ZAC /PLAGLI have been 
demonstrated recently (17,18,27- 29,31). ZAC, PIAGLI and LOTI 
share coding sequences with a zinc finger motif (27 -29) but have 
different 5' ends (see above). Using differential display, LOTI was 
originally identified as a gene whose expression is lost on transfor- 
mation in ovarian cancer, suggesting a tumor suppressor function. 
Such a function is supported by the fact that ZAC has similar activ- 
ities to p53 in inducing cell cycle arrest and apoptosis, in LLC-PK1 
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Figure 3. Restriction enzyme and contig map around NV149. (a) Restriction enzyme map for Notl, BssHII, Smal and PvuII. The open box indicates the region 
covered by the spot clone. This clone was used for the Southern hybridization analysis in Figure 2. Numerals in parentheses refer to position relative to the NV149 
Notl site. (b) PAC contig map. This is derived from the results of the chromosome 6 sequencing project ( http : / /www.sanger.ac.uk/HGP /Chr6 ). (c) ZAC / PLAGLI 
gene structure. Three alternative forms of this gene, ZAC, PLAGLI and LOT!, were reported. ZAC consists of 3 exons (hatched area), named Exonl(ZAC), 
Exon2(ZAC) and Exon3(ZAC). The PLAGL1 transcript also consists of 3 exons (gray area), Exonl(PLAGLI), Exon2(PLAGLI) and Exon3(ZAC). 
Exon2(PLAGLI) lies within the 3' part of Exonl(ZAC), sharing the same intron donor site. The acceptor site of Exon2(PLAGL1) is thus located inside 
Exonl(ZAC). LOT! is a chimeric clone (see text). (d) Exon structure and primers used in this study. Nucleotide positions refer to the ZAC cDNA sequence, 
AJ006354. Polymorphisms used for analysis of imprinted expression are indicated by arrowheads. Horizontal arrows represent primers. The sizes of fragments 
generated by AvaII digestion for analysis of the nucleotide 1029 polymorphism are indicated. 
However, ZAC was originally identified through its ability to 
induce expression of the gene for the type 1 receptor for PACAP 
(17,18). Initially, Zacl, the mouse ortholog of ZAC, was isolated in 
an expression cloning experiment that also identified the PACAPI- 
R itself and p53 (17). Importantly, it has been recognized for some 
time that PACAP is produced by pancreatic neural cells and is an 
extraordinarily potent autocrine regulator of glucose -stimulated 
insulin release (19,20). This immediately suggests that ZAC may be 
involved in the pathogenesis of TNDM, as a result of its effects on 
PACAP1 -R expression in the islet, and quite possibly also as a 
mediator of (3 -cell apoptosis (recalling that most TNDM patients 
eventually develop permanent diabetes). 
More recently, Maebayashi et al. found that Z4C /PLAGLI is 
expressed at a very high level in the suprachiasmatic nucleus (SCN) 
during the early postnatal days (32). In mammals, the SCN is a 
central circadian pacemaker that regulates numerous behavioral and 
physiological rhythms. The similarity between the time course of 
the ZACIPL4GLI expression and that of TNDM provide further 
support for the hypothesis that ZAC /PLAGLI is responsible for 
TNDM. 
Genetic analysis of TNDM and its causative mechanism 
In TNDM patients, several genetic abnormalities have been 
described: paternal uniparental disomy (UPD) of 6q24, segmental 










4:Y_l }. .. .1 














r`I lLi laiIil ,JJr 






1y r, i 
M :ßfl. _.',_."e. Wt' 1, ..4+J\ 
CC TC AT CAGC T IT C AG TGGCA 







Figure 4. Imprinted expression of ZAC/PLAGLI. (a) RT-PCR and genomic PCR 
products were sequenced with primer. PLAGLIexIbI2. Amplification was carried 
out with primer pairs PLAGLIexIbf2 + PLAGLIex2r2 for RT-PCR or 
+ PLAGLIexlbrl for genomic PCR. Arrows indicate the 
polymorphic base. Only the paternally inherited allele (F) could be detected in the 
RT-PCR product (b) Using the nucleotide 1029 polymorphism, monoallelic 
expression of mixed PLAGLI- and ZAC-type transcripts was examined in placentae 
(lanes 1g, Ir. 2g and 2r). Amplification was caned out with primer pairs, 
PLAGLIexlb+2f1 and PLAGLlex2r2 for RT -PCR. or PLAGLlex2f1 and 
PLAGLlex2r2 for genomic PCR. g and r represent genomic and cDNA -derived 
products, respectively. When the polymorphic base was G, it created an Avail site 
which fragmented the 148 bp band to 103 and 45 bp. Two individuals show a clear 
monoallelic expression pattern. 
trisomy of 6q24, dominant inheritance with a normal karyotype, 
as well as cases with no known genetic abnormality (14). The 
UPD6 cases suggest either a loss of function from a maternally 
expressed gene or increased expression of a paternally expressed 
one. The former possibility is excluded by the existence of 
patients with TNDM due to paternal duplication (partial trisomy) 
of 6q24. The cause of TNDM is therefore likely to be over - 
expression of a paternally expressed imprinted gene. 
For TNDM cases with normal karyotypes, therefore, the 
following are possible pathogenetic mechanisms: (i) upregula- 
tion of the causative gene, possibly due to biallelic expression 
in place of monoallelic (`imprinting mutation'); (ii) a coding 
region mutation which activates protein function; (iii) 
submicroscopic reduplication of paternal 6q24 resulting in two 
expressed copies of the gene. 
We examined the eight TNDM patients including two 
patients with uniparental paternal disomy (one Hungarian and 
the other Japanese) and six patients with a normal biparental 
chromosome complement We first sequenced ZACIPLAGLI 
centromere 
TNDM 







Figures. Radiation hybrid map around the ZAC IPLAGLI region. The Sanger Centre 
map constructed from the GeneBridge4 radiation hybrid panel is cited in this Figure 
(http: / /webace.sanger.ac.uk SANGER_chmm6 rhmap 03_11_98 ). 
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Figure 6. Methylation status of TNDM patients. (a) Schematic representation 
of sodium bisulfite conversion of methylated and unmethylated sequences. 
PCR amplification with primers NV I49BSSu2 and NV149BSSI2 generates a 
152 bp product. A new Taql site is generated at nucleotide -133 (Fig. 3) only 
if the original template was methylated. (b) The DNA identification numbers 
follow the report by Hermann et al. (33). J 1, J2 and J3 indicate Japanese 
patients. Patients 3 and J3, who are the cases with paternal uniparental disomy 
of chromosome 6 (UPD6), show only an unmethylated pattern, whereas the 
other patients exhibit normal methylation profiles. Both paternal alleles in 
UPD6 retain their imprinted demethylated status, whereas the differential 
methylation of maternal and paternal NV149 alleles is also retained in the 
TNDM patients with biparental origin of chromosome 6. 
in all patients. No mutation in coding region nor in the 5' -UTR 
and putative promoter region was found. Because the methyla- 
tion status of the NV149 region was expected to indicate the 
expression status of ZAC IPLAGLI, blood DNA from the 
patients were investigated using sodium bisulfite deamination 
(Fig. 6). This converts unmethylated C to U, but leaves 5- 
methylC unconverted. After PCR amplification of bisulphite- 
treated DNA, an original CC *GA sequence (C* is methylated 
C) at nucleotide 133 is altered to TCGA (Taal site), whereas 
CCGA (unmethylated) is converted to TTGA. A 152 bp frag- 
ment was PCR- amplified from bisulphite- treated patient DNA 
and assayed with Taql. In Figure 6, lanes 3 and J3, patients 3 
(33) and J3 who are the Hungarian and Japanese paternal 
UPD6 cases, respectively, show, as expected, an unmethylated 
pattern of both alleles. 
The methylation profiles of the TNDM patients with normal 
biparental DNA (Fig. 6, lanes 2, 4, 5, 6, J 1 and J2) showed 
monoallelic methylation patterns. This indicates that maternal 
imprinting is not erased in these patients, and consequently 
lends no additional support to implicate ZAC in TNDM. Unfor- 
tunately, the expression of ZACIPLAGLI in white blood cells 
is at very low level, and upregulation could not be reliably 
demonstrated. Definitive proof that ZAC is the TNDM gene 
may have to await the availability of other pathological mate- 
rial from TNDM patients, so that experiments can be 
performed to search for a switch from monoallelic to biallelic 
expression. None the less, the collective data strongly suggest 
ZACIPLAGLI as a candidate gene for TNDM. 
MATERIALS AND METHODS 
Human parthenogenetic chimera and androgenetic mole 
samples 
Blood samples were obtained from patient FD and age -matched, 
normal Scottish females. The complete hydatidiform mole and 
normal placental villi was prepared as described by Arima et al. 
(34). DNA was extracted according to an established method 
(35). 
RLGS-M 
RLGS was originally reported by our group (21). The protocol for 
RLGS in this experiment was described elsewhere (11). RLGS -M 
was performed as described by Kawai et al (22). In brief, genomic 
DNA was blocked by nucleotide analogs ( dGTPaS, dCTPaS, 
ddATP and ddTTP) with DNA polymerase I to reduce background. 
The DNA was digested with a methylation- sensitive restriction 
enzyme and then 5'- protuding ends were labeled in a fill -in reaction. 
The second digestion was carried out with a 6 bp recognizing 
restriction enzyme. The labeled and size -reduced DNA samples 
were electrophoresed through a 0.8% agarose tube gel (first - 
dimension separation). These samples were treated with a third 
restriction enzyme. In -gel samples were subjected to second - 
dimension 5% polyacrylamide gel electrophoresis. The gel was 
dried and autoradiographed. In this study, the restriction enzyme 
combinations Ascl EcoRV Mbol and Notl Pstl -PvulI were used. 
The genomic DNA fragment corresponding to an RLGS -M spot 
was cloned according to a previously described protocol (11). 
RH mapping 
The GeneBridge 4 Radiation Hybrid Mapping Panel was purchased 
from Research Genetics (Huntsville, AL). Amplification was 
carried out with primers, NV149v2u1 (GCGAGGAGGGTGT- 
GCCTITG) and NV 149v211 (GGCCCGTTGGCGAGGT- 
TAGAG), under the following conditions: denaturation at 94 °C for 
2 min and 30 cycles of 96 °C for 30 s, 60 °C for 30 s and 72 °C for 
1 min. PCR products were electrophoresed in 3% agarose gel. The 
Sanger Centre 1998 GENE MAP SERVER for the GB4 panel 
( http:// www. sanger .ac.uk/RHserver/RHserver.shtml ) was used for 
calculation of the map position. 
Methylation analysis of the NV149 NotI site 
Genomic DNAs (10 µg) from placentae and peripheral blood 
lymphocytes were separated into two aliquots which were subse- 
quently treated with or without methylation- sensitive enzymes 
Notl, BssHll or SmaI. Both aliquots were then amplified with 
primers NV149v2uml (ACGGCATCTGCCATTTGTCA) and 
NV 149v211. PCR conditions were the same as for RH mapping. 
PCR products were sequenced using primer NV149v2u1. Big - 
Dye terminator reaction chemistry with an ABI 377 DNA 
sequencer was used. For Southern blotting, 5 µg of digested 
DNAs were treated with Pvuil and electrophoresed in a 1% 
agarose gel. According to standard protocols, DNAs were trans- 
ferred to nylon membrane and were hybridized with a probe of 
NV149 spot clone, labeled by random priming. 
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Imprinted or monoallelic expression of ZAC /PLAGLI 
Monoallelic expression of ZAC/PLAGLI, was investigated in three 
ways. First, RT -PCR direct sequencing was carried out in a Japa- 
nese family, heterozygous at nucleotide 219 (nucleotide positions 
refer to the published ZAC cDNA sequence, AJ006354). RNA 
(3 µg) from placenta was reverse transcribed using oligo-dg) 8 and 
SuperScriptlI (Stratagene, La Jolla, CA) according to the manufac- 
turer's protocol. As a PCR reaction template 1/50 of the reaction 
mixture was used with primers, PLAGLlexlbf2 (AACGT- 
TAATAAATCACII'AGGCGAGA) and PLAGLlex2r2 (CTGA- 
CCAAATGCTGTGCCAT). As a reference, genomic DNAs were 
amplified with primers PLAGLlexlbf2 and PLAGLlexlbrl 
(ACCTCCAGCATGTTCTTGCC). RT -PCR and genomic PCR 
products were sequenced with primer PLAGLlexlbf2. 
Second, using three independent first -trimester fetuses (AC, 
HM and JC) heterozygous at nucleotide 875, six tissues (heart, 
kidney, muscle, cord, adrenal and lung) were analyzed. Using 
mismatched primer, ZAC -RT5' (GGAATGTTTTCCTAGCT- 
TCATTCCCGTAC) and downstream primer, ZAC- RT3'(2) 
(GGACCTCTCAGCTGTCACTAGCT), PCR on the RT 
product generated a 205 bp product. Digestion with BscWI 
produced bands of 205 bp if the polymorphic base was T 
(uncut), or 176 bp if the polymorphic base was G. 
Third, PCR -RFLP was carried out using a polymorphism at 
nucleotide 1029. cDNAs from whole blood cells and placentae 
were subjected to PCR amplification with primers, PLAGL l ex lbf 1 
(TCAACCTTCTTGCACTGCAAA) and PLAGLIex2 +3r1 (AT- 
GGGTAGCCATATGCCTCA). PCR conditions were 2 min at 
94 °C, followed by 25 cycles (96 °C, 60 °C and 72 °C for 30 s, 30 s 
and 1 min, respectively). PCR products (1/20) were further ampli- 
fied using nested primers, PLAGLlexlb +2f1 (CCTGTCACT- 
CAGTAGCCAA) and PLAGLlex2r2, by 20 cycles under the 
same conditions. Reference genomic DNAs were amplified with 
primers, PLAGLlex2f1 (TGATTCTGAAGCGGTCAGGG) and 
PLAGLlex2f2. These PCR products were digested with Avail and 
electrophoresed through 6% polyacrylamide gels. Digestion with 
AvaII gave bands of size 148 bp if the polymorphic base was C, and 
103 and 45 by if it was G. 
Methylation status of NVI49 in TNDM patients 
Unmethylated cytosine was converted to uracil by sodium 
bisulfite using a standard protocol (36). Briefly, 0.5 µg of 
Pvull- treated DNA was incubated at 37 °C for 10 min in 56 µl 
of 0.2 M NaOH. Thirty microliters of 10 mM hydroquinone 
and 520 µl of 3.6 M sodium bisulfite (final concentration 
3.1 M) were added. These samples were incubated at 55 °C for 
16 h, followed by desalting with Geneclean (Bio101, Carlsbad, 
CA) and dissolved in 50 pl distilled water. After addition of 
5.5 pl of 3 M NaOH and incubation at room temperature for 
5 min, samples were ethanol precipitated and dissolved in 
10 pl of TE (10 mM Tris -HCI, 0.1 mM EDTA pH 8). One 
microliter was used as PCR template for amplification with 
primers, NV149BSSu2 (GGGGTAGTYGTGTTTATAGTT- 
TAGTA) and NV149BSSI2 (CRAACACCCAAACAC - 
CTACCCTA), under the following conditions: denaturation at 
94 °C for 2 min and 35 cycles of 96 °C for 20 s, 60 °C for 30 s 
and 72 °C for 1 min. PCR products were digested with Taql and 
electrophoresed on a 6% polyacrylamide gel. The original 
sequence CCGA 133 bp upstream from the NotI site was 
converted to UCGA, if the C in the CpG dinucleotide was 
460 Human Molecular Genetics, 2000, Vol. 9, No. 3 
methylated, or UUGA, if it was unmethylated. The 152 bp 
PCR product is digested by Taql to 91 and 61 bp products if 
derived from a methylated allele. 
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